DDI-MedLine.d161.s3	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	106-153	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	281-324	false	in the present study , we tested whether the highly specific metabotropic glutamate receptor dg antagonist , druga , reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of drugb .
DDI-MedLine.d161.s4	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	21-64	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	150-197	false	weekly intramuscular druga injections ( dg dg mg / kg body weight ) , in combination with daily administration of drugb or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine versus dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle ) .
DDI-MedLine.d161.s4	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	21-64	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	321-364	false	weekly intramuscular druga injections ( dg dg mg / kg body weight ) , in combination with daily administration of dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugb / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine versus dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle ) .
DDI-MedLine.d161.s4	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	21-64	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	366-413	false	weekly intramuscular druga injections ( dg dg mg / kg body weight ) , in combination with daily administration of dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / drugb versus dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle ) .
DDI-MedLine.d161.s4	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	21-64	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	422-465	false	weekly intramuscular druga injections ( dg dg mg / kg body weight ) , in combination with daily administration of dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine versus drugb / vehicle ) .
DDI-MedLine.d161.s4	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	150-197	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	321-364	false	weekly intramuscular dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine injections ( dg dg mg / kg body weight ) , in combination with daily administration of druga or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugb / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine versus dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle ) .
DDI-MedLine.d161.s4	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	150-197	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	366-413	false	weekly intramuscular dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine injections ( dg dg mg / kg body weight ) , in combination with daily administration of druga or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / drugb versus dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle ) .
DDI-MedLine.d161.s4	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	150-197	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	422-465	false	weekly intramuscular dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine injections ( dg dg mg / kg body weight ) , in combination with daily administration of druga or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine versus drugb / vehicle ) .
DDI-MedLine.d161.s4	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	321-364	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	366-413	false	weekly intramuscular dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine injections ( dg dg mg / kg body weight ) , in combination with daily administration of dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( druga / drugb versus dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle ) .
DDI-MedLine.d161.s4	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	321-364	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	422-465	false	weekly intramuscular dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine injections ( dg dg mg / kg body weight ) , in combination with daily administration of dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( druga / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine versus drugb / vehicle ) .
DDI-MedLine.d161.s4	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	366-413	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	422-465	false	weekly intramuscular dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine injections ( dg dg mg / kg body weight ) , in combination with daily administration of dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / druga versus drugb / vehicle ) .
DDI-MedLine.d161.s5	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	18-61	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	78-121	false	after dg weeks of druga treatment , all drugb / vehicle treated animals displayed parkinsonian symptoms , whereas none of the dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine treated monkeys were significantly affected .
DDI-MedLine.d161.s5	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	18-61	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	200-243	false	after dg weeks of druga treatment , all dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle treated animals displayed parkinsonian symptoms , whereas none of the drugb / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine treated monkeys were significantly affected .
DDI-MedLine.d161.s5	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	18-61	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	245-292	false	after dg weeks of druga treatment , all dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle treated animals displayed parkinsonian symptoms , whereas none of the dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / drugb treated monkeys were significantly affected .
DDI-MedLine.d161.s5	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	78-121	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	200-243	false	after dg weeks of dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine treatment , all druga / vehicle treated animals displayed parkinsonian symptoms , whereas none of the drugb / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine treated monkeys were significantly affected .
DDI-MedLine.d161.s5	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	78-121	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	245-292	false	after dg weeks of dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine treatment , all druga / vehicle treated animals displayed parkinsonian symptoms , whereas none of the dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / drugb treated monkeys were significantly affected .
DDI-MedLine.d161.s5	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	200-243	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	245-292	effect	after dg weeks of dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine treatment , all dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle treated animals displayed parkinsonian symptoms , whereas none of the druga / drugb treated monkeys were significantly affected .
DDI-MedLine.d161.s6	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	349-392	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	394-441	effect	these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in druga / drugb treated animals than in dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle treated monkeys .
DDI-MedLine.d161.s6	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	349-392	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	467-510	false	these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in druga / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine treated animals than in drugb / vehicle treated monkeys .
DDI-MedLine.d161.s6	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	394-441	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	467-510	false	these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / druga treated animals than in drugb / vehicle treated monkeys .
DDI-MedLine.d161.s7	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	4-51	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	100-143	effect	the druga treatment also had a significant effect on the drugb induced loss of norepinephrine neurons in the locus coeruleus and adjoining a5 and a7 noradrenaline cell groups .
DDI-MedLine.d161.s8	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	3-46	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	283-326	false	in druga / vehicle treated animals , almost dg % loss of tyrosine hydroxylase positive norepinephrine neurons was found in locus coeruleus / a5 / a7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than dg % of control values in drugb / dg [ ( dg methyl dg , dg thiazol dg yl ) ethynyl ] pyridine treated monkeys .
DDI-MedLine.d161.s8	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	3-46	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	328-375	false	in druga / vehicle treated animals , almost dg % loss of tyrosine hydroxylase positive norepinephrine neurons was found in locus coeruleus / a5 / a7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than dg % of control values in dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / drugb treated monkeys .
DDI-MedLine.d161.s8	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	283-326	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	328-375	effect	in dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine / vehicle treated animals , almost dg % loss of tyrosine hydroxylase positive norepinephrine neurons was found in locus coeruleus / a5 / a7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than dg % of control values in druga / drugb treated monkeys .
DDI-MedLine.d161.s9	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	99-146	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	171-214	effect	our data demonstrate that chronic treatment with the metabotropic glutamate receptor dg antagonist , druga , significantly reduces drugb toxicity towards dopaminergic and noradrenergic cell groups in non human primates .
DDI-MedLine.d185.s0	ketoconazole	drug	10-21	panobinostat	drug	82-93	false	effect of druga mediated cyp3a4 inhibition on clinical pharmacokinetics of drugb ( lbh589 ) , an orally active histone deacetylase inhibitor .
DDI-MedLine.d185.s0	ketoconazole	drug	10-21	LBH589	drug	96-101	false	effect of druga mediated cyp3a4 inhibition on clinical pharmacokinetics of panobinostat ( drugb ) , an orally active histone deacetylase inhibitor .
DDI-MedLine.d185.s0	ketoconazole	drug	10-21	histone deacetylase inhibitor	group	122-150	false	effect of druga mediated cyp3a4 inhibition on clinical pharmacokinetics of panobinostat ( lbh589 ) , an orally active drugb .
DDI-MedLine.d185.s0	panobinostat	drug	82-93	LBH589	drug	96-101	false	effect of ketoconazole mediated cyp3a4 inhibition on clinical pharmacokinetics of druga ( drugb ) , an orally active histone deacetylase inhibitor .
DDI-MedLine.d185.s0	panobinostat	drug	82-93	histone deacetylase inhibitor	group	122-150	false	effect of ketoconazole mediated cyp3a4 inhibition on clinical pharmacokinetics of druga ( lbh589 ) , an orally active drugb .
DDI-MedLine.d185.s0	LBH589	drug	96-101	histone deacetylase inhibitor	group	122-150	false	effect of ketoconazole mediated cyp3a4 inhibition on clinical pharmacokinetics of panobinostat ( druga ) , an orally active drugb .
DDI-MedLine.d185.s2	ketoconazole	drug	61-72	panobinostat	drug	113-124	false	this study evaluated the effect of a potent cyp3a inhibitor , druga , on the pharmacokinetics and safety of drugb .
DDI-MedLine.d185.s5	panobinostat	drug	19-30	ketoconazole	drug	62-73	false	on day dg , a single druga dose was co administered with drugb .
DDI-MedLine.d185.s7	ketoconazole	drug	19-30	panobinostat	drug	92-103	mechanism	in the presence of druga , there was dg and dg fold increase in c ( max ) and auc of drugb , respectively .
DDI-MedLine.d185.s12	panobinostat	drug	21-32	panobinostat	drug	96-107	false	co administration of druga with cyp3a inhibitors is feasible as the observed increase in drugb pk parameters was not considered clinically relevant .
DDI-MedLine.d185.s13	panobinostat	drug	104-115	panobinostat	drug	176-187	false	considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of druga was not studied with cyp3a inhibitors , close monitoring of drugb related adverse events is necessary .
DDI-MedLine.d231.s0	moxifloxacin	drug	21-32	lomefloxacin	drug	38-49	false	interaction study of druga and drugb with co administered drugs .
DDI-MedLine.d231.s1	Moxifloxacin	drug	0-11	lomefloxacin	drug	17-28	false	druga and drugb are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections .
DDI-MedLine.d231.s1	Moxifloxacin	drug	0-11	fluoroquinolone antibiotics	group	34-60	false	druga and lomefloxacin are drugb used in treating urinary and respiratory tract infections .
DDI-MedLine.d231.s1	lomefloxacin	drug	17-28	fluoroquinolone antibiotics	group	34-60	false	moxifloxacin and druga are drugb used in treating urinary and respiratory tract infections .
DDI-MedLine.d231.s3	moxifloxacin	drug	6-17	fluoroquinolones	group	36-51	false	being druga and lomefloxacin drugb the interaction study of was carried out with sucralfate , gelusil , erythromycin and multi minerals .
DDI-MedLine.d231.s3	moxifloxacin	drug	6-17	sucralfate	drug	99-108	false	being druga and lomefloxacin fluoroquinolones the interaction study of was carried out with drugb , gelusil , erythromycin and multi minerals .
DDI-MedLine.d231.s3	moxifloxacin	drug	6-17	gelusil	brand	111-117	false	being druga and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , drugb , erythromycin and multi minerals .
DDI-MedLine.d231.s3	moxifloxacin	drug	6-17	erythromycin	drug	120-131	false	being druga and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , gelusil , drugb and multi minerals .
DDI-MedLine.d231.s3	moxifloxacin	drug	6-17	multi minerals	group	137-150	false	being druga and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , gelusil , erythromycin and drugb .
DDI-MedLine.d231.s3	fluoroquinolones	group	36-51	sucralfate	drug	99-108	false	being moxifloxacin and lomefloxacin druga the interaction study of was carried out with drugb , gelusil , erythromycin and multi minerals .
DDI-MedLine.d231.s3	fluoroquinolones	group	36-51	gelusil	brand	111-117	false	being moxifloxacin and lomefloxacin druga the interaction study of was carried out with sucralfate , drugb , erythromycin and multi minerals .
DDI-MedLine.d231.s3	fluoroquinolones	group	36-51	erythromycin	drug	120-131	false	being moxifloxacin and lomefloxacin druga the interaction study of was carried out with sucralfate , gelusil , drugb and multi minerals .
DDI-MedLine.d231.s3	fluoroquinolones	group	36-51	multi minerals	group	137-150	false	being moxifloxacin and lomefloxacin druga the interaction study of was carried out with sucralfate , gelusil , erythromycin and drugb .
DDI-MedLine.d231.s3	sucralfate	drug	99-108	gelusil	brand	111-117	false	being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with druga , drugb , erythromycin and multi minerals .
DDI-MedLine.d231.s3	sucralfate	drug	99-108	erythromycin	drug	120-131	false	being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with druga , gelusil , drugb and multi minerals .
DDI-MedLine.d231.s3	sucralfate	drug	99-108	multi minerals	group	137-150	false	being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with druga , gelusil , erythromycin and drugb .
DDI-MedLine.d231.s3	gelusil	brand	111-117	erythromycin	drug	120-131	false	being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , druga , drugb and multi minerals .
DDI-MedLine.d231.s3	gelusil	brand	111-117	multi minerals	group	137-150	false	being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , druga , erythromycin and drugb .
DDI-MedLine.d231.s3	erythromycin	drug	120-131	multi minerals	group	137-150	false	being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate , gelusil , druga and drugb .
DDI-MedLine.d231.s6	moxifloxacin	drug	16-27	lomefloxacin	drug	33-44	false	the response of druga and drugb after interaction with co administered drugs at different conditions and temperature were noted using a shimadzu hplc system with pda detector .
DDI-MedLine.d231.s8	Moxifloxacin	drug	0-11	Lomefloxacin	drug	17-28	false	druga and drugb reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	Moxifloxacin	drug	0-11	sucralfate	drug	49-58	mechanism	druga and lomefloxacin reacts faster with drugb and gelusil in acidic media whereas with erythromycin in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	Moxifloxacin	drug	0-11	gelusil	brand	64-70	mechanism	druga and lomefloxacin reacts faster with sucralfate and drugb in acidic media whereas with erythromycin in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	Moxifloxacin	drug	0-11	erythromycin	drug	101-112	mechanism	druga and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with drugb in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	Moxifloxacin	drug	0-11	multi-minerals	group	133-146	mechanism	druga and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and drugb in neutral media .
DDI-MedLine.d231.s8	Lomefloxacin	drug	17-28	sucralfate	drug	49-58	mechanism	moxifloxacin and druga reacts faster with drugb and gelusil in acidic media whereas with erythromycin in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	Lomefloxacin	drug	17-28	gelusil	brand	64-70	mechanism	moxifloxacin and druga reacts faster with sucralfate and drugb in acidic media whereas with erythromycin in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	Lomefloxacin	drug	17-28	erythromycin	drug	101-112	mechanism	moxifloxacin and druga reacts faster with sucralfate and gelusil in acidic media whereas with drugb in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	Lomefloxacin	drug	17-28	multi-minerals	group	133-146	mechanism	moxifloxacin and druga reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and drugb in neutral media .
DDI-MedLine.d231.s8	sucralfate	drug	49-58	gelusil	brand	64-70	false	moxifloxacin and lomefloxacin reacts faster with druga and drugb in acidic media whereas with erythromycin in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	sucralfate	drug	49-58	erythromycin	drug	101-112	false	moxifloxacin and lomefloxacin reacts faster with druga and gelusil in acidic media whereas with drugb in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	sucralfate	drug	49-58	multi-minerals	group	133-146	false	moxifloxacin and lomefloxacin reacts faster with druga and gelusil in acidic media whereas with erythromycin in basic media and drugb in neutral media .
DDI-MedLine.d231.s8	gelusil	brand	64-70	erythromycin	drug	101-112	false	moxifloxacin and lomefloxacin reacts faster with sucralfate and druga in acidic media whereas with drugb in basic media and multi minerals in neutral media .
DDI-MedLine.d231.s8	gelusil	brand	64-70	multi-minerals	group	133-146	false	moxifloxacin and lomefloxacin reacts faster with sucralfate and druga in acidic media whereas with erythromycin in basic media and drugb in neutral media .
DDI-MedLine.d231.s8	erythromycin	drug	101-112	multi-minerals	group	133-146	false	moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with druga in basic media and drugb in neutral media .
DDI-MedLine.d216.s0	S-ketamine	drug	17-26	itraconazole	drug	45-56	false	exposure to oral druga is unaffected by drugb but greatly increased by ticlopidine .
DDI-MedLine.d216.s0	S-ketamine	drug	17-26	ticlopidine	drug	83-93	effect	exposure to oral druga is unaffected by itraconazole but greatly increased by drugb .
DDI-MedLine.d216.s0	itraconazole	drug	45-56	ticlopidine	drug	83-93	false	exposure to oral s ketamine is unaffected by druga but greatly increased by drugb .
DDI-MedLine.d216.s1	S-ketamine	drug	51-60	ticlopidine	drug	107-117	false	this study examined drug drug interactions of oral druga with the cytochrome p450 ( cyp ) dg inhibitor drugb and the cyp3a inhibitor itraconazole .
DDI-MedLine.d216.s1	S-ketamine	drug	51-60	itraconazole	drug	143-154	false	this study examined drug drug interactions of oral druga with the cytochrome p450 ( cyp ) dg inhibitor ticlopidine and the cyp3a inhibitor drugb .
DDI-MedLine.d216.s1	ticlopidine	drug	107-117	itraconazole	drug	143-154	false	this study examined drug drug interactions of oral s ketamine with the cytochrome p450 ( cyp ) dg inhibitor druga and the cyp3a inhibitor drugb .
DDI-MedLine.d216.s2	S-ketamine	drug	87-96	ticlopidine	drug	128-138	false	in this randomized , blinded , crossover study , dg healthy volunteers ingested dg mg / kg druga after pretreatments with oral drugb ( dg mg twice daily ) , itraconazole ( dg mg once daily ) , or placebo in dg day treatment periods at intervals of dg weeks .
DDI-MedLine.d216.s2	S-ketamine	drug	87-96	itraconazole	drug	162-173	false	in this randomized , blinded , crossover study , dg healthy volunteers ingested dg mg / kg druga after pretreatments with oral ticlopidine ( dg mg twice daily ) , drugb ( dg mg once daily ) , or placebo in dg day treatment periods at intervals of dg weeks .
DDI-MedLine.d216.s2	ticlopidine	drug	128-138	itraconazole	drug	162-173	false	in this randomized , blinded , crossover study , dg healthy volunteers ingested dg mg / kg s ketamine after pretreatments with oral druga ( dg mg twice daily ) , drugb ( dg mg once daily ) , or placebo in dg day treatment periods at intervals of dg weeks .
DDI-MedLine.d216.s3	Ticlopidine	drug	0-10	ketamine	drug	134-141	mechanism	druga treatment increased the mean area under the plasma concentration time curve extrapolated to infinity ( auc ( dg ) ) of oral drugb by dg fold , whereas itraconazole treatment did not increase the exposure to s ketamine .
DDI-MedLine.d216.s3	Ticlopidine	drug	0-10	itraconazole	drug	164-175	false	druga treatment increased the mean area under the plasma concentration time curve extrapolated to infinity ( auc ( dg ) ) of oral ketamine by dg fold , whereas drugb treatment did not increase the exposure to s ketamine .
DDI-MedLine.d216.s3	Ticlopidine	drug	0-10	S-ketamine	drug	220-229	false	druga treatment increased the mean area under the plasma concentration time curve extrapolated to infinity ( auc ( dg ) ) of oral ketamine by dg fold , whereas itraconazole treatment did not increase the exposure to drugb .
DDI-MedLine.d216.s3	ketamine	drug	134-141	itraconazole	drug	164-175	false	ticlopidine treatment increased the mean area under the plasma concentration time curve extrapolated to infinity ( auc ( dg ) ) of oral druga by dg fold , whereas drugb treatment did not increase the exposure to s ketamine .
DDI-MedLine.d216.s3	ketamine	drug	134-141	S-ketamine	drug	220-229	false	ticlopidine treatment increased the mean area under the plasma concentration time curve extrapolated to infinity ( auc ( dg ) ) of oral druga by dg fold , whereas itraconazole treatment did not increase the exposure to drugb .
DDI-MedLine.d216.s3	itraconazole	drug	164-175	S-ketamine	drug	220-229	false	ticlopidine treatment increased the mean area under the plasma concentration time curve extrapolated to infinity ( auc ( dg ) ) of oral ketamine by dg fold , whereas druga treatment did not increase the exposure to drugb .
DDI-MedLine.d216.s4	norketamine	drug_n	13-23	ketamine	drug	39-46	false	the ratio of druga auc ( dg ) to drugb auc ( dg ) was significantly decreased in the ticlopidine ( p & lt ; dg ) and itraconazole phases ( p = dg ) as compared to placebo .
DDI-MedLine.d216.s4	norketamine	drug_n	13-23	ticlopidine	drug	94-104	false	the ratio of druga auc ( dg ) to ketamine auc ( dg ) was significantly decreased in the drugb ( p & lt ; dg ) and itraconazole phases ( p = dg ) as compared to placebo .
DDI-MedLine.d216.s4	norketamine	drug_n	13-23	itraconazole	drug	125-136	false	the ratio of druga auc ( dg ) to ketamine auc ( dg ) was significantly decreased in the ticlopidine ( p & lt ; dg ) and drugb phases ( p = dg ) as compared to placebo .
DDI-MedLine.d216.s4	ketamine	drug	39-46	ticlopidine	drug	94-104	false	the ratio of norketamine auc ( dg ) to druga auc ( dg ) was significantly decreased in the drugb ( p & lt ; dg ) and itraconazole phases ( p = dg ) as compared to placebo .
DDI-MedLine.d216.s4	ketamine	drug	39-46	itraconazole	drug	125-136	false	the ratio of norketamine auc ( dg ) to druga auc ( dg ) was significantly decreased in the ticlopidine ( p & lt ; dg ) and drugb phases ( p = dg ) as compared to placebo .
DDI-MedLine.d216.s4	ticlopidine	drug	94-104	itraconazole	drug	125-136	false	the ratio of norketamine auc ( dg ) to ketamine auc ( dg ) was significantly decreased in the druga ( p & lt ; dg ) and drugb phases ( p = dg ) as compared to placebo .
DDI-MedLine.d216.s5	ticlopidine	drug	7-17	itraconazole	drug	23-34	false	in the druga and drugb phases , the areas under the effect time curves ( self reported drowsiness and performance ) were significantly higher than those in the placebo phase ( p < dg ) .
DDI-MedLine.d216.s6	S-ketamine	drug	40-49	ticlopidine	drug	91-101	advise	the findings suggest that the dosage of druga should be reduced in patients receiving drugb .
DDI-MedLine.d180.s1	3-Deazaneplanocin A	drug_n	4-22	DZNep	drug_n	25-29	false	the druga ( drugb ) , one of s adenosylhomocysteine ( adohcy ) hydrolase inhibitors , has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia .
DDI-MedLine.d180.s10	DZNep	drug_n	46-50	DZNep	drug_n	92-96	false	we also found that bcl dg was overexpressed in druga insensitive cells , and cotreatment with drugb and abt dg , a bcl dg family inhibitor , synergistically inhibited growth and induced apoptosis of dznep insensitive mm cells .
DDI-MedLine.d180.s10	DZNep	drug_n	46-50	ABT-737	drug_n	102-108	false	we also found that bcl dg was overexpressed in druga insensitive cells , and cotreatment with dznep and drugb , a bcl dg family inhibitor , synergistically inhibited growth and induced apoptosis of dznep insensitive mm cells .
DDI-MedLine.d180.s10	DZNep	drug_n	46-50	DZNep	drug_n	195-199	false	we also found that bcl dg was overexpressed in druga insensitive cells , and cotreatment with dznep and abt dg , a bcl dg family inhibitor , synergistically inhibited growth and induced apoptosis of drugb insensitive mm cells .
DDI-MedLine.d180.s10	DZNep	drug_n	92-96	ABT-737	drug_n	102-108	effect	we also found that bcl dg was overexpressed in dznep insensitive cells , and cotreatment with druga and drugb , a bcl dg family inhibitor , synergistically inhibited growth and induced apoptosis of dznep insensitive mm cells .
DDI-MedLine.d180.s10	DZNep	drug_n	92-96	DZNep	drug_n	195-199	false	we also found that bcl dg was overexpressed in dznep insensitive cells , and cotreatment with druga and abt dg , a bcl dg family inhibitor , synergistically inhibited growth and induced apoptosis of drugb insensitive mm cells .
DDI-MedLine.d180.s10	ABT-737	drug_n	102-108	DZNep	drug_n	195-199	false	we also found that bcl dg was overexpressed in dznep insensitive cells , and cotreatment with dznep and druga , a bcl dg family inhibitor , synergistically inhibited growth and induced apoptosis of drugb insensitive mm cells .
DDI-MedLine.d180.s12	DZNep	drug_n	13-17	ABT-737	drug_n	106-112	false	in addition , druga insensitivity might be associated with overexpression of bcl dg , and the combination of drugb and dznep could synergistically induced apoptosis .
DDI-MedLine.d180.s12	DZNep	drug_n	13-17	DZNep	drug_n	118-122	false	in addition , druga insensitivity might be associated with overexpression of bcl dg , and the combination of abt dg and drugb could synergistically induced apoptosis .
DDI-MedLine.d180.s12	ABT-737	drug_n	106-112	DZNep	drug_n	118-122	effect	in addition , dznep insensitivity might be associated with overexpression of bcl dg , and the combination of druga and drugb could synergistically induced apoptosis .
DDI-MedLine.d208.s0	Implanon	brand	0-7	antiretroviral	group	47-60	effect	druga failure in an hiv positive woman on drugb therapy resulting in two ectopic pregnancies .
DDI-MedLine.d208.s3	antiretroviral	group	59-72	Implanon	brand	138-145	effect	we present an interesting case of an hiv positive woman on druga therapy having tubal pregnancies on two separate occasions with drugb in place .
DDI-MedLine.d218.s0	Antidepressant	group	0-13	warfarin	drug	15-22	false	druga drugb interaction and associated gastrointestinal bleeding risk in a case control study .
DDI-MedLine.d218.s3	antidepressant	group	47-60	warfarin	drug	133-140	false	we sought to evaluate whether initiation of an druga increases the risk of hospitalization for gastrointestinal bleeding in drugb users .
DDI-MedLine.d218.s5	warfarin	drug	18-25	warfarin	drug	69-76	false	in total , dg , dg druga users contributed dg , dg person years of drugb use .
DDI-MedLine.d218.s8	Warfarin	drug	0-7	citalopram	drug	91-100	effect	druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugb ( or = dg [ dg % ci , dg dg ] ) , fluoxetine ( or = dg [ dg % ci , dg dg ] ) , paroxetine ( or = dg [ dg % ci , dg dg ] ) , amitriptyline ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s8	Warfarin	drug	0-7	fluoxetine	drug	139-148	effect	druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram ( or = dg [ dg % ci , dg dg ] ) , drugb ( or = dg [ dg % ci , dg dg ] ) , paroxetine ( or = dg [ dg % ci , dg dg ] ) , amitriptyline ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s8	Warfarin	drug	0-7	paroxetine	drug	187-196	effect	druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram ( or = dg [ dg % ci , dg dg ] ) , fluoxetine ( or = dg [ dg % ci , dg dg ] ) , drugb ( or = dg [ dg % ci , dg dg ] ) , amitriptyline ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s8	Warfarin	drug	0-7	amitriptyline	drug	235-247	effect	druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram ( or = dg [ dg % ci , dg dg ] ) , fluoxetine ( or = dg [ dg % ci , dg dg ] ) , paroxetine ( or = dg [ dg % ci , dg dg ] ) , drugb ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s8	citalopram	drug	91-100	fluoxetine	drug	139-148	false	warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of druga ( or = dg [ dg % ci , dg dg ] ) , drugb ( or = dg [ dg % ci , dg dg ] ) , paroxetine ( or = dg [ dg % ci , dg dg ] ) , amitriptyline ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s8	citalopram	drug	91-100	paroxetine	drug	187-196	false	warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of druga ( or = dg [ dg % ci , dg dg ] ) , fluoxetine ( or = dg [ dg % ci , dg dg ] ) , drugb ( or = dg [ dg % ci , dg dg ] ) , amitriptyline ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s8	citalopram	drug	91-100	amitriptyline	drug	235-247	false	warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of druga ( or = dg [ dg % ci , dg dg ] ) , fluoxetine ( or = dg [ dg % ci , dg dg ] ) , paroxetine ( or = dg [ dg % ci , dg dg ] ) , drugb ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s8	fluoxetine	drug	139-148	paroxetine	drug	187-196	false	warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram ( or = dg [ dg % ci , dg dg ] ) , druga ( or = dg [ dg % ci , dg dg ] ) , drugb ( or = dg [ dg % ci , dg dg ] ) , amitriptyline ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s8	fluoxetine	drug	139-148	amitriptyline	drug	235-247	false	warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram ( or = dg [ dg % ci , dg dg ] ) , druga ( or = dg [ dg % ci , dg dg ] ) , paroxetine ( or = dg [ dg % ci , dg dg ] ) , drugb ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s8	paroxetine	drug	187-196	amitriptyline	drug	235-247	false	warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram ( or = dg [ dg % ci , dg dg ] ) , fluoxetine ( or = dg [ dg % ci , dg dg ] ) , druga ( or = dg [ dg % ci , dg dg ] ) , drugb ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s9	mirtazapine	drug	5-15	warfarin	drug	57-64	effect	also druga , which is not believed to interact with drugb , increased the risk of gi bleeding ( or = dg [ dg % ci , dg dg ] ) .
DDI-MedLine.d218.s10	Warfarin	drug	0-7	citalopram	drug	29-38	effect	druga users who initiated drugb , fluoxetine , paroxetine , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	Warfarin	drug	0-7	fluoxetine	drug	41-50	effect	druga users who initiated citalopram , drugb , paroxetine , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	Warfarin	drug	0-7	paroxetine	drug	53-62	effect	druga users who initiated citalopram , fluoxetine , drugb , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	Warfarin	drug	0-7	amitriptyline	drug	65-77	effect	druga users who initiated citalopram , fluoxetine , paroxetine , drugb , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	Warfarin	drug	0-7	mirtazapine	drug	83-93	effect	druga users who initiated citalopram , fluoxetine , paroxetine , amitriptyline , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	citalopram	drug	29-38	fluoxetine	drug	41-50	false	warfarin users who initiated druga , drugb , paroxetine , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	citalopram	drug	29-38	paroxetine	drug	53-62	false	warfarin users who initiated druga , fluoxetine , drugb , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	citalopram	drug	29-38	amitriptyline	drug	65-77	false	warfarin users who initiated druga , fluoxetine , paroxetine , drugb , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	citalopram	drug	29-38	mirtazapine	drug	83-93	false	warfarin users who initiated druga , fluoxetine , paroxetine , amitriptyline , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	fluoxetine	drug	41-50	paroxetine	drug	53-62	false	warfarin users who initiated citalopram , druga , drugb , amitriptyline , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	fluoxetine	drug	41-50	amitriptyline	drug	65-77	false	warfarin users who initiated citalopram , druga , paroxetine , drugb , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	fluoxetine	drug	41-50	mirtazapine	drug	83-93	false	warfarin users who initiated citalopram , druga , paroxetine , amitriptyline , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	paroxetine	drug	53-62	amitriptyline	drug	65-77	false	warfarin users who initiated citalopram , fluoxetine , druga , drugb , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	paroxetine	drug	53-62	mirtazapine	drug	83-93	false	warfarin users who initiated citalopram , fluoxetine , druga , amitriptyline , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d218.s10	amitriptyline	drug	65-77	mirtazapine	drug	83-93	false	warfarin users who initiated citalopram , fluoxetine , paroxetine , druga , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
DDI-MedLine.d189.s3	1-aminobenzotriazole	drug_n	94-113	ABT	drug_n	116-118	false	the incubations were performed in the absence and presence of the non specific cyp inhibitor , druga ( drugb ) and isoform specific inhibitors .
DDI-MedLine.d189.s7	ABT	drug_n	0-2	precocene I	drug_n	30-40	effect	druga decreased the toxicity of drugb , increased exposure to parent compound , and decreased metabolite levels in a dose dependent manner .
DDI-MedLine.d189.s8	precocene I	drug_n	67-77	tranylcypromine	drug	104-118	false	of the isoform specific cyp inhibitors tested for an effect on the druga metabolite profile , only drugb was noticeably effective , indicating a role of cyps dg , dg , 2cl9 , and dg .
DDI-MedLine.d189.s9	ABT	drug_n	71-73	diethyldithiocarbamate	drug_n	75-96	false	with respect to toxicity , the order of cyp inhibitor effectiveness was druga > drugb ~ tranylcypromine > ketoconazole .
DDI-MedLine.d189.s9	ABT	drug_n	71-73	tranylcypromine	drug	98-112	false	with respect to toxicity , the order of cyp inhibitor effectiveness was druga > diethyldithiocarbamate ~ drugb > ketoconazole .
DDI-MedLine.d189.s9	ABT	drug_n	71-73	ketoconazole	drug	114-125	false	with respect to toxicity , the order of cyp inhibitor effectiveness was druga > diethyldithiocarbamate ~ tranylcypromine > drugb .
DDI-MedLine.d189.s9	diethyldithiocarbamate	drug_n	75-96	tranylcypromine	drug	98-112	false	with respect to toxicity , the order of cyp inhibitor effectiveness was abt > druga ~ drugb > ketoconazole .
DDI-MedLine.d189.s9	diethyldithiocarbamate	drug_n	75-96	ketoconazole	drug	114-125	false	with respect to toxicity , the order of cyp inhibitor effectiveness was abt > druga ~ tranylcypromine > drugb .
DDI-MedLine.d189.s9	tranylcypromine	drug	98-112	ketoconazole	drug	114-125	false	with respect to toxicity , the order of cyp inhibitor effectiveness was abt > diethyldithiocarbamate ~ druga > drugb .
DDI-MedLine.d189.s10	Furafylline	drug_n	0-10	sulfaphenazole	drug_n	16-29	false	druga and drugb had no effect , while quinidine appeared to augment precocene i toxicity .
DDI-MedLine.d189.s10	Furafylline	drug_n	0-10	quinidine	drug	52-60	false	druga and sulfaphenazole had no effect , while drugb appeared to augment precocene i toxicity .
DDI-MedLine.d189.s10	Furafylline	drug_n	0-10	precocene I	drug_n	82-92	false	druga and sulfaphenazole had no effect , while quinidine appeared to augment drugb toxicity .
DDI-MedLine.d189.s10	sulfaphenazole	drug_n	16-29	quinidine	drug	52-60	false	furafylline and druga had no effect , while drugb appeared to augment precocene i toxicity .
DDI-MedLine.d189.s10	sulfaphenazole	drug_n	16-29	precocene I	drug_n	82-92	false	furafylline and druga had no effect , while quinidine appeared to augment drugb toxicity .
DDI-MedLine.d189.s10	quinidine	drug	52-60	precocene I	drug_n	82-92	effect	furafylline and sulfaphenazole had no effect , while druga appeared to augment drugb toxicity .
DDI-MedLine.d189.s11	precocene I	drug_n	103-113	precocene I	drug_n	165-175	false	these results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of druga and therefore may not be an appropriate model for drugb metabolism .
DDI-MedLine.d190.s1	adeno-associated virus-2	drug_n	145-168	AAV2	drug_n	171-174	false	to determine whether the co injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of druga ( drugb ) .
DDI-MedLine.d190.s2	AAV2	drug_n	0-3	collagenase	drug_n	214-224	false	druga containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugb , hyaluronan lyase , heparinase iii , or chondroitin abc lyase .
DDI-MedLine.d190.s2	AAV2	drug_n	0-3	hyaluronan lyase	drug_n	227-242	false	druga containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , drugb , heparinase iii , or chondroitin abc lyase .
DDI-MedLine.d190.s2	AAV2	drug_n	0-3	heparinase III	drug_n	245-258	false	druga containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , hyaluronan lyase , drugb , or chondroitin abc lyase .
DDI-MedLine.d190.s2	AAV2	drug_n	0-3	chondroitin ABC lyase	drug_n	264-284	false	druga containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , hyaluronan lyase , heparinase iii , or drugb .
DDI-MedLine.d190.s2	collagenase	drug_n	214-224	hyaluronan lyase	drug_n	227-242	false	aav2 containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including druga , drugb , heparinase iii , or chondroitin abc lyase .
DDI-MedLine.d190.s2	collagenase	drug_n	214-224	heparinase III	drug_n	245-258	false	aav2 containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including druga , hyaluronan lyase , drugb , or chondroitin abc lyase .
DDI-MedLine.d190.s2	collagenase	drug_n	214-224	chondroitin ABC lyase	drug_n	264-284	false	aav2 containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including druga , hyaluronan lyase , heparinase iii , or drugb .
DDI-MedLine.d190.s2	hyaluronan lyase	drug_n	227-242	heparinase III	drug_n	245-258	false	aav2 containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , druga , drugb , or chondroitin abc lyase .
DDI-MedLine.d190.s2	hyaluronan lyase	drug_n	227-242	chondroitin ABC lyase	drug_n	264-284	false	aav2 containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , druga , heparinase iii , or drugb .
DDI-MedLine.d190.s2	heparinase III	drug_n	245-258	chondroitin ABC lyase	drug_n	264-284	false	aav2 containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase , hyaluronan lyase , druga , or drugb .
DDI-MedLine.d190.s5	heparinase III	drug_n	16-29	chondroitin ABC lyase	drug_n	34-54	false	the addition of druga or drugb greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina .
DDI-MedLine.d190.s6	Hyaluronan lyase	drug_n	0-15	collagenase	drug_n	42-52	false	druga had a limited effect and drugb was ineffective .
DDI-MedLine.d190.s7	heparinase III	drug_n	58-71	chondroitin ABC lyase	drug_n	77-97	false	electroretinograms survived with higher concentrations of druga and drugb than were required for optimal retinal transduction .
DDI-MedLine.d190.s8	AAV2	drug_n	0-3	heparinase III	drug_n	66-79	effect	druga mediated retinal transduction is improved by co injection of drugb or chondroitin abc lyase .
DDI-MedLine.d190.s8	AAV2	drug_n	0-3	chondroitin ABC lyase	drug_n	84-104	effect	druga mediated retinal transduction is improved by co injection of heparinase iii or drugb .
DDI-MedLine.d190.s8	heparinase III	drug_n	66-79	chondroitin ABC lyase	drug_n	84-104	false	aav2 mediated retinal transduction is improved by co injection of druga or drugb .
DDI-MedLine.d199.s0	ketamine	drug	71-78	propofol	drug	84-91	false	prevention of emergence agitation in seven children receiving low dose druga and drugb total intravenous anesthesia .
DDI-MedLine.d199.s2	ketamine	drug	95-102	propofol	drug	124-131	false	we retrospectively reviewed the records of dg pediatric oncology patients who received low dose druga in conjunction with drugb for total intravenous anesthesia ( tiva ) repeatedly for radiation therapy .
DDI-MedLine.d199.s3	propofol	drug	61-68	ketamine	drug	161-168	false	ea signs were observed in all dg patients in association with druga tiva but did not recur in any of dg subsequent anesthetics sessions during which low dose drugb was added to propofol .
DDI-MedLine.d199.s3	propofol	drug	61-68	propofol	drug	183-190	false	ea signs were observed in all dg patients in association with druga tiva but did not recur in any of dg subsequent anesthetics sessions during which low dose ketamine was added to drugb .
DDI-MedLine.d199.s3	ketamine	drug	161-168	propofol	drug	183-190	false	ea signs were observed in all dg patients in association with propofol tiva but did not recur in any of dg subsequent anesthetics sessions during which low dose druga was added to drugb .
DDI-MedLine.d199.s4	ketamine	drug	51-58	propofol	drug	69-76	effect	based on this experience , we suggest that low dose druga added to drugb may be associated with prevention of ea in children with a history of ea with propofol tiva .
DDI-MedLine.d199.s4	ketamine	drug	51-58	propofol	drug	156-163	false	based on this experience , we suggest that low dose druga added to propofol may be associated with prevention of ea in children with a history of ea with drugb tiva .
DDI-MedLine.d199.s4	propofol	drug	69-76	propofol	drug	156-163	false	based on this experience , we suggest that low dose ketamine added to druga may be associated with prevention of ea in children with a history of ea with drugb tiva .
DDI-MedLine.d209.s1	Tamoxifen	drug	0-8	estrogen antagonist	group	14-32	false	druga , an drugb , is the standard hormone treatment for breast cancer .
DDI-MedLine.d209.s5	Paroxetine	drug	0-9	fluoxetine	drug	15-24	false	druga and drugb reduce the plasma concentration of endoxifen by about dg % .
DDI-MedLine.d209.s5	Paroxetine	drug	0-9	endoxifen	drug_n	61-69	mechanism	druga and fluoxetine reduce the plasma concentration of drugb by about dg % .
DDI-MedLine.d209.s5	fluoxetine	drug	15-24	endoxifen	drug_n	61-69	mechanism	paroxetine and druga reduce the plasma concentration of drugb by about dg % .
DDI-MedLine.d209.s9	tamoxifen	drug	85-93	SSRI antidepressants	group	125-144	advise	it is better to avoid prescribing isoenzyme cyp dg inhibitors to women treated with druga for breast cancer , especially drugb such as paroxetine and fluoxetine .
DDI-MedLine.d209.s9	tamoxifen	drug	85-93	paroxetine	drug	154-163	advise	it is better to avoid prescribing isoenzyme cyp dg inhibitors to women treated with druga for breast cancer , especially ssri antidepressants such as drugb and fluoxetine .
DDI-MedLine.d209.s9	tamoxifen	drug	85-93	fluoxetine	drug	169-178	advise	it is better to avoid prescribing isoenzyme cyp dg inhibitors to women treated with druga for breast cancer , especially ssri antidepressants such as paroxetine and drugb .
DDI-MedLine.d209.s9	SSRI antidepressants	group	125-144	paroxetine	drug	154-163	false	it is better to avoid prescribing isoenzyme cyp dg inhibitors to women treated with tamoxifen for breast cancer , especially druga such as drugb and fluoxetine .
DDI-MedLine.d209.s9	SSRI antidepressants	group	125-144	fluoxetine	drug	169-178	false	it is better to avoid prescribing isoenzyme cyp dg inhibitors to women treated with tamoxifen for breast cancer , especially druga such as paroxetine and drugb .
DDI-MedLine.d209.s9	paroxetine	drug	154-163	fluoxetine	drug	169-178	false	it is better to avoid prescribing isoenzyme cyp dg inhibitors to women treated with tamoxifen for breast cancer , especially ssri antidepressants such as druga and drugb .
DDI-MedLine.d209.s10	antidepressant drug	group	35-53	antidepressants	group	68-82	false	depression does not always require druga therapy , and drugb have no proven preventive impact on hot flushes linked to the menopause .
DDI-MedLine.d209.s11	antidepressant	group	24-37	tamoxifen	drug	95-103	advise	if in certain cases , an druga is considered necessary , it may be advisable to replace drugb with anastrozole .
DDI-MedLine.d209.s11	antidepressant	group	24-37	anastrozole	drug	110-120	false	if in certain cases , an druga is considered necessary , it may be advisable to replace tamoxifen with drugb .
DDI-MedLine.d209.s11	tamoxifen	drug	95-103	anastrozole	drug	110-120	false	if in certain cases , an antidepressant is considered necessary , it may be advisable to replace druga with drugb .
DDI-MedLine.d184.s0	Amphetamine	drug	0-10	quinpirole	drug_n	128-137	false	druga locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with drugb .
DDI-MedLine.d184.s2	quinpirole	drug_n	53-62	amphetamine	drug	88-98	false	the objective was to analyze the effects of neonatal druga treatment on effects of drugb in adolescent rats using locomotor sensitization and conditioned place preference procedures .
DDI-MedLine.d184.s5	quinpirole	drug_n	25-34	amphetamine	drug	55-65	effect	in female rats , neonatal druga treatment enhanced drugb locomotor sensitization compared with quinpirole free controls sensitized to amphetamine .
DDI-MedLine.d184.s5	quinpirole	drug_n	25-34	quinpirole	drug_n	105-114	false	in female rats , neonatal druga treatment enhanced amphetamine locomotor sensitization compared with drugb free controls sensitized to amphetamine .
DDI-MedLine.d184.s5	quinpirole	drug_n	25-34	amphetamine	drug	144-154	false	in female rats , neonatal druga treatment enhanced amphetamine locomotor sensitization compared with quinpirole free controls sensitized to drugb .
DDI-MedLine.d184.s5	amphetamine	drug	55-65	quinpirole	drug_n	105-114	false	in female rats , neonatal quinpirole treatment enhanced druga locomotor sensitization compared with drugb free controls sensitized to amphetamine .
DDI-MedLine.d184.s5	amphetamine	drug	55-65	amphetamine	drug	144-154	false	in female rats , neonatal quinpirole treatment enhanced druga locomotor sensitization compared with quinpirole free controls sensitized to drugb .
DDI-MedLine.d184.s5	quinpirole	drug_n	105-114	amphetamine	drug	144-154	false	in female rats , neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with druga free controls sensitized to drugb .
DDI-MedLine.d184.s6	amphetamine	drug	40-50	quinpirole	drug_n	136-145	false	male rats demonstrated sensitization to druga , although this was muted compared with female rats , and were unaffected by neonatal drugb .
DDI-MedLine.d184.s8	quinpirole	drug_n	27-36	amphetamine	drug	65-75	false	rats treated with neonatal druga enhanced time spent in the drugb paired context compared with quinpirole free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d184.s8	quinpirole	drug_n	27-36	quinpirole	drug_n	106-115	false	rats treated with neonatal druga enhanced time spent in the amphetamine paired context compared with drugb free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d184.s8	quinpirole	drug_n	27-36	amphetamine	drug	148-158	false	rats treated with neonatal druga enhanced time spent in the amphetamine paired context compared with quinpirole free controls conditioned with drugb , but only female controls conditioned with amphetamine spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d184.s8	quinpirole	drug_n	27-36	amphetamine	drug	203-213	false	rats treated with neonatal druga enhanced time spent in the amphetamine paired context compared with quinpirole free controls conditioned with amphetamine , but only female controls conditioned with drugb spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d184.s8	amphetamine	drug	65-75	quinpirole	drug_n	106-115	false	rats treated with neonatal quinpirole enhanced time spent in the druga paired context compared with drugb free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d184.s8	amphetamine	drug	65-75	amphetamine	drug	148-158	false	rats treated with neonatal quinpirole enhanced time spent in the druga paired context compared with quinpirole free controls conditioned with drugb , but only female controls conditioned with amphetamine spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d184.s8	amphetamine	drug	65-75	amphetamine	drug	203-213	false	rats treated with neonatal quinpirole enhanced time spent in the druga paired context compared with quinpirole free controls conditioned with amphetamine , but only female controls conditioned with drugb spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d184.s8	quinpirole	drug_n	106-115	amphetamine	drug	148-158	false	rats treated with neonatal quinpirole enhanced time spent in the amphetamine paired context compared with druga free controls conditioned with drugb , but only female controls conditioned with amphetamine spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d184.s8	quinpirole	drug_n	106-115	amphetamine	drug	203-213	false	rats treated with neonatal quinpirole enhanced time spent in the amphetamine paired context compared with druga free controls conditioned with amphetamine , but only female controls conditioned with drugb spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d184.s8	amphetamine	drug	148-158	amphetamine	drug	203-213	false	rats treated with neonatal quinpirole enhanced time spent in the amphetamine paired context compared with quinpirole free controls conditioned with druga , but only female controls conditioned with drugb spent more time in the drug paired context compared with saline treated controls .
DDI-MedLine.d213.s0	cyclosporine	drug	49-60	tacrolimus	drug	87-96	false	in vivo cyp3a activity is significantly lower in druga treated as compared with drugb treated renal allograft recipients .
DDI-MedLine.d213.s1	cyclosporine	drug	33-44	tacrolimus	drug	50-59	false	in vitro studies have identified druga and drugb as cyp3a inhibitors .
DDI-MedLine.d213.s3	midazolam	drug	27-35	cyclosporine	drug	181-192	mechanism	systemic and apparent oral druga clearance were dg % ( dg dg vs. dg dg ml / min , p = dg ) and dg % ( dg dg vs. dg dg ml / min , p = dg ) , respectively , lower in drugb treated patients ( n = dg ) than in matched tacrolimus treated patients ( n = dg ) .
DDI-MedLine.d213.s3	midazolam	drug	27-35	tacrolimus	drug	236-245	false	systemic and apparent oral druga clearance were dg % ( dg dg vs. dg dg ml / min , p = dg ) and dg % ( dg dg vs. dg dg ml / min , p = dg ) , respectively , lower in cyclosporine treated patients ( n = dg ) than in matched drugb treated patients ( n = dg ) .
DDI-MedLine.d213.s3	cyclosporine	drug	181-192	tacrolimus	drug	236-245	false	systemic and apparent oral midazolam clearance were dg % ( dg dg vs. dg dg ml / min , p = dg ) and dg % ( dg dg vs. dg dg ml / min , p = dg ) , respectively , lower in druga treated patients ( n = dg ) than in matched drugb treated patients ( n = dg ) .
DDI-MedLine.d213.s4	midazolam	drug	21-29	tacrolimus	drug	95-104	false	the latter displayed druga clearances similar to those in two larger cohorts of nonmatched drugb treated patients ( n = dg and n = dg ) and to those receiving a calcineurin inhibitor free regimen ( n = dg ) .
DDI-MedLine.d213.s4	midazolam	drug	21-29	calcineurin inhibitor	group	168-188	false	the latter displayed druga clearances similar to those in two larger cohorts of nonmatched tacrolimus treated patients ( n = dg and n = dg ) and to those receiving a drugb free regimen ( n = dg ) .
DDI-MedLine.d213.s4	tacrolimus	drug	95-104	calcineurin inhibitor	group	168-188	false	the latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched druga treated patients ( n = dg and n = dg ) and to those receiving a drugb free regimen ( n = dg ) .
DDI-MedLine.d213.s5	cyclosporine	drug	112-123	tacrolimus	drug	149-158	false	this implies that in vivo hepatic and first pass cyp3a activities are significantly lower in patients receiving druga than in those receiving drugb , indicating that , at the doses generally used in clinical practice , cyclosporine is the stronger of the two with respect to cyp3a inhibition .
DDI-MedLine.d213.s5	cyclosporine	drug	112-123	cyclosporine	drug	228-239	false	this implies that in vivo hepatic and first pass cyp3a activities are significantly lower in patients receiving druga than in those receiving tacrolimus , indicating that , at the doses generally used in clinical practice , drugb is the stronger of the two with respect to cyp3a inhibition .
DDI-MedLine.d213.s5	tacrolimus	drug	149-158	cyclosporine	drug	228-239	false	this implies that in vivo hepatic and first pass cyp3a activities are significantly lower in patients receiving cyclosporine than in those receiving druga , indicating that , at the doses generally used in clinical practice , drugb is the stronger of the two with respect to cyp3a inhibition .
DDI-MedLine.d166.s0	cinacalcet	drug	40-49	darbepoetin	drug	83-93	false	improved parathyroid hormone control by druga is associated with reduction in drugb requirement in patients with end stage renal disease .
DDI-MedLine.d166.s1	erythropoietin	drug	75-88	EPO	drug	91-93	false	uncontrolled hy per parathyroidism causes bone marrow fibrosis , leading to druga ( drugb ) resistance .
DDI-MedLine.d166.s2	cinacalcet	drug	23-32	darbepoetin	drug	118-128	false	medical treatment with druga is effective in reducing plasma parathyroid hormone ( pth ) levels , but its effect on drugb dosing is unknown .
DDI-MedLine.d166.s6	darbepoetin	drug	70-80	cinacalcet	drug	127-136	false	the primary objective of the study was to ascertain the difference in druga responsiveness before and after dg months of drugb therapy .
DDI-MedLine.d166.s17	cinacalcet	drug	20-29	darbepoetin	drug	64-74	effect	reduction of pth by druga is associated with a decrease in drugb requirement .
DDI-MedLine.d217.s0	celecoxib	drug	15-23	anti-cancer drugs	group	40-56	effect	interaction of druga with different drugb is antagonistic in breast but not in other cancer cells .
DDI-MedLine.d217.s2	cyclooxygenase-2 inhibitors	group	39-65	chemotherapeutic agents	group	120-142	false	this study investigates the ability of druga to sensitize cells from different origins to several drugb .
DDI-MedLine.d217.s4	5-FU	drug	130-133	cisplatin	drug	136-144	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to druga , drugb , doxorubicin and etoposide celecoxib following different incubation schedules were analyzed .
DDI-MedLine.d217.s4	5-FU	drug	130-133	doxorubicin	drug	147-157	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to druga , cisplatin , drugb and etoposide celecoxib following different incubation schedules were analyzed .
DDI-MedLine.d217.s4	5-FU	drug	130-133	etoposide	drug	163-171	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to druga , cisplatin , doxorubicin and drugb celecoxib following different incubation schedules were analyzed .
DDI-MedLine.d217.s4	5-FU	drug	130-133	celecoxib	drug	175-183	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to druga , cisplatin , doxorubicin and etoposide drugb following different incubation schedules were analyzed .
DDI-MedLine.d217.s4	cisplatin	drug	136-144	doxorubicin	drug	147-157	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to dg fu , druga , drugb and etoposide celecoxib following different incubation schedules were analyzed .
DDI-MedLine.d217.s4	cisplatin	drug	136-144	etoposide	drug	163-171	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to dg fu , druga , doxorubicin and drugb celecoxib following different incubation schedules were analyzed .
DDI-MedLine.d217.s4	cisplatin	drug	136-144	celecoxib	drug	175-183	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to dg fu , druga , doxorubicin and etoposide drugb following different incubation schedules were analyzed .
DDI-MedLine.d217.s4	doxorubicin	drug	147-157	etoposide	drug	163-171	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to dg fu , cisplatin , druga and drugb celecoxib following different incubation schedules were analyzed .
DDI-MedLine.d217.s4	doxorubicin	drug	147-157	celecoxib	drug	175-183	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to dg fu , cisplatin , druga and etoposide drugb following different incubation schedules were analyzed .
DDI-MedLine.d217.s4	etoposide	drug	163-171	celecoxib	drug	175-183	false	the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to dg fu , cisplatin , doxorubicin and druga drugb following different incubation schedules were analyzed .
DDI-MedLine.d217.s5	celecoxib	drug	28-36	celecoxib	drug	136-144	false	we found antagonism between druga and the four drugs in the breast cancer cells mcf7 following all incubation schedules and between drugb and doxorubicin in all cell lines except for two combinations in hct116 cells .
DDI-MedLine.d217.s5	celecoxib	drug	28-36	doxorubicin	drug	150-160	false	we found antagonism between druga and the four drugs in the breast cancer cells mcf7 following all incubation schedules and between celecoxib and drugb in all cell lines except for two combinations in hct116 cells .
DDI-MedLine.d217.s5	celecoxib	drug	136-144	doxorubicin	drug	150-160	effect	we found antagonism between celecoxib and the four drugs in the breast cancer cells mcf7 following all incubation schedules and between druga and drugb in all cell lines except for two combinations in hct116 cells .
DDI-MedLine.d217.s11	celecoxib	drug	51-59	doxorubicin	drug	121-131	false	these results , if confirmed in vivo , indicate that druga is not a suitable chemosensitizer for breast cancer or with drugb for other cancers .
DDI-MedLine.d143.s0	clopidogrel	drug	21-31	proton pump inhibitors	group	37-58	false	[ interaction between druga and drugb ] .
DDI-MedLine.d143.s1	proton pump inhibitors	group	29-50	clopidogrel	drug	56-66	false	the drug interaction between druga and drugb has been the subject of much study in recent years .
DDI-MedLine.d143.s2	proton pump inhibitors	group	46-67	clopidogrel	drug	119-129	false	contradictory results regarding the effect of druga on platelet reactivity and on clinical outcome in drugb treated patients have been reported in literature .
DDI-MedLine.d143.s3	omeprazole	drug	19-28	clopidogrel	drug	34-44	mechanism	concomitant use of druga and drugb was found to decrease the exposure ( auc ) to clopidogrel 's active metabolite by dg % and to sharply increase platelet reactivity , as a result of inhibition by omeprazole of cyp2c19 , a cytochrome p450 ( cyp ) enzyme .
DDI-MedLine.d143.s3	omeprazole	drug	19-28	omeprazole	drug	203-212	false	concomitant use of druga and clopidogrel was found to decrease the exposure ( auc ) to clopidogrel 's active metabolite by dg % and to sharply increase platelet reactivity , as a result of inhibition by drugb of cyp2c19 , a cytochrome p450 ( cyp ) enzyme .
DDI-MedLine.d143.s3	clopidogrel	drug	34-44	omeprazole	drug	203-212	false	concomitant use of omeprazole and druga was found to decrease the exposure ( auc ) to clopidogrel 's active metabolite by dg % and to sharply increase platelet reactivity , as a result of inhibition by drugb of cyp2c19 , a cytochrome p450 ( cyp ) enzyme .
DDI-MedLine.d143.s4	Pantoprazole	drug	0-11	clopidogrel	drug	41-51	mechanism	druga has a much weaker effect on drugb 's pharmacokinetics and on platelet reactivity during concomitant use .
DDI-MedLine.d143.s5	proton pump inhibitors	group	27-48	clopidogrel	drug	80-90	false	the influence of the other druga when used simultaneously with drugb has not yet been investigated in adequately randomized studies .
DDI-MedLine.d143.s6	clopidogrel	drug	50-60	omeprazole	drug	89-98	advise	regulatory agencies state that the combination of druga and the cyp2c19 inhibitors drugb and esomeprazole should be avoided .
DDI-MedLine.d143.s6	clopidogrel	drug	50-60	esomeprazole	drug	104-115	advise	regulatory agencies state that the combination of druga and the cyp2c19 inhibitors omeprazole and drugb should be avoided .
DDI-MedLine.d143.s6	omeprazole	drug	89-98	esomeprazole	drug	104-115	false	regulatory agencies state that the combination of clopidogrel and the cyp2c19 inhibitors druga and drugb should be avoided .
DDI-MedLine.d143.s7	proton pump inhibitors	group	97-118	clopidogrel	drug	124-134	false	to date , there is no conclusive evidence of a clinically relevant interaction between any of the druga and drugb .
DDI-MedLine.d163.s0	minocycline	drug	21-31	fosfomycin	drug	47-56	false	in vitro activity of druga combined with drugb against clinical isolates of methicillin resistant staphylococcus aureus .
DDI-MedLine.d163.s0	minocycline	drug	21-31	methicillin	drug	87-97	false	in vitro activity of druga combined with fosfomycin against clinical isolates of drugb resistant staphylococcus aureus .
DDI-MedLine.d163.s0	fosfomycin	drug	47-56	methicillin	drug	87-97	false	in vitro activity of minocycline combined with druga against clinical isolates of drugb resistant staphylococcus aureus .
DDI-MedLine.d163.s1	minocycline	drug	54-64	fosfomycin	drug	80-89	false	this study aimed to evaluate the in vitro activity of druga combined with drugb against isolates of methicillin resistant staphylococcus aureus ( mrsa ) .
DDI-MedLine.d163.s1	minocycline	drug	54-64	methicillin	drug	111-121	false	this study aimed to evaluate the in vitro activity of druga combined with fosfomycin against isolates of drugb resistant staphylococcus aureus ( mrsa ) .
DDI-MedLine.d163.s1	fosfomycin	drug	80-89	methicillin	drug	111-121	false	this study aimed to evaluate the in vitro activity of minocycline combined with druga against isolates of drugb resistant staphylococcus aureus ( mrsa ) .
DDI-MedLine.d163.s4	minocycline	drug	31-41	fosfomycin	drug	47-56	false	the susceptibility results for druga and drugb were interpreted according to the most relevant criteria .
DDI-MedLine.d163.s7	minocycline	drug	19-29	fosfomycin	drug	35-44	effect	the combination of druga and drugb can be synergistic against mrsa .
DDI-MedLine.d181.s4	levothyroxine	drug	85-97	simeticone	drug	148-157	int	the authors report the case of an infant with confirmed congenital hypothyroidism on druga who experienced a possible drug interaction with drugb .
DDI-MedLine.d181.s6	Infacol	brand	42-48	levothyroxine	drug	78-90	false	questioning revealed the child was taking druga drops before feeds while on drugb .
DDI-MedLine.d181.s8	thyroxine	drug	20-28	simeticone	drug	35-44	false	drug interaction of druga with drugb has not been reported previously and is not listed in the british national formulary for children .
DDI-MedLine.d169.s0	Calcium	drug	0-6	heme iron	drug	70-78	false	druga does not inhibit the absorption of dg milligrams of nonheme or drugb at doses less than dg milligrams in nonpregnant women .
DDI-MedLine.d169.s1	Calcium	drug	0-6	heme iron	drug	95-103	mechanism	druga is the only known component in the diet that may affect absorption of both nonheme and drugb .
DDI-MedLine.d169.s2	calcium	drug	28-34	iron	drug	46-49	mechanism	however , the evidence for a druga effect on drugb absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components , because it was detected in single meal studies .
DDI-MedLine.d169.s2	calcium	drug	28-34	calcium	drug	123-129	false	however , the evidence for a druga effect on iron absorption mainly comes from studies that did not isolate the effect of drugb from that of other dietary components , because it was detected in single meal studies .
DDI-MedLine.d169.s2	iron	drug	46-49	calcium	drug	123-129	false	however , the evidence for a calcium effect on druga absorption mainly comes from studies that did not isolate the effect of drugb from that of other dietary components , because it was detected in single meal studies .
DDI-MedLine.d169.s3	calcium	drug	52-58	heme iron	drug	89-97	false	our objective was to establish potential effects of druga on absorption of nonheme and drugb and the dose response for this effect in the absence of a meal .
DDI-MedLine.d169.s5	calcium	drug	28-34	nonheme iron	drug	88-99	false	we evaluated the effects of druga doses between dg and dg mg on absorption of dg mg drugb ( as ferrous sulfate ) .
DDI-MedLine.d169.s5	calcium	drug	28-34	ferrous sulfate	drug	105-119	false	we evaluated the effects of druga doses between dg and dg mg on absorption of dg mg nonheme iron ( as drugb ) .
DDI-MedLine.d169.s5	nonheme iron	drug	88-99	ferrous sulfate	drug	105-119	false	we evaluated the effects of calcium doses between dg and dg mg on absorption of dg mg druga ( as drugb ) .
DDI-MedLine.d169.s6	calcium	drug	33-39	heme iron	drug	92-100	false	we also evaluated the effects of druga doses between dg and dg mg on absorption of dg mg drugb [ as concentrated rbc ( crbc ) ] .
DDI-MedLine.d169.s7	Calcium	drug	0-6	calcium chloride	drug	28-43	false	druga was administered as drugb in all studies and minerals were ingested on an empty stomach .
DDI-MedLine.d169.s7	Calcium	drug	0-6	minerals	group	64-71	false	druga was administered as calcium chloride in all studies and drugb were ingested on an empty stomach .
DDI-MedLine.d169.s7	calcium chloride	drug	28-43	minerals	group	64-71	false	calcium was administered as druga in all studies and drugb were ingested on an empty stomach .
DDI-MedLine.d169.s8	Calcium	drug	0-6	nonheme iron	drug	35-46	mechanism	druga doses dg mg diminished drugb absorption by an average of dg % .
DDI-MedLine.d169.s9	calcium	drug	2-8	heme iron	drug	55-63	mechanism	a druga dose of dg mg diminished absorption of dg mg drugb by dg % .
DDI-MedLine.d179.s0	sunitinib	drug	32-40	docetaxel	drug	46-54	int	synergistic interaction between druga and drugb is sequence dependent in human non small lung cancer with egfr tkis resistant mutation .
DDI-MedLine.d179.s2	sunitinib	drug	66-74	sunitinib	drug	131-139	false	this study was aimed to investigate the efficacy of single use of druga and that of concurrent or sequential administration of drugb and docetaxel in nsclc cell lines that are resistant to egfr tkis .
DDI-MedLine.d179.s2	sunitinib	drug	66-74	docetaxel	drug	145-153	false	this study was aimed to investigate the efficacy of single use of druga and that of concurrent or sequential administration of sunitinib and drugb in nsclc cell lines that are resistant to egfr tkis .
DDI-MedLine.d179.s2	sunitinib	drug	131-139	docetaxel	drug	145-153	false	this study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of druga and drugb in nsclc cell lines that are resistant to egfr tkis .
DDI-MedLine.d179.s3	sunitinib	drug	84-92	docetaxel	drug	97-105	false	nsclc cell lines with egfr t790m mutation and k ras mutation were exposed to either druga or drugb or both based on various sequential administrations .
DDI-MedLine.d179.s5	Sunitinib	drug	0-8	docetaxel	drug	118-126	false	druga exhibited dose dependent growth inhibition in nsclc cell lines and arrested cell cycle at g1 phase , whereas drugb arrested at s phase .
DDI-MedLine.d179.s6	sunitinib	drug	37-45	docetaxel	drug	51-59	effect	although single or concurrent use of druga and drugb has some anti proliferative effects , the sequential administrations of both drugs remarkably enhanced anti tumor activity .
DDI-MedLine.d179.s7	docetaxel	drug	27-35	sunitinib	drug	49-57	effect	when cells were exposed to druga followed by drugb , synergism was observed .
DDI-MedLine.d179.s8	docetaxel	drug	102-110	sunitinib	drug	179-187	effect	the molecular basis of this synergism is that the signaling pathways that were initially activated by druga exposure were efficiently suppressed by the subsequent exposure to drugb .
DDI-MedLine.d179.s10	Sunitinib	drug	0-8	docetaxel	drug	166-174	false	druga as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of drugb followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration .
DDI-MedLine.d179.s10	Sunitinib	drug	0-8	sunitinib	drug	188-196	false	druga as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of docetaxel followed by drugb is superior to sunitinib followed by docetaxel and concurrent administration .
DDI-MedLine.d179.s10	Sunitinib	drug	0-8	sunitinib	drug	213-221	false	druga as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to drugb followed by docetaxel and concurrent administration .
DDI-MedLine.d179.s10	Sunitinib	drug	0-8	docetaxel	drug	235-243	false	druga as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by drugb and concurrent administration .
DDI-MedLine.d179.s10	docetaxel	drug	166-174	sunitinib	drug	188-196	effect	sunitinib as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of druga followed by drugb is superior to sunitinib followed by docetaxel and concurrent administration .
DDI-MedLine.d179.s10	docetaxel	drug	166-174	sunitinib	drug	213-221	false	sunitinib as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of druga followed by sunitinib is superior to drugb followed by docetaxel and concurrent administration .
DDI-MedLine.d179.s10	docetaxel	drug	166-174	docetaxel	drug	235-243	false	sunitinib as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of druga followed by sunitinib is superior to sunitinib followed by drugb and concurrent administration .
DDI-MedLine.d179.s10	sunitinib	drug	188-196	sunitinib	drug	213-221	false	sunitinib as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of docetaxel followed by druga is superior to drugb followed by docetaxel and concurrent administration .
DDI-MedLine.d179.s10	sunitinib	drug	188-196	docetaxel	drug	235-243	false	sunitinib as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of docetaxel followed by druga is superior to sunitinib followed by drugb and concurrent administration .
DDI-MedLine.d179.s10	sunitinib	drug	213-221	docetaxel	drug	235-243	false	sunitinib as a single agent exhibits anti proliferative effects in vitro in nsclc cell lines with egfr t790m and k ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to druga followed by drugb and concurrent administration .
DDI-MedLine.d204.s0	piperacillin	drug	31-42	methylglyoxal	drug_n	48-60	false	distinct synergistic action of druga and drugb against pseudomonas aeruginosa .
DDI-MedLine.d204.s7	piperacillin	drug	84-95	carbenicillin	drug	98-110	false	results revealed that the strains were resistant to many drugs at high levels , only druga , drugb , amikacin and ciprofloxacin showed resistances at comparatively lower levels .
DDI-MedLine.d204.s7	piperacillin	drug	84-95	amikacin	drug	113-120	false	results revealed that the strains were resistant to many drugs at high levels , only druga , carbenicillin , drugb and ciprofloxacin showed resistances at comparatively lower levels .
DDI-MedLine.d204.s7	piperacillin	drug	84-95	ciprofloxacin	drug	126-138	false	results revealed that the strains were resistant to many drugs at high levels , only druga , carbenicillin , amikacin and drugb showed resistances at comparatively lower levels .
DDI-MedLine.d204.s7	carbenicillin	drug	98-110	amikacin	drug	113-120	false	results revealed that the strains were resistant to many drugs at high levels , only piperacillin , druga , drugb and ciprofloxacin showed resistances at comparatively lower levels .
DDI-MedLine.d204.s7	carbenicillin	drug	98-110	ciprofloxacin	drug	126-138	false	results revealed that the strains were resistant to many drugs at high levels , only piperacillin , druga , amikacin and drugb showed resistances at comparatively lower levels .
DDI-MedLine.d204.s7	amikacin	drug	113-120	ciprofloxacin	drug	126-138	false	results revealed that the strains were resistant to many drugs at high levels , only piperacillin , carbenicillin , druga and drugb showed resistances at comparatively lower levels .
DDI-MedLine.d204.s9	methylglyoxal	drug_n	70-82	piperacillin	drug	88-99	effect	distinct and statistically significant synergism was observed between druga and drugb by disc diffusion tests when compared with their individual effects .
DDI-MedLine.d204.s11	methylglyoxal	drug_n	30-42	carbenicillin	drug	62-74	effect	synergism was also noted when druga was combined with drugb and amikacin .
DDI-MedLine.d204.s11	methylglyoxal	drug_n	30-42	amikacin	drug	80-87	effect	synergism was also noted when druga was combined with carbenicillin and drugb .
DDI-MedLine.d204.s11	carbenicillin	drug	62-74	amikacin	drug	80-87	false	synergism was also noted when methylglyoxal was combined with druga and drugb .
DDI-MedLine.d159.s0	acetyl-l-carnitine	drug	21-38	alpha lipoic acid	drug_n	45-61	false	protective effect of druga and drugb against the acute toxicity of diepoxybutane to human lymphocytes .
DDI-MedLine.d159.s6	acetyl-l-carnitine	drug	5-22	alpha-lipoic acid	drug	115-131	effect	( ii ) druga elicits a significant protective effect on deb induced toxicity , which was potentiated by drugb .
DDI-MedLine.d214.s0	hemantane	drug_n	14-22	doxycycline	drug	28-38	false	[ influence of druga and drugb on mptp evoked behavior violations in c57bl / dg mice ] .
DDI-MedLine.d214.s1	anti-parkinsonian drug	group	15-36	hemantane	drug_n	38-46	false	the effects of druga drugb [ ( dg adamantyl ) hexamethylenimine ] ( dg mg / kg , p. o . )
DDI-MedLine.d214.s1	anti-parkinsonian drug	group	15-36	(2-adamantyl)hexamethylenimine	drug_n	49-78	false	the effects of druga hemantane [ drugb ] ( dg mg / kg , p. o . )
DDI-MedLine.d214.s1	hemantane	drug_n	38-46	(2-adamantyl)hexamethylenimine	drug_n	49-78	false	the effects of anti parkinsonian drug druga [ drugb ] ( dg mg / kg , p. o . )
DDI-MedLine.d214.s2	antibiotic drug	group	7-21	doxycycline	drug	23-33	false	and / or druga drugb ( dg mg / kg , p. o. ) , as well as that of neurotoxin dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine ( mptp ) ( dg x dg mg / kg , i. p . )
DDI-MedLine.d214.s2	antibiotic drug	group	7-21	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	drug_n	85-128	false	and / or druga doxycycline ( dg mg / kg , p. o. ) , as well as that of neurotoxin drugb ( mptp ) ( dg x dg mg / kg , i. p . )
DDI-MedLine.d214.s2	antibiotic drug	group	7-21	MPTP	drug_n	131-134	false	and / or druga doxycycline ( dg mg / kg , p. o. ) , as well as that of neurotoxin dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine ( drugb ) ( dg x dg mg / kg , i. p . )
DDI-MedLine.d214.s2	doxycycline	drug	23-33	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	drug_n	85-128	false	and / or antibiotic drug druga ( dg mg / kg , p. o. ) , as well as that of neurotoxin drugb ( mptp ) ( dg x dg mg / kg , i. p . )
DDI-MedLine.d214.s2	doxycycline	drug	23-33	MPTP	drug_n	131-134	false	and / or antibiotic drug druga ( dg mg / kg , p. o. ) , as well as that of neurotoxin dg methyl dg phenyl dg , dg , dg , dg tetrahydropyridine ( drugb ) ( dg x dg mg / kg , i. p . )
DDI-MedLine.d214.s2	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	drug_n	85-128	MPTP	drug_n	131-134	false	and / or antibiotic drug doxycycline ( dg mg / kg , p. o. ) , as well as that of neurotoxin druga ( drugb ) ( dg x dg mg / kg , i. p . )
DDI-MedLine.d214.s5	hemantane	drug_n	24-32	doxycycline	drug	37-47	effect	acute administration of druga or drugb failed to influence locomotion in mice , while their combination normalized motor activity .
DDI-MedLine.d194.s0	dasatinib	drug	25-33	paclitaxel	drug	44-53	effect	the role of p27 ( kip1 ) in druga enhanced drugb cytotoxicity in human ovarian cancer cells .
DDI-MedLine.d194.s4	dasatinib	drug	14-22	paclitaxel	drug	65-74	false	the effect of druga , an inhibitor of src and abl kinases , on drugb sensitivity was measured in ovarian cancer cells and hey xenografts .
DDI-MedLine.d194.s5	dasatinib	drug	64-72	paclitaxel	drug	78-87	false	the roles of p27 ( kip1 ) , bcl dg , and cdk1 in apoptosis induced by druga and drugb were assessed using a terminal deoxynucleotidyl transferase mediated dutp nick end labeling ( tunel ) assay , sirna knockdown of gene expression , transfection with bcl dg and cdk1 expression vectors , and flow cytometry .
DDI-MedLine.d194.s9	dasatinib	drug	23-31	paclitaxel	drug	38-47	effect	hey cells treated with druga plus drugb formed fewer colonies than did cells treated with either agent alone .
DDI-MedLine.d194.s10	dasatinib	drug	45-53	paclitaxel	drug	60-69	effect	treatment of hey xenograft bearing mice with druga plus drugb inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , dasatinib + paclitaxel vs paclitaxel : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s10	dasatinib	drug	45-53	dasatinib	drug	171-179	false	treatment of hey xenograft bearing mice with druga plus paclitaxel inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugb + paclitaxel vs paclitaxel : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s10	dasatinib	drug	45-53	paclitaxel	drug	183-192	false	treatment of hey xenograft bearing mice with druga plus paclitaxel inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , dasatinib + drugb vs paclitaxel : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s10	dasatinib	drug	45-53	paclitaxel	drug	197-206	false	treatment of hey xenograft bearing mice with druga plus paclitaxel inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , dasatinib + paclitaxel vs drugb : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s10	paclitaxel	drug	60-69	dasatinib	drug	171-179	false	treatment of hey xenograft bearing mice with dasatinib plus druga inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugb + paclitaxel vs paclitaxel : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s10	paclitaxel	drug	60-69	paclitaxel	drug	183-192	false	treatment of hey xenograft bearing mice with dasatinib plus druga inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , dasatinib + drugb vs paclitaxel : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s10	paclitaxel	drug	60-69	paclitaxel	drug	197-206	false	treatment of hey xenograft bearing mice with dasatinib plus druga inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , dasatinib + paclitaxel vs drugb : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s10	dasatinib	drug	171-179	paclitaxel	drug	183-192	false	treatment of hey xenograft bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , druga + drugb vs paclitaxel : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s10	dasatinib	drug	171-179	paclitaxel	drug	197-206	false	treatment of hey xenograft bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , druga + paclitaxel vs drugb : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s10	paclitaxel	drug	183-192	paclitaxel	drug	197-206	false	treatment of hey xenograft bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , dasatinib + druga vs drugb : dg vs. dg cm3 , difference = dg cm3 , dg % confidence interval [ ci ] = dg to dg cm3 , p = .014 ) ;
DDI-MedLine.d194.s11	dasatinib	drug	0-8	paclitaxel	drug	12-21	false	druga + drugb vs .
DDI-MedLine.d194.s15	dasatinib	drug	43-51	paclitaxel	drug	58-67	false	the sirna knockdown of p27 ( kip1 ) decreased druga and drugb induced apoptosis compared with a negative control sirna ( sub g1 fraction , control sirna vs. p27 ( kip1 ) sirna : dg % vs. dg % , difference = dg % , dg % ci = dg % to dg % , p = .017 ) .
DDI-MedLine.d194.s16	dasatinib	drug	82-90	paclitaxel	drug	133-142	effect	studies with forced expression and sirna knockdown of bcl dg and cdk1 suggest that druga mediated induction of p27 ( kip1 ) enhanced drugb induced apoptosis by negatively regulating bcl dg and cdk1 expression .
DDI-MedLine.d194.s17	dasatinib	drug	63-71	paclitaxel	drug	82-91	effect	inhibition of src family and abl kinases with either sirnas or druga enhances drugb sensitivity of ovarian cancer cells through p27 ( kip1 ) mediated suppression of bcl dg and cdk1 expression .
DDI-MedLine.d211.s0	lenalidomide	drug	17-28	CCI-779	drug	34-40	false	phase i trial of druga and drugb in patients with relapsed multiple myeloma : evidence for lenalidomide cci dg interaction via p glycoprotein .
DDI-MedLine.d211.s0	lenalidomide	drug	17-28	lenalidomide	drug	99-110	false	phase i trial of druga and cci dg in patients with relapsed multiple myeloma : evidence for drugb cci dg interaction via p glycoprotein .
DDI-MedLine.d211.s0	lenalidomide	drug	17-28	CCI-779	drug	112-118	false	phase i trial of druga and cci dg in patients with relapsed multiple myeloma : evidence for lenalidomide drugb interaction via p glycoprotein .
DDI-MedLine.d211.s0	CCI-779	drug	34-40	lenalidomide	drug	99-110	false	phase i trial of lenalidomide and druga in patients with relapsed multiple myeloma : evidence for drugb cci dg interaction via p glycoprotein .
DDI-MedLine.d211.s0	CCI-779	drug	34-40	CCI-779	drug	112-118	false	phase i trial of lenalidomide and druga in patients with relapsed multiple myeloma : evidence for lenalidomide drugb interaction via p glycoprotein .
DDI-MedLine.d211.s0	lenalidomide	drug	99-110	CCI-779	drug	112-118	false	phase i trial of lenalidomide and cci dg in patients with relapsed multiple myeloma : evidence for druga drugb interaction via p glycoprotein .
DDI-MedLine.d211.s2	lenalidomide	drug	31-42	CCI-779	drug	68-74	effect	the preclinical combination of druga with the mtor inhibitor drugb has displayed synergy in vitro and represents a novel combination in mm .
DDI-MedLine.d154.s0	avian influenza vaccines	group	77-100	ginseng stem-and-leaf saponins	drug_n	128-157	false	enhancement of humoral immune responses to inactivated newcastle disease and druga by oral administration of drugb in chickens .
DDI-MedLine.d154.s2	ginseng stem-and-leaf saponins	drug_n	81-110	GSLS	drug_n	113-116	false	the objective of this study was to evaluate the effect of oral administration of druga ( drugb ) on the humoral immune responses of chickens to inactivated nd and ai vaccines .
DDI-MedLine.d154.s3	GSLS	drug_n	40-43	inactivated ND vaccine	drug	145-166	false	in experiment dg , oral administration of druga at a dose of dg mg / kg of bw for dg d on the immune response in chickens intramuscularly injected with drugb was evaluated .
DDI-MedLine.d154.s5	GSLS	drug_n	37-40	inactivated AI vaccines	drug	87-109	effect	in experiment dg , the same regimen of druga was administered to chickens inoculated with drugb , and an enhanced serum antibody response to ai vaccination was also observed .
DDI-MedLine.d154.s6	GSLS	drug_n	26-29	GSLS	drug_n	96-99	false	considering the safety of druga , because no adverse effect was found throughout the experiments , drugb may be a promising oral adjuvant to improve immunization in poultry .
DDI-MedLine.d147.s0	dacarbazine	drug	15-25	imexon	drug_n	31-36	false	interaction of druga and drugb , in vitro and in vivo , in human a375 melanoma cells .
DDI-MedLine.d147.s1	dacarbazine	drug	67-77	DTIC	drug	80-83	false	we evaluated mechanisms of interaction between the alkyating agent druga ( drugb ) and the pro oxidant , imexon , in the human a375 melanoma cell line .
DDI-MedLine.d147.s1	dacarbazine	drug	67-77	imexon	drug	107-112	false	we evaluated mechanisms of interaction between the alkyating agent druga ( dtic ) and the pro oxidant , drugb , in the human a375 melanoma cell line .
DDI-MedLine.d147.s1	DTIC	drug	80-83	imexon	drug	107-112	false	we evaluated mechanisms of interaction between the alkyating agent dacarbazine ( druga ) and the pro oxidant , drugb , in the human a375 melanoma cell line .
DDI-MedLine.d147.s2	DTIC	drug	14-17	imexon	drug	23-28	false	the effect of druga and drugb , alone and in combination , was evaluated for growth inhibition ( mtt ) , radiolabeled drug uptake , cellular thiol content ( hplc ) , and dna strand breaks ( comet assay ) .
DDI-MedLine.d147.s6	imexon	drug	69-74	DTIC	drug	84-87	false	there was a > dg % reduction in cellular glutathione and cysteine with druga but not drugb .
DDI-MedLine.d147.s8	Imexon	drug	0-5	dacarbazine	drug	11-21	effect	druga and drugb show additive effects in vitro but not in vivo in human a375 melanoma cells .
DDI-MedLine.d164.s0	Lapatinib	drug	0-8	herceptin	brand	19-27	effect	druga enhances drugb mediated antibody dependent cellular cytotoxicity by up regulation of cell surface her2 expression .
DDI-MedLine.d164.s1	lapatinib	drug	41-49	Herceptin	brand	65-73	effect	although it was previously reported that druga combined with drugb improved the progression free survival rate compared with lapatinib alone for patients with herceptin refractory her2 positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s1	lapatinib	drug	41-49	lapatinib	drug	133-141	false	although it was previously reported that druga combined with herceptin improved the progression free survival rate compared with drugb alone for patients with herceptin refractory her2 positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s1	lapatinib	drug	41-49	Herceptin	brand	167-175	false	although it was previously reported that druga combined with herceptin improved the progression free survival rate compared with lapatinib alone for patients with drugb refractory her2 positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s1	Herceptin	brand	65-73	lapatinib	drug	133-141	false	although it was previously reported that lapatinib combined with druga improved the progression free survival rate compared with drugb alone for patients with herceptin refractory her2 positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s1	Herceptin	brand	65-73	Herceptin	brand	167-175	false	although it was previously reported that lapatinib combined with druga improved the progression free survival rate compared with lapatinib alone for patients with drugb refractory her2 positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s1	lapatinib	drug	133-141	Herceptin	brand	167-175	false	although it was previously reported that lapatinib combined with herceptin improved the progression free survival rate compared with druga alone for patients with drugb refractory her2 positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
DDI-MedLine.d164.s2	lapatinib	drug	17-25	Herceptin	brand	42-50	false	we evaluated how druga interacts with drugb in her2 positive breast cancer , with a particular focus on herceptin mediated antibody dependent cellular cytotoxicity ( adcc ) .
DDI-MedLine.d164.s2	lapatinib	drug	17-25	Herceptin	brand	111-119	false	we evaluated how druga interacts with herceptin in her2 positive breast cancer , with a particular focus on drugb mediated antibody dependent cellular cytotoxicity ( adcc ) .
DDI-MedLine.d164.s2	Herceptin	brand	42-50	Herceptin	brand	111-119	false	we evaluated how lapatinib interacts with druga in her2 positive breast cancer , with a particular focus on drugb mediated antibody dependent cellular cytotoxicity ( adcc ) .
DDI-MedLine.d164.s3	lapatinib	drug	22-30	Herceptin	brand	149-157	effect	in an in vitro assay , druga induced her2 expression at the cell surface of her2 positive breast cancer cell lines , leading to the enhancement of drugb mediated adcc .
DDI-MedLine.d164.s4	Herceptin	brand	56-64	lapatinib	drug	86-94	effect	furthermore , we present a case report in which a second druga treatment following drugb resulted in the marked shrinkage of multiple metastatic tumors in her2 positive breast cancer .
DDI-MedLine.d164.s5	Lapatinib	drug	0-8	Herceptin	brand	44-52	false	druga may have the potential to convert drugb refractory to herceptin sensitive tumors in her2 positive breast cancer by up regulation of the cell surface expression of her2 .
DDI-MedLine.d164.s5	Lapatinib	drug	0-8	Herceptin	brand	68-76	false	druga may have the potential to convert herceptin refractory to drugb sensitive tumors in her2 positive breast cancer by up regulation of the cell surface expression of her2 .
DDI-MedLine.d164.s5	Herceptin	brand	44-52	Herceptin	brand	68-76	false	lapatinib may have the potential to convert druga refractory to drugb sensitive tumors in her2 positive breast cancer by up regulation of the cell surface expression of her2 .
DDI-MedLine.d201.s4	cross-reacting material 197	drug_n	180-206	CRM197	drug_n	209-214	false	the aim of the present study was to investigate whether hb egf is a therapeutic target for t all , and to further elucidate the antitumor effects of a specific inhibitor of hb egf , druga ( drugb ) .
DDI-MedLine.d201.s5	CRM197	drug_n	88-93	anticancer agent	group	139-154	false	we elucidated the expression of hb egf in t all cell lines , and evaluated the effect of druga on these cells alone or in combination with drugb .
DDI-MedLine.d201.s9	CRM197	drug_n	0-5	CRM197	drug_n	62-67	false	druga induced apoptosis , and furthermore , the combination of drugb plus doxorubicin enhanced cytotoxicity in a t all cell line .
DDI-MedLine.d201.s9	CRM197	drug_n	0-5	doxorubicin	drug	74-84	false	druga induced apoptosis , and furthermore , the combination of crm197 plus drugb enhanced cytotoxicity in a t all cell line .
DDI-MedLine.d201.s9	CRM197	drug_n	62-67	doxorubicin	drug	74-84	effect	crm197 induced apoptosis , and furthermore , the combination of druga plus drugb enhanced cytotoxicity in a t all cell line .
DDI-MedLine.d227.s0	Ephedrine	drug	0-8	dexmedetomidine	drug	49-63	effect	druga enhances the antinociceptive effect of drugb in mice .
DDI-MedLine.d227.s2	ephedrine	drug	75-83	dexmedetomidine	drug	103-117	false	the purpose of this study was to evaluate whether the psychostimulant drug druga has any effect on drugb induced antinociception and locomotor inhibitor activity in mice in acute application .
DDI-MedLine.d227.s6	ephedrine	drug	17-25	dexmedetomidine	drug	59-73	false	saline + saline , druga ( dg mg / kg ) + saline , saline + drugb ( dg g / kg ) and ephedrine ( dg mg / kg ) + dexmedetomidine ( dg g / kg ) , intraperitoneally , dg min before hot plate or holed open field tests .
DDI-MedLine.d227.s6	ephedrine	drug	17-25	ephedrine	drug	93-101	false	saline + saline , druga ( dg mg / kg ) + saline , saline + dexmedetomidine ( dg g / kg ) and drugb ( dg mg / kg ) + dexmedetomidine ( dg g / kg ) , intraperitoneally , dg min before hot plate or holed open field tests .
DDI-MedLine.d227.s6	ephedrine	drug	17-25	dexmedetomidine	drug	118-132	false	saline + saline , druga ( dg mg / kg ) + saline , saline + dexmedetomidine ( dg g / kg ) and ephedrine ( dg mg / kg ) + drugb ( dg g / kg ) , intraperitoneally , dg min before hot plate or holed open field tests .
DDI-MedLine.d227.s6	dexmedetomidine	drug	59-73	ephedrine	drug	93-101	false	saline + saline , ephedrine ( dg mg / kg ) + saline , saline + druga ( dg g / kg ) and drugb ( dg mg / kg ) + dexmedetomidine ( dg g / kg ) , intraperitoneally , dg min before hot plate or holed open field tests .
DDI-MedLine.d227.s6	dexmedetomidine	drug	59-73	dexmedetomidine	drug	118-132	false	saline + saline , ephedrine ( dg mg / kg ) + saline , saline + druga ( dg g / kg ) and ephedrine ( dg mg / kg ) + drugb ( dg g / kg ) , intraperitoneally , dg min before hot plate or holed open field tests .
DDI-MedLine.d227.s6	ephedrine	drug	93-101	dexmedetomidine	drug	118-132	false	saline + saline , ephedrine ( dg mg / kg ) + saline , saline + dexmedetomidine ( dg g / kg ) and druga ( dg mg / kg ) + drugb ( dg g / kg ) , intraperitoneally , dg min before hot plate or holed open field tests .
DDI-MedLine.d227.s7	dexmedetomidine	drug	64-78	ephedrine	drug	96-104	effect	in the hot plate test in mice , co administration of dg g / kg druga with dg mg / kg drugb intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by dexmedetomidine .
DDI-MedLine.d227.s7	dexmedetomidine	drug	64-78	dexmedetomidine	drug	205-219	false	in the hot plate test in mice , co administration of dg g / kg druga with dg mg / kg ephedrine intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by drugb .
DDI-MedLine.d227.s7	ephedrine	drug	96-104	dexmedetomidine	drug	205-219	false	in the hot plate test in mice , co administration of dg g / kg dexmedetomidine with dg mg / kg druga intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by drugb .
DDI-MedLine.d227.s8	dexmedetomidine	drug	53-67	ephedrine	drug	89-97	effect	at the same time , the locomotor inhibitory effect of druga was counteracted by drugb .
DDI-MedLine.d227.s9	dexmedetomidine	drug	49-63	ephedrine	drug	70-78	effect	we concluded that the combined administration of druga with drugb may have beneficial effects in the treatment of pain without causing sedation , which limits the use of dexmedetomidine as an analgesic in humans .
DDI-MedLine.d227.s9	dexmedetomidine	drug	49-63	dexmedetomidine	drug	183-197	false	we concluded that the combined administration of druga with ephedrine may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugb as an analgesic in humans .
DDI-MedLine.d227.s9	dexmedetomidine	drug	49-63	analgesic	group	205-213	false	we concluded that the combined administration of druga with ephedrine may have beneficial effects in the treatment of pain without causing sedation , which limits the use of dexmedetomidine as an drugb in humans .
DDI-MedLine.d227.s9	ephedrine	drug	70-78	dexmedetomidine	drug	183-197	false	we concluded that the combined administration of dexmedetomidine with druga may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugb as an analgesic in humans .
DDI-MedLine.d227.s9	ephedrine	drug	70-78	analgesic	group	205-213	false	we concluded that the combined administration of dexmedetomidine with druga may have beneficial effects in the treatment of pain without causing sedation , which limits the use of dexmedetomidine as an drugb in humans .
DDI-MedLine.d227.s9	dexmedetomidine	drug	183-197	analgesic	group	205-213	false	we concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation , which limits the use of druga as an drugb in humans .
DDI-MedLine.d200.s0	amlodipine	drug	31-40	valsartan	drug	42-50	false	[ efficacy of fixed combination druga / drugb in hospitalized patients with hypertensive disease ]
DDI-MedLine.d200.s1	amlodipine	drug	35-44	valsartan	drug	46-54	false	efficacy and tolerability of fixed druga / drugb combination was studied in dg patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology .
DDI-MedLine.d200.s2	amlodipine	drug	106-115	valsartan	drug	117-125	false	all patients had indications for antihypertensive therapy and were randomized either to fixed combination druga / drugb ( n=43 ) or to therapy which corresponded to the hospital formulary ( n=43 ) .
DDI-MedLine.d200.s7	amlodipine	drug	56-65	valsartan	drug	67-75	false	rate of achievement of target bp with fixed combination druga / drugb ( dg % ) was comparable with that on traditional therapy ( dg % ) .
DDI-MedLine.d200.s8	amlodipine	drug	33-42	valsartan	drug	44-52	effect	but the use of fixed combination druga / drugb compared with traditional therapy was associated with lower clinical and self measured bp , quicker achievement of target bp ( 5.8+ / dg and 9.2+ / dg days , respectively , dg ) , lesser number of antihypertensive drugs ( 2.5+ / dg and 3.0+ / dg days , respectively ) , lower rate of concealed inefficacy of treatment ( dg and dg % , respectively , dg ) .
DDI-MedLine.d200.s8	amlodipine	drug	33-42	antihypertensive drugs	group	247-268	false	but the use of fixed combination druga / valsartan compared with traditional therapy was associated with lower clinical and self measured bp , quicker achievement of target bp ( 5.8+ / dg and 9.2+ / dg days , respectively , dg ) , lesser number of drugb ( 2.5+ / dg and 3.0+ / dg days , respectively ) , lower rate of concealed inefficacy of treatment ( dg and dg % , respectively , dg ) .
DDI-MedLine.d200.s8	valsartan	drug	44-52	antihypertensive drugs	group	247-268	false	but the use of fixed combination amlodipine / druga compared with traditional therapy was associated with lower clinical and self measured bp , quicker achievement of target bp ( 5.8+ / dg and 9.2+ / dg days , respectively , dg ) , lesser number of drugb ( 2.5+ / dg and 3.0+ / dg days , respectively ) , lower rate of concealed inefficacy of treatment ( dg and dg % , respectively , dg ) .
DDI-MedLine.d200.s10	amlodipine	drug	75-84	valsartan	drug	86-94	effect	we have demonstrated appropriateness of inhospital administration of fixed druga / drugb combination as an approach allowing to achieve target bp in shorter time , with the use of fewer antihypertensive drugs , and diminishing concealed inefficacy of treatment .
DDI-MedLine.d200.s10	amlodipine	drug	75-84	antihypertensive drugs	group	192-213	false	we have demonstrated appropriateness of inhospital administration of fixed druga / valsartan combination as an approach allowing to achieve target bp in shorter time , with the use of fewer drugb , and diminishing concealed inefficacy of treatment .
DDI-MedLine.d200.s10	valsartan	drug	86-94	antihypertensive drugs	group	192-213	false	we have demonstrated appropriateness of inhospital administration of fixed amlodipine / druga combination as an approach allowing to achieve target bp in shorter time , with the use of fewer drugb , and diminishing concealed inefficacy of treatment .
DDI-MedLine.d193.s0	Ticagrelor	drug	0-9	Brilinta	brand	12-19	false	druga ( drugb ) better than clopidogrel ( plavix )
DDI-MedLine.d193.s0	Ticagrelor	drug	0-9	clopidogrel	drug	35-45	false	druga ( brilinta ) better than drugb ( plavix )
DDI-MedLine.d193.s0	Ticagrelor	drug	0-9	Plavix	brand	48-53	false	druga ( brilinta ) better than clopidogrel ( drugb )
DDI-MedLine.d193.s0	Brilinta	brand	12-19	clopidogrel	drug	35-45	false	ticagrelor ( druga ) better than drugb ( plavix )
DDI-MedLine.d193.s0	Brilinta	brand	12-19	Plavix	brand	48-53	false	ticagrelor ( druga ) better than clopidogrel ( drugb )
DDI-MedLine.d193.s0	clopidogrel	drug	35-45	Plavix	brand	48-53	false	ticagrelor ( brilinta ) better than druga ( drugb )
DDI-MedLine.d193.s1	ticagrelor	drug	21-30	Brilinta	brand	33-40	false	the fda has approved druga ( drugb astrazeneca ) , an oral antiplatelet drug , for use with low dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
DDI-MedLine.d193.s1	ticagrelor	drug	21-30	antiplatelet drug	group	64-80	false	the fda has approved druga ( brilinta astrazeneca ) , an oral drugb , for use with low dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
DDI-MedLine.d193.s1	ticagrelor	drug	21-30	aspirin	brand	105-111	effect	the fda has approved druga ( brilinta astrazeneca ) , an oral antiplatelet drug , for use with low dose drugb to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
DDI-MedLine.d193.s1	Brilinta	brand	33-40	antiplatelet drug	group	64-80	false	the fda has approved ticagrelor ( druga astrazeneca ) , an oral drugb , for use with low dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
DDI-MedLine.d193.s1	Brilinta	brand	33-40	aspirin	brand	105-111	effect	the fda has approved ticagrelor ( druga astrazeneca ) , an oral antiplatelet drug , for use with low dose drugb to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
DDI-MedLine.d193.s1	antiplatelet drug	group	64-80	aspirin	brand	105-111	false	the fda has approved ticagrelor ( brilinta astrazeneca ) , an oral druga , for use with low dose drugb to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
DDI-MedLine.d193.s2	clopidogrel	drug	21-31	Plavix	brand	34-39	false	it will compete with druga ( drugb ) and prasugrel ( effient ) for such use .
DDI-MedLine.d193.s2	clopidogrel	drug	21-31	prasugrel	drug	46-54	false	it will compete with druga ( plavix ) and drugb ( effient ) for such use .
DDI-MedLine.d193.s2	clopidogrel	drug	21-31	Effient	brand	57-63	false	it will compete with druga ( plavix ) and prasugrel ( drugb ) for such use .
DDI-MedLine.d193.s2	Plavix	brand	34-39	prasugrel	drug	46-54	false	it will compete with clopidogrel ( druga ) and drugb ( effient ) for such use .
DDI-MedLine.d193.s2	Plavix	brand	34-39	Effient	brand	57-63	false	it will compete with clopidogrel ( druga ) and prasugrel ( drugb ) for such use .
DDI-MedLine.d193.s2	prasugrel	drug	46-54	Effient	brand	57-63	false	it will compete with clopidogrel ( plavix ) and druga ( drugb ) for such use .
DDI-MedLine.d195.s0	piperine	drug_n	13-20	ibuprofen	drug	25-33	false	influence of druga on drugb induced antinociception and its pharmacokinetics .
DDI-MedLine.d195.s4	piperine	drug_n	21-28	ibuprofen	drug	112-120	effect	in the present study druga ( dg mg / kg ) significantly increased the dose dependent antinociceptive activity of drugb evaluated by both acetic acid writhing and formalin test , when it was administered with ibuprofen .
DDI-MedLine.d195.s4	piperine	drug_n	21-28	acetic acid	drug	140-150	false	in the present study druga ( dg mg / kg ) significantly increased the dose dependent antinociceptive activity of ibuprofen evaluated by both drugb writhing and formalin test , when it was administered with ibuprofen .
DDI-MedLine.d195.s4	piperine	drug_n	21-28	ibuprofen	drug	210-218	false	in the present study druga ( dg mg / kg ) significantly increased the dose dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test , when it was administered with drugb .
DDI-MedLine.d195.s4	ibuprofen	drug	112-120	acetic acid	drug	140-150	false	in the present study piperine ( dg mg / kg ) significantly increased the dose dependent antinociceptive activity of druga evaluated by both drugb writhing and formalin test , when it was administered with ibuprofen .
DDI-MedLine.d195.s4	ibuprofen	drug	112-120	ibuprofen	drug	210-218	false	in the present study piperine ( dg mg / kg ) significantly increased the dose dependent antinociceptive activity of druga evaluated by both acetic acid writhing and formalin test , when it was administered with drugb .
DDI-MedLine.d195.s4	acetic acid	drug	140-150	ibuprofen	drug	210-218	false	in the present study piperine ( dg mg / kg ) significantly increased the dose dependent antinociceptive activity of ibuprofen evaluated by both druga writhing and formalin test , when it was administered with drugb .
DDI-MedLine.d195.s5	Ibuprofen	drug	0-8	piperine	drug_n	80-87	mechanism	druga plasma concentration was also increased when it was administered with drugb .
DDI-MedLine.d195.s6	ibuprofen	drug	44-52	piperine	drug_n	77-84	mechanism	the synergistic antinociception activity of druga when administered with drugb can be attributed to increased plasma concentration of ibuprofen .
DDI-MedLine.d195.s6	ibuprofen	drug	44-52	ibuprofen	drug	141-149	false	the synergistic antinociception activity of druga when administered with piperine can be attributed to increased plasma concentration of drugb .
DDI-MedLine.d195.s6	piperine	drug_n	77-84	ibuprofen	drug	141-149	false	the synergistic antinociception activity of ibuprofen when administered with druga can be attributed to increased plasma concentration of drugb .
DDI-MedLine.d195.s7	piperine	drug_n	41-48	ibuprofen	drug	90-98	effect	from this study it can be concluded that druga can be used as a bioenhancer along with drugb .
DDI-DrugBank.d610.s0	abacavir	drug	30-37	lamivudine	drug	82-91	false	pharmacokinetic properties of druga were not altered by the addition of either drugb or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0	abacavir	drug	30-37	zidovudine	drug	96-105	false	pharmacokinetic properties of druga were not altered by the addition of either lamivudine or drugb or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0	abacavir	drug	30-37	lamivudine	drug	129-138	false	pharmacokinetic properties of druga were not altered by the addition of either lamivudine or zidovudine or the combination of drugb and zidovudine .
DDI-DrugBank.d610.s0	abacavir	drug	30-37	zidovudine	drug	144-153	false	pharmacokinetic properties of druga were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and drugb .
DDI-DrugBank.d610.s0	lamivudine	drug	82-91	zidovudine	drug	96-105	false	pharmacokinetic properties of abacavir were not altered by the addition of either druga or drugb or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0	lamivudine	drug	82-91	lamivudine	drug	129-138	false	pharmacokinetic properties of abacavir were not altered by the addition of either druga or zidovudine or the combination of drugb and zidovudine .
DDI-DrugBank.d610.s0	lamivudine	drug	82-91	zidovudine	drug	144-153	false	pharmacokinetic properties of abacavir were not altered by the addition of either druga or zidovudine or the combination of lamivudine and drugb .
DDI-DrugBank.d610.s0	zidovudine	drug	96-105	lamivudine	drug	129-138	false	pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or druga or the combination of drugb and zidovudine .
DDI-DrugBank.d610.s0	zidovudine	drug	96-105	zidovudine	drug	144-153	false	pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or druga or the combination of lamivudine and drugb .
DDI-DrugBank.d610.s0	lamivudine	drug	129-138	zidovudine	drug	144-153	false	pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of druga and drugb .
DDI-DrugBank.d610.s1	lamivudine	drug	37-46	zidovudine	drug	51-60	false	no clinically significant changes to druga or drugb pharmacokinetics were observed following concomitant administration of abacavir .
DDI-DrugBank.d610.s1	lamivudine	drug	37-46	abacavir	drug	133-140	false	no clinically significant changes to druga or zidovudine pharmacokinetics were observed following concomitant administration of drugb .
DDI-DrugBank.d610.s1	zidovudine	drug	51-60	abacavir	drug	133-140	false	no clinically significant changes to lamivudine or druga pharmacokinetics were observed following concomitant administration of drugb .
DDI-DrugBank.d610.s2	Abacavir	drug	0-7	ethanol	drug	60-66	false	druga has no effect on the pharmacokinetic properties of drugb .
DDI-DrugBank.d610.s3	Ethanol	drug	0-6	abacavir	drug	37-44	mechanism	druga decreases the elimination of drugb causing an increase in overall exposure . the addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir .
DDI-DrugBank.d610.s3	Ethanol	drug	0-6	methadone	drug	104-112	false	druga decreases the elimination of abacavir causing an increase in overall exposure . the addition of drugb has no clinically significant effect on the pharmacokinetic properties of abacavir .
DDI-DrugBank.d610.s3	Ethanol	drug	0-6	abacavir	drug	188-195	false	druga decreases the elimination of abacavir causing an increase in overall exposure . the addition of methadone has no clinically significant effect on the pharmacokinetic properties of drugb .
DDI-DrugBank.d610.s3	abacavir	drug	37-44	methadone	drug	104-112	false	ethanol decreases the elimination of druga causing an increase in overall exposure . the addition of drugb has no clinically significant effect on the pharmacokinetic properties of abacavir .
DDI-DrugBank.d610.s3	abacavir	drug	37-44	abacavir	drug	188-195	false	ethanol decreases the elimination of druga causing an increase in overall exposure . the addition of methadone has no clinically significant effect on the pharmacokinetic properties of drugb .
DDI-DrugBank.d610.s3	methadone	drug	104-112	abacavir	drug	188-195	false	ethanol decreases the elimination of abacavir causing an increase in overall exposure . the addition of druga has no clinically significant effect on the pharmacokinetic properties of drugb .
DDI-DrugBank.d610.s4	methadone	drug	49-57	ZIAGEN	brand	118-123	mechanism	in a study of dg hiv infected patients receiving druga maintenance therapy ( dg mg and dg mg daily ) with dg mg of drugb twice daily ( twice the currently recommended dose ) , oral methadone clearance increased dg % ( dg % ci dg % to dg % ) .
DDI-DrugBank.d610.s4	methadone	drug	49-57	methadone	drug	182-190	false	in a study of dg hiv infected patients receiving druga maintenance therapy ( dg mg and dg mg daily ) with dg mg of ziagen twice daily ( twice the currently recommended dose ) , oral drugb clearance increased dg % ( dg % ci dg % to dg % ) .
DDI-DrugBank.d610.s4	ZIAGEN	brand	118-123	methadone	drug	182-190	false	in a study of dg hiv infected patients receiving methadone maintenance therapy ( dg mg and dg mg daily ) with dg mg of druga twice daily ( twice the currently recommended dose ) , oral drugb clearance increased dg % ( dg % ci dg % to dg % ) .
DDI-DrugBank.d572.s0	Cholestyramine	drug	0-13	cholestyramine	drug	28-41	false	druga : concomitant drugb administration decreased the mean auc of total ezetimibe approximately dg % .
DDI-DrugBank.d572.s0	Cholestyramine	drug	0-13	ezetimibe	drug	90-98	false	druga : concomitant cholestyramine administration decreased the mean auc of total drugb approximately dg % .
DDI-DrugBank.d572.s0	cholestyramine	drug	28-41	ezetimibe	drug	90-98	mechanism	cholestyramine : concomitant druga administration decreased the mean auc of total drugb approximately dg % .
DDI-DrugBank.d572.s1	ezetimibe	drug	46-54	cholestyramine	drug	59-72	effect	the incremental ldl c reduction due to adding druga to drugb may be reduced by this interaction .
DDI-DrugBank.d572.s2	Fibrates	group	0-7	ezetimibe	drug	42-50	false	druga : the safety and effectiveness of drugb administered with fibrates have not been established .
DDI-DrugBank.d572.s2	Fibrates	group	0-7	fibrates	group	70-77	false	druga : the safety and effectiveness of ezetimibe administered with drugb have not been established .
DDI-DrugBank.d572.s2	ezetimibe	drug	42-50	fibrates	group	70-77	false	fibrates : the safety and effectiveness of druga administered with drugb have not been established .
DDI-DrugBank.d572.s5	ZETIA	brand	21-25	fibrates	group	32-39	advise	co administration of druga with drugb is not recommended until use in patients is studied .
DDI-DrugBank.d572.s6	Fenofibrate	drug	0-10	fenofibrate	drug	53-63	false	druga : in a pharmacokinetic study , concomitant drugb administration increased total ezetimibe concentrations approximately dg fold .
DDI-DrugBank.d572.s6	Fenofibrate	drug	0-10	ezetimibe	drug	96-104	false	druga : in a pharmacokinetic study , concomitant fenofibrate administration increased total drugb concentrations approximately dg fold .
DDI-DrugBank.d572.s6	fenofibrate	drug	53-63	ezetimibe	drug	96-104	mechanism	fenofibrate : in a pharmacokinetic study , concomitant druga administration increased total drugb concentrations approximately dg fold .
DDI-DrugBank.d572.s7	Gemfibrozil	drug	0-10	gemfibrozil	drug	53-63	false	druga : in a pharmacokinetic study , concomitant drugb administration increased total ezetimibe concentrations approximately dg fold .
DDI-DrugBank.d572.s7	Gemfibrozil	drug	0-10	ezetimibe	drug	96-104	false	druga : in a pharmacokinetic study , concomitant gemfibrozil administration increased total drugb concentrations approximately dg fold .
DDI-DrugBank.d572.s7	gemfibrozil	drug	53-63	ezetimibe	drug	96-104	false	gemfibrozil : in a pharmacokinetic study , concomitant druga administration increased total drugb concentrations approximately dg fold .
DDI-DrugBank.d572.s8	HMG-CoA reductase inhibitors	group	0-27	ezetimibe	drug	100-108	false	druga : no clinically significant pharmacokinetic interactions were seen when drugb was co administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	HMG-CoA reductase inhibitors	group	0-27	atorvastatin	drug	135-146	false	druga : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with drugb , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	HMG-CoA reductase inhibitors	group	0-27	simvastatin	drug	149-159	false	druga : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , drugb , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	HMG-CoA reductase inhibitors	group	0-27	pravastatin	drug	162-172	false	druga : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , simvastatin , drugb , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	HMG-CoA reductase inhibitors	group	0-27	lovastatin	drug	175-184	false	druga : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , simvastatin , pravastatin , drugb , or fluvastatin .
DDI-DrugBank.d572.s8	HMG-CoA reductase inhibitors	group	0-27	fluvastatin	drug	190-200	false	druga : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , simvastatin , pravastatin , lovastatin , or drugb .
DDI-DrugBank.d572.s8	ezetimibe	drug	100-108	atorvastatin	drug	135-146	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when druga was co administered with drugb , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	ezetimibe	drug	100-108	simvastatin	drug	149-159	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when druga was co administered with atorvastatin , drugb , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	ezetimibe	drug	100-108	pravastatin	drug	162-172	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when druga was co administered with atorvastatin , simvastatin , drugb , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	ezetimibe	drug	100-108	lovastatin	drug	175-184	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when druga was co administered with atorvastatin , simvastatin , pravastatin , drugb , or fluvastatin .
DDI-DrugBank.d572.s8	ezetimibe	drug	100-108	fluvastatin	drug	190-200	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when druga was co administered with atorvastatin , simvastatin , pravastatin , lovastatin , or drugb .
DDI-DrugBank.d572.s8	atorvastatin	drug	135-146	simvastatin	drug	149-159	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with druga , drugb , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	atorvastatin	drug	135-146	pravastatin	drug	162-172	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with druga , simvastatin , drugb , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	atorvastatin	drug	135-146	lovastatin	drug	175-184	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with druga , simvastatin , pravastatin , drugb , or fluvastatin .
DDI-DrugBank.d572.s8	atorvastatin	drug	135-146	fluvastatin	drug	190-200	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with druga , simvastatin , pravastatin , lovastatin , or drugb .
DDI-DrugBank.d572.s8	simvastatin	drug	149-159	pravastatin	drug	162-172	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , druga , drugb , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8	simvastatin	drug	149-159	lovastatin	drug	175-184	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , druga , pravastatin , drugb , or fluvastatin .
DDI-DrugBank.d572.s8	simvastatin	drug	149-159	fluvastatin	drug	190-200	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , druga , pravastatin , lovastatin , or drugb .
DDI-DrugBank.d572.s8	pravastatin	drug	162-172	lovastatin	drug	175-184	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , simvastatin , druga , drugb , or fluvastatin .
DDI-DrugBank.d572.s8	pravastatin	drug	162-172	fluvastatin	drug	190-200	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , simvastatin , druga , lovastatin , or drugb .
DDI-DrugBank.d572.s8	lovastatin	drug	175-184	fluvastatin	drug	190-200	false	hmg coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co administered with atorvastatin , simvastatin , pravastatin , druga , or drugb .
DDI-DrugBank.d572.s9	Cyclosporine	drug	0-11	ezetimibe	drug	24-32	false	druga : the total drugb level increased dg fold in one renal transplant patient receiving multiple medications , including cyclosporine .
DDI-DrugBank.d572.s9	Cyclosporine	drug	0-11	cyclosporine	drug	132-143	false	druga : the total ezetimibe level increased dg fold in one renal transplant patient receiving multiple medications , including drugb .
DDI-DrugBank.d572.s9	ezetimibe	drug	24-32	cyclosporine	drug	132-143	mechanism	cyclosporine : the total druga level increased dg fold in one renal transplant patient receiving multiple medications , including drugb .
DDI-DrugBank.d572.s10	ezetimibe	drug	23-31	cyclosporine	drug	37-48	advise	patients who take both druga and drugb should be carefully monitored .
DDI-DrugBank.d572.s11	ezetimibe	drug	99-107	ezetimibe	drug	271-279	false	carcinogenesis , mutagenesis , impairment of fertility a dg week dietary carcinogenicity study with druga was conducted in rats at doses up to dg mg / kg / day ( males ) and dg mg / kg / day ( females ) ( ~ dg times the human exposure at dg mg daily based on auc0 24hr for total drugb ) .
DDI-DrugBank.d572.s12	ezetimibe	drug	46-54	ezetimibe	drug	187-195	false	a dg week dietary carcinogenicity study with druga was also conducted in mice at doses up to dg mg / kg / day ( > dg times the human exposure at dg mg daily based on auc0 24hr for total drugb ) .
DDI-DrugBank.d572.s17	ezetimibe	drug	38-46	ezetimibe	drug	240-248	false	in oral ( gavage ) fertility studies of druga conducted in rats , there was no evidence of reproductive toxicity at doses up to dg mg / kg / day in male or female rats ( ~ dg times the human exposure at dg mg daily based on auc0 24hr for total drugb ) .
DDI-DrugBank.d572.s22	ezetimibe	drug	24-32	ezetimibe	drug	186-194	false	in rabbits treated with druga , an increased incidence of extra thoracic ribs was observed at dg mg / kg / day ( dg times the human exposure at dg mg daily based on auc0 24hr for total drugb ) .
DDI-DrugBank.d572.s24	ezetimibe	drug	25-33	HMG-CoA reductase inhibitors	group	61-88	false	multiple dose studies of druga given in combination with drugb ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures .
DDI-DrugBank.d572.s24	ezetimibe	drug	25-33	statins	group	91-97	false	multiple dose studies of druga given in combination with hmg coa reductase inhibitors ( drugb ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures .
DDI-DrugBank.d572.s24	ezetimibe	drug	25-33	ezetimibe	drug	158-166	false	multiple dose studies of druga given in combination with hmg coa reductase inhibitors ( statins ) in rats and rabbits during organogenesis result in higher drugb and statin exposures .
DDI-DrugBank.d572.s24	HMG-CoA reductase inhibitors	group	61-88	statins	group	91-97	false	multiple dose studies of ezetimibe given in combination with druga ( drugb ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures .
DDI-DrugBank.d572.s24	HMG-CoA reductase inhibitors	group	61-88	ezetimibe	drug	158-166	false	multiple dose studies of ezetimibe given in combination with druga ( statins ) in rats and rabbits during organogenesis result in higher drugb and statin exposures .
DDI-DrugBank.d572.s24	statins	group	91-97	ezetimibe	drug	158-166	false	multiple dose studies of ezetimibe given in combination with hmg coa reductase inhibitors ( druga ) in rats and rabbits during organogenesis result in higher drugb and statin exposures .
DDI-DrugBank.d572.s27	ZETIA	brand	5-9	HMG-CoA reductase inhibitor	group	35-61	false	when druga is administered with an drugb in a woman of childbearing potential , refer to the pregnancy category and package labeling for the hmg coa reductase inhibitor .
DDI-DrugBank.d572.s27	ZETIA	brand	5-9	HMG-CoA reductase inhibitor	drug	162-188	false	when druga is administered with an hmg coa reductase inhibitor in a woman of childbearing potential , refer to the pregnancy category and package labeling for the drugb .
DDI-DrugBank.d572.s27	HMG-CoA reductase inhibitor	group	35-61	HMG-CoA reductase inhibitor	drug	162-188	false	when zetia is administered with an druga in a woman of childbearing potential , refer to the pregnancy category and package labeling for the drugb .
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Coumarin-type anticoagulants	group	66-93	false	these are described in greater detail below : oral druga , drugb , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Phenytoin	drug	96-104	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , drugb , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Cyclosporine	drug	107-118	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , drugb , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Rifampin	drug	121-128	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , drugb , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Theophylline	drug	131-142	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , drugb , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Terfenadine	drug	145-155	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , drugb , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Cisapride	drug	158-166	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , drugb , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Astemizole	drug	169-178	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , drugb , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Rifabutin	drug	181-189	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , drugb , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	hypoglycemics	group	240-252	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	51-63	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral druga , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Phenytoin	drug	96-104	false	these are described in greater detail below : oral hypoglycemics , druga , drugb , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Cyclosporine	drug	107-118	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , drugb , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Rifampin	drug	121-128	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , drugb , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Theophylline	drug	131-142	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , drugb , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Terfenadine	drug	145-155	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , theophylline , drugb , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Cisapride	drug	158-166	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , drugb , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Astemizole	drug	169-178	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , drugb , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Rifabutin	drug	181-189	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , drugb , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Coumarin-type anticoagulants	group	66-93	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , druga , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	Cyclosporine	drug	107-118	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , drugb , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	Rifampin	drug	121-128	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , drugb , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	Theophylline	drug	131-142	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , drugb , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	Terfenadine	drug	145-155	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , theophylline , drugb , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	Cisapride	drug	158-166	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , theophylline , terfenadine , drugb , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	Astemizole	drug	169-178	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , theophylline , terfenadine , cisapride , drugb , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	Rifabutin	drug	181-189	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , drugb , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Phenytoin	drug	96-104	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , druga , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	Rifampin	drug	121-128	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , drugb , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	Theophylline	drug	131-142	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , drugb , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	Terfenadine	drug	145-155	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , theophylline , drugb , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	Cisapride	drug	158-166	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , theophylline , terfenadine , drugb , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	Astemizole	drug	169-178	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , theophylline , terfenadine , cisapride , drugb , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	Rifabutin	drug	181-189	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , theophylline , terfenadine , cisapride , astemizole , drugb , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cyclosporine	drug	107-118	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , druga , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	Theophylline	drug	131-142	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , drugb , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	Terfenadine	drug	145-155	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , theophylline , drugb , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	Cisapride	drug	158-166	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , theophylline , terfenadine , drugb , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	Astemizole	drug	169-178	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , theophylline , terfenadine , cisapride , drugb , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	Rifabutin	drug	181-189	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , theophylline , terfenadine , cisapride , astemizole , drugb , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , theophylline , terfenadine , cisapride , astemizole , rifabutin , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifampin	drug	121-128	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , druga , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Theophylline	drug	131-142	Terfenadine	drug	145-155	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , druga , drugb , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Theophylline	drug	131-142	Cisapride	drug	158-166	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , druga , terfenadine , drugb , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Theophylline	drug	131-142	Astemizole	drug	169-178	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , druga , terfenadine , cisapride , drugb , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Theophylline	drug	131-142	Rifabutin	drug	181-189	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , druga , terfenadine , cisapride , astemizole , drugb , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Theophylline	drug	131-142	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , druga , terfenadine , cisapride , astemizole , rifabutin , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Theophylline	drug	131-142	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , druga , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Theophylline	drug	131-142	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , druga , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Theophylline	drug	131-142	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , druga , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Theophylline	drug	131-142	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , druga , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Terfenadine	drug	145-155	Cisapride	drug	158-166	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , druga , drugb , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Terfenadine	drug	145-155	Astemizole	drug	169-178	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , druga , cisapride , drugb , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Terfenadine	drug	145-155	Rifabutin	drug	181-189	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , druga , cisapride , astemizole , drugb , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Terfenadine	drug	145-155	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , druga , cisapride , astemizole , rifabutin , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Terfenadine	drug	145-155	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , druga , cisapride , astemizole , rifabutin , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Terfenadine	drug	145-155	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , druga , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Terfenadine	drug	145-155	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , druga , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Terfenadine	drug	145-155	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , druga , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Cisapride	drug	158-166	Astemizole	drug	169-178	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , druga , drugb , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cisapride	drug	158-166	Rifabutin	drug	181-189	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , druga , astemizole , drugb , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cisapride	drug	158-166	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , druga , astemizole , rifabutin , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cisapride	drug	158-166	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , druga , astemizole , rifabutin , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cisapride	drug	158-166	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , druga , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cisapride	drug	158-166	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , druga , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Cisapride	drug	158-166	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , druga , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Astemizole	drug	169-178	Rifabutin	drug	181-189	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , druga , drugb , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Astemizole	drug	169-178	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , druga , rifabutin , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Astemizole	drug	169-178	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , druga , rifabutin , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Astemizole	drug	169-178	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , druga , rifabutin , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Astemizole	drug	169-178	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , druga , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Astemizole	drug	169-178	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , druga , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Rifabutin	drug	181-189	Tacrolimus	drug	192-201	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , druga , drugb , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifabutin	drug	181-189	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , druga , tacrolimus , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifabutin	drug	181-189	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , druga , tacrolimus , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifabutin	drug	181-189	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , druga , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Rifabutin	drug	181-189	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , druga , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Tacrolimus	drug	192-201	Short-acting benzodiazepines	group	204-231	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , druga , drugb , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Tacrolimus	drug	192-201	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , druga , short acting benzodiazepines , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Tacrolimus	drug	192-201	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , druga , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Tacrolimus	drug	192-201	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , druga , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	Short-acting benzodiazepines	group	204-231	hypoglycemics	group	240-252	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , druga , oral drugb : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Short-acting benzodiazepines	group	204-231	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , druga , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	Short-acting benzodiazepines	group	204-231	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , druga , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	hypoglycemics	group	240-252	DIFLUCAN	brand	325-332	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral druga : clinically significant hypoglycemia may be precipitated by the use of drugb with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2	hypoglycemics	group	240-252	hypoglycemic agents	group	344-362	false	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral druga : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral drugb ;
DDI-DrugBank.d776.s2	DIFLUCAN	brand	325-332	hypoglycemic agents	group	344-362	effect	these are described in greater detail below : oral hypoglycemics , coumarin type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of druga with oral drugb ;
DDI-DrugBank.d776.s3	DIFLUCAN	brand	78-85	glyburide	drug	91-99	effect	one fatality has been reported from hypoglycemia in association with combined druga and drugb use .
DDI-DrugBank.d776.s4	DIFLUCAN	brand	0-7	tolbutamide	drug	35-45	mechanism	druga reduces the metabolism of drugb , glyburide , and glipizide and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4	DIFLUCAN	brand	0-7	glyburide	drug	48-56	mechanism	druga reduces the metabolism of tolbutamide , drugb , and glipizide and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4	DIFLUCAN	brand	0-7	glipizide	drug	63-71	mechanism	druga reduces the metabolism of tolbutamide , glyburide , and drugb and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4	tolbutamide	drug	35-45	glyburide	drug	48-56	false	diflucan reduces the metabolism of druga , drugb , and glipizide and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4	tolbutamide	drug	35-45	glipizide	drug	63-71	false	diflucan reduces the metabolism of druga , glyburide , and drugb and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4	glyburide	drug	48-56	glipizide	drug	63-71	false	diflucan reduces the metabolism of tolbutamide , druga , and drugb and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s5	DIFLUCAN	brand	5-12	sulfonylurea oral hypoglycemic agents	group	56-92	advise	when druga is used concomitantly with these or other drugb , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary .
DDI-DrugBank.d776.s5	DIFLUCAN	brand	5-12	sulfonylurea	group	174-185	false	when druga is used concomitantly with these or other sulfonylurea oral hypoglycemic agents , blood glucose concentrations should be carefully monitored and the dose of the drugb should be adjusted as necessary .
DDI-DrugBank.d776.s5	sulfonylurea oral hypoglycemic agents	group	56-92	sulfonylurea	group	174-185	false	when diflucan is used concomitantly with these or other druga , blood glucose concentrations should be carefully monitored and the dose of the drugb should be adjusted as necessary .
DDI-DrugBank.d776.s6	Coumarin-type anticoagulants	group	0-27	DIFLUCAN	brand	98-105	false	druga : prothrombin time may be increased in patients receiving concomitant drugb and coumarin type anticoagulants .
DDI-DrugBank.d776.s6	Coumarin-type anticoagulants	group	0-27	coumarin-type anticoagulants	group	111-138	false	druga : prothrombin time may be increased in patients receiving concomitant diflucan and drugb .
DDI-DrugBank.d776.s6	DIFLUCAN	brand	98-105	coumarin-type anticoagulants	group	111-138	effect	coumarin type anticoagulants : prothrombin time may be increased in patients receiving concomitant druga and drugb .
DDI-DrugBank.d776.s7	azole antifungals	group	44-60	fluconazole	drug	242-252	false	in post marketing experience , as with other druga , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving drugb concurrently with warfarin .
DDI-DrugBank.d776.s7	azole antifungals	group	44-60	warfarin	drug	272-279	false	in post marketing experience , as with other druga , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with drugb .
DDI-DrugBank.d776.s7	fluconazole	drug	242-252	warfarin	drug	272-279	effect	in post marketing experience , as with other azole antifungals , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving druga concurrently with drugb .
DDI-DrugBank.d776.s8	DIFLUCAN	brand	61-68	coumarin-type anticoagulants	group	74-101	advise	careful monitoring of prothrombin time in patients receiving druga and drugb is recommended .
DDI-DrugBank.d776.s10	Phenytoin	drug	0-8	DIFLUCAN	brand	11-18	false	druga : drugb increases the plasma concentrations of phenytoin .
DDI-DrugBank.d776.s10	Phenytoin	drug	0-8	phenytoin	drug	59-67	false	druga : diflucan increases the plasma concentrations of drugb .
DDI-DrugBank.d776.s10	DIFLUCAN	brand	11-18	phenytoin	drug	59-67	mechanism	phenytoin : druga increases the plasma concentrations of drugb .
DDI-DrugBank.d776.s11	phenytoin	drug	22-30	DIFLUCAN	brand	69-76	false	careful monitoring of druga concentrations in patients receiving drugb and phenytoin is recommended .
DDI-DrugBank.d776.s11	phenytoin	drug	22-30	phenytoin	drug	82-90	false	careful monitoring of druga concentrations in patients receiving diflucan and drugb is recommended .
DDI-DrugBank.d776.s11	DIFLUCAN	brand	69-76	phenytoin	drug	82-90	advise	careful monitoring of phenytoin concentrations in patients receiving druga and drugb is recommended .
DDI-DrugBank.d776.s13	Cyclosporine	drug	0-11	DIFLUCAN	brand	14-21	false	druga : drugb may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment .
DDI-DrugBank.d776.s13	Cyclosporine	drug	0-11	cyclosporine	drug	50-61	false	druga : diflucan may significantly increase drugb levels in renal transplant patients with or without renal impairment .
DDI-DrugBank.d776.s13	DIFLUCAN	brand	14-21	cyclosporine	drug	50-61	mechanism	cyclosporine : druga may significantly increase drugb levels in renal transplant patients with or without renal impairment .
DDI-DrugBank.d776.s14	cyclosporine	drug	22-33	DIFLUCAN	brand	108-115	false	careful monitoring of druga concentrations and serum creatinine is recommended in patients receiving drugb and cyclosporine .
DDI-DrugBank.d776.s14	cyclosporine	drug	22-33	cyclosporine	drug	121-132	false	careful monitoring of druga concentrations and serum creatinine is recommended in patients receiving diflucan and drugb .
DDI-DrugBank.d776.s14	DIFLUCAN	brand	108-115	cyclosporine	drug	121-132	advise	careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving druga and drugb .
DDI-DrugBank.d776.s16	Rifampin	drug	0-7	Rifampin	drug	10-17	false	druga : drugb enhances the metabolism of concurrently administered diflucan .
DDI-DrugBank.d776.s16	Rifampin	drug	0-7	DIFLUCAN	brand	72-79	false	druga : rifampin enhances the metabolism of concurrently administered drugb .
DDI-DrugBank.d776.s16	Rifampin	drug	10-17	DIFLUCAN	brand	72-79	mechanism	rifampin : druga enhances the metabolism of concurrently administered drugb .
DDI-DrugBank.d776.s17	DIFLUCAN	brand	93-100	rifampin	drug	131-138	advise	depending on clinical circumstances , consideration should be given to increasing the dose of druga when it is administered with drugb .
DDI-DrugBank.d776.s18	Theophylline	drug	0-11	DIFLUCAN	brand	14-21	false	druga : drugb increases the serum concentrations of theophylline .
DDI-DrugBank.d776.s18	Theophylline	drug	0-11	theophylline	drug	61-72	false	druga : diflucan increases the serum concentrations of drugb .
DDI-DrugBank.d776.s18	DIFLUCAN	brand	14-21	theophylline	drug	61-72	mechanism	theophylline : druga increases the serum concentrations of drugb .
DDI-DrugBank.d776.s19	theophylline	drug	28-39	DIFLUCAN	brand	78-85	false	careful monitoring of serum druga concentrations in patients receiving drugb and theophylline is recommended .
DDI-DrugBank.d776.s19	theophylline	drug	28-39	theophylline	drug	91-102	false	careful monitoring of serum druga concentrations in patients receiving diflucan and drugb is recommended .
DDI-DrugBank.d776.s19	DIFLUCAN	brand	78-85	theophylline	drug	91-102	advise	careful monitoring of serum theophylline concentrations in patients receiving druga and drugb is recommended .
DDI-DrugBank.d776.s20	Terfenadine	drug	0-10	azole antifungals	group	139-155	false	druga : because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving drugb in conjunction with terfenadine , interaction studies have been performed .
DDI-DrugBank.d776.s20	Terfenadine	drug	0-10	terfenadine	drug	177-187	false	druga : because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving azole antifungals in conjunction with drugb , interaction studies have been performed .
DDI-DrugBank.d776.s20	azole antifungals	group	139-155	terfenadine	drug	177-187	effect	terfenadine : because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving druga in conjunction with drugb , interaction studies have been performed .
DDI-DrugBank.d776.s22	fluconazole	drug	51-61	DIFLUCAN	brand	81-88	false	another study at a dg mg and dg mg daily dose of druga demonstrated that drugb taken in doses of dg mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly .
DDI-DrugBank.d776.s22	fluconazole	drug	51-61	terfenadine	drug	175-185	false	another study at a dg mg and dg mg daily dose of druga demonstrated that diflucan taken in doses of dg mg per day or greater significantly increases plasma levels of drugb when taken concomitantly .
DDI-DrugBank.d776.s22	DIFLUCAN	brand	81-88	terfenadine	drug	175-185	mechanism	another study at a dg mg and dg mg daily dose of fluconazole demonstrated that druga taken in doses of dg mg per day or greater significantly increases plasma levels of drugb when taken concomitantly .
DDI-DrugBank.d776.s23	fluconazole	drug	20-30	terfenadine	drug	67-77	advise	the combined use of druga at doses of dg mg or greater with drugb is contraindicated .
DDI-DrugBank.d776.s24	fluconazole	drug	24-34	terfenadine	drug	72-82	advise	the coadministration of druga at doses lower than dg mg / day with drugb should be carefully monitored .
DDI-DrugBank.d776.s25	Cisapride	drug	0-8	fluconazole	drug	103-113	false	druga : there have been reports of cardiac events , including torsade de pointes in patients to whom drugb and cisapride were coadministered .
DDI-DrugBank.d776.s25	Cisapride	drug	0-8	cisapride	drug	119-127	false	druga : there have been reports of cardiac events , including torsade de pointes in patients to whom fluconazole and drugb were coadministered .
DDI-DrugBank.d776.s25	fluconazole	drug	103-113	cisapride	drug	119-127	effect	cisapride : there have been reports of cardiac events , including torsade de pointes in patients to whom druga and drugb were coadministered .
DDI-DrugBank.d776.s26	fluconazole	drug	42-52	cisapride	drug	76-84	mechanism	a controlled study found that concomitant druga dg mg once daily and drugb dg mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of qtc interval .
DDI-DrugBank.d776.s26	fluconazole	drug	42-52	cisapride	drug	143-151	false	a controlled study found that concomitant druga dg mg once daily and cisapride dg mg four times a day yielded a significant increase in drugb plasma levels and prolongation of qtc interval .
DDI-DrugBank.d776.s26	cisapride	drug	76-84	cisapride	drug	143-151	false	a controlled study found that concomitant fluconazole dg mg once daily and druga dg mg four times a day yielded a significant increase in drugb plasma levels and prolongation of qtc interval .
DDI-DrugBank.d776.s27	fluconazole	drug	20-30	cisapride	drug	37-45	advise	the combined use of druga with drugb is contraindicated .
DDI-DrugBank.d776.s28	Astemizole	drug	0-9	fluconazole	drug	23-33	false	druga : the use of drugb in patients concurrently taking astemizole or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs .
DDI-DrugBank.d776.s28	Astemizole	drug	0-9	astemizole	drug	67-76	false	druga : the use of fluconazole in patients concurrently taking drugb or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs .
DDI-DrugBank.d776.s28	fluconazole	drug	23-33	astemizole	drug	67-76	mechanism	astemizole : the use of druga in patients concurrently taking drugb or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs .
DDI-DrugBank.d776.s31	Rifabutin	drug	0-8	fluconazole	drug	66-76	false	druga : there have been reports of uveitis in patients to whom drugb and rifabutin were coadministered .
DDI-DrugBank.d776.s31	Rifabutin	drug	0-8	rifabutin	drug	82-90	false	druga : there have been reports of uveitis in patients to whom fluconazole and drugb were coadministered .
DDI-DrugBank.d776.s31	fluconazole	drug	66-76	rifabutin	drug	82-90	effect	rifabutin : there have been reports of uveitis in patients to whom druga and drugb were coadministered .
DDI-DrugBank.d776.s32	rifabutin	drug	19-27	fluconazole	drug	33-43	advise	patients receiving druga and drugb concomitantly should be carefully monitored .
DDI-DrugBank.d776.s33	Tacrolimus	drug	0-9	fluconazole	drug	74-84	false	druga : there have been reports of nephrotoxicity in patients to whom drugb and tacrolimus were coadministered .
DDI-DrugBank.d776.s33	Tacrolimus	drug	0-9	tacrolimus	drug	90-99	false	druga : there have been reports of nephrotoxicity in patients to whom fluconazole and drugb were coadministered .
DDI-DrugBank.d776.s33	fluconazole	drug	74-84	tacrolimus	drug	90-99	effect	tacrolimus : there have been reports of nephrotoxicity in patients to whom druga and drugb were coadministered .
DDI-DrugBank.d776.s34	tacrolimus	drug	19-28	fluconazole	drug	34-44	advise	patients receiving druga and drugb concomitantly should be carefully monitored .
DDI-DrugBank.d776.s35	Short-acting Benzodiazepines	group	0-27	midazolam	drug	63-71	false	druga : following oral administration of drugb , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects .
DDI-DrugBank.d776.s35	Short-acting Benzodiazepines	group	0-27	fluconazole	drug	74-84	false	druga : following oral administration of midazolam , drugb resulted in substantial increases in midazolam concentrations and psychomotor effects .
DDI-DrugBank.d776.s35	Short-acting Benzodiazepines	group	0-27	midazolam	drug	123-131	false	druga : following oral administration of midazolam , fluconazole resulted in substantial increases in drugb concentrations and psychomotor effects .
DDI-DrugBank.d776.s35	midazolam	drug	63-71	fluconazole	drug	74-84	mechanism	short acting benzodiazepines : following oral administration of druga , drugb resulted in substantial increases in midazolam concentrations and psychomotor effects .
DDI-DrugBank.d776.s35	midazolam	drug	63-71	midazolam	drug	123-131	false	short acting benzodiazepines : following oral administration of druga , fluconazole resulted in substantial increases in drugb concentrations and psychomotor effects .
DDI-DrugBank.d776.s35	fluconazole	drug	74-84	midazolam	drug	123-131	false	short acting benzodiazepines : following oral administration of midazolam , druga resulted in substantial increases in drugb concentrations and psychomotor effects .
DDI-DrugBank.d776.s36	midazolam	drug	15-23	fluconazole	drug	88-98	effect	this effect on druga appears to be more pronounced following oral administration of drugb than with fluconazole administered intravenously .
DDI-DrugBank.d776.s36	midazolam	drug	15-23	fluconazole	drug	110-120	false	this effect on druga appears to be more pronounced following oral administration of fluconazole than with drugb administered intravenously .
DDI-DrugBank.d776.s36	fluconazole	drug	88-98	fluconazole	drug	110-120	false	this effect on midazolam appears to be more pronounced following oral administration of druga than with drugb administered intravenously .
DDI-DrugBank.d776.s37	short-acting benzodiazepines	group	3-30	fluconazole	drug	122-132	advise	if druga , which are metabolized by the cytochrome p450 system , are concomitantly administered with drugb , consideration should be given to decreasing the benzodiazepine dosage , and the patients should be appropriately monitored .
DDI-DrugBank.d776.s37	short-acting benzodiazepines	group	3-30	benzodiazepine	group	183-196	false	if druga , which are metabolized by the cytochrome p450 system , are concomitantly administered with fluconazole , consideration should be given to decreasing the drugb dosage , and the patients should be appropriately monitored .
DDI-DrugBank.d776.s37	fluconazole	drug	122-132	benzodiazepine	group	183-196	false	if short acting benzodiazepines , which are metabolized by the cytochrome p450 system , are concomitantly administered with druga , consideration should be given to decreasing the drugb dosage , and the patients should be appropriately monitored .
DDI-DrugBank.d776.s38	Fluconazole	drug	0-10	ethinyl estradiol	drug	40-56	mechanism	druga tablets coadministered with drugb and levonorgestrel containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38	Fluconazole	drug	0-10	levonorgestrel	drug	63-76	mechanism	druga tablets coadministered with ethinyl estradiol and drugb containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38	Fluconazole	drug	0-10	contraceptives	group	94-107	false	druga tablets coadministered with ethinyl estradiol and levonorgestrel containing oral drugb produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38	Fluconazole	drug	0-10	ethinyl estradiol	drug	146-162	false	druga tablets coadministered with ethinyl estradiol and levonorgestrel containing oral contraceptives produced an overall mean increase in drugb and levonorgestrel levels ;
DDI-DrugBank.d776.s38	Fluconazole	drug	0-10	levonorgestrel	drug	168-181	false	druga tablets coadministered with ethinyl estradiol and levonorgestrel containing oral contraceptives produced an overall mean increase in ethinyl estradiol and drugb levels ;
DDI-DrugBank.d776.s38	ethinyl estradiol	drug	40-56	levonorgestrel	drug	63-76	false	fluconazole tablets coadministered with druga and drugb containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38	ethinyl estradiol	drug	40-56	contraceptives	group	94-107	false	fluconazole tablets coadministered with druga and levonorgestrel containing oral drugb produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38	ethinyl estradiol	drug	40-56	ethinyl estradiol	drug	146-162	false	fluconazole tablets coadministered with druga and levonorgestrel containing oral contraceptives produced an overall mean increase in drugb and levonorgestrel levels ;
DDI-DrugBank.d776.s38	ethinyl estradiol	drug	40-56	levonorgestrel	drug	168-181	false	fluconazole tablets coadministered with druga and levonorgestrel containing oral contraceptives produced an overall mean increase in ethinyl estradiol and drugb levels ;
DDI-DrugBank.d776.s38	levonorgestrel	drug	63-76	contraceptives	group	94-107	false	fluconazole tablets coadministered with ethinyl estradiol and druga containing oral drugb produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38	levonorgestrel	drug	63-76	ethinyl estradiol	drug	146-162	false	fluconazole tablets coadministered with ethinyl estradiol and druga containing oral contraceptives produced an overall mean increase in drugb and levonorgestrel levels ;
DDI-DrugBank.d776.s38	levonorgestrel	drug	63-76	levonorgestrel	drug	168-181	false	fluconazole tablets coadministered with ethinyl estradiol and druga containing oral contraceptives produced an overall mean increase in ethinyl estradiol and drugb levels ;
DDI-DrugBank.d776.s38	contraceptives	group	94-107	ethinyl estradiol	drug	146-162	false	fluconazole tablets coadministered with ethinyl estradiol and levonorgestrel containing oral druga produced an overall mean increase in drugb and levonorgestrel levels ;
DDI-DrugBank.d776.s38	contraceptives	group	94-107	levonorgestrel	drug	168-181	false	fluconazole tablets coadministered with ethinyl estradiol and levonorgestrel containing oral druga produced an overall mean increase in ethinyl estradiol and drugb levels ;
DDI-DrugBank.d776.s38	ethinyl estradiol	drug	146-162	levonorgestrel	drug	168-181	false	fluconazole tablets coadministered with ethinyl estradiol and levonorgestrel containing oral contraceptives produced an overall mean increase in druga and drugb levels ;
DDI-DrugBank.d776.s39	ethinyl estradiol	drug	68-84	levonorgestrel	drug	90-103	false	however , in some patients there were decreases up to dg % and dg % of druga and drugb levels .
DDI-DrugBank.d776.s40	ethinyl estradiol	drug	76-92	levonorgestrel	drug	98-111	false	the data presently available indicate that the decreases in some individual druga and drugb auc values with fluconazole treatment are likely the result of random variation .
DDI-DrugBank.d776.s40	ethinyl estradiol	drug	76-92	fluconazole	drug	129-139	false	the data presently available indicate that the decreases in some individual druga and levonorgestrel auc values with drugb treatment are likely the result of random variation .
DDI-DrugBank.d776.s40	levonorgestrel	drug	98-111	fluconazole	drug	129-139	false	the data presently available indicate that the decreases in some individual ethinyl estradiol and druga auc values with drugb treatment are likely the result of random variation .
DDI-DrugBank.d776.s41	fluconazole	drug	29-39	ethinyl estradiol	drug	71-87	mechanism	while there is evidence that druga can inhibit the metabolism of drugb and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	fluconazole	drug	29-39	levonorgestrel	drug	93-106	mechanism	while there is evidence that druga can inhibit the metabolism of ethinyl estradiol and drugb , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	fluconazole	drug	29-39	fluconazole	drug	135-145	false	while there is evidence that druga can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that drugb is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	fluconazole	drug	29-39	ethinyl estradiol	drug	167-183	false	while there is evidence that druga can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of drugb or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	fluconazole	drug	29-39	levonorgestrel	drug	188-201	false	while there is evidence that druga can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or drugb metabolism .
DDI-DrugBank.d776.s41	ethinyl estradiol	drug	71-87	levonorgestrel	drug	93-106	false	while there is evidence that fluconazole can inhibit the metabolism of druga and drugb , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	ethinyl estradiol	drug	71-87	fluconazole	drug	135-145	false	while there is evidence that fluconazole can inhibit the metabolism of druga and levonorgestrel , there is no evidence that drugb is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	ethinyl estradiol	drug	71-87	ethinyl estradiol	drug	167-183	false	while there is evidence that fluconazole can inhibit the metabolism of druga and levonorgestrel , there is no evidence that fluconazole is a net inducer of drugb or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	ethinyl estradiol	drug	71-87	levonorgestrel	drug	188-201	false	while there is evidence that fluconazole can inhibit the metabolism of druga and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or drugb metabolism .
DDI-DrugBank.d776.s41	levonorgestrel	drug	93-106	fluconazole	drug	135-145	false	while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and druga , there is no evidence that drugb is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	levonorgestrel	drug	93-106	ethinyl estradiol	drug	167-183	false	while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and druga , there is no evidence that fluconazole is a net inducer of drugb or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	levonorgestrel	drug	93-106	levonorgestrel	drug	188-201	false	while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and druga , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or drugb metabolism .
DDI-DrugBank.d776.s41	fluconazole	drug	135-145	ethinyl estradiol	drug	167-183	false	while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that druga is a net inducer of drugb or levonorgestrel metabolism .
DDI-DrugBank.d776.s41	fluconazole	drug	135-145	levonorgestrel	drug	188-201	false	while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that druga is a net inducer of ethinyl estradiol or drugb metabolism .
DDI-DrugBank.d776.s41	ethinyl estradiol	drug	167-183	levonorgestrel	drug	188-201	false	while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of druga or drugb metabolism .
DDI-DrugBank.d716.s0	mazindol	drug	16-23	monoamine oxidase inhibitor	group	45-71	advise	you can not take druga if you have taken a drugb ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	mazindol	drug	16-23	MAOI	group	74-77	advise	you can not take druga if you have taken a monoamine oxidase inhibitor ( drugb ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	mazindol	drug	16-23	isocarboxazid	drug	88-100	advise	you can not take druga if you have taken a monoamine oxidase inhibitor ( maoi ) such as drugb ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	mazindol	drug	16-23	Marplan	brand	103-109	advise	you can not take druga if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( drugb ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	mazindol	drug	16-23	tranylcypromine	drug	113-127	advise	you can not take druga if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , drugb ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	mazindol	drug	16-23	Parnate	brand	130-136	advise	you can not take druga if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( drugb ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	mazindol	drug	16-23	phenelzine	drug	143-152	advise	you can not take druga if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or drugb ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	mazindol	drug	16-23	Nardil	brand	155-160	advise	you can not take druga if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( drugb ) in the last dg days .
DDI-DrugBank.d716.s0	monoamine oxidase inhibitor	group	45-71	MAOI	group	74-77	false	you can not take mazindol if you have taken a druga ( drugb ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	monoamine oxidase inhibitor	group	45-71	isocarboxazid	drug	88-100	false	you can not take mazindol if you have taken a druga ( maoi ) such as drugb ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	monoamine oxidase inhibitor	group	45-71	Marplan	brand	103-109	false	you can not take mazindol if you have taken a druga ( maoi ) such as isocarboxazid ( drugb ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	monoamine oxidase inhibitor	group	45-71	tranylcypromine	drug	113-127	false	you can not take mazindol if you have taken a druga ( maoi ) such as isocarboxazid ( marplan ) , drugb ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	monoamine oxidase inhibitor	group	45-71	Parnate	brand	130-136	false	you can not take mazindol if you have taken a druga ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( drugb ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	monoamine oxidase inhibitor	group	45-71	phenelzine	drug	143-152	false	you can not take mazindol if you have taken a druga ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or drugb ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	monoamine oxidase inhibitor	group	45-71	Nardil	brand	155-160	false	you can not take mazindol if you have taken a druga ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( drugb ) in the last dg days .
DDI-DrugBank.d716.s0	MAOI	group	74-77	isocarboxazid	drug	88-100	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( druga ) such as drugb ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	MAOI	group	74-77	Marplan	brand	103-109	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( druga ) such as isocarboxazid ( drugb ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	MAOI	group	74-77	tranylcypromine	drug	113-127	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( druga ) such as isocarboxazid ( marplan ) , drugb ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	MAOI	group	74-77	Parnate	brand	130-136	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( druga ) such as isocarboxazid ( marplan ) , tranylcypromine ( drugb ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	MAOI	group	74-77	phenelzine	drug	143-152	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( druga ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or drugb ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	MAOI	group	74-77	Nardil	brand	155-160	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( druga ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( drugb ) in the last dg days .
DDI-DrugBank.d716.s0	isocarboxazid	drug	88-100	Marplan	brand	103-109	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as druga ( drugb ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	isocarboxazid	drug	88-100	tranylcypromine	drug	113-127	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as druga ( marplan ) , drugb ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	isocarboxazid	drug	88-100	Parnate	brand	130-136	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as druga ( marplan ) , tranylcypromine ( drugb ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	isocarboxazid	drug	88-100	phenelzine	drug	143-152	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as druga ( marplan ) , tranylcypromine ( parnate ) , or drugb ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	isocarboxazid	drug	88-100	Nardil	brand	155-160	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as druga ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( drugb ) in the last dg days .
DDI-DrugBank.d716.s0	Marplan	brand	103-109	tranylcypromine	drug	113-127	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( druga ) , drugb ( parnate ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	Marplan	brand	103-109	Parnate	brand	130-136	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( druga ) , tranylcypromine ( drugb ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	Marplan	brand	103-109	phenelzine	drug	143-152	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( druga ) , tranylcypromine ( parnate ) , or drugb ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	Marplan	brand	103-109	Nardil	brand	155-160	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( druga ) , tranylcypromine ( parnate ) , or phenelzine ( drugb ) in the last dg days .
DDI-DrugBank.d716.s0	tranylcypromine	drug	113-127	Parnate	brand	130-136	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , druga ( drugb ) , or phenelzine ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	tranylcypromine	drug	113-127	phenelzine	drug	143-152	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , druga ( parnate ) , or drugb ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	tranylcypromine	drug	113-127	Nardil	brand	155-160	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , druga ( parnate ) , or phenelzine ( drugb ) in the last dg days .
DDI-DrugBank.d716.s0	Parnate	brand	130-136	phenelzine	drug	143-152	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( druga ) , or drugb ( nardil ) in the last dg days .
DDI-DrugBank.d716.s0	Parnate	brand	130-136	Nardil	brand	155-160	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( druga ) , or phenelzine ( drugb ) in the last dg days .
DDI-DrugBank.d716.s0	phenelzine	drug	143-152	Nardil	brand	155-160	false	you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or druga ( drugb ) in the last dg days .
DDI-DrugBank.d716.s1	insulin	drug	11-17	mazindol	drug	92-99	advise	changes in druga and other diabetes drug therapies may be necessary during treatment with drugb .
DDI-DrugBank.d716.s2	Mazindol	drug	0-7	guanethidine	drug	35-46	effect	druga may reduce the effects of drugb ( ismelin ) .
DDI-DrugBank.d716.s2	Mazindol	drug	0-7	Ismelin	brand	49-55	effect	druga may reduce the effects of guanethidine ( drugb ) .
DDI-DrugBank.d716.s2	guanethidine	drug	35-46	Ismelin	brand	49-55	false	mazindol may reduce the effects of druga ( drugb ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	amitriptyline	drug	101-113	false	before taking this medication , tell your doctor if you are taking a druga such as drugb ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	Elavil	brand	116-121	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( drugb ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	amoxapine	drug	125-133	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , drugb ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	Asendin	brand	136-142	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( drugb ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	doxepin	drug	146-152	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , drugb ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	Sinequan	brand	155-162	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( drugb ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	nortriptyline	drug	166-178	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , drugb ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	Pamelor	brand	181-187	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( drugb ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	imipramine	drug	191-200	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , drugb ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	tricyclic antidepressant	group	68-91	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a druga such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	Elavil	brand	116-121	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( drugb ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	amoxapine	drug	125-133	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , drugb ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	Asendin	brand	136-142	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( drugb ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	doxepin	drug	146-152	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , drugb ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	Sinequan	brand	155-162	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( drugb ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	nortriptyline	drug	166-178	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , drugb ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	Pamelor	brand	181-187	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( drugb ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	imipramine	drug	191-200	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , drugb ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	amitriptyline	drug	101-113	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as druga ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	amoxapine	drug	125-133	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , drugb ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	Asendin	brand	136-142	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( drugb ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	doxepin	drug	146-152	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , drugb ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	Sinequan	brand	155-162	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( drugb ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	nortriptyline	drug	166-178	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , drugb ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	Pamelor	brand	181-187	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( drugb ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	imipramine	drug	191-200	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , drugb ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	Elavil	brand	116-121	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( druga ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	Asendin	brand	136-142	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( drugb ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	doxepin	drug	146-152	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , drugb ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	Sinequan	brand	155-162	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( drugb ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	nortriptyline	drug	166-178	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , drugb ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	Pamelor	brand	181-187	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , nortriptyline ( drugb ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	imipramine	drug	191-200	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , drugb ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	amoxapine	drug	125-133	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , druga ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	doxepin	drug	146-152	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , drugb ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	Sinequan	brand	155-162	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( drugb ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	nortriptyline	drug	166-178	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , drugb ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	Pamelor	brand	181-187	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , nortriptyline ( drugb ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	imipramine	drug	191-200	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , drugb ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	Asendin	brand	136-142	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( druga ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	Sinequan	brand	155-162	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( drugb ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	nortriptyline	drug	166-178	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , drugb ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	Pamelor	brand	181-187	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , nortriptyline ( drugb ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	imipramine	drug	191-200	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , nortriptyline ( pamelor ) , drugb ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	doxepin	drug	146-152	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , druga ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	nortriptyline	drug	166-178	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , drugb ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	Pamelor	brand	181-187	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , nortriptyline ( drugb ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	imipramine	drug	191-200	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , nortriptyline ( pamelor ) , drugb ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , nortriptyline ( pamelor ) , imipramine ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	Sinequan	brand	155-162	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( druga ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	nortriptyline	drug	166-178	Pamelor	brand	181-187	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , druga ( drugb ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	nortriptyline	drug	166-178	imipramine	drug	191-200	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , druga ( pamelor ) , drugb ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	nortriptyline	drug	166-178	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , druga ( pamelor ) , imipramine ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	nortriptyline	drug	166-178	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , druga ( pamelor ) , imipramine ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	nortriptyline	drug	166-178	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , druga ( pamelor ) , imipramine ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	nortriptyline	drug	166-178	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , druga ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	nortriptyline	drug	166-178	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , druga ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	nortriptyline	drug	166-178	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , druga ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	nortriptyline	drug	166-178	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , druga ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	Pamelor	brand	181-187	imipramine	drug	191-200	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( druga ) , drugb ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Pamelor	brand	181-187	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( druga ) , imipramine ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Pamelor	brand	181-187	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( druga ) , imipramine ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Pamelor	brand	181-187	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( druga ) , imipramine ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Pamelor	brand	181-187	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( druga ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Pamelor	brand	181-187	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( druga ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Pamelor	brand	181-187	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( druga ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	Pamelor	brand	181-187	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( druga ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	imipramine	drug	191-200	Tofranil	brand	203-210	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , druga ( drugb ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	imipramine	drug	191-200	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , druga ( tofranil ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	imipramine	drug	191-200	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , druga ( tofranil ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	imipramine	drug	191-200	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , druga ( tofranil ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	imipramine	drug	191-200	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , druga ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	imipramine	drug	191-200	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , druga ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	imipramine	drug	191-200	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , druga ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	Tofranil	brand	203-210	clomipramine	drug	214-225	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( druga ) , drugb ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Tofranil	brand	203-210	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( druga ) , clomipramine ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Tofranil	brand	203-210	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( druga ) , clomipramine ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Tofranil	brand	203-210	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( druga ) , clomipramine ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Tofranil	brand	203-210	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( druga ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	Tofranil	brand	203-210	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( druga ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	clomipramine	drug	214-225	Anafranil	brand	228-236	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , druga ( drugb ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	clomipramine	drug	214-225	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , druga ( anafranil ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	clomipramine	drug	214-225	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , druga ( anafranil ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	clomipramine	drug	214-225	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , druga ( anafranil ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	clomipramine	drug	214-225	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , druga ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	Anafranil	brand	228-236	protriptyline	drug	240-252	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( druga ) , drugb ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Anafranil	brand	228-236	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( druga ) , protriptyline ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	Anafranil	brand	228-236	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( druga ) , protriptyline ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	Anafranil	brand	228-236	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( druga ) , protriptyline ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	protriptyline	drug	240-252	Vivactil	brand	255-262	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , druga ( drugb ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5	protriptyline	drug	240-252	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , druga ( vivactil ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	protriptyline	drug	240-252	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , druga ( vivactil ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	Vivactil	brand	255-262	desipramine	drug	269-279	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( druga ) , or drugb ( norpramin ) .
DDI-DrugBank.d716.s5	Vivactil	brand	255-262	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( druga ) , or desipramine ( drugb ) .
DDI-DrugBank.d716.s5	desipramine	drug	269-279	Norpramin	brand	282-290	false	before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or druga ( drugb ) .
DDI-DrugBank.d679.s0	cimetidine	drug	35-44	mebendazole	drug	55-65	mechanism	preliminary evidence suggests that druga inhibits drugb metabolism and may result in an increase in plasma concentrations of mebendazole .
DDI-DrugBank.d679.s0	cimetidine	drug	35-44	mebendazole	drug	136-146	false	preliminary evidence suggests that druga inhibits mebendazole metabolism and may result in an increase in plasma concentrations of drugb .
DDI-DrugBank.d679.s0	mebendazole	drug	55-65	mebendazole	drug	136-146	false	preliminary evidence suggests that cimetidine inhibits druga metabolism and may result in an increase in plasma concentrations of drugb .
DDI-DrugBank.d579.s0	antibiotics	group	19-29	sulfonamides	group	35-46	false	patients receiving druga and drugb generally should not be treated with ganglion blockers .
DDI-DrugBank.d579.s0	antibiotics	group	19-29	ganglion blockers	group	85-101	advise	patients receiving druga and sulfonamides generally should not be treated with drugb .
DDI-DrugBank.d579.s0	sulfonamides	group	35-46	ganglion blockers	group	85-101	advise	patients receiving antibiotics and druga generally should not be treated with drugb .
DDI-DrugBank.d579.s1	Mecamylamine	drug	14-25	antihypertensive drugs	group	67-88	effect	the action of druga may be potentiated by anesthesia , other drugb and alcohol .
DDI-DrugBank.d579.s1	Mecamylamine	drug	14-25	alcohol	drug	94-100	effect	the action of druga may be potentiated by anesthesia , other antihypertensive drugs and drugb .
DDI-DrugBank.d579.s1	antihypertensive drugs	group	67-88	alcohol	drug	94-100	false	the action of mecamylamine may be potentiated by anesthesia , other druga and drugb .
DDI-DrugBank.d623.s1	Aminoglutethimide	drug	0-16	depo-subQ provera 104	brand	50-70	mechanism	druga administered concomitantly with drugb may significantly decrease the serum concentrations of mpa .
DDI-DrugBank.d623.s1	Aminoglutethimide	drug	0-16	MPA	drug	127-129	false	druga administered concomitantly with depo subq provera dg may significantly decrease the serum concentrations of drugb .
DDI-DrugBank.d623.s1	depo-subQ provera 104	brand	50-70	MPA	drug	127-129	false	aminoglutethimide administered concomitantly with druga may significantly decrease the serum concentrations of drugb .
DDI-DrugBank.d688.s0	zidovudine	drug	104-113	rifabutin	drug	118-126	false	pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of druga or drugb to warrant dosage adjustment when megestrol acetate is administered with these drugs .
DDI-DrugBank.d688.s0	zidovudine	drug	104-113	megestrol acetate	drug	162-178	false	pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of druga or rifabutin to warrant dosage adjustment when drugb is administered with these drugs .
DDI-DrugBank.d688.s0	rifabutin	drug	118-126	megestrol acetate	drug	162-178	false	pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or druga to warrant dosage adjustment when drugb is administered with these drugs .
DDI-DrugBank.d688.s1	megestrol acetate	drug	62-78	indinavir	drug	84-92	mechanism	a pharmacokinetic study demonstrated that coadministration of druga and drugb results in a significant decrease in the pharmacokinetic parameters ( ~ dg % for cmax and ~ dg % for auc ) of indinavir .
DDI-DrugBank.d688.s1	megestrol acetate	drug	62-78	indinavir	drug	198-206	false	a pharmacokinetic study demonstrated that coadministration of druga and indinavir results in a significant decrease in the pharmacokinetic parameters ( ~ dg % for cmax and ~ dg % for auc ) of drugb .
DDI-DrugBank.d688.s1	indinavir	drug	84-92	indinavir	drug	198-206	false	a pharmacokinetic study demonstrated that coadministration of megestrol acetate and druga results in a significant decrease in the pharmacokinetic parameters ( ~ dg % for cmax and ~ dg % for auc ) of drugb .
DDI-DrugBank.d688.s2	indinavir	drug	35-43	megestrol acetate	drug	92-108	advise	administration of a higher dose of druga should be considered when coadministering with drugb .
DDI-DrugBank.d688.s3	indinavir	drug	15-23	zidovudine	drug	26-35	false	the effects of druga , drugb or rifabutin on the pharmacokinetics of megestrol acetate were not studied .
DDI-DrugBank.d688.s3	indinavir	drug	15-23	rifabutin	drug	40-48	false	the effects of druga , zidovudine or drugb on the pharmacokinetics of megestrol acetate were not studied .
DDI-DrugBank.d688.s3	indinavir	drug	15-23	megestrol acetate	drug	77-93	false	the effects of druga , zidovudine or rifabutin on the pharmacokinetics of drugb were not studied .
DDI-DrugBank.d688.s3	zidovudine	drug	26-35	rifabutin	drug	40-48	false	the effects of indinavir , druga or drugb on the pharmacokinetics of megestrol acetate were not studied .
DDI-DrugBank.d688.s3	zidovudine	drug	26-35	megestrol acetate	drug	77-93	false	the effects of indinavir , druga or rifabutin on the pharmacokinetics of drugb were not studied .
DDI-DrugBank.d688.s3	rifabutin	drug	40-48	megestrol acetate	drug	77-93	false	the effects of indinavir , zidovudine or druga on the pharmacokinetics of drugb were not studied .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	aspirin	brand	49-55	int	druga may interact with the following drugs : drugb and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	NSAIDs	group	67-72	int	druga may interact with the following drugs : aspirin and other drugb ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	melatonin	drug	85-93	false	druga may interact with the following drugs : aspirin and other nsaids ( may lower drugb levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	fluvoxamine	drug	104-114	int	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , drugb ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	melatonin	drug	141-149	false	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral drugb is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	beta blockers	group	188-200	int	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , drugb ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	melatonin	drug	216-224	false	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease drugb levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	fluoxetine	drug	235-244	int	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , drugb ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	progestin	group	299-307	int	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	melatonin	drug	330-338	false	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	progestin	group	345-353	false	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	benzodiazepenes	group	395-409	int	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	corticosteroids	group	521-535	int	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	melatonin	drug	558-566	false	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	corticosteroids	group	572-586	false	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	Melatonin	drug	0-8	corticosteroids	group	627-641	false	druga may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	NSAIDs	group	67-72	false	melatonin may interact with the following drugs : druga and other drugb ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	melatonin	drug	85-93	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower drugb levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	fluvoxamine	drug	104-114	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , drugb ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	melatonin	drug	141-149	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral drugb is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	beta blockers	group	188-200	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , drugb ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	melatonin	drug	216-224	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease drugb levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	fluoxetine	drug	235-244	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , drugb ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	progestin	group	299-307	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	melatonin	drug	330-338	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	progestin	group	345-353	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	melatonin	drug	558-566	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	aspirin	brand	49-55	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : druga and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	melatonin	drug	85-93	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower drugb levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	fluvoxamine	drug	104-114	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , drugb ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	melatonin	drug	141-149	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral drugb is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	beta blockers	group	188-200	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , drugb ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	melatonin	drug	216-224	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease drugb levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	fluoxetine	drug	235-244	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , drugb ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	progestin	group	299-307	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	melatonin	drug	330-338	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	progestin	group	345-353	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	NSAIDs	group	67-72	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other druga ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	fluvoxamine	drug	104-114	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , drugb ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	melatonin	drug	141-149	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral drugb is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	beta blockers	group	188-200	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , drugb ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	melatonin	drug	216-224	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease drugb levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	fluoxetine	drug	235-244	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , drugb ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	progestin	group	299-307	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	melatonin	drug	330-338	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	progestin	group	345-353	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	85-93	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower druga levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	melatonin	drug	141-149	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral drugb is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	beta blockers	group	188-200	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , drugb ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	melatonin	drug	216-224	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease drugb levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	fluoxetine	drug	235-244	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , drugb ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	progestin	group	299-307	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	melatonin	drug	330-338	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	progestin	group	345-353	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluvoxamine	drug	104-114	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , druga ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	beta blockers	group	188-200	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , drugb ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	melatonin	drug	216-224	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease drugb levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	fluoxetine	drug	235-244	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , drugb ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	progestin	group	299-307	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	melatonin	drug	330-338	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	progestin	group	345-353	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	141-149	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral druga is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	melatonin	drug	216-224	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease drugb levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	fluoxetine	drug	235-244	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease melatonin levels ) , drugb ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	progestin	group	299-307	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	melatonin	drug	330-338	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	progestin	group	345-353	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	beta blockers	group	188-200	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , druga ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	melatonin	drug	216-224	fluoxetine	drug	235-244	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease druga levels ) , drugb ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	216-224	progestin	group	299-307	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease druga levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	216-224	melatonin	drug	330-338	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease druga levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	216-224	progestin	group	345-353	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease druga levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	216-224	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease druga levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	216-224	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease druga levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	216-224	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease druga levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	216-224	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease druga levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	216-224	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease druga levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	fluoxetine	drug	235-244	progestin	group	299-307	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , druga ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluoxetine	drug	235-244	melatonin	drug	330-338	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , druga ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluoxetine	drug	235-244	progestin	group	345-353	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , druga ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluoxetine	drug	235-244	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , druga ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluoxetine	drug	235-244	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , druga ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluoxetine	drug	235-244	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , druga ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluoxetine	drug	235-244	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , druga ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	fluoxetine	drug	235-244	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , druga ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	progestin	group	299-307	melatonin	drug	330-338	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , druga ( coadministration of drugb with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	299-307	progestin	group	345-353	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , druga ( coadministration of melatonin with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	299-307	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , druga ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	299-307	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , druga ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	299-307	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , druga ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	299-307	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , druga ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	299-307	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , druga ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	melatonin	drug	330-338	progestin	group	345-353	effect	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of druga with drugb can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	330-338	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of druga with progestin can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	330-338	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of druga with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	330-338	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of druga with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	330-338	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of druga with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	330-338	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of druga with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	progestin	group	345-353	benzodiazepenes	group	395-409	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with druga can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	345-353	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with druga can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	345-353	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with druga can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	345-353	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with druga can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	progestin	group	345-353	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with druga can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	benzodiazepenes	group	395-409	corticosteroids	group	521-535	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , druga and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	benzodiazepenes	group	395-409	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , druga and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	benzodiazepenes	group	395-409	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , druga and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	benzodiazepenes	group	395-409	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , druga and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	corticosteroids	group	521-535	melatonin	drug	558-566	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and druga ( coadministration of drugb and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	corticosteroids	group	521-535	corticosteroids	group	572-586	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and druga ( coadministration of melatonin and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	corticosteroids	group	521-535	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and druga ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	melatonin	drug	558-566	corticosteroids	group	572-586	effect	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of druga and drugb may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0	melatonin	drug	558-566	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of druga and corticosteroids may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d643.s0	corticosteroids	group	572-586	corticosteroids	group	627-641	false	melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and druga may interfere with the efficacy of the drugb ) .
DDI-DrugBank.d597.s0	ACE inhibitors	group	0-13	NSAIDs	group	36-41	false	druga reports suggest that drugb may diminish the antihypertensive effect of angiotensin converting enzyme ( ace ) inhibitors .
DDI-DrugBank.d597.s0	ACE inhibitors	group	0-13	angiotensin-converting enzyme (ACE) inhibitors	group	87-132	false	druga reports suggest that nsaids may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d597.s0	NSAIDs	group	36-41	angiotensin-converting enzyme (ACE) inhibitors	group	87-132	effect	ace inhibitors reports suggest that druga may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d597.s1	NSAIDs	group	66-71	ACE inhibitors	group	92-105	advise	this interaction should be given consideration in patients taking druga concomitantly with drugb .
DDI-DrugBank.d597.s2	Aspirin	brand	0-6	aspirin	brand	39-45	false	druga : concomitant administration of drugb ( dg mg tid ) to healthy volunteers tended to increase the auc ( dg % ) and cmax ( dg % ) of meloxicam .
DDI-DrugBank.d597.s2	Aspirin	brand	0-6	meloxicam	drug	134-142	false	druga : concomitant administration of aspirin ( dg mg tid ) to healthy volunteers tended to increase the auc ( dg % ) and cmax ( dg % ) of drugb .
DDI-DrugBank.d597.s2	aspirin	brand	39-45	meloxicam	drug	134-142	mechanism	aspirin : concomitant administration of druga ( dg mg tid ) to healthy volunteers tended to increase the auc ( dg % ) and cmax ( dg % ) of drugb .
DDI-DrugBank.d597.s4	NSAIDs	group	23-28	meloxicam	drug	61-69	false	however , as with other druga , concomitant administration of drugb and aspirin is not generally recommended because of the potential for increased adverse effects .
DDI-DrugBank.d597.s4	NSAIDs	group	23-28	aspirin	brand	75-81	advise	however , as with other druga , concomitant administration of meloxicam and drugb is not generally recommended because of the potential for increased adverse effects .
DDI-DrugBank.d597.s4	meloxicam	drug	61-69	aspirin	brand	75-81	advise	however , as with other nsaids , concomitant administration of druga and drugb is not generally recommended because of the potential for increased adverse effects .
DDI-DrugBank.d597.s5	aspirin	brand	39-45	MOBIC	brand	52-56	effect	concomitant administration of low dose druga with drugb may result in an increased rate of gi ulceration or other complications , compared to use of mobic alone .
DDI-DrugBank.d597.s5	aspirin	brand	39-45	MOBIC	brand	150-154	false	concomitant administration of low dose druga with mobic may result in an increased rate of gi ulceration or other complications , compared to use of drugb alone .
DDI-DrugBank.d597.s5	MOBIC	brand	52-56	MOBIC	brand	150-154	false	concomitant administration of low dose aspirin with druga may result in an increased rate of gi ulceration or other complications , compared to use of drugb alone .
DDI-DrugBank.d597.s6	MOBIC	brand	0-4	aspirin	brand	30-36	false	druga is not a substitute for drugb for cardiovascular prophylaxis .
DDI-DrugBank.d597.s7	Cholestyramine	drug	0-13	cholestyramine	drug	48-61	false	druga : pretreatment for four days with drugb significantly increased the clearance of meloxicam by dg % .
DDI-DrugBank.d597.s7	Cholestyramine	drug	0-13	meloxicam	drug	104-112	false	druga : pretreatment for four days with cholestyramine significantly increased the clearance of drugb by dg % .
DDI-DrugBank.d597.s7	cholestyramine	drug	48-61	meloxicam	drug	104-112	mechanism	cholestyramine : pretreatment for four days with druga significantly increased the clearance of drugb by dg % .
DDI-DrugBank.d597.s11	Cimetidine	drug	0-9	cimetidine	drug	49-58	false	druga : concomitant administration of dg mg drugb qid did not alter the single dose pharmacokinetics of dg mg meloxicam .
DDI-DrugBank.d597.s11	Cimetidine	drug	0-9	meloxicam	drug	120-128	false	druga : concomitant administration of dg mg cimetidine qid did not alter the single dose pharmacokinetics of dg mg drugb .
DDI-DrugBank.d597.s11	cimetidine	drug	49-58	meloxicam	drug	120-128	false	cimetidine : concomitant administration of dg mg druga qid did not alter the single dose pharmacokinetics of dg mg drugb .
DDI-DrugBank.d597.s12	Digoxin	drug	0-6	Meloxicam	drug	9-17	false	druga : drugb dg mg once daily for dg days did not alter the plasma concentration profile of digoxin after b acetyldigoxin administration for dg days at clinical doses .
DDI-DrugBank.d597.s12	Digoxin	drug	0-6	digoxin	drug	97-103	false	druga : meloxicam dg mg once daily for dg days did not alter the plasma concentration profile of drugb after b acetyldigoxin administration for dg days at clinical doses .
DDI-DrugBank.d597.s12	Meloxicam	drug	9-17	digoxin	drug	97-103	false	digoxin : druga dg mg once daily for dg days did not alter the plasma concentration profile of drugb after b acetyldigoxin administration for dg days at clinical doses .
DDI-DrugBank.d597.s13	digoxin	drug	67-73	meloxicam	drug	79-87	false	in vitro testing found no protein binding drug interaction between druga and drugb .
DDI-DrugBank.d597.s14	Furosemide	drug	0-9	NSAIDs	group	86-91	false	druga : clinical studies , as well as post marketing observations , have shown that drugb can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients .
DDI-DrugBank.d597.s14	Furosemide	drug	0-9	furosemide	drug	130-139	false	druga : clinical studies , as well as post marketing observations , have shown that nsaids can reduce the natriuretic effect of drugb and thiazide diuretics in some patients .
DDI-DrugBank.d597.s14	Furosemide	drug	0-9	thiazide diuretics	group	145-162	false	druga : clinical studies , as well as post marketing observations , have shown that nsaids can reduce the natriuretic effect of furosemide and drugb in some patients .
DDI-DrugBank.d597.s14	NSAIDs	group	86-91	furosemide	drug	130-139	effect	furosemide : clinical studies , as well as post marketing observations , have shown that druga can reduce the natriuretic effect of drugb and thiazide diuretics in some patients .
DDI-DrugBank.d597.s14	NSAIDs	group	86-91	thiazide diuretics	group	145-162	effect	furosemide : clinical studies , as well as post marketing observations , have shown that druga can reduce the natriuretic effect of furosemide and drugb in some patients .
DDI-DrugBank.d597.s14	furosemide	drug	130-139	thiazide diuretics	group	145-162	false	furosemide : clinical studies , as well as post marketing observations , have shown that nsaids can reduce the natriuretic effect of druga and drugb in some patients .
DDI-DrugBank.d597.s16	furosemide	drug	13-22	meloxicam	drug	35-43	false	studies with druga agents and drugb have not demonstrated a reduction in natriuretic effect .
DDI-DrugBank.d597.s17	Furosemide	drug	0-9	meloxicam	drug	113-121	false	druga : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of drugb .
DDI-DrugBank.d597.s18	furosemide	drug	46-55	MOBIC	brand	61-65	advise	nevertheless , during concomitant therapy with druga and drugb , patients should be observed closely for signs of declining renal function , as well as to assure diuretic efficacy .
DDI-DrugBank.d597.s19	Lithium	drug	0-6	NSAIDs	group	29-34	false	druga : in clinical trials , drugb have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance .
DDI-DrugBank.d597.s19	Lithium	drug	0-6	lithium	drug	73-79	false	druga : in clinical trials , nsaids have produced an elevation of plasma drugb levels and a reduction in renal lithium clearance .
DDI-DrugBank.d597.s19	Lithium	drug	0-6	lithium	drug	113-119	false	druga : in clinical trials , nsaids have produced an elevation of plasma lithium levels and a reduction in renal drugb clearance .
DDI-DrugBank.d597.s19	NSAIDs	group	29-34	lithium	drug	73-79	mechanism	lithium : in clinical trials , druga have produced an elevation of plasma drugb levels and a reduction in renal lithium clearance .
DDI-DrugBank.d597.s19	NSAIDs	group	29-34	lithium	drug	113-119	false	lithium : in clinical trials , druga have produced an elevation of plasma lithium levels and a reduction in renal drugb clearance .
DDI-DrugBank.d597.s19	lithium	drug	73-79	lithium	drug	113-119	false	lithium : in clinical trials , nsaids have produced an elevation of plasma druga levels and a reduction in renal drugb clearance .
DDI-DrugBank.d597.s20	lithium	drug	56-62	lithium	drug	130-136	false	in a study conducted in healthy subjects , mean pre dose druga concentration and auc were increased by dg % in subjects receiving drugb doses ranging from dg to dg mg bid with meloxicam dg mg qd as compared to subjects receiving lithium alone .
DDI-DrugBank.d597.s20	lithium	drug	56-62	meloxicam	drug	181-189	false	in a study conducted in healthy subjects , mean pre dose druga concentration and auc were increased by dg % in subjects receiving lithium doses ranging from dg to dg mg bid with drugb dg mg qd as compared to subjects receiving lithium alone .
DDI-DrugBank.d597.s20	lithium	drug	56-62	lithium	drug	234-240	false	in a study conducted in healthy subjects , mean pre dose druga concentration and auc were increased by dg % in subjects receiving lithium doses ranging from dg to dg mg bid with meloxicam dg mg qd as compared to subjects receiving drugb alone .
DDI-DrugBank.d597.s20	lithium	drug	130-136	meloxicam	drug	181-189	mechanism	in a study conducted in healthy subjects , mean pre dose lithium concentration and auc were increased by dg % in subjects receiving druga doses ranging from dg to dg mg bid with drugb dg mg qd as compared to subjects receiving lithium alone .
DDI-DrugBank.d597.s20	lithium	drug	130-136	lithium	drug	234-240	false	in a study conducted in healthy subjects , mean pre dose lithium concentration and auc were increased by dg % in subjects receiving druga doses ranging from dg to dg mg bid with meloxicam dg mg qd as compared to subjects receiving drugb alone .
DDI-DrugBank.d597.s20	meloxicam	drug	181-189	lithium	drug	234-240	false	in a study conducted in healthy subjects , mean pre dose lithium concentration and auc were increased by dg % in subjects receiving lithium doses ranging from dg to dg mg bid with druga dg mg qd as compared to subjects receiving drugb alone .
DDI-DrugBank.d597.s22	lithium	drug	12-18	MOBIC	brand	63-67	advise	patients on druga treatment should be closely monitored when drugb is introduced or withdrawn .
DDI-DrugBank.d597.s23	Methotrexate	drug	0-11	meloxicam	drug	106-114	false	druga : a study in dg rheumatoid arthritis ( ra ) patients evaluated the effects of multiple doses of drugb on the pharmacokinetics of methotrexate taken once weekly .
DDI-DrugBank.d597.s23	Methotrexate	drug	0-11	methotrexate	drug	143-154	false	druga : a study in dg rheumatoid arthritis ( ra ) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of drugb taken once weekly .
DDI-DrugBank.d597.s23	meloxicam	drug	106-114	methotrexate	drug	143-154	false	methotrexate : a study in dg rheumatoid arthritis ( ra ) patients evaluated the effects of multiple doses of druga on the pharmacokinetics of drugb taken once weekly .
DDI-DrugBank.d597.s24	Meloxicam	drug	0-8	methotrexate	drug	87-98	false	druga did not have a significant effect on the pharmacokinetics of single doses of drugb .
DDI-DrugBank.d597.s25	methotrexate	drug	10-21	meloxicam	drug	40-48	false	in vitro , druga did not displace drugb from its human serum binding sites .
DDI-DrugBank.d597.s26	Warfarin	drug	0-7	MOBIC	brand	118-122	false	druga : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing drugb therapy in patients receiving warfarin or similar agents , since these patients are at an increased risk of bleeding .
DDI-DrugBank.d597.s26	Warfarin	drug	0-7	warfarin	drug	154-161	false	druga : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing mobic therapy in patients receiving drugb or similar agents , since these patients are at an increased risk of bleeding .
DDI-DrugBank.d597.s26	MOBIC	brand	118-122	warfarin	drug	154-161	advise	warfarin : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing druga therapy in patients receiving drugb or similar agents , since these patients are at an increased risk of bleeding .
DDI-DrugBank.d597.s27	meloxicam	drug	14-22	warfarin	drug	55-62	false	the effect of druga on the anticoagulant effect of drugb was studied in a group of healthy subjects receiving daily doses of warfarin that produced an inr ( international normalized ratio ) between dg and dg .
DDI-DrugBank.d597.s27	meloxicam	drug	14-22	warfarin	drug	132-139	false	the effect of druga on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of drugb that produced an inr ( international normalized ratio ) between dg and dg .
DDI-DrugBank.d597.s27	warfarin	drug	55-62	warfarin	drug	132-139	false	the effect of meloxicam on the anticoagulant effect of druga was studied in a group of healthy subjects receiving daily doses of drugb that produced an inr ( international normalized ratio ) between dg and dg .
DDI-DrugBank.d597.s28	meloxicam	drug	19-27	warfarin	drug	43-50	false	in these subjects , druga did not alter drugb pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time .
DDI-DrugBank.d597.s28	meloxicam	drug	19-27	warfarin	drug	109-116	false	in these subjects , druga did not alter warfarin pharmacokinetics and the average anticoagulant effect of drugb as determined by prothrombin time .
DDI-DrugBank.d597.s28	warfarin	drug	43-50	warfarin	drug	109-116	false	in these subjects , meloxicam did not alter druga pharmacokinetics and the average anticoagulant effect of drugb as determined by prothrombin time .
DDI-DrugBank.d597.s30	MOBIC	brand	42-46	warfarin	drug	53-60	advise	caution should be used when administering druga with drugb since patients on warfarin may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
DDI-DrugBank.d597.s30	MOBIC	brand	42-46	warfarin	drug	80-87	false	caution should be used when administering druga with warfarin since patients on drugb may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
DDI-DrugBank.d597.s30	warfarin	drug	53-60	warfarin	drug	80-87	false	caution should be used when administering mobic with druga since patients on drugb may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
DDI-DrugBank.d625.s0	ALKERAN	brand	71-77	live organism vaccines	group	98-119	false	drug interactions there are no known drug / drug interactions with oral druga vaccinations with drugb are not recommended in immunocompromised individuals nalidixic acid together with high dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0	ALKERAN	brand	71-77	Nalidixic acid	drug	175-188	false	drug interactions there are no known drug / drug interactions with oral druga vaccinations with live organism vaccines are not recommended in immunocompromised individuals drugb together with high dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0	ALKERAN	brand	71-77	melphalan	drug	226-234	false	drug interactions there are no known drug / drug interactions with oral druga vaccinations with live organism vaccines are not recommended in immunocompromised individuals nalidixic acid together with high dose intravenous drugb has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0	live organism vaccines	group	98-119	Nalidixic acid	drug	175-188	false	drug interactions there are no known drug / drug interactions with oral alkeran vaccinations with druga are not recommended in immunocompromised individuals drugb together with high dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0	live organism vaccines	group	98-119	melphalan	drug	226-234	false	drug interactions there are no known drug / drug interactions with oral alkeran vaccinations with druga are not recommended in immunocompromised individuals nalidixic acid together with high dose intravenous drugb has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0	Nalidixic acid	drug	175-188	melphalan	drug	226-234	effect	drug interactions there are no known drug / drug interactions with oral alkeran vaccinations with live organism vaccines are not recommended in immunocompromised individuals druga together with high dose intravenous drugb has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s1	melphalan	drug	126-134	cyclosporin	drug	166-176	effect	impaired renal function has been described in bone marrow transplant patients who were conditioned with high dose intravenous druga and who subsequently received drugb to prevent graft versus host disease
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	amantadine	drug	92-101	effect	the following agents may increase certain actions or side effects of druga : drugb , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	antiarrhythmic agents of class I	group	104-135	effect	the following agents may increase certain actions or side effects of druga : amantadine , drugb ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	quinidine	drug	144-152	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , drugb ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	antihistamines	group	156-169	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , drugb , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	antipsychotic agents	group	172-191	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , drugb ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	phenothiazines	group	200-213	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , drugb ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	benzodiazepines	group	217-231	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , drugb , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	MAO inhibitors	group	234-247	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , drugb , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	narcotic analgesics	group	250-268	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , drugb ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	meperidine	drug	277-286	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	nitrates	group	290-297	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	nitrites	group	303-310	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	sympathomimetic agents	group	313-334	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	anticholinergic drugs	group	69-89	tricyclic antidepressants	group	337-361	effect	the following agents may increase certain actions or side effects of druga : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	antiarrhythmic agents of class I	group	104-135	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , drugb ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	quinidine	drug	144-152	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , drugb ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	antihistamines	group	156-169	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , drugb , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	antipsychotic agents	group	172-191	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , drugb ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	phenothiazines	group	200-213	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , drugb ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	benzodiazepines	group	217-231	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , drugb , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	MAO inhibitors	group	234-247	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , drugb , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	narcotic analgesics	group	250-268	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , drugb ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	meperidine	drug	277-286	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	amantadine	drug	92-101	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : druga , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	quinidine	drug	144-152	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , drugb ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	antihistamines	group	156-169	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , drugb , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	antipsychotic agents	group	172-191	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , drugb ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	phenothiazines	group	200-213	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , drugb ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	benzodiazepines	group	217-231	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , drugb , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	MAO inhibitors	group	234-247	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , drugb , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	narcotic analgesics	group	250-268	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , drugb ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	meperidine	drug	277-286	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antiarrhythmic agents of class I	group	104-135	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , druga ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	antihistamines	group	156-169	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , drugb , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	antipsychotic agents	group	172-191	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , drugb ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	phenothiazines	group	200-213	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , antipsychotic agents ( e.g. , drugb ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	benzodiazepines	group	217-231	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , drugb , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	MAO inhibitors	group	234-247	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , drugb , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	narcotic analgesics	group	250-268	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , drugb ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	meperidine	drug	277-286	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	quinidine	drug	144-152	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , druga ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	antipsychotic agents	group	172-191	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , drugb ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	phenothiazines	group	200-213	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , antipsychotic agents ( e.g. , drugb ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	benzodiazepines	group	217-231	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , antipsychotic agents ( e.g. , phenothiazines ) , drugb , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	MAO inhibitors	group	234-247	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , drugb , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	narcotic analgesics	group	250-268	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , drugb ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	meperidine	drug	277-286	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antihistamines	group	156-169	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , druga , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antipsychotic agents	group	172-191	phenothiazines	group	200-213	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , druga ( e.g. , drugb ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antipsychotic agents	group	172-191	benzodiazepines	group	217-231	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , druga ( e.g. , phenothiazines ) , drugb , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antipsychotic agents	group	172-191	MAO inhibitors	group	234-247	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , druga ( e.g. , phenothiazines ) , benzodiazepines , drugb , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antipsychotic agents	group	172-191	narcotic analgesics	group	250-268	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , druga ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , drugb ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antipsychotic agents	group	172-191	meperidine	drug	277-286	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , druga ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antipsychotic agents	group	172-191	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , druga ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antipsychotic agents	group	172-191	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , druga ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antipsychotic agents	group	172-191	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , druga ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	antipsychotic agents	group	172-191	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , druga ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	phenothiazines	group	200-213	benzodiazepines	group	217-231	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , druga ) , drugb , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	phenothiazines	group	200-213	MAO inhibitors	group	234-247	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , druga ) , benzodiazepines , drugb , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	phenothiazines	group	200-213	narcotic analgesics	group	250-268	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , druga ) , benzodiazepines , mao inhibitors , drugb ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	phenothiazines	group	200-213	meperidine	drug	277-286	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , druga ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	phenothiazines	group	200-213	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , druga ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	phenothiazines	group	200-213	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , druga ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	phenothiazines	group	200-213	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , druga ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	phenothiazines	group	200-213	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , druga ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	benzodiazepines	group	217-231	MAO inhibitors	group	234-247	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , druga , drugb , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	benzodiazepines	group	217-231	narcotic analgesics	group	250-268	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , druga , mao inhibitors , drugb ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	benzodiazepines	group	217-231	meperidine	drug	277-286	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , druga , mao inhibitors , narcotic analgesics ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	benzodiazepines	group	217-231	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , druga , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	benzodiazepines	group	217-231	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , druga , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	benzodiazepines	group	217-231	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , druga , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	benzodiazepines	group	217-231	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , druga , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	MAO inhibitors	group	234-247	narcotic analgesics	group	250-268	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , druga , drugb ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	MAO inhibitors	group	234-247	meperidine	drug	277-286	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , druga , narcotic analgesics ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	MAO inhibitors	group	234-247	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , druga , narcotic analgesics ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	MAO inhibitors	group	234-247	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , druga , narcotic analgesics ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	MAO inhibitors	group	234-247	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , druga , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	MAO inhibitors	group	234-247	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , druga , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	narcotic analgesics	group	250-268	meperidine	drug	277-286	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , druga ( e.g. , drugb ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	narcotic analgesics	group	250-268	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , druga ( e.g. , meperidine ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	narcotic analgesics	group	250-268	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , druga ( e.g. , meperidine ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	narcotic analgesics	group	250-268	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , druga ( e.g. , meperidine ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	narcotic analgesics	group	250-268	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , druga ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	meperidine	drug	277-286	nitrates	group	290-297	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , druga ) , drugb and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	meperidine	drug	277-286	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , druga ) , nitrates and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	meperidine	drug	277-286	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , druga ) , nitrates and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	meperidine	drug	277-286	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , druga ) , nitrates and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	nitrates	group	290-297	nitrites	group	303-310	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , druga and drugb , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	nitrates	group	290-297	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , druga and nitrites , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	nitrates	group	290-297	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , druga and nitrites , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	nitrites	group	303-310	sympathomimetic agents	group	313-334	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and druga , drugb , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	nitrites	group	303-310	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and druga , sympathomimetic agents , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0	sympathomimetic agents	group	313-334	tricyclic antidepressants	group	337-361	false	the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , druga , drugb , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s1	Anticholinergics	group	0-15	antiglaucoma agents	group	43-61	effect	druga antagonize the effects of drugb .
DDI-DrugBank.d585.s2	Anticholinergic drugs	group	0-20	corticosteroids	group	133-147	effect	druga in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as drugb .
DDI-DrugBank.d585.s3	Anticholinergic agents	group	0-21	digoxin	drug	122-128	mechanism	druga may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of drugb ;
DDI-DrugBank.d585.s5	Anticholinergic drugs	group	0-20	metoclopramide	drug	104-117	effect	druga may antagonize the effects of drugs that alter gastrointestinal motility , such as drugb .
DDI-DrugBank.d585.s6	antacids	group	8-15	anticholinergic agents	group	54-75	mechanism	because druga may interfere with the absorption of drugb , simultaneous use of these drugs should be avoided .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	MEPERIDINE	drug	59-68	false	interaction with other druga : drugb should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	NARCOTIC ANALGESICS	group	175-193	false	interaction with other druga : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugb , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	ANESTHETICS	group	204-214	false	interaction with other druga : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general drugb , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	PHENOTHIAZINES	group	217-230	false	interaction with other druga : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , drugb , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	TRANQUILIZERS	group	239-251	false	interaction with other druga : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other drugb , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	SEDATIVE-HYPNOTICS	group	254-271	false	interaction with other druga : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , drugb ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	BARBITURATES	group	284-295	false	interaction with other druga : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including drugb ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false	interaction with other druga : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , drugb and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	CNS DEPRESSANTS	group	335-349	false	interaction with other druga : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other drugb ( including alcohol ) .
DDI-DrugBank.d703.s0	Central Nervous System Depressants	group	23-56	ALCOHOL	drug	362-368	false	interaction with other druga : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including drugb ) .
DDI-DrugBank.d703.s0	MEPERIDINE	drug	59-68	NARCOTIC ANALGESICS	group	175-193	advise	interaction with other central nervous system depressants : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugb , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	MEPERIDINE	drug	59-68	ANESTHETICS	group	204-214	advise	interaction with other central nervous system depressants : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general drugb , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	MEPERIDINE	drug	59-68	PHENOTHIAZINES	group	217-230	advise	interaction with other central nervous system depressants : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , drugb , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	MEPERIDINE	drug	59-68	TRANQUILIZERS	group	239-251	advise	interaction with other central nervous system depressants : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other drugb , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	MEPERIDINE	drug	59-68	SEDATIVE-HYPNOTICS	group	254-271	advise	interaction with other central nervous system depressants : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , drugb ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	MEPERIDINE	drug	59-68	BARBITURATES	group	284-295	advise	interaction with other central nervous system depressants : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including drugb ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	MEPERIDINE	drug	59-68	TRICYCLIC ANTIDEPRESSANTS	group	299-323	advise	interaction with other central nervous system depressants : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , drugb and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	MEPERIDINE	drug	59-68	CNS DEPRESSANTS	group	335-349	advise	interaction with other central nervous system depressants : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other drugb ( including alcohol ) .
DDI-DrugBank.d703.s0	MEPERIDINE	drug	59-68	ALCOHOL	drug	362-368	advise	interaction with other central nervous system depressants : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including drugb ) .
DDI-DrugBank.d703.s0	NARCOTIC ANALGESICS	group	175-193	ANESTHETICS	group	204-214	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general drugb , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	NARCOTIC ANALGESICS	group	175-193	PHENOTHIAZINES	group	217-230	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general anesthetics , drugb , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	NARCOTIC ANALGESICS	group	175-193	TRANQUILIZERS	group	239-251	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general anesthetics , phenothiazines , other drugb , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	NARCOTIC ANALGESICS	group	175-193	SEDATIVE-HYPNOTICS	group	254-271	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general anesthetics , phenothiazines , other tranquilizers , drugb ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	NARCOTIC ANALGESICS	group	175-193	BARBITURATES	group	284-295	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including drugb ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	NARCOTIC ANALGESICS	group	175-193	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , drugb and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	NARCOTIC ANALGESICS	group	175-193	CNS DEPRESSANTS	group	335-349	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other drugb ( including alcohol ) .
DDI-DrugBank.d703.s0	NARCOTIC ANALGESICS	group	175-193	ALCOHOL	drug	362-368	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including drugb ) .
DDI-DrugBank.d703.s0	ANESTHETICS	group	204-214	PHENOTHIAZINES	group	217-230	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general druga , drugb , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	ANESTHETICS	group	204-214	TRANQUILIZERS	group	239-251	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general druga , phenothiazines , other drugb , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	ANESTHETICS	group	204-214	SEDATIVE-HYPNOTICS	group	254-271	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general druga , phenothiazines , other tranquilizers , drugb ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	ANESTHETICS	group	204-214	BARBITURATES	group	284-295	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general druga , phenothiazines , other tranquilizers , sedative hypnotics ( including drugb ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	ANESTHETICS	group	204-214	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general druga , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , drugb and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	ANESTHETICS	group	204-214	CNS DEPRESSANTS	group	335-349	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general druga , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other drugb ( including alcohol ) .
DDI-DrugBank.d703.s0	ANESTHETICS	group	204-214	ALCOHOL	drug	362-368	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general druga , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including drugb ) .
DDI-DrugBank.d703.s0	PHENOTHIAZINES	group	217-230	TRANQUILIZERS	group	239-251	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , druga , other drugb , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	PHENOTHIAZINES	group	217-230	SEDATIVE-HYPNOTICS	group	254-271	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , druga , other tranquilizers , drugb ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	PHENOTHIAZINES	group	217-230	BARBITURATES	group	284-295	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , druga , other tranquilizers , sedative hypnotics ( including drugb ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	PHENOTHIAZINES	group	217-230	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , druga , other tranquilizers , sedative hypnotics ( including barbiturates ) , drugb and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	PHENOTHIAZINES	group	217-230	CNS DEPRESSANTS	group	335-349	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , druga , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other drugb ( including alcohol ) .
DDI-DrugBank.d703.s0	PHENOTHIAZINES	group	217-230	ALCOHOL	drug	362-368	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , druga , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including drugb ) .
DDI-DrugBank.d703.s0	TRANQUILIZERS	group	239-251	SEDATIVE-HYPNOTICS	group	254-271	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other druga , drugb ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	TRANQUILIZERS	group	239-251	BARBITURATES	group	284-295	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other druga , sedative hypnotics ( including drugb ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	TRANQUILIZERS	group	239-251	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other druga , sedative hypnotics ( including barbiturates ) , drugb and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	TRANQUILIZERS	group	239-251	CNS DEPRESSANTS	group	335-349	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other druga , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other drugb ( including alcohol ) .
DDI-DrugBank.d703.s0	TRANQUILIZERS	group	239-251	ALCOHOL	drug	362-368	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other druga , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including drugb ) .
DDI-DrugBank.d703.s0	SEDATIVE-HYPNOTICS	group	254-271	BARBITURATES	group	284-295	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , druga ( including drugb ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	SEDATIVE-HYPNOTICS	group	254-271	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , druga ( including barbiturates ) , drugb and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	SEDATIVE-HYPNOTICS	group	254-271	CNS DEPRESSANTS	group	335-349	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , druga ( including barbiturates ) , tricyclic antidepressants and other drugb ( including alcohol ) .
DDI-DrugBank.d703.s0	SEDATIVE-HYPNOTICS	group	254-271	ALCOHOL	drug	362-368	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , druga ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including drugb ) .
DDI-DrugBank.d703.s0	BARBITURATES	group	284-295	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including druga ) , drugb and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0	BARBITURATES	group	284-295	CNS DEPRESSANTS	group	335-349	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including druga ) , tricyclic antidepressants and other drugb ( including alcohol ) .
DDI-DrugBank.d703.s0	BARBITURATES	group	284-295	ALCOHOL	drug	362-368	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including druga ) , tricyclic antidepressants and other cns depressants ( including drugb ) .
DDI-DrugBank.d703.s0	TRICYCLIC ANTIDEPRESSANTS	group	299-323	CNS DEPRESSANTS	group	335-349	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , druga and other drugb ( including alcohol ) .
DDI-DrugBank.d703.s0	TRICYCLIC ANTIDEPRESSANTS	group	299-323	ALCOHOL	drug	362-368	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , druga and other cns depressants ( including drugb ) .
DDI-DrugBank.d703.s0	CNS DEPRESSANTS	group	335-349	ALCOHOL	drug	362-368	false	interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative hypnotics ( including barbiturates ) , tricyclic antidepressants and other druga ( including drugb ) .
DDI-DrugBank.d636.s0	anticonvulsants	group	5-19	Mephenytoin	drug	39-49	int	some druga may interact with drugb .
DDI-DrugBank.d636.s2	anticonvulsants	group	6-20	divalproex sodium	drug	30-46	false	those druga include drugb , valproic acid , and phenobarbital .
DDI-DrugBank.d636.s2	anticonvulsants	group	6-20	valproic acid	drug	49-61	false	those druga include divalproex sodium , drugb , and phenobarbital .
DDI-DrugBank.d636.s2	anticonvulsants	group	6-20	phenobarbital	drug	68-80	false	those druga include divalproex sodium , valproic acid , and drugb .
DDI-DrugBank.d636.s2	divalproex sodium	drug	30-46	valproic acid	drug	49-61	false	those anticonvulsants include druga , drugb , and phenobarbital .
DDI-DrugBank.d636.s2	divalproex sodium	drug	30-46	phenobarbital	drug	68-80	false	those anticonvulsants include druga , valproic acid , and drugb .
DDI-DrugBank.d636.s2	valproic acid	drug	49-61	phenobarbital	drug	68-80	false	those anticonvulsants include divalproex sodium , druga , and drugb .
DDI-DrugBank.d636.s3	Mephenytoin	drug	0-10	steroid medications	group	75-93	effect	druga may also affect the effects of other drugs , which include some drugb , warfarin , certain heart medicines , birth control pills , anti infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	Mephenytoin	drug	0-10	warfarin	drug	96-103	effect	druga may also affect the effects of other drugs , which include some steroid medications , drugb , certain heart medicines , birth control pills , anti infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	Mephenytoin	drug	0-10	anti-infective medicines	group	152-175	effect	druga may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , drugb , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	Mephenytoin	drug	0-10	furosemide	drug	178-187	effect	druga may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti infective medicines , drugb and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	Mephenytoin	drug	0-10	theophylline	drug	193-204	effect	druga may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti infective medicines , furosemide and drugb please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	Mephenytoin	drug	0-10	Mephenytoin	drug	223-233	false	druga may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti infective medicines , furosemide and theophylline please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	steroid medications	group	75-93	warfarin	drug	96-103	false	mephenytoin may also affect the effects of other drugs , which include some druga , drugb , certain heart medicines , birth control pills , anti infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	steroid medications	group	75-93	anti-infective medicines	group	152-175	false	mephenytoin may also affect the effects of other drugs , which include some druga , warfarin , certain heart medicines , birth control pills , drugb , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	steroid medications	group	75-93	furosemide	drug	178-187	false	mephenytoin may also affect the effects of other drugs , which include some druga , warfarin , certain heart medicines , birth control pills , anti infective medicines , drugb and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	steroid medications	group	75-93	theophylline	drug	193-204	false	mephenytoin may also affect the effects of other drugs , which include some druga , warfarin , certain heart medicines , birth control pills , anti infective medicines , furosemide and drugb please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	steroid medications	group	75-93	Mephenytoin	drug	223-233	false	mephenytoin may also affect the effects of other drugs , which include some druga , warfarin , certain heart medicines , birth control pills , anti infective medicines , furosemide and theophylline please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	warfarin	drug	96-103	anti-infective medicines	group	152-175	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , druga , certain heart medicines , birth control pills , drugb , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	warfarin	drug	96-103	furosemide	drug	178-187	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , druga , certain heart medicines , birth control pills , anti infective medicines , drugb and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	warfarin	drug	96-103	theophylline	drug	193-204	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , druga , certain heart medicines , birth control pills , anti infective medicines , furosemide and drugb please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	warfarin	drug	96-103	Mephenytoin	drug	223-233	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , druga , certain heart medicines , birth control pills , anti infective medicines , furosemide and theophylline please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	anti-infective medicines	group	152-175	furosemide	drug	178-187	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , druga , drugb and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	anti-infective medicines	group	152-175	theophylline	drug	193-204	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , druga , furosemide and drugb please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	anti-infective medicines	group	152-175	Mephenytoin	drug	223-233	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , druga , furosemide and theophylline please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	furosemide	drug	178-187	theophylline	drug	193-204	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti infective medicines , druga and drugb please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	furosemide	drug	178-187	Mephenytoin	drug	223-233	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti infective medicines , druga and theophylline please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3	theophylline	drug	193-204	Mephenytoin	drug	223-233	false	mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti infective medicines , furosemide and druga please note that drugb may interact with other drugs that are not listed here .
DDI-DrugBank.d699.s0	Mequitazine	drug	0-10	CNS depressant	group	30-43	int	druga can interact with drugb , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0	Mequitazine	drug	0-10	antichlolinergic	group	46-61	int	druga can interact with cns depressant , drugb , tca , maois , and alcohol .
DDI-DrugBank.d699.s0	Mequitazine	drug	0-10	TCA	group	64-66	int	druga can interact with cns depressant , antichlolinergic , drugb , maois , and alcohol .
DDI-DrugBank.d699.s0	Mequitazine	drug	0-10	MAOIs	group	69-73	int	druga can interact with cns depressant , antichlolinergic , tca , drugb , and alcohol .
DDI-DrugBank.d699.s0	Mequitazine	drug	0-10	alcohol	drug	80-86	int	druga can interact with cns depressant , antichlolinergic , tca , maois , and drugb .
DDI-DrugBank.d699.s0	CNS depressant	group	30-43	antichlolinergic	group	46-61	false	mequitazine can interact with druga , drugb , tca , maois , and alcohol .
DDI-DrugBank.d699.s0	CNS depressant	group	30-43	TCA	group	64-66	false	mequitazine can interact with druga , antichlolinergic , drugb , maois , and alcohol .
DDI-DrugBank.d699.s0	CNS depressant	group	30-43	MAOIs	group	69-73	false	mequitazine can interact with druga , antichlolinergic , tca , drugb , and alcohol .
DDI-DrugBank.d699.s0	CNS depressant	group	30-43	alcohol	drug	80-86	false	mequitazine can interact with druga , antichlolinergic , tca , maois , and drugb .
DDI-DrugBank.d699.s0	antichlolinergic	group	46-61	TCA	group	64-66	false	mequitazine can interact with cns depressant , druga , drugb , maois , and alcohol .
DDI-DrugBank.d699.s0	antichlolinergic	group	46-61	MAOIs	group	69-73	false	mequitazine can interact with cns depressant , druga , tca , drugb , and alcohol .
DDI-DrugBank.d699.s0	antichlolinergic	group	46-61	alcohol	drug	80-86	false	mequitazine can interact with cns depressant , druga , tca , maois , and drugb .
DDI-DrugBank.d699.s0	TCA	group	64-66	MAOIs	group	69-73	false	mequitazine can interact with cns depressant , antichlolinergic , druga , drugb , and alcohol .
DDI-DrugBank.d699.s0	TCA	group	64-66	alcohol	drug	80-86	false	mequitazine can interact with cns depressant , antichlolinergic , druga , maois , and drugb .
DDI-DrugBank.d699.s0	MAOIs	group	69-73	alcohol	drug	80-86	false	mequitazine can interact with cns depressant , antichlolinergic , tca , druga , and drugb .
DDI-DrugBank.d762.s0	Probenecid	drug	0-9	meropenem	drug	25-33	mechanism	druga competes with drugb for active tubular secretion and thus inhibits the renal excretion of meropenem .
DDI-DrugBank.d762.s0	Probenecid	drug	0-9	meropenem	drug	105-113	false	druga competes with meropenem for active tubular secretion and thus inhibits the renal excretion of drugb .
DDI-DrugBank.d762.s0	meropenem	drug	25-33	meropenem	drug	105-113	false	probenecid competes with druga for active tubular secretion and thus inhibits the renal excretion of drugb .
DDI-DrugBank.d762.s2	probenecid	drug	35-44	meropenem	drug	51-59	advise	therefore , the coadministration of druga with drugb is not recommended .
DDI-DrugBank.d762.s3	meropenem	drug	23-31	valproic acid	drug	60-72	mechanism	there is evidence that druga may reduce serum levels of drugb to subtherapeutic levels ( therapeutic range considered to be dg to dg g / ml total valproate ) .
DDI-DrugBank.d762.s3	meropenem	drug	23-31	valproate	drug	159-167	false	there is evidence that druga may reduce serum levels of valproic acid to subtherapeutic levels ( therapeutic range considered to be dg to dg g / ml total drugb ) .
DDI-DrugBank.d762.s3	valproic acid	drug	60-72	valproate	drug	159-167	false	there is evidence that meropenem may reduce serum levels of druga to subtherapeutic levels ( therapeutic range considered to be dg to dg g / ml total drugb ) .
DDI-DrugBank.d746.s0	ARAMINE	brand	0-6	digitalis	group	86-94	false	druga should be used with caution in digitalized patients , since the combination of drugb and sympathomimetic amines may cause ectopic arrhythmias .
DDI-DrugBank.d746.s0	ARAMINE	brand	0-6	sympathomimetic amines	group	100-121	false	druga should be used with caution in digitalized patients , since the combination of digitalis and drugb may cause ectopic arrhythmias .
DDI-DrugBank.d746.s0	digitalis	group	86-94	sympathomimetic amines	group	100-121	effect	aramine should be used with caution in digitalized patients , since the combination of druga and drugb may cause ectopic arrhythmias .
DDI-DrugBank.d746.s1	Monoamine oxidase inhibitors	group	0-27	tricyclic antidepressants	group	32-56	false	druga or drugb may potentiate the action of sympathomimetic amines .
DDI-DrugBank.d746.s1	Monoamine oxidase inhibitors	group	0-27	sympathomimetic amines	group	87-108	effect	druga or tricyclic antidepressants may potentiate the action of drugb .
DDI-DrugBank.d746.s1	tricyclic antidepressants	group	32-56	sympathomimetic amines	group	87-108	effect	monoamine oxidase inhibitors or druga may potentiate the action of drugb .
DDI-DrugBank.d605.s0	SKELAXIN	brand	0-7	alcohol	drug	36-42	effect	druga may enhance the effects of drugb , barbiturates and other cns depressants .
DDI-DrugBank.d605.s0	SKELAXIN	brand	0-7	barbiturates	group	45-56	effect	druga may enhance the effects of alcohol , drugb and other cns depressants .
DDI-DrugBank.d605.s0	SKELAXIN	brand	0-7	CNS depressants	group	68-82	effect	druga may enhance the effects of alcohol , barbiturates and other drugb .
DDI-DrugBank.d605.s0	alcohol	drug	36-42	barbiturates	group	45-56	false	skelaxin may enhance the effects of druga , drugb and other cns depressants .
DDI-DrugBank.d605.s0	alcohol	drug	36-42	CNS depressants	group	68-82	false	skelaxin may enhance the effects of druga , barbiturates and other drugb .
DDI-DrugBank.d605.s0	barbiturates	group	45-56	CNS depressants	group	68-82	false	skelaxin may enhance the effects of alcohol , druga and other drugb .
DDI-DrugBank.d630.s1	aspirin	brand	52-58	methazolamide	drug	64-76	advise	caution is advised for patients receiving high dose druga and drugb concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high dose aspirin and carbonic anhydrase inhibitors .
DDI-DrugBank.d630.s1	aspirin	brand	52-58	aspirin	brand	195-201	false	caution is advised for patients receiving high dose druga and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high dose drugb and carbonic anhydrase inhibitors .
DDI-DrugBank.d630.s1	aspirin	brand	52-58	carbonic anhydrase inhibitors	group	207-235	false	caution is advised for patients receiving high dose druga and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high dose aspirin and drugb .
DDI-DrugBank.d630.s1	methazolamide	drug	64-76	aspirin	brand	195-201	false	caution is advised for patients receiving high dose aspirin and druga concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high dose drugb and carbonic anhydrase inhibitors .
DDI-DrugBank.d630.s1	methazolamide	drug	64-76	carbonic anhydrase inhibitors	group	207-235	false	caution is advised for patients receiving high dose aspirin and druga concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high dose aspirin and drugb .
DDI-DrugBank.d630.s1	aspirin	brand	195-201	carbonic anhydrase inhibitors	group	207-235	effect	caution is advised for patients receiving high dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high dose druga and drugb .
DDI-DrugBank.d634.s0	Anticoagulants	group	0-13	anticoagulants	group	44-57	false	druga ( oral ) : the activity of oral drugb may be potentiated by anti vitamin k activity attributed to methimazole .
DDI-DrugBank.d634.s0	Anticoagulants	group	0-13	methimazole	drug	119-129	false	druga ( oral ) : the activity of oral anticoagulants may be potentiated by anti vitamin k activity attributed to drugb .
DDI-DrugBank.d634.s0	anticoagulants	group	44-57	methimazole	drug	119-129	effect	anticoagulants ( oral ) : the activity of oral druga may be potentiated by anti vitamin k activity attributed to drugb .
DDI-DrugBank.d634.s3	Digitalis glycosides	group	0-19	digitalis glycoside	group	101-119	false	druga : serum digitalis levels may be increased when hyperthyroid patients on a stable drugb regimen become euthyroid ;
DDI-DrugBank.d634.s5	Theophylline	drug	0-11	Theophylline	drug	14-25	false	druga : drugb clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid ;
DDI-DrugBank.d634.s5	Theophylline	drug	0-11	theophylline	drug	89-100	false	druga : theophylline clearance may decrease when hyperthyroid patients on a stable drugb regimen become euthyroid ;
DDI-DrugBank.d634.s5	Theophylline	drug	14-25	theophylline	drug	89-100	false	theophylline : druga clearance may decrease when hyperthyroid patients on a stable drugb regimen become euthyroid ;
DDI-DrugBank.d756.s0	opioids	group	38-44	levomepromazine	drug	95-109	effect	dosages of concomitantly administered druga should be reduced by approximately half , because drugb amplifies the therapeutic actions and side effects of opioids .
DDI-DrugBank.d756.s0	opioids	group	38-44	opioids	group	165-171	false	dosages of concomitantly administered druga should be reduced by approximately half , because levomepromazine amplifies the therapeutic actions and side effects of drugb .
DDI-DrugBank.d756.s0	levomepromazine	drug	95-109	opioids	group	165-171	effect	dosages of concomitantly administered opioids should be reduced by approximately half , because druga amplifies the therapeutic actions and side effects of drugb .
DDI-DrugBank.d756.s1	tramadol	drug	17-24	Ultram	brand	27-32	false	combination with druga ( drugb ) is associated with increased risk of seizures .
DDI-DrugBank.d756.s2	levomepromazine	drug	63-77	benzodiazepines	group	93-107	effect	additive sedative effects and confusional states may emerge if druga is given with drugb or barbiturates .
DDI-DrugBank.d756.s2	levomepromazine	drug	63-77	barbiturates	group	112-123	effect	additive sedative effects and confusional states may emerge if druga is given with benzodiazepines or drugb .
DDI-DrugBank.d756.s2	benzodiazepines	group	93-107	barbiturates	group	112-123	false	additive sedative effects and confusional states may emerge if levomepromazine is given with druga or drugb .
DDI-DrugBank.d756.s4	levomepromazine	drug	38-52	anticholinergic drugs	group	65-85	advise	exert particular caution in combining druga with other drugb ( tricyclic antidepressants and antiparkinsonian agents ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4	levomepromazine	drug	38-52	tricyclic antidepressants	group	88-112	advise	exert particular caution in combining druga with other anticholinergic drugs ( drugb and antiparkinsonian agents ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4	levomepromazine	drug	38-52	antiparkinsonian-agents	group	118-140	advise	exert particular caution in combining druga with other anticholinergic drugs ( tricyclic antidepressants and drugb ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4	anticholinergic drugs	group	65-85	tricyclic antidepressants	group	88-112	false	exert particular caution in combining levomepromazine with other druga ( drugb and antiparkinsonian agents ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4	anticholinergic drugs	group	65-85	antiparkinsonian-agents	group	118-140	false	exert particular caution in combining levomepromazine with other druga ( tricyclic antidepressants and drugb ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4	tricyclic antidepressants	group	88-112	antiparkinsonian-agents	group	118-140	false	exert particular caution in combining levomepromazine with other anticholinergic drugs ( druga and drugb ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s7	Caffeine	drug	0-7	ephedrine	drug	35-43	false	druga and / or stimulantes of the drugb / amphetamine type may counteract the specific actions of levomepromazine .
DDI-DrugBank.d756.s7	Caffeine	drug	0-7	amphetamine	drug	45-55	false	druga and / or stimulantes of the ephedrine / drugb type may counteract the specific actions of levomepromazine .
DDI-DrugBank.d756.s7	Caffeine	drug	0-7	levomepromazine	drug	101-115	effect	druga and / or stimulantes of the ephedrine / amphetamine type may counteract the specific actions of drugb .
DDI-DrugBank.d756.s7	ephedrine	drug	35-43	amphetamine	drug	45-55	false	caffeine and / or stimulantes of the druga / drugb type may counteract the specific actions of levomepromazine .
DDI-DrugBank.d756.s7	ephedrine	drug	35-43	levomepromazine	drug	101-115	effect	caffeine and / or stimulantes of the druga / amphetamine type may counteract the specific actions of drugb .
DDI-DrugBank.d756.s7	amphetamine	drug	45-55	levomepromazine	drug	101-115	effect	caffeine and / or stimulantes of the ephedrine / druga type may counteract the specific actions of drugb .
DDI-DrugBank.d587.s0	Celontin	brand	6-13	methsuximide	drug	16-27	false	since druga ( drugb ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0	Celontin	brand	6-13	antiepileptic drugs	group	74-92	advise	since druga ( methsuximide ) may interact with concurrently administered drugb , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0	Celontin	brand	6-13	methsuximide	drug	167-178	false	since druga ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg drugb may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0	Celontin	brand	6-13	phenytoin	drug	222-230	false	since druga ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of drugb and phenobarbital ) .
DDI-DrugBank.d587.s0	Celontin	brand	6-13	phenobarbital	drug	236-248	false	since druga ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and drugb ) .
DDI-DrugBank.d587.s0	methsuximide	drug	16-27	antiepileptic drugs	group	74-92	advise	since celontin ( druga ) may interact with concurrently administered drugb , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0	methsuximide	drug	16-27	methsuximide	drug	167-178	false	since celontin ( druga ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg drugb may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0	methsuximide	drug	16-27	phenytoin	drug	222-230	false	since celontin ( druga ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of drugb and phenobarbital ) .
DDI-DrugBank.d587.s0	methsuximide	drug	16-27	phenobarbital	drug	236-248	false	since celontin ( druga ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and drugb ) .
DDI-DrugBank.d587.s0	antiepileptic drugs	group	74-92	methsuximide	drug	167-178	false	since celontin ( methsuximide ) may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary ( eg drugb may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0	antiepileptic drugs	group	74-92	phenytoin	drug	222-230	false	since celontin ( methsuximide ) may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of drugb and phenobarbital ) .
DDI-DrugBank.d587.s0	antiepileptic drugs	group	74-92	phenobarbital	drug	236-248	false	since celontin ( methsuximide ) may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and drugb ) .
DDI-DrugBank.d587.s0	methsuximide	drug	167-178	phenytoin	drug	222-230	mechanism	since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg druga may increase the plasma concentrations of drugb and phenobarbital ) .
DDI-DrugBank.d587.s0	methsuximide	drug	167-178	phenobarbital	drug	236-248	mechanism	since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg druga may increase the plasma concentrations of phenytoin and drugb ) .
DDI-DrugBank.d587.s0	phenytoin	drug	222-230	phenobarbital	drug	236-248	false	since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of druga and drugb ) .
DDI-DrugBank.d736.s1	steroids	group	50-57	ACTH	drug	62-65	false	hypokalemia may develop during concomitant use of druga or drugb .
DDI-DrugBank.d736.s3	Thiazides	group	0-8	norepinephrine	drug	50-63	effect	druga may decrease arterial responsiveness to drugb .
DDI-DrugBank.d736.s5	Thiazide drugs	group	0-13	tubocurarine	drug	50-61	effect	druga may increase the responsiveness of drugb .
DDI-DrugBank.d736.s6	Lithium	drug	0-6	thiazides	group	38-46	mechanism	druga renal clearance is reduced by drugb , increasing the risk of lithium toxicity .
DDI-DrugBank.d736.s6	Lithium	drug	0-6	lithium	drug	72-78	false	druga renal clearance is reduced by thiazides , increasing the risk of drugb toxicity .
DDI-DrugBank.d736.s6	thiazides	group	38-46	lithium	drug	72-78	false	lithium renal clearance is reduced by druga , increasing the risk of drugb toxicity .
DDI-DrugBank.d736.s7	Thiazides	group	0-8	antihypertensive drugs	group	55-76	effect	druga may add to or potentiate the action of other drugb .
DDI-DrugBank.d779.s0	methyldopa	drug	5-14	antihypertensive drugs	group	35-56	effect	when druga is used with other drugb , potentiation of antihypertensive effect may occur .
DDI-DrugBank.d779.s2	anesthetics	group	38-48	methyldopa	drug	58-67	advise	patients may require reduced doses of druga when on drugb .
DDI-DrugBank.d779.s5	methyldopa	drug	5-14	lithium	drug	20-26	advise	when druga and drugb are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity .
DDI-DrugBank.d779.s5	methyldopa	drug	5-14	lithium	drug	110-116	false	when druga and lithium are given concomitantly the patient should be carefully monitored for symptoms of drugb toxicity .
DDI-DrugBank.d779.s5	lithium	drug	20-26	lithium	drug	110-116	false	when methyldopa and druga are given concomitantly the patient should be carefully monitored for symptoms of drugb toxicity .
DDI-DrugBank.d779.s7	methyldopa	drug	65-74	ferrous sulfate	drug	101-115	mechanism	several studies demonstrate a decrease in the bioavailability of druga when it is ingested with drugb or ferrous gluconate .
DDI-DrugBank.d779.s7	methyldopa	drug	65-74	ferrous gluconate	drug	120-136	mechanism	several studies demonstrate a decrease in the bioavailability of druga when it is ingested with ferrous sulfate or drugb .
DDI-DrugBank.d779.s7	ferrous sulfate	drug	101-115	ferrous gluconate	drug	120-136	false	several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with druga or drugb .
DDI-DrugBank.d779.s9	methyldopa	drug	20-29	ferrous sulfate	drug	36-50	advise	coadministration of druga with drugb or ferrous gluconate is not recommended .
DDI-DrugBank.d779.s9	methyldopa	drug	20-29	ferrous gluconate	drug	55-71	advise	coadministration of druga with ferrous sulfate or drugb is not recommended .
DDI-DrugBank.d779.s9	ferrous sulfate	drug	36-50	ferrous gluconate	drug	55-71	false	coadministration of methyldopa with druga or drugb is not recommended .
DDI-DrugBank.d779.s16	Methyldopa	drug	0-9	VMA	drug_n	50-52	false	druga does not interfere with measurement of drugb ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16	Methyldopa	drug	0-9	vanillylmandelic acid	drug_n	55-75	false	druga does not interfere with measurement of vma ( drugb ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16	Methyldopa	drug	0-9	VMA	drug_n	139-141	false	druga does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert drugb to vanillin .
DDI-DrugBank.d779.s16	Methyldopa	drug	0-9	vanillin	drug_n	146-153	false	druga does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to drugb .
DDI-DrugBank.d779.s16	VMA	drug_n	50-52	vanillylmandelic acid	drug_n	55-75	false	methyldopa does not interfere with measurement of druga ( drugb ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16	VMA	drug_n	50-52	VMA	drug_n	139-141	false	methyldopa does not interfere with measurement of druga ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert drugb to vanillin .
DDI-DrugBank.d779.s16	VMA	drug_n	50-52	vanillin	drug_n	146-153	false	methyldopa does not interfere with measurement of druga ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to drugb .
DDI-DrugBank.d779.s16	vanillylmandelic acid	drug_n	55-75	VMA	drug_n	139-141	false	methyldopa does not interfere with measurement of vma ( druga ) , a test for pheochromocytoma , by those methods which convert drugb to vanillin .
DDI-DrugBank.d779.s16	vanillylmandelic acid	drug_n	55-75	vanillin	drug_n	146-153	false	methyldopa does not interfere with measurement of vma ( druga ) , a test for pheochromocytoma , by those methods which convert vma to drugb .
DDI-DrugBank.d779.s16	VMA	drug_n	139-141	vanillin	drug_n	146-153	false	methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert druga to drugb .
DDI-DrugBank.d675.s0	Macrolide Antibiotics	group	25-45	Protease Inhibitors	group	51-69	false	cyp dg inhibitors ( e.g. druga and drugb ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s0	Macrolide Antibiotics	group	25-45	ergot alkaloid drugs	group	178-197	false	cyp dg inhibitors ( e.g. druga and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugb ( e.g. dihydroergotamine and ergotamine ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s0	Macrolide Antibiotics	group	25-45	dihydroergotamine	drug	205-221	false	cyp dg inhibitors ( e.g. druga and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. drugb and ergotamine ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s0	Macrolide Antibiotics	group	25-45	ergotamine	drug	227-236	false	cyp dg inhibitors ( e.g. druga and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and drugb ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s0	Protease Inhibitors	group	51-69	ergot alkaloid drugs	group	178-197	false	cyp dg inhibitors ( e.g. macrolide antibiotics and druga ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugb ( e.g. dihydroergotamine and ergotamine ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s0	Protease Inhibitors	group	51-69	dihydroergotamine	drug	205-221	false	cyp dg inhibitors ( e.g. macrolide antibiotics and druga ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. drugb and ergotamine ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s0	Protease Inhibitors	group	51-69	ergotamine	drug	227-236	false	cyp dg inhibitors ( e.g. macrolide antibiotics and druga ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and drugb ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s0	ergot alkaloid drugs	group	178-197	dihydroergotamine	drug	205-221	false	cyp dg inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain druga ( e.g. drugb and ergotamine ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s0	ergot alkaloid drugs	group	178-197	ergotamine	drug	227-236	false	cyp dg inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain druga ( e.g. dihydroergotamine and drugb ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s0	dihydroergotamine	drug	205-221	ergotamine	drug	227-236	false	cyp dg inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. druga and drugb ) and potent cyp dg inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	erythromycin	drug	92-103	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , drugb , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	troleandomycin	drug	106-119	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , drugb , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	clarithromycin	drug	122-135	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , drugb ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	reverse transcriptase inhibitors	group	155-186	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or drugb ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	ritonavir	drug	195-203	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , drugb , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	indinavir	drug	206-214	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , drugb , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	nelfinavir	drug	217-226	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , drugb , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	delavirdine	drug	229-239	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , drugb ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	azole antifungals	group	245-261	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or drugb ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	macrolide antibiotics	group	63-83	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include druga ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	troleandomycin	drug	106-119	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , drugb , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	clarithromycin	drug	122-135	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , drugb ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	reverse transcriptase inhibitors	group	155-186	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , clarithromycin ) , hiv protease or drugb ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	ritonavir	drug	195-203	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , drugb , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	indinavir	drug	206-214	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , drugb , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	nelfinavir	drug	217-226	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , drugb , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	delavirdine	drug	229-239	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , drugb ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	azole antifungals	group	245-261	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or drugb ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	erythromycin	drug	92-103	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , druga , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	clarithromycin	drug	122-135	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , drugb ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	reverse transcriptase inhibitors	group	155-186	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , clarithromycin ) , hiv protease or drugb ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	ritonavir	drug	195-203	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , drugb , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	indinavir	drug	206-214	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , drugb , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	nelfinavir	drug	217-226	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , drugb , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	delavirdine	drug	229-239	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , drugb ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	azole antifungals	group	245-261	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or drugb ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	troleandomycin	drug	106-119	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , druga , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	clarithromycin	drug	122-135	reverse transcriptase inhibitors	group	155-186	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , druga ) , hiv protease or drugb ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	clarithromycin	drug	122-135	ritonavir	drug	195-203	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , druga ) , hiv protease or reverse transcriptase inhibitors ( e.g. , drugb , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	clarithromycin	drug	122-135	indinavir	drug	206-214	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , druga ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , drugb , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	clarithromycin	drug	122-135	nelfinavir	drug	217-226	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , druga ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , drugb , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	clarithromycin	drug	122-135	delavirdine	drug	229-239	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , druga ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , drugb ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	clarithromycin	drug	122-135	azole antifungals	group	245-261	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , druga ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or drugb ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	clarithromycin	drug	122-135	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , druga ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	clarithromycin	drug	122-135	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , druga ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	clarithromycin	drug	122-135	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , druga ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	reverse transcriptase inhibitors	group	155-186	ritonavir	drug	195-203	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or druga ( e.g. , drugb , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	reverse transcriptase inhibitors	group	155-186	indinavir	drug	206-214	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or druga ( e.g. , ritonavir , drugb , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	reverse transcriptase inhibitors	group	155-186	nelfinavir	drug	217-226	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or druga ( e.g. , ritonavir , indinavir , drugb , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	reverse transcriptase inhibitors	group	155-186	delavirdine	drug	229-239	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or druga ( e.g. , ritonavir , indinavir , nelfinavir , drugb ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	reverse transcriptase inhibitors	group	155-186	azole antifungals	group	245-261	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or druga ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or drugb ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	reverse transcriptase inhibitors	group	155-186	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or druga ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	reverse transcriptase inhibitors	group	155-186	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or druga ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	reverse transcriptase inhibitors	group	155-186	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or druga ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	ritonavir	drug	195-203	indinavir	drug	206-214	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , druga , drugb , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	ritonavir	drug	195-203	nelfinavir	drug	217-226	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , druga , indinavir , drugb , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	ritonavir	drug	195-203	delavirdine	drug	229-239	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , druga , indinavir , nelfinavir , drugb ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	ritonavir	drug	195-203	azole antifungals	group	245-261	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , druga , indinavir , nelfinavir , delavirdine ) or drugb ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	ritonavir	drug	195-203	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , druga , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	ritonavir	drug	195-203	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , druga , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	ritonavir	drug	195-203	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , druga , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	indinavir	drug	206-214	nelfinavir	drug	217-226	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , druga , drugb , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	indinavir	drug	206-214	delavirdine	drug	229-239	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , druga , nelfinavir , drugb ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	indinavir	drug	206-214	azole antifungals	group	245-261	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , druga , nelfinavir , delavirdine ) or drugb ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	indinavir	drug	206-214	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , druga , nelfinavir , delavirdine ) or azole antifungals ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	indinavir	drug	206-214	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , druga , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	indinavir	drug	206-214	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , druga , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	nelfinavir	drug	217-226	delavirdine	drug	229-239	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , druga , drugb ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	nelfinavir	drug	217-226	azole antifungals	group	245-261	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , druga , delavirdine ) or drugb ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	nelfinavir	drug	217-226	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , druga , delavirdine ) or azole antifungals ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	nelfinavir	drug	217-226	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , druga , delavirdine ) or azole antifungals ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	nelfinavir	drug	217-226	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , druga , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	delavirdine	drug	229-239	azole antifungals	group	245-261	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , druga ) or drugb ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	delavirdine	drug	229-239	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , druga ) or azole antifungals ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	delavirdine	drug	229-239	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , druga ) or azole antifungals ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	delavirdine	drug	229-239	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , druga ) or azole antifungals ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	azole antifungals	group	245-261	ketoconazole	drug	270-281	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or druga ( e.g. , drugb , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2	azole antifungals	group	245-261	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or druga ( e.g. , ketoconazole , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	azole antifungals	group	245-261	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or druga ( e.g. , ketoconazole , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	ketoconazole	drug	270-281	itraconazole	drug	284-295	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , druga , drugb , voriconazole ) .
DDI-DrugBank.d675.s2	ketoconazole	drug	270-281	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , druga , itraconazole , drugb ) .
DDI-DrugBank.d675.s2	itraconazole	drug	284-295	voriconazole	drug	298-309	false	examples of some of the more potent cyp dg inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , druga , drugb ) .
DDI-DrugBank.d675.s4	saquinavir	drug	31-40	nefazodone	drug	43-52	false	less potent inhibitors include druga , drugb , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	saquinavir	drug	31-40	fluconazole	drug	55-65	false	less potent inhibitors include druga , nefazodone , drugb , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	saquinavir	drug	31-40	fluoxetine	drug	86-95	false	less potent inhibitors include druga , nefazodone , fluconazole , grapefruit juice , drugb , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	saquinavir	drug	31-40	fluvoxamine	drug	98-108	false	less potent inhibitors include druga , nefazodone , fluconazole , grapefruit juice , fluoxetine , drugb , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	saquinavir	drug	31-40	zileuton	drug	111-118	false	less potent inhibitors include druga , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , drugb , and clotrimazole .
DDI-DrugBank.d675.s4	saquinavir	drug	31-40	clotrimazole	drug	125-136	false	less potent inhibitors include druga , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and drugb .
DDI-DrugBank.d675.s4	nefazodone	drug	43-52	fluconazole	drug	55-65	false	less potent inhibitors include saquinavir , druga , drugb , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	nefazodone	drug	43-52	fluoxetine	drug	86-95	false	less potent inhibitors include saquinavir , druga , fluconazole , grapefruit juice , drugb , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	nefazodone	drug	43-52	fluvoxamine	drug	98-108	false	less potent inhibitors include saquinavir , druga , fluconazole , grapefruit juice , fluoxetine , drugb , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	nefazodone	drug	43-52	zileuton	drug	111-118	false	less potent inhibitors include saquinavir , druga , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , drugb , and clotrimazole .
DDI-DrugBank.d675.s4	nefazodone	drug	43-52	clotrimazole	drug	125-136	false	less potent inhibitors include saquinavir , druga , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and drugb .
DDI-DrugBank.d675.s4	fluconazole	drug	55-65	fluoxetine	drug	86-95	false	less potent inhibitors include saquinavir , nefazodone , druga , grapefruit juice , drugb , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	fluconazole	drug	55-65	fluvoxamine	drug	98-108	false	less potent inhibitors include saquinavir , nefazodone , druga , grapefruit juice , fluoxetine , drugb , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	fluconazole	drug	55-65	zileuton	drug	111-118	false	less potent inhibitors include saquinavir , nefazodone , druga , grapefruit juice , fluoxetine , fluvoxamine , drugb , and clotrimazole .
DDI-DrugBank.d675.s4	fluconazole	drug	55-65	clotrimazole	drug	125-136	false	less potent inhibitors include saquinavir , nefazodone , druga , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and drugb .
DDI-DrugBank.d675.s4	fluoxetine	drug	86-95	fluvoxamine	drug	98-108	false	less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , druga , drugb , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4	fluoxetine	drug	86-95	zileuton	drug	111-118	false	less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , druga , fluvoxamine , drugb , and clotrimazole .
DDI-DrugBank.d675.s4	fluoxetine	drug	86-95	clotrimazole	drug	125-136	false	less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , druga , fluvoxamine , zileuton , and drugb .
DDI-DrugBank.d675.s4	fluvoxamine	drug	98-108	zileuton	drug	111-118	false	less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , druga , drugb , and clotrimazole .
DDI-DrugBank.d675.s4	fluvoxamine	drug	98-108	clotrimazole	drug	125-136	false	less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , druga , zileuton , and drugb .
DDI-DrugBank.d675.s4	zileuton	drug	111-118	clotrimazole	drug	125-136	false	less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , druga , and drugb .
DDI-DrugBank.d675.s7	Methergine	brand	33-42	methylergonovine maleate	drug	48-71	false	caution should be exercised when druga ( drugb ) is used concurrently with other vasoconstrictors or ergot alkaloids .
DDI-DrugBank.d675.s7	Methergine	brand	33-42	vasoconstrictors	group	106-121	advise	caution should be exercised when druga ( methylergonovine maleate ) is used concurrently with other drugb or ergot alkaloids .
DDI-DrugBank.d675.s7	Methergine	brand	33-42	ergot alkaloids	group	126-140	advise	caution should be exercised when druga ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or drugb .
DDI-DrugBank.d675.s7	methylergonovine maleate	drug	48-71	vasoconstrictors	group	106-121	advise	caution should be exercised when methergine ( druga ) is used concurrently with other drugb or ergot alkaloids .
DDI-DrugBank.d675.s7	methylergonovine maleate	drug	48-71	ergot alkaloids	group	126-140	false	caution should be exercised when methergine ( druga ) is used concurrently with other vasoconstrictors or drugb .
DDI-DrugBank.d675.s7	vasoconstrictors	group	106-121	ergot alkaloids	group	126-140	false	caution should be exercised when methergine ( methylergonovine maleate ) is used concurrently with other druga or drugb .
DDI-DrugBank.d638.s0	Ritalin	brand	0-6	guanethidine	drug	47-58	effect	druga may decrease the hypotensive effect of drugb .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	coumarin anticoagulants	group	82-104	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of drugb , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	anticonvulsants	group	107-121	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of coumarin anticoagulants , drugb ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	phenobarbital	drug	124-136	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( drugb , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	diphenylhydantoin	drug	139-155	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , drugb , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	primidone	drug	158-166	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , drugb ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	phenylbutazone	drug	170-183	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , drugb , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	tricyclic drugs	group	190-204	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and drugb ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	imipramine	drug	207-216	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( drugb , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	clomipramine	drug	219-230	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , drugb , desipramine ) .
DDI-DrugBank.d638.s2	Ritalin	brand	44-50	desipramine	drug	233-243	mechanism	human pharmacologic studies have shown that druga may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , drugb ) .
DDI-DrugBank.d638.s2	coumarin anticoagulants	group	82-104	anticonvulsants	group	107-121	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of druga , drugb ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	coumarin anticoagulants	group	82-104	phenobarbital	drug	124-136	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of druga , anticonvulsants ( drugb , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	coumarin anticoagulants	group	82-104	diphenylhydantoin	drug	139-155	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of druga , anticonvulsants ( phenobarbital , drugb , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	coumarin anticoagulants	group	82-104	primidone	drug	158-166	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of druga , anticonvulsants ( phenobarbital , diphenylhydantoin , drugb ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	coumarin anticoagulants	group	82-104	phenylbutazone	drug	170-183	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of druga , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , drugb , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	coumarin anticoagulants	group	82-104	tricyclic drugs	group	190-204	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of druga , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and drugb ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	coumarin anticoagulants	group	82-104	imipramine	drug	207-216	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of druga , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( drugb , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	coumarin anticoagulants	group	82-104	clomipramine	drug	219-230	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of druga , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , drugb , desipramine ) .
DDI-DrugBank.d638.s2	coumarin anticoagulants	group	82-104	desipramine	drug	233-243	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of druga , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , drugb ) .
DDI-DrugBank.d638.s2	anticonvulsants	group	107-121	phenobarbital	drug	124-136	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , druga ( drugb , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	anticonvulsants	group	107-121	diphenylhydantoin	drug	139-155	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , druga ( phenobarbital , drugb , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	anticonvulsants	group	107-121	primidone	drug	158-166	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , druga ( phenobarbital , diphenylhydantoin , drugb ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	anticonvulsants	group	107-121	phenylbutazone	drug	170-183	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , druga ( phenobarbital , diphenylhydantoin , primidone ) , drugb , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	anticonvulsants	group	107-121	tricyclic drugs	group	190-204	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , druga ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and drugb ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	anticonvulsants	group	107-121	imipramine	drug	207-216	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , druga ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( drugb , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	anticonvulsants	group	107-121	clomipramine	drug	219-230	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , druga ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , drugb , desipramine ) .
DDI-DrugBank.d638.s2	anticonvulsants	group	107-121	desipramine	drug	233-243	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , druga ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , drugb ) .
DDI-DrugBank.d638.s2	phenobarbital	drug	124-136	diphenylhydantoin	drug	139-155	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( druga , drugb , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	phenobarbital	drug	124-136	primidone	drug	158-166	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( druga , diphenylhydantoin , drugb ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	phenobarbital	drug	124-136	phenylbutazone	drug	170-183	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( druga , diphenylhydantoin , primidone ) , drugb , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	phenobarbital	drug	124-136	tricyclic drugs	group	190-204	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( druga , diphenylhydantoin , primidone ) , phenylbutazone , and drugb ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	phenobarbital	drug	124-136	imipramine	drug	207-216	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( druga , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( drugb , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	phenobarbital	drug	124-136	clomipramine	drug	219-230	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( druga , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , drugb , desipramine ) .
DDI-DrugBank.d638.s2	phenobarbital	drug	124-136	desipramine	drug	233-243	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( druga , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , drugb ) .
DDI-DrugBank.d638.s2	diphenylhydantoin	drug	139-155	primidone	drug	158-166	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , druga , drugb ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	diphenylhydantoin	drug	139-155	phenylbutazone	drug	170-183	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , druga , primidone ) , drugb , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	diphenylhydantoin	drug	139-155	tricyclic drugs	group	190-204	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , druga , primidone ) , phenylbutazone , and drugb ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	diphenylhydantoin	drug	139-155	imipramine	drug	207-216	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , druga , primidone ) , phenylbutazone , and tricyclic drugs ( drugb , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	diphenylhydantoin	drug	139-155	clomipramine	drug	219-230	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , druga , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , drugb , desipramine ) .
DDI-DrugBank.d638.s2	diphenylhydantoin	drug	139-155	desipramine	drug	233-243	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , druga , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , drugb ) .
DDI-DrugBank.d638.s2	primidone	drug	158-166	phenylbutazone	drug	170-183	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , druga ) , drugb , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	primidone	drug	158-166	tricyclic drugs	group	190-204	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , druga ) , phenylbutazone , and drugb ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	primidone	drug	158-166	imipramine	drug	207-216	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , druga ) , phenylbutazone , and tricyclic drugs ( drugb , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	primidone	drug	158-166	clomipramine	drug	219-230	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , druga ) , phenylbutazone , and tricyclic drugs ( imipramine , drugb , desipramine ) .
DDI-DrugBank.d638.s2	primidone	drug	158-166	desipramine	drug	233-243	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , druga ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , drugb ) .
DDI-DrugBank.d638.s2	phenylbutazone	drug	170-183	tricyclic drugs	group	190-204	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , druga , and drugb ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	phenylbutazone	drug	170-183	imipramine	drug	207-216	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , druga , and tricyclic drugs ( drugb , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	phenylbutazone	drug	170-183	clomipramine	drug	219-230	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , druga , and tricyclic drugs ( imipramine , drugb , desipramine ) .
DDI-DrugBank.d638.s2	phenylbutazone	drug	170-183	desipramine	drug	233-243	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , druga , and tricyclic drugs ( imipramine , clomipramine , drugb ) .
DDI-DrugBank.d638.s2	tricyclic drugs	group	190-204	imipramine	drug	207-216	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and druga ( drugb , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2	tricyclic drugs	group	190-204	clomipramine	drug	219-230	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and druga ( imipramine , drugb , desipramine ) .
DDI-DrugBank.d638.s2	tricyclic drugs	group	190-204	desipramine	drug	233-243	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and druga ( imipramine , clomipramine , drugb ) .
DDI-DrugBank.d638.s2	imipramine	drug	207-216	clomipramine	drug	219-230	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( druga , drugb , desipramine ) .
DDI-DrugBank.d638.s2	imipramine	drug	207-216	desipramine	drug	233-243	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( druga , clomipramine , drugb ) .
DDI-DrugBank.d638.s2	clomipramine	drug	219-230	desipramine	drug	233-243	false	human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , druga , drugb ) .
DDI-DrugBank.d638.s5	methylphenidate	drug	20-34	clonidine	drug	56-64	false	the safety of using druga in combination with drugb or other centrally acting alpha dg agonists has not been systemically evaluated .
DDI-DrugBank.d638.s5	methylphenidate	drug	20-34	alpha-2 agonists	group	92-107	false	the safety of using druga in combination with clonidine or other centrally acting drugb has not been systemically evaluated .
DDI-DrugBank.d638.s5	clonidine	drug	56-64	alpha-2 agonists	group	92-107	false	the safety of using methylphenidate in combination with druga or other centrally acting drugb has not been systemically evaluated .
DDI-DrugBank.d578.s1	cyclosporin	drug	62-72	methylprednisolone	drug	78-95	mechanism	mutual inhibition of metabolism occurs with concurrent use of druga and drugb ;
DDI-DrugBank.d578.s3	methylprednisolone	drug	54-71	cyclosporin	drug	77-87	effect	convulsions have been reported with concurrent use of druga and drugb .
DDI-DrugBank.d578.s4	phenobarbital	drug	42-54	phenytoin	drug	57-65	false	drugs that induce hepatic enzymes such as druga , drugb , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4	phenobarbital	drug	42-54	rifampin	drug	72-79	false	drugs that induce hepatic enzymes such as druga , phenytoin , and drugb may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4	phenobarbital	drug	42-54	methylprednisolone	drug	111-128	mechanism	drugs that induce hepatic enzymes such as druga , phenytoin , and rifampin may increase the clearance of drugb and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4	phenobarbital	drug	42-54	methylprednisolone	drug	159-176	advise	drugs that induce hepatic enzymes such as druga , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in drugb dose to achieve the desired response .
DDI-DrugBank.d578.s4	phenytoin	drug	57-65	rifampin	drug	72-79	false	drugs that induce hepatic enzymes such as phenobarbital , druga , and drugb may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4	phenytoin	drug	57-65	methylprednisolone	drug	111-128	mechanism	drugs that induce hepatic enzymes such as phenobarbital , druga , and rifampin may increase the clearance of drugb and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4	phenytoin	drug	57-65	methylprednisolone	drug	159-176	advise	drugs that induce hepatic enzymes such as phenobarbital , druga , and rifampin may increase the clearance of methylprednisolone and may require increased in drugb dose to achieve the desired response .
DDI-DrugBank.d578.s4	rifampin	drug	72-79	methylprednisolone	drug	111-128	mechanism	drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and druga may increase the clearance of drugb and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4	rifampin	drug	72-79	methylprednisolone	drug	159-176	advise	drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and druga may increase the clearance of methylprednisolone and may require increased in drugb dose to achieve the desired response .
DDI-DrugBank.d578.s4	methylprednisolone	drug	111-128	methylprednisolone	drug	159-176	false	drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of druga and may require increased in drugb dose to achieve the desired response .
DDI-DrugBank.d578.s5	troleandomycin	drug	14-27	ketoconazole	drug	33-44	false	drugs such as druga and drugb may inhibit the metabolism of methylprednisolone and thus decrease its clearance .
DDI-DrugBank.d578.s5	troleandomycin	drug	14-27	methylprednisolone	drug	76-93	mechanism	drugs such as druga and ketoconazole may inhibit the metabolism of drugb and thus decrease its clearance .
DDI-DrugBank.d578.s5	ketoconazole	drug	33-44	methylprednisolone	drug	76-93	mechanism	drugs such as troleandomycin and druga may inhibit the metabolism of drugb and thus decrease its clearance .
DDI-DrugBank.d578.s7	Methylprednisolone	drug	0-17	aspirin	brand	67-73	mechanism	druga may increase the clearance of chronic high dose drugb .
DDI-DrugBank.d578.s8	salicylate	group	29-38	salicylate	group	77-86	false	this could lead to decreased druga serum levels or increase the risk of drugb toxicity when methylprednisolone is withdrawn .
DDI-DrugBank.d578.s8	salicylate	group	29-38	methylprednisolone	drug	102-119	false	this could lead to decreased druga serum levels or increase the risk of salicylate toxicity when drugb is withdrawn .
DDI-DrugBank.d578.s8	salicylate	group	77-86	methylprednisolone	drug	102-119	effect	this could lead to decreased salicylate serum levels or increase the risk of druga toxicity when drugb is withdrawn .
DDI-DrugBank.d578.s9	Aspirin	brand	0-6	corticosteroids	group	54-68	advise	druga should be used cautiously in conjunction with drugb in patients suffering from hypoprothrombinemia .
DDI-DrugBank.d578.s10	methylprednisolone	drug	14-31	anticoagulants	group	41-54	false	the effect of druga on oral drugb is variable .
DDI-DrugBank.d578.s11	anticoagulant	group	63-75	corticosteroids	group	106-120	effect	there are reports of enhanced as well as diminished effects of druga when given concurrently with drugb .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	antidepressants	group	34-48	false	druga may interact with drugb ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	tricyclic	group	51-59	int	druga may interact with antidepressants ( drugb type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	MAO inhibitors	group	68-81	int	druga may interact with antidepressants ( tricyclic type ) , drugb ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	phenelzine	drug	90-99	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , drugb , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	linezolid	drug	102-110	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , drugb , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	tranylcypromine	drug	113-127	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , drugb , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	isocarboxazid	drug	130-142	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , drugb , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	selegiline	drug	145-154	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , drugb , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	furazolidone	drug	157-168	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , drugb ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	quinidine	drug	172-180	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	amantadine	drug	183-192	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	antihistamines	group	195-208	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	diphenhydramine	drug	217-231	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	anticholinergics	group	241-256	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	potassium chloride	drug	259-276	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	antacids	group	291-298	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	absorbent-type anti-diarrhea medicines	group	301-338	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	kaolin	drug	347-352	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	pectin	drug	354-359	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	phenothiazines	group	363-376	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	chlorpromazine	drug	385-398	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	Methscopolamine	drug	0-14	promethazine	drug	401-412	int	druga may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	tricyclic	group	51-59	false	methscopolamine may interact with druga ( drugb type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	MAO inhibitors	group	68-81	false	methscopolamine may interact with druga ( tricyclic type ) , drugb ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	phenelzine	drug	90-99	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , drugb , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	linezolid	drug	102-110	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , drugb , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	tranylcypromine	drug	113-127	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , drugb , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	isocarboxazid	drug	130-142	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , drugb , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	selegiline	drug	145-154	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , drugb , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	furazolidone	drug	157-168	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , drugb ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	quinidine	drug	172-180	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	amantadine	drug	183-192	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	antihistamines	group	195-208	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	diphenhydramine	drug	217-231	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	anticholinergics	group	241-256	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	potassium chloride	drug	259-276	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	antacids	group	291-298	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	kaolin	drug	347-352	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	pectin	drug	354-359	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	phenothiazines	group	363-376	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	chlorpromazine	drug	385-398	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	antidepressants	group	34-48	promethazine	drug	401-412	false	methscopolamine may interact with druga ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	MAO inhibitors	group	68-81	false	methscopolamine may interact with antidepressants ( druga type ) , drugb ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	phenelzine	drug	90-99	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , drugb , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	linezolid	drug	102-110	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , drugb , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	tranylcypromine	drug	113-127	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , drugb , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	isocarboxazid	drug	130-142	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , drugb , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	selegiline	drug	145-154	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , drugb , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	furazolidone	drug	157-168	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , drugb ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	quinidine	drug	172-180	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	amantadine	drug	183-192	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	tricyclic	group	51-59	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( druga type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	phenelzine	drug	90-99	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , drugb , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	linezolid	drug	102-110	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , drugb , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	tranylcypromine	drug	113-127	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , drugb , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	isocarboxazid	drug	130-142	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , drugb , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	selegiline	drug	145-154	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , drugb , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	furazolidone	drug	157-168	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , drugb ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	quinidine	drug	172-180	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	amantadine	drug	183-192	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	MAO inhibitors	group	68-81	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , druga ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	linezolid	drug	102-110	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , drugb , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	tranylcypromine	drug	113-127	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , drugb , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	isocarboxazid	drug	130-142	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , drugb , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	selegiline	drug	145-154	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , drugb , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	furazolidone	drug	157-168	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , drugb ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	quinidine	drug	172-180	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	amantadine	drug	183-192	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	phenelzine	drug	90-99	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , druga , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	tranylcypromine	drug	113-127	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , drugb , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	isocarboxazid	drug	130-142	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , drugb , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	selegiline	drug	145-154	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , drugb , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	furazolidone	drug	157-168	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , drugb ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	quinidine	drug	172-180	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	amantadine	drug	183-192	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	linezolid	drug	102-110	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , druga , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	isocarboxazid	drug	130-142	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , drugb , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	selegiline	drug	145-154	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , drugb , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	furazolidone	drug	157-168	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , drugb ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	quinidine	drug	172-180	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	amantadine	drug	183-192	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	tranylcypromine	drug	113-127	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , druga , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	selegiline	drug	145-154	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , drugb , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	furazolidone	drug	157-168	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , drugb ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	quinidine	drug	172-180	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	amantadine	drug	183-192	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	isocarboxazid	drug	130-142	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , druga , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	furazolidone	drug	157-168	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , drugb ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	quinidine	drug	172-180	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	amantadine	drug	183-192	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	selegiline	drug	145-154	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , druga , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	quinidine	drug	172-180	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , drugb , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	amantadine	drug	183-192	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	furazolidone	drug	157-168	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , druga ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	amantadine	drug	183-192	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , drugb , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	quinidine	drug	172-180	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , druga , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	antihistamines	group	195-208	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , drugb ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	amantadine	drug	183-192	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , druga , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	diphenhydramine	drug	217-231	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , drugb ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , diphenhydramine ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , diphenhydramine ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	antihistamines	group	195-208	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , druga ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	diphenhydramine	drug	217-231	anticholinergics	group	241-256	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , druga ) , other drugb , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	diphenhydramine	drug	217-231	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , druga ) , other anticholinergics , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	diphenhydramine	drug	217-231	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , druga ) , other anticholinergics , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	diphenhydramine	drug	217-231	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , druga ) , other anticholinergics , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	diphenhydramine	drug	217-231	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , druga ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	diphenhydramine	drug	217-231	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , druga ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	diphenhydramine	drug	217-231	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , druga ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	diphenhydramine	drug	217-231	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , druga ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	diphenhydramine	drug	217-231	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , druga ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	anticholinergics	group	241-256	potassium chloride	drug	259-276	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other druga , drugb supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	anticholinergics	group	241-256	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other druga , potassium chloride supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	anticholinergics	group	241-256	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other druga , potassium chloride supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	anticholinergics	group	241-256	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other druga , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	anticholinergics	group	241-256	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other druga , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	anticholinergics	group	241-256	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other druga , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	anticholinergics	group	241-256	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other druga , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	anticholinergics	group	241-256	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other druga , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	potassium chloride	drug	259-276	antacids	group	291-298	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , druga supplements , drugb , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	potassium chloride	drug	259-276	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , druga supplements , antacids , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	potassium chloride	drug	259-276	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , druga supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	potassium chloride	drug	259-276	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , druga supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	potassium chloride	drug	259-276	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , druga supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	potassium chloride	drug	259-276	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , druga supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	potassium chloride	drug	259-276	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , druga supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	antacids	group	291-298	absorbent-type anti-diarrhea medicines	group	301-338	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , druga , drugb ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antacids	group	291-298	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , druga , absorbent type anti diarrhea medicines ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antacids	group	291-298	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , druga , absorbent type anti diarrhea medicines ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antacids	group	291-298	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , druga , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	antacids	group	291-298	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , druga , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	antacids	group	291-298	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , druga , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	absorbent-type anti-diarrhea medicines	group	301-338	kaolin	drug	347-352	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , druga ( e.g. , drugb pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	absorbent-type anti-diarrhea medicines	group	301-338	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , druga ( e.g. , kaolin drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	absorbent-type anti-diarrhea medicines	group	301-338	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , druga ( e.g. , kaolin pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	absorbent-type anti-diarrhea medicines	group	301-338	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , druga ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	absorbent-type anti-diarrhea medicines	group	301-338	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , druga ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	kaolin	drug	347-352	pectin	drug	354-359	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , druga drugb ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	kaolin	drug	347-352	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , druga pectin ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	kaolin	drug	347-352	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , druga pectin ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	kaolin	drug	347-352	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , druga pectin ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	pectin	drug	354-359	phenothiazines	group	363-376	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin druga ) , drugb ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0	pectin	drug	354-359	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin druga ) , phenothiazines ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	pectin	drug	354-359	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin druga ) , phenothiazines ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	phenothiazines	group	363-376	chlorpromazine	drug	385-398	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , druga ( e.g. , drugb , promethazine ) .
DDI-DrugBank.d655.s0	phenothiazines	group	363-376	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , druga ( e.g. , chlorpromazine , drugb ) .
DDI-DrugBank.d655.s0	chlorpromazine	drug	385-398	promethazine	drug	401-412	false	methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent type anti diarrhea medicines ( e.g. , kaolin pectin ) , phenothiazines ( e.g. , druga , drugb ) .
DDI-DrugBank.d600.s1	alcohol	drug	18-24	CNS depression-producing drugs	group	36-65	false	concurrent use of druga and other drugb may increase the cns depressant effects of methyprylon or these other medications .
DDI-DrugBank.d600.s1	alcohol	drug	18-24	methyprylon	drug	110-120	effect	concurrent use of druga and other cns depression producing drugs may increase the cns depressant effects of drugb or these other medications .
DDI-DrugBank.d600.s1	CNS depression-producing drugs	group	36-65	methyprylon	drug	110-120	effect	concurrent use of alcohol and other druga may increase the cns depressant effects of drugb or these other medications .
DDI-DrugBank.d696.s0	Methysergide	drug	0-11	narcotic analgesics	group	51-69	effect	druga may reverse the analgesic activity of drugb .
DDI-DrugBank.d696.s1	vasoconstrictor agents	group	20-41	ergot alkaloids	group	53-67	false	concurrent use with druga including drugb , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1	vasoconstrictor agents	group	20-41	sumatriptan	drug	70-80	false	concurrent use with druga including ergot alkaloids , drugb , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1	vasoconstrictor agents	group	20-41	nicotine	drug	87-94	false	concurrent use with druga including ergot alkaloids , sumatriptan , and drugb ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1	ergot alkaloids	group	53-67	sumatriptan	drug	70-80	false	concurrent use with vasoconstrictor agents including druga , drugb , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1	ergot alkaloids	group	53-67	nicotine	drug	87-94	false	concurrent use with vasoconstrictor agents including druga , sumatriptan , and drugb ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1	sumatriptan	drug	70-80	nicotine	drug	87-94	false	concurrent use with vasoconstrictor agents including ergot alkaloids , druga , and drugb ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d652.s0	metoclopramide	drug	15-28	anticholinergic drugs	group	78-98	effect	the effects of druga on gastrointestinal motility are antagonized by drugb and narcotic analgesics .
DDI-DrugBank.d652.s0	metoclopramide	drug	15-28	narcotic analgesics	group	104-122	effect	the effects of druga on gastrointestinal motility are antagonized by anticholinergic drugs and drugb .
DDI-DrugBank.d652.s0	anticholinergic drugs	group	78-98	narcotic analgesics	group	104-122	false	the effects of metoclopramide on gastrointestinal motility are antagonized by druga and drugb .
DDI-DrugBank.d652.s1	metoclopramide	drug	41-54	alcohol	drug	70-76	effect	additive sedative effects can occur when druga is given with drugb , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1	metoclopramide	drug	41-54	sedatives	group	79-87	effect	additive sedative effects can occur when druga is given with alcohol , drugb , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1	metoclopramide	drug	41-54	hypnotics	group	90-98	effect	additive sedative effects can occur when druga is given with alcohol , sedatives , drugb , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1	metoclopramide	drug	41-54	narcotics	group	101-109	effect	additive sedative effects can occur when druga is given with alcohol , sedatives , hypnotics , drugb , or tranquilizers .
DDI-DrugBank.d652.s1	metoclopramide	drug	41-54	tranquilizers	group	115-127	effect	additive sedative effects can occur when druga is given with alcohol , sedatives , hypnotics , narcotics , or drugb .
DDI-DrugBank.d652.s1	alcohol	drug	70-76	sedatives	group	79-87	false	additive sedative effects can occur when metoclopramide is given with druga , drugb , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1	alcohol	drug	70-76	hypnotics	group	90-98	false	additive sedative effects can occur when metoclopramide is given with druga , sedatives , drugb , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1	alcohol	drug	70-76	narcotics	group	101-109	false	additive sedative effects can occur when metoclopramide is given with druga , sedatives , hypnotics , drugb , or tranquilizers .
DDI-DrugBank.d652.s1	alcohol	drug	70-76	tranquilizers	group	115-127	false	additive sedative effects can occur when metoclopramide is given with druga , sedatives , hypnotics , narcotics , or drugb .
DDI-DrugBank.d652.s1	sedatives	group	79-87	hypnotics	group	90-98	false	additive sedative effects can occur when metoclopramide is given with alcohol , druga , drugb , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1	sedatives	group	79-87	narcotics	group	101-109	false	additive sedative effects can occur when metoclopramide is given with alcohol , druga , hypnotics , drugb , or tranquilizers .
DDI-DrugBank.d652.s1	sedatives	group	79-87	tranquilizers	group	115-127	false	additive sedative effects can occur when metoclopramide is given with alcohol , druga , hypnotics , narcotics , or drugb .
DDI-DrugBank.d652.s1	hypnotics	group	90-98	narcotics	group	101-109	false	additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , druga , drugb , or tranquilizers .
DDI-DrugBank.d652.s1	hypnotics	group	90-98	tranquilizers	group	115-127	false	additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , druga , narcotics , or drugb .
DDI-DrugBank.d652.s1	narcotics	group	101-109	tranquilizers	group	115-127	false	additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , druga , or drugb .
DDI-DrugBank.d652.s2	metoclopramide	drug	17-30	monoamine oxi-dase inhibitors	group	173-201	advise	the finding that druga releases catecholamines in patients with essential hypertension suggests that it should be used cautiously , if at all , in patients receiving drugb .
DDI-DrugBank.d652.s3	digoxin	drug	62-68	metoclopramide	drug	74-87	mechanism	absorption of drugs from the stomach may be diminished ( e.g. , druga ) by drugb , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	digoxin	drug	62-68	acetaminophen	drug	189-201	false	absorption of drugs from the stomach may be diminished ( e.g. , druga ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugb , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	digoxin	drug	62-68	tetracycline	drug	204-215	false	absorption of drugs from the stomach may be diminished ( e.g. , druga ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , drugb , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	digoxin	drug	62-68	levodopa	drug	218-225	false	absorption of drugs from the stomach may be diminished ( e.g. , druga ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , drugb , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	digoxin	drug	62-68	ethanol	drug	228-234	false	absorption of drugs from the stomach may be diminished ( e.g. , druga ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , drugb , cyclosporine ) .
DDI-DrugBank.d652.s3	digoxin	drug	62-68	cyclosporine	drug	237-248	false	absorption of drugs from the stomach may be diminished ( e.g. , druga ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , drugb ) .
DDI-DrugBank.d652.s3	metoclopramide	drug	74-87	acetaminophen	drug	189-201	mechanism	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by druga , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugb , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	metoclopramide	drug	74-87	tetracycline	drug	204-215	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by druga , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , drugb , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	metoclopramide	drug	74-87	levodopa	drug	218-225	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by druga , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , drugb , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	metoclopramide	drug	74-87	ethanol	drug	228-234	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by druga , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , drugb , cyclosporine ) .
DDI-DrugBank.d652.s3	metoclopramide	drug	74-87	cyclosporine	drug	237-248	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by druga , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , drugb ) .
DDI-DrugBank.d652.s3	acetaminophen	drug	189-201	tetracycline	drug	204-215	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , druga , drugb , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	acetaminophen	drug	189-201	levodopa	drug	218-225	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , druga , tetracycline , drugb , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	acetaminophen	drug	189-201	ethanol	drug	228-234	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , druga , tetracycline , levodopa , drugb , cyclosporine ) .
DDI-DrugBank.d652.s3	acetaminophen	drug	189-201	cyclosporine	drug	237-248	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , druga , tetracycline , levodopa , ethanol , drugb ) .
DDI-DrugBank.d652.s3	tetracycline	drug	204-215	levodopa	drug	218-225	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , druga , drugb , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3	tetracycline	drug	204-215	ethanol	drug	228-234	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , druga , levodopa , drugb , cyclosporine ) .
DDI-DrugBank.d652.s3	tetracycline	drug	204-215	cyclosporine	drug	237-248	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , druga , levodopa , ethanol , drugb ) .
DDI-DrugBank.d652.s3	levodopa	drug	218-225	ethanol	drug	228-234	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , druga , drugb , cyclosporine ) .
DDI-DrugBank.d652.s3	levodopa	drug	218-225	cyclosporine	drug	237-248	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , druga , ethanol , drugb ) .
DDI-DrugBank.d652.s3	ethanol	drug	228-234	cyclosporine	drug	237-248	false	absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , druga , drugb ) .
DDI-DrugBank.d652.s6	metoclopramide	drug	22-35	insulin	drug	124-130	advise	because the action of druga will influence the delivery of food to the intestines and thus the rate of absorption , drugb dosage or timing of dosage may require adjustment .
DDI-DrugBank.d588.s0	Diuretics	group	0-8	Furosemide	drug	11-20	false	druga : drugb and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0	Diuretics	group	0-8	loop diuretics	group	41-54	false	druga : furosemide and probably other drugb given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0	Diuretics	group	0-8	metolazone	drug	81-90	false	druga : furosemide and probably other loop diuretics given concomitantly with drugb can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0	Furosemide	drug	11-20	loop diuretics	group	41-54	false	diuretics : druga and probably other drugb given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0	Furosemide	drug	11-20	metolazone	drug	81-90	effect	diuretics : druga and probably other loop diuretics given concomitantly with drugb can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0	loop diuretics	group	41-54	metolazone	drug	81-90	effect	diuretics : furosemide and probably other druga given concomitantly with drugb can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s1	Antihypertensives	group	6-22	MYKROX	brand	30-35	false	other druga : when drugb tablets are used with other antihypertensive drugs , care must be taken , especially during initial therapy .
DDI-DrugBank.d588.s1	Antihypertensives	group	6-22	antihypertensive drugs	group	65-86	false	other druga : when mykrox tablets are used with other drugb , care must be taken , especially during initial therapy .
DDI-DrugBank.d588.s1	MYKROX	brand	30-35	antihypertensive drugs	group	65-86	advise	other antihypertensives : when druga tablets are used with other drugb , care must be taken , especially during initial therapy .
DDI-DrugBank.d588.s3	Alcohol	drug	0-6	Barbiturates	group	9-20	false	druga , drugb , and narcotics : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy .
DDI-DrugBank.d588.s3	Alcohol	drug	0-6	Narcotics	group	27-35	false	druga , barbiturates , and drugb : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy .
DDI-DrugBank.d588.s3	Alcohol	drug	0-6	metolazone	drug	150-159	false	druga , barbiturates , and narcotics : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with drugb therapy .
DDI-DrugBank.d588.s3	Barbiturates	group	9-20	Narcotics	group	27-35	false	alcohol , druga , and drugb : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy .
DDI-DrugBank.d588.s3	Barbiturates	group	9-20	metolazone	drug	150-159	false	alcohol , druga , and narcotics : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with drugb therapy .
DDI-DrugBank.d588.s3	Narcotics	group	27-35	metolazone	drug	150-159	false	alcohol , barbiturates , and druga : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with drugb therapy .
DDI-DrugBank.d588.s4	Digitalis Glycosides	group	0-19	Diuretic	group	22-29	false	druga : drugb induced hypokalemia can increase the sensitivity of the myocardium to digitalis .
DDI-DrugBank.d588.s4	Digitalis Glycosides	group	0-19	digitalis	group	101-109	false	druga : diuretic induced hypokalemia can increase the sensitivity of the myocardium to drugb .
DDI-DrugBank.d588.s4	Diuretic	group	22-29	digitalis	group	101-109	effect	digitalis glycosides : druga induced hypokalemia can increase the sensitivity of the myocardium to drugb .
DDI-DrugBank.d588.s6	Corticosteroids	group	0-14	ACTH	drug	19-22	false	druga or drugb : may increase the risk of hypokalemia and increase salt and water retention .
DDI-DrugBank.d588.s7	Lithium	drug	0-6	lithium	drug	15-21	false	druga : serum drugb levels may increase .
DDI-DrugBank.d588.s8	Curariform Drugs	group	0-15	Diuretic	group	18-25	false	druga : drugb induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8	Curariform Drugs	group	0-15	curariform drugs	group	93-108	false	druga : diuretic induced hypokalemia may enhance neuromuscular blocking effects of drugb ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8	Curariform Drugs	group	0-15	tubocurarine	drug	119-130	false	druga : diuretic induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as drugb ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8	Diuretic	group	18-25	curariform drugs	group	93-108	effect	curariform drugs : druga induced hypokalemia may enhance neuromuscular blocking effects of drugb ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8	Diuretic	group	18-25	tubocurarine	drug	119-130	effect	curariform drugs : druga induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as drugb ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8	curariform drugs	group	93-108	tubocurarine	drug	119-130	false	curariform drugs : diuretic induced hypokalemia may enhance neuromuscular blocking effects of druga ( such as drugb ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s10	Salicylates	group	0-10	Non-Steroidal Anti-Inflammatory Drugs	group	22-58	false	druga and other drugb : may decrease the antihypertensive effects of mykrox tablets .
DDI-DrugBank.d588.s10	Salicylates	group	0-10	MYKROX	brand	106-111	effect	druga and other non steroidal anti inflammatory drugs : may decrease the antihypertensive effects of drugb tablets .
DDI-DrugBank.d588.s10	Non-Steroidal Anti-Inflammatory Drugs	group	22-58	MYKROX	brand	106-111	effect	salicylates and other druga : may decrease the antihypertensive effects of drugb tablets .
DDI-DrugBank.d588.s11	Sympathomimetics	group	0-15	Metolazone	drug	18-27	false	druga : drugb may decrease arterial responsiveness to norepinephrine , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
DDI-DrugBank.d588.s11	Sympathomimetics	group	0-15	norepinephrine	drug	69-82	false	druga : metolazone may decrease arterial responsiveness to drugb , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
DDI-DrugBank.d588.s11	Metolazone	drug	18-27	norepinephrine	drug	69-82	effect	sympathomimetics : druga may decrease arterial responsiveness to drugb , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
DDI-DrugBank.d588.s12	Methenamine	drug	0-10	metolazone	drug	75-84	effect	druga : efficacy may be decreased due to urinary alkalizing effect of drugb .
DDI-DrugBank.d588.s13	Anticoagulants	group	0-13	Metolazone	drug	16-25	false	druga : drugb , as well as other thiazide like diuretics , may affect the hypoprothrombinemic response to anticoagulants ;
DDI-DrugBank.d588.s13	Anticoagulants	group	0-13	thiazide-like diuretics	group	45-67	false	druga : metolazone , as well as other drugb , may affect the hypoprothrombinemic response to anticoagulants ;
DDI-DrugBank.d588.s13	Anticoagulants	group	0-13	anticoagulants	group	117-130	false	druga : metolazone , as well as other thiazide like diuretics , may affect the hypoprothrombinemic response to drugb ;
DDI-DrugBank.d588.s13	Metolazone	drug	16-25	thiazide-like diuretics	group	45-67	false	anticoagulants : druga , as well as other drugb , may affect the hypoprothrombinemic response to anticoagulants ;
DDI-DrugBank.d588.s13	Metolazone	drug	16-25	anticoagulants	group	117-130	effect	anticoagulants : druga , as well as other thiazide like diuretics , may affect the hypoprothrombinemic response to drugb ;
DDI-DrugBank.d588.s13	thiazide-like diuretics	group	45-67	anticoagulants	group	117-130	false	anticoagulants : metolazone , as well as other druga , may affect the hypoprothrombinemic response to drugb ;
DDI-DrugBank.d706.s0	reserpine	drug	37-45	beta-blocking agents	group	92-111	effect	catecholamine depleting drugs ( e.g. , druga ) may have an additive effect when given with drugb .
DDI-DrugBank.d629.s0	metronidazole	drug	5-17	coumarin	group	79-86	effect	oral druga has been reported to potentiate the anticoagulant effect of drugb and warfarin , resulting in a prolongation of prothrombin time .
DDI-DrugBank.d629.s0	metronidazole	drug	5-17	warfarin	drug	92-99	effect	oral druga has been reported to potentiate the anticoagulant effect of coumarin and drugb , resulting in a prolongation of prothrombin time .
DDI-DrugBank.d629.s0	coumarin	group	79-86	warfarin	drug	92-99	false	oral metronidazole has been reported to potentiate the anticoagulant effect of druga and drugb , resulting in a prolongation of prothrombin time .
DDI-DrugBank.d629.s1	METROGEL	brand	46-53	metronidazole	drug	56-68	false	drug interactions should be kept in mind when druga ( drugb gel ) , dg % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption .
DDI-DrugBank.d629.s1	METROGEL	brand	46-53	metronidazole	drug	201-213	false	drug interactions should be kept in mind when druga ( metronidazole gel ) , dg % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical drugb administration because of low absorption .
DDI-DrugBank.d629.s1	metronidazole	drug	56-68	metronidazole	drug	201-213	false	drug interactions should be kept in mind when metrogel ( druga gel ) , dg % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical drugb administration because of low absorption .
DDI-DrugBank.d678.s1	Metopirone	brand	18-27	phenytoin	drug	47-55	mechanism	the metabolism of druga is accelerated by drugb ;
DDI-DrugBank.d678.s4	Metopirone	brand	0-9	acetaminophen	drug	43-55	mechanism	druga inhibits the glucuronidation of drugb and could possibly potentiate acetaminophen toxicity .
DDI-DrugBank.d678.s4	Metopirone	brand	0-9	acetaminophen	drug	87-99	effect	druga inhibits the glucuronidation of acetaminophen and could possibly potentiate drugb toxicity .
DDI-DrugBank.d678.s4	acetaminophen	drug	43-55	acetaminophen	drug	87-99	false	metopirone inhibits the glucuronidation of druga and could possibly potentiate drugb toxicity .
DDI-DrugBank.d715.s0	DEMSER	brand	44-49	phenothiazines	group	73-86	advise	caution should be observed in administering druga to patients receiving drugb or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
DDI-DrugBank.d715.s0	DEMSER	brand	44-49	haloperidol	drug	91-101	advise	caution should be observed in administering druga to patients receiving phenothiazines or drugb because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
DDI-DrugBank.d715.s0	phenothiazines	group	73-86	haloperidol	drug	91-101	false	caution should be observed in administering demser to patients receiving druga or drugb because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
DDI-DrugBank.d715.s1	DEMSER	brand	18-23	alcohol	drug	30-36	effect	concurrent use of druga with drugb or other cns depressants can increase their sedative effects .
DDI-DrugBank.d715.s1	DEMSER	brand	18-23	CNS depressants	drug	47-61	effect	concurrent use of druga with alcohol or other drugb can increase their sedative effects .
DDI-DrugBank.d715.s1	alcohol	drug	30-36	CNS depressants	drug	47-61	false	concurrent use of demser with druga or other drugb can increase their sedative effects .
DDI-DrugBank.d633.s0	MEXITIL	brand	6-12	mexiletine	drug	171-180	false	since druga is a substrate for the metabolic pathways involving cyp2d6 and cyp1a2 enzymes , inhibition or induction of either of these enzymes would be expected to alter drugb plasma concentrations .
DDI-DrugBank.d633.s1	mexiletine	drug	74-83	fluvoxamine	drug	140-150	mechanism	in a formal , single dose interaction study ( n = dg males ) the clearance of druga was decreased by dg % following the coadministration of drugb , an inhibitor of cyp1a2 .
DDI-DrugBank.d633.s2	propafenone	drug	101-111	mexiletine	drug	143-152	false	in another formal study ( n = dg extensive and n = dg poor metabolizers of cyp2d6 ) , coadministration of druga did not alter the kinetics of drugb in the poor cyp2d6 metabolizer group .
DDI-DrugBank.d633.s4	propafenone	drug	62-72	mexiletine	drug	137-146	false	in this crossover steady state study , the pharmacokinetics of druga were unaffected in either phenotype by the coadministration of drugb .
DDI-DrugBank.d633.s5	mexiletine	drug	12-21	propafenone	drug	26-36	false	addition of druga to drugb did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than propafenone alone .
DDI-DrugBank.d633.s5	mexiletine	drug	12-21	propafenone	drug	141-151	false	addition of druga to propafenone did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than drugb alone .
DDI-DrugBank.d633.s5	propafenone	drug	26-36	propafenone	drug	141-151	false	addition of mexiletine to druga did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than drugb alone .
DDI-DrugBank.d633.s6	mexiletine	drug	66-75	mexiletine	drug	103-112	false	when concomitant administration of either of these two drugs with druga is initiated , the dose of drugb should be slowly titrated to desired effect .
DDI-DrugBank.d633.s7	Mexitil	brand	37-43	antihypertensive	group	111-126	false	in a large compassionate use program druga has been used concurrently with commonly employed antianginal , drugb , and anticoagulant drugs without observed interactions .
DDI-DrugBank.d633.s7	Mexitil	brand	37-43	anticoagulant drugs	group	133-151	false	in a large compassionate use program druga has been used concurrently with commonly employed antianginal , antihypertensive , and drugb without observed interactions .
DDI-DrugBank.d633.s7	antihypertensive	group	111-126	anticoagulant drugs	group	133-151	false	in a large compassionate use program mexitil has been used concurrently with commonly employed antianginal , druga , and drugb without observed interactions .
DDI-DrugBank.d633.s8	antiarrhythmics	group	13-27	quinidine	drug	37-45	false	a variety of druga such as drugb or propranolol were also added , sometimes with improved control of ventricular ectopy .
DDI-DrugBank.d633.s8	antiarrhythmics	group	13-27	propranolol	drug	50-60	false	a variety of druga such as quinidine or drugb were also added , sometimes with improved control of ventricular ectopy .
DDI-DrugBank.d633.s8	quinidine	drug	37-45	propranolol	drug	50-60	false	a variety of antiarrhythmics such as druga or drugb were also added , sometimes with improved control of ventricular ectopy .
DDI-DrugBank.d633.s9	phenytoin	drug	5-13	rifampin	drug	56-63	false	when druga or other hepatic enzyme inducers such as drugb and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9	phenytoin	drug	5-13	phenobarbital	drug	69-81	false	when druga or other hepatic enzyme inducers such as rifampin and drugb have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9	phenytoin	drug	5-13	Mexitil	brand	117-123	mechanism	when druga or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with drugb , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9	phenytoin	drug	5-13	Mexitil	brand	137-143	false	when druga or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered drugb plasma levels have been reported .
DDI-DrugBank.d633.s9	rifampin	drug	56-63	phenobarbital	drug	69-81	false	when phenytoin or other hepatic enzyme inducers such as druga and drugb have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9	rifampin	drug	56-63	Mexitil	brand	117-123	mechanism	when phenytoin or other hepatic enzyme inducers such as druga and phenobarbital have been taken concurrently with drugb , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9	rifampin	drug	56-63	Mexitil	brand	137-143	false	when phenytoin or other hepatic enzyme inducers such as druga and phenobarbital have been taken concurrently with mexitil , lowered drugb plasma levels have been reported .
DDI-DrugBank.d633.s9	phenobarbital	drug	69-81	Mexitil	brand	117-123	mechanism	when phenytoin or other hepatic enzyme inducers such as rifampin and druga have been taken concurrently with drugb , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9	phenobarbital	drug	69-81	Mexitil	brand	137-143	false	when phenytoin or other hepatic enzyme inducers such as rifampin and druga have been taken concurrently with mexitil , lowered drugb plasma levels have been reported .
DDI-DrugBank.d633.s9	Mexitil	brand	117-123	Mexitil	brand	137-143	false	when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with druga , lowered drugb plasma levels have been reported .
DDI-DrugBank.d633.s11	benzodiazepines	group	19-33	Mexitil	brand	60-66	false	in a formal study , druga were shown not to affect drugb plasma concentrations .
DDI-DrugBank.d633.s12	Mexitil	brand	64-70	digoxin	drug	79-85	false	ecg intervals ( pr , qrs , and qt ) were not affected by concurrent druga and drugb , diuretics , or propranolol .
DDI-DrugBank.d633.s12	Mexitil	brand	64-70	diuretics	group	88-96	false	ecg intervals ( pr , qrs , and qt ) were not affected by concurrent druga and digoxin , drugb , or propranolol .
DDI-DrugBank.d633.s12	Mexitil	brand	64-70	propranolol	drug	102-112	false	ecg intervals ( pr , qrs , and qt ) were not affected by concurrent druga and digoxin , diuretics , or drugb .
DDI-DrugBank.d633.s12	digoxin	drug	79-85	diuretics	group	88-96	false	ecg intervals ( pr , qrs , and qt ) were not affected by concurrent mexitil and druga , drugb , or propranolol .
DDI-DrugBank.d633.s12	digoxin	drug	79-85	propranolol	drug	102-112	false	ecg intervals ( pr , qrs , and qt ) were not affected by concurrent mexitil and druga , diuretics , or drugb .
DDI-DrugBank.d633.s12	diuretics	group	88-96	propranolol	drug	102-112	false	ecg intervals ( pr , qrs , and qt ) were not affected by concurrent mexitil and digoxin , druga , or drugb .
DDI-DrugBank.d633.s13	cimetidine	drug	29-38	Mexitil	brand	44-50	mechanism	concurrent administration of druga and drugb has been reported to increase , decrease , or leave unchanged mexitil plasma levels ;
DDI-DrugBank.d633.s13	cimetidine	drug	29-38	Mexitil	brand	115-121	false	concurrent administration of druga and mexitil has been reported to increase , decrease , or leave unchanged drugb plasma levels ;
DDI-DrugBank.d633.s13	Mexitil	brand	44-50	Mexitil	brand	115-121	false	concurrent administration of cimetidine and druga has been reported to increase , decrease , or leave unchanged drugb plasma levels ;
DDI-DrugBank.d633.s15	Mexitil	brand	0-6	digoxin	drug	32-38	false	druga does not alter serum drugb levels but magnesium aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15	Mexitil	brand	0-6	magnesium-aluminum hydroxide	drug	51-78	false	druga does not alter serum digoxin levels but drugb , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15	Mexitil	brand	0-6	Mexitil	brand	133-139	false	druga does not alter serum digoxin levels but magnesium aluminum hydroxide , when used to treat gastrointestinal symptoms due to drugb , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15	Mexitil	brand	0-6	digoxin	drug	178-184	false	druga does not alter serum digoxin levels but magnesium aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum drugb levels .
DDI-DrugBank.d633.s15	digoxin	drug	32-38	magnesium-aluminum hydroxide	drug	51-78	false	mexitil does not alter serum druga levels but drugb , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15	digoxin	drug	32-38	Mexitil	brand	133-139	false	mexitil does not alter serum druga levels but magnesium aluminum hydroxide , when used to treat gastrointestinal symptoms due to drugb , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15	digoxin	drug	32-38	digoxin	drug	178-184	false	mexitil does not alter serum druga levels but magnesium aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum drugb levels .
DDI-DrugBank.d633.s15	magnesium-aluminum hydroxide	drug	51-78	Mexitil	brand	133-139	false	mexitil does not alter serum digoxin levels but druga , when used to treat gastrointestinal symptoms due to drugb , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15	magnesium-aluminum hydroxide	drug	51-78	digoxin	drug	178-184	mechanism	mexitil does not alter serum digoxin levels but druga , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum drugb levels .
DDI-DrugBank.d633.s15	Mexitil	brand	133-139	digoxin	drug	178-184	false	mexitil does not alter serum digoxin levels but magnesium aluminum hydroxide , when used to treat gastrointestinal symptoms due to druga , has been reported to lower serum drugb levels .
DDI-DrugBank.d633.s16	Mexitil	brand	18-24	theophylline	drug	33-44	mechanism	concurrent use of druga and drugb may lead to increased plasma theophylline levels .
DDI-DrugBank.d633.s16	Mexitil	brand	18-24	theophylline	drug	75-86	false	concurrent use of druga and theophylline may lead to increased plasma drugb levels .
DDI-DrugBank.d633.s16	theophylline	drug	33-44	theophylline	drug	75-86	false	concurrent use of mexitil and druga may lead to increased plasma drugb levels .
DDI-DrugBank.d633.s18	Mexitil	brand	91-97	Theophylline	drug	103-114	false	this increase was observed at the first test point which was the second day after starting druga . drugb plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	91-97	Mexitil	brand	146-152	false	this increase was observed at the first test point which was the second day after starting druga . theophylline plasma levels returned to pre drugb values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	91-97	Mexitil	brand	200-206	false	this increase was observed at the first test point which was the second day after starting druga . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing drugb . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	91-97	Mexitil	brand	215-221	false	this increase was observed at the first test point which was the second day after starting druga . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if drugb and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	91-97	theophylline	drug	227-238	false	this increase was observed at the first test point which was the second day after starting druga . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and drugb are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	91-97	theophylline	drug	269-280	false	this increase was observed at the first test point which was the second day after starting druga . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , drugb blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	91-97	Mexitil	brand	338-344	false	this increase was observed at the first test point which was the second day after starting druga . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the drugb dose is changed .
DDI-DrugBank.d633.s18	Theophylline	drug	103-114	Mexitil	brand	146-152	false	this increase was observed at the first test point which was the second day after starting mexitil . druga plasma levels returned to pre drugb values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Theophylline	drug	103-114	Mexitil	brand	200-206	mechanism	this increase was observed at the first test point which was the second day after starting mexitil . druga plasma levels returned to pre mexitil values within dg hours after discontinuing drugb . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Theophylline	drug	103-114	Mexitil	brand	215-221	false	this increase was observed at the first test point which was the second day after starting mexitil . druga plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if drugb and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Theophylline	drug	103-114	theophylline	drug	227-238	false	this increase was observed at the first test point which was the second day after starting mexitil . druga plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and drugb are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Theophylline	drug	103-114	theophylline	drug	269-280	false	this increase was observed at the first test point which was the second day after starting mexitil . druga plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , drugb blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Theophylline	drug	103-114	Mexitil	brand	338-344	false	this increase was observed at the first test point which was the second day after starting mexitil . druga plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the drugb dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	146-152	Mexitil	brand	200-206	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre druga values within dg hours after discontinuing drugb . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	146-152	Mexitil	brand	215-221	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre druga values within dg hours after discontinuing mexitil . if drugb and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	146-152	theophylline	drug	227-238	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre druga values within dg hours after discontinuing mexitil . if mexitil and drugb are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	146-152	theophylline	drug	269-280	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre druga values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , drugb blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	146-152	Mexitil	brand	338-344	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre druga values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the drugb dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	200-206	Mexitil	brand	215-221	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing druga . if drugb and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	200-206	theophylline	drug	227-238	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing druga . if mexitil and drugb are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	200-206	theophylline	drug	269-280	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing druga . if mexitil and theophylline are to be used concurrently , drugb blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	200-206	Mexitil	brand	338-344	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing druga . if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the drugb dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	215-221	theophylline	drug	227-238	advise	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if druga and drugb are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	215-221	theophylline	drug	269-280	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if druga and theophylline are to be used concurrently , drugb blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	Mexitil	brand	215-221	Mexitil	brand	338-344	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if druga and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the drugb dose is changed .
DDI-DrugBank.d633.s18	theophylline	drug	227-238	theophylline	drug	269-280	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and druga are to be used concurrently , drugb blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18	theophylline	drug	227-238	Mexitil	brand	338-344	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and druga are to be used concurrently , theophylline blood levels should be monitored , particularly when the drugb dose is changed .
DDI-DrugBank.d633.s18	theophylline	drug	269-280	Mexitil	brand	338-344	false	this increase was observed at the first test point which was the second day after starting mexitil . theophylline plasma levels returned to pre mexitil values within dg hours after discontinuing mexitil . if mexitil and theophylline are to be used concurrently , druga blood levels should be monitored , particularly when the drugb dose is changed .
DDI-DrugBank.d633.s20	caffeine	drug	99-106	Mexitil	brand	158-164	mechanism	additionally , in one controlled study in five normal subjects and seven patients , the clearance of druga was decreased dg % following the administration of drugb .
DDI-DrugBank.d783.s0	Posicor	brand	0-6	terfenadine	drug	78-88	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs drugb , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	Posicor	brand	0-6	astemizole	drug	91-100	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs terfenadine , drugb , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	Posicor	brand	0-6	cisapride	drug	103-111	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs terfenadine , astemizole , drugb , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	Posicor	brand	0-6	cyclosporine	drug	114-125	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs terfenadine , astemizole , cisapride , drugb , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	Posicor	brand	0-6	tricyclic antidepressants	group	132-156	mechanism	druga inhibits some of the liver 's ability to metabolize some other drugs terfenadine , astemizole , cisapride , cyclosporine , and drugb .
DDI-DrugBank.d783.s0	terfenadine	drug	78-88	astemizole	drug	91-100	false	posicor inhibits some of the liver 's ability to metabolize some other drugs druga , drugb , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	terfenadine	drug	78-88	cisapride	drug	103-111	false	posicor inhibits some of the liver 's ability to metabolize some other drugs druga , astemizole , drugb , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	terfenadine	drug	78-88	cyclosporine	drug	114-125	false	posicor inhibits some of the liver 's ability to metabolize some other drugs druga , astemizole , cisapride , drugb , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	terfenadine	drug	78-88	tricyclic antidepressants	group	132-156	false	posicor inhibits some of the liver 's ability to metabolize some other drugs druga , astemizole , cisapride , cyclosporine , and drugb .
DDI-DrugBank.d783.s0	astemizole	drug	91-100	cisapride	drug	103-111	false	posicor inhibits some of the liver 's ability to metabolize some other drugs terfenadine , druga , drugb , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	astemizole	drug	91-100	cyclosporine	drug	114-125	false	posicor inhibits some of the liver 's ability to metabolize some other drugs terfenadine , druga , cisapride , drugb , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	astemizole	drug	91-100	tricyclic antidepressants	group	132-156	false	posicor inhibits some of the liver 's ability to metabolize some other drugs terfenadine , druga , cisapride , cyclosporine , and drugb .
DDI-DrugBank.d783.s0	cisapride	drug	103-111	cyclosporine	drug	114-125	false	posicor inhibits some of the liver 's ability to metabolize some other drugs terfenadine , astemizole , druga , drugb , and tricyclic antidepressants .
DDI-DrugBank.d783.s0	cisapride	drug	103-111	tricyclic antidepressants	group	132-156	false	posicor inhibits some of the liver 's ability to metabolize some other drugs terfenadine , astemizole , druga , cyclosporine , and drugb .
DDI-DrugBank.d783.s0	cyclosporine	drug	114-125	tricyclic antidepressants	group	132-156	false	posicor inhibits some of the liver 's ability to metabolize some other drugs terfenadine , astemizole , cisapride , druga , and drugb .
DDI-DrugBank.d735.s0	MYCAMINE	brand	140-147	mycophenolate mofetil	drug	153-173	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugb , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	MYCAMINE	brand	140-147	cyclosporine	drug	176-187	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and mycophenolate mofetil , drugb , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	MYCAMINE	brand	140-147	tacrolimus	drug	190-199	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and mycophenolate mofetil , cyclosporine , drugb , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	MYCAMINE	brand	140-147	prednisolone	drug	202-213	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and mycophenolate mofetil , cyclosporine , tacrolimus , drugb , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	MYCAMINE	brand	140-147	sirolimus	drug	216-224	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , drugb , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	MYCAMINE	brand	140-147	nifedipine	drug	227-236	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , drugb , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	MYCAMINE	brand	140-147	fluconazole	drug	239-249	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , drugb , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	MYCAMINE	brand	140-147	ritonavir	drug	252-260	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , drugb , and rifampin .
DDI-DrugBank.d735.s0	MYCAMINE	brand	140-147	rifampin	drug	267-274	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and drugb .
DDI-DrugBank.d735.s0	mycophenolate mofetil	drug	153-173	cyclosporine	drug	176-187	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and druga , drugb , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	mycophenolate mofetil	drug	153-173	tacrolimus	drug	190-199	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and druga , cyclosporine , drugb , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	mycophenolate mofetil	drug	153-173	prednisolone	drug	202-213	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and druga , cyclosporine , tacrolimus , drugb , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	mycophenolate mofetil	drug	153-173	sirolimus	drug	216-224	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and druga , cyclosporine , tacrolimus , prednisolone , drugb , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	mycophenolate mofetil	drug	153-173	nifedipine	drug	227-236	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and druga , cyclosporine , tacrolimus , prednisolone , sirolimus , drugb , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	mycophenolate mofetil	drug	153-173	fluconazole	drug	239-249	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and druga , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , drugb , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	mycophenolate mofetil	drug	153-173	ritonavir	drug	252-260	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and druga , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , drugb , and rifampin .
DDI-DrugBank.d735.s0	mycophenolate mofetil	drug	153-173	rifampin	drug	267-274	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and druga , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and drugb .
DDI-DrugBank.d735.s0	cyclosporine	drug	176-187	tacrolimus	drug	190-199	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , druga , drugb , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	cyclosporine	drug	176-187	prednisolone	drug	202-213	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , druga , tacrolimus , drugb , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	cyclosporine	drug	176-187	sirolimus	drug	216-224	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , druga , tacrolimus , prednisolone , drugb , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	cyclosporine	drug	176-187	nifedipine	drug	227-236	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , druga , tacrolimus , prednisolone , sirolimus , drugb , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	cyclosporine	drug	176-187	fluconazole	drug	239-249	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , druga , tacrolimus , prednisolone , sirolimus , nifedipine , drugb , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	cyclosporine	drug	176-187	ritonavir	drug	252-260	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , druga , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , drugb , and rifampin .
DDI-DrugBank.d735.s0	cyclosporine	drug	176-187	rifampin	drug	267-274	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , druga , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and drugb .
DDI-DrugBank.d735.s0	tacrolimus	drug	190-199	prednisolone	drug	202-213	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , druga , drugb , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	tacrolimus	drug	190-199	sirolimus	drug	216-224	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , druga , prednisolone , drugb , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	tacrolimus	drug	190-199	nifedipine	drug	227-236	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , druga , prednisolone , sirolimus , drugb , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	tacrolimus	drug	190-199	fluconazole	drug	239-249	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , druga , prednisolone , sirolimus , nifedipine , drugb , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	tacrolimus	drug	190-199	ritonavir	drug	252-260	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , druga , prednisolone , sirolimus , nifedipine , fluconazole , drugb , and rifampin .
DDI-DrugBank.d735.s0	tacrolimus	drug	190-199	rifampin	drug	267-274	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , druga , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and drugb .
DDI-DrugBank.d735.s0	prednisolone	drug	202-213	sirolimus	drug	216-224	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , druga , drugb , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	prednisolone	drug	202-213	nifedipine	drug	227-236	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , druga , sirolimus , drugb , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	prednisolone	drug	202-213	fluconazole	drug	239-249	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , druga , sirolimus , nifedipine , drugb , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	prednisolone	drug	202-213	ritonavir	drug	252-260	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , druga , sirolimus , nifedipine , fluconazole , drugb , and rifampin .
DDI-DrugBank.d735.s0	prednisolone	drug	202-213	rifampin	drug	267-274	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , druga , sirolimus , nifedipine , fluconazole , ritonavir , and drugb .
DDI-DrugBank.d735.s0	sirolimus	drug	216-224	nifedipine	drug	227-236	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , druga , drugb , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	sirolimus	drug	216-224	fluconazole	drug	239-249	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , druga , nifedipine , drugb , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	sirolimus	drug	216-224	ritonavir	drug	252-260	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , druga , nifedipine , fluconazole , drugb , and rifampin .
DDI-DrugBank.d735.s0	sirolimus	drug	216-224	rifampin	drug	267-274	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , druga , nifedipine , fluconazole , ritonavir , and drugb .
DDI-DrugBank.d735.s0	nifedipine	drug	227-236	fluconazole	drug	239-249	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , druga , drugb , ritonavir , and rifampin .
DDI-DrugBank.d735.s0	nifedipine	drug	227-236	ritonavir	drug	252-260	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , druga , fluconazole , drugb , and rifampin .
DDI-DrugBank.d735.s0	nifedipine	drug	227-236	rifampin	drug	267-274	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , druga , fluconazole , ritonavir , and drugb .
DDI-DrugBank.d735.s0	fluconazole	drug	239-249	ritonavir	drug	252-260	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , druga , drugb , and rifampin .
DDI-DrugBank.d735.s0	fluconazole	drug	239-249	rifampin	drug	267-274	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , druga , ritonavir , and drugb .
DDI-DrugBank.d735.s0	ritonavir	drug	252-260	rifampin	drug	267-274	false	a total of dg clinical drug drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , druga , and drugb .
DDI-DrugBank.d735.s2	MYCAMINE	brand	58-65	mycophenolate mofetil	drug	70-90	false	there was no effect of a single dose or multiple doses of druga on drugb , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	MYCAMINE	brand	58-65	cyclosporine	drug	93-104	false	there was no effect of a single dose or multiple doses of druga on mycophenolate mofetil , drugb , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	MYCAMINE	brand	58-65	tacrolimus	drug	107-116	false	there was no effect of a single dose or multiple doses of druga on mycophenolate mofetil , cyclosporine , drugb , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	MYCAMINE	brand	58-65	prednisolone	drug	119-130	false	there was no effect of a single dose or multiple doses of druga on mycophenolate mofetil , cyclosporine , tacrolimus , drugb , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	MYCAMINE	brand	58-65	fluconazole	drug	137-147	false	there was no effect of a single dose or multiple doses of druga on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and drugb pharmacokinetics .
DDI-DrugBank.d735.s2	mycophenolate mofetil	drug	70-90	cyclosporine	drug	93-104	false	there was no effect of a single dose or multiple doses of mycamine on druga , drugb , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	mycophenolate mofetil	drug	70-90	tacrolimus	drug	107-116	false	there was no effect of a single dose or multiple doses of mycamine on druga , cyclosporine , drugb , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	mycophenolate mofetil	drug	70-90	prednisolone	drug	119-130	false	there was no effect of a single dose or multiple doses of mycamine on druga , cyclosporine , tacrolimus , drugb , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	mycophenolate mofetil	drug	70-90	fluconazole	drug	137-147	false	there was no effect of a single dose or multiple doses of mycamine on druga , cyclosporine , tacrolimus , prednisolone , and drugb pharmacokinetics .
DDI-DrugBank.d735.s2	cyclosporine	drug	93-104	tacrolimus	drug	107-116	false	there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , druga , drugb , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	cyclosporine	drug	93-104	prednisolone	drug	119-130	false	there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , druga , tacrolimus , drugb , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	cyclosporine	drug	93-104	fluconazole	drug	137-147	false	there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , druga , tacrolimus , prednisolone , and drugb pharmacokinetics .
DDI-DrugBank.d735.s2	tacrolimus	drug	107-116	prednisolone	drug	119-130	false	there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , druga , drugb , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2	tacrolimus	drug	107-116	fluconazole	drug	137-147	false	there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , druga , prednisolone , and drugb pharmacokinetics .
DDI-DrugBank.d735.s2	prednisolone	drug	119-130	fluconazole	drug	137-147	false	there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , druga , and drugb pharmacokinetics .
DDI-DrugBank.d735.s3	Sirolimus	drug	0-8	MYCAMINE	brand	90-97	mechanism	druga auc was increased by dg % with no effect on cmax in the presence of steady state drugb compared with sirolimus alone .
DDI-DrugBank.d735.s3	Sirolimus	drug	0-8	sirolimus	drug	113-121	false	druga auc was increased by dg % with no effect on cmax in the presence of steady state mycamine compared with drugb alone .
DDI-DrugBank.d735.s3	MYCAMINE	brand	90-97	sirolimus	drug	113-121	false	sirolimus auc was increased by dg % with no effect on cmax in the presence of steady state druga compared with drugb alone .
DDI-DrugBank.d735.s4	Nifedipine	drug	0-9	MYCAMINE	brand	101-108	mechanism	druga auc and cmax were increased by dg % and dg % , respectively , in the presence of steady state drugb compared with nifedipine alone .
DDI-DrugBank.d735.s4	Nifedipine	drug	0-9	nifedipine	drug	124-133	false	druga auc and cmax were increased by dg % and dg % , respectively , in the presence of steady state mycamine compared with drugb alone .
DDI-DrugBank.d735.s4	MYCAMINE	brand	101-108	nifedipine	drug	124-133	false	nifedipine auc and cmax were increased by dg % and dg % , respectively , in the presence of steady state druga compared with drugb alone .
DDI-DrugBank.d735.s5	sirolimus	drug	19-27	nifedipine	drug	32-41	false	patients receiving druga or drugb in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	sirolimus	drug	19-27	MYCAMINE	brand	63-70	advise	patients receiving druga or nifedipine in combination with drugb should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	sirolimus	drug	19-27	sirolimus	drug	96-104	false	patients receiving druga or nifedipine in combination with mycamine should be monitored for drugb or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	sirolimus	drug	19-27	nifedipine	drug	109-118	false	patients receiving druga or nifedipine in combination with mycamine should be monitored for sirolimus or drugb toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	sirolimus	drug	19-27	sirolimus	drug	133-141	false	patients receiving druga or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and drugb or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	sirolimus	drug	19-27	nifedipine	drug	146-155	false	patients receiving druga or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or drugb dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	nifedipine	drug	32-41	MYCAMINE	brand	63-70	advise	patients receiving sirolimus or druga in combination with drugb should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	nifedipine	drug	32-41	sirolimus	drug	96-104	false	patients receiving sirolimus or druga in combination with mycamine should be monitored for drugb or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	nifedipine	drug	32-41	nifedipine	drug	109-118	false	patients receiving sirolimus or druga in combination with mycamine should be monitored for sirolimus or drugb toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	nifedipine	drug	32-41	sirolimus	drug	133-141	false	patients receiving sirolimus or druga in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and drugb or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	nifedipine	drug	32-41	nifedipine	drug	146-155	false	patients receiving sirolimus or druga in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or drugb dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	MYCAMINE	brand	63-70	sirolimus	drug	96-104	false	patients receiving sirolimus or nifedipine in combination with druga should be monitored for drugb or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	MYCAMINE	brand	63-70	nifedipine	drug	109-118	false	patients receiving sirolimus or nifedipine in combination with druga should be monitored for sirolimus or drugb toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	MYCAMINE	brand	63-70	sirolimus	drug	133-141	false	patients receiving sirolimus or nifedipine in combination with druga should be monitored for sirolimus or nifedipine toxicity and drugb or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	MYCAMINE	brand	63-70	nifedipine	drug	146-155	false	patients receiving sirolimus or nifedipine in combination with druga should be monitored for sirolimus or nifedipine toxicity and sirolimus or drugb dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	sirolimus	drug	96-104	nifedipine	drug	109-118	false	patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for druga or drugb toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	sirolimus	drug	96-104	sirolimus	drug	133-141	false	patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for druga or nifedipine toxicity and drugb or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	sirolimus	drug	96-104	nifedipine	drug	146-155	false	patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for druga or nifedipine toxicity and sirolimus or drugb dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	nifedipine	drug	109-118	sirolimus	drug	133-141	false	patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or druga toxicity and drugb or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	nifedipine	drug	109-118	nifedipine	drug	146-155	false	patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or druga toxicity and sirolimus or drugb dosage should be reduced if necessary .
DDI-DrugBank.d735.s5	sirolimus	drug	133-141	nifedipine	drug	146-155	false	patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and druga or drugb dosage should be reduced if necessary .
DDI-DrugBank.d752.s0	midazolam	drug	74-82	azole antimycotics	group	228-245	advise	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of drugb , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0	midazolam	drug	74-82	protease inhibitors	group	248-266	advise	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of azole antimycotics , drugb , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0	midazolam	drug	74-82	calcium channel antagonists	group	269-295	advise	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , drugb , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0	midazolam	drug	74-82	macrolide antibiotics	group	302-322	advise	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and drugb ) .
DDI-DrugBank.d752.s0	azole antimycotics	group	228-245	protease inhibitors	group	248-266	false	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of druga , drugb , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0	azole antimycotics	group	228-245	calcium channel antagonists	group	269-295	false	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of druga , protease inhibitors , drugb , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0	azole antimycotics	group	228-245	macrolide antibiotics	group	302-322	false	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of druga , protease inhibitors , calcium channel antagonists , and drugb ) .
DDI-DrugBank.d752.s0	protease inhibitors	group	248-266	calcium channel antagonists	group	269-295	false	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of azole antimycotics , druga , drugb , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0	protease inhibitors	group	248-266	macrolide antibiotics	group	302-322	false	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of azole antimycotics , druga , calcium channel antagonists , and drugb ) .
DDI-DrugBank.d752.s0	calcium channel antagonists	group	269-295	macrolide antibiotics	group	302-322	false	drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 dg enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , druga , and drugb ) .
DDI-DrugBank.d752.s1	erythromycin	drug	14-25	diltiazem	drug	28-36	false	drugs such as druga , drugb , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	erythromycin	drug	14-25	verapamil	drug	39-47	false	drugs such as druga , diltiazem , drugb , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	erythromycin	drug	14-25	ketoconazole	drug	50-61	false	drugs such as druga , diltiazem , verapamil , drugb , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	erythromycin	drug	14-25	fluconazole	drug	64-74	false	drugs such as druga , diltiazem , verapamil , ketoconazole , drugb and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	erythromycin	drug	14-25	itraconazole	drug	80-91	false	drugs such as druga , diltiazem , verapamil , ketoconazole , fluconazole and drugb were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	erythromycin	drug	14-25	midazolam	drug	171-179	mechanism	drugs such as druga , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1	diltiazem	drug	28-36	verapamil	drug	39-47	false	drugs such as erythromycin , druga , drugb , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	diltiazem	drug	28-36	ketoconazole	drug	50-61	false	drugs such as erythromycin , druga , verapamil , drugb , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	diltiazem	drug	28-36	fluconazole	drug	64-74	false	drugs such as erythromycin , druga , verapamil , ketoconazole , drugb and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	diltiazem	drug	28-36	itraconazole	drug	80-91	false	drugs such as erythromycin , druga , verapamil , ketoconazole , fluconazole and drugb were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	diltiazem	drug	28-36	midazolam	drug	171-179	mechanism	drugs such as erythromycin , druga , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1	verapamil	drug	39-47	ketoconazole	drug	50-61	false	drugs such as erythromycin , diltiazem , druga , drugb , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	verapamil	drug	39-47	fluconazole	drug	64-74	false	drugs such as erythromycin , diltiazem , druga , ketoconazole , drugb and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	verapamil	drug	39-47	itraconazole	drug	80-91	false	drugs such as erythromycin , diltiazem , druga , ketoconazole , fluconazole and drugb were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	verapamil	drug	39-47	midazolam	drug	171-179	mechanism	drugs such as erythromycin , diltiazem , druga , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1	ketoconazole	drug	50-61	fluconazole	drug	64-74	false	drugs such as erythromycin , diltiazem , verapamil , druga , drugb and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	ketoconazole	drug	50-61	itraconazole	drug	80-91	false	drugs such as erythromycin , diltiazem , verapamil , druga , fluconazole and drugb were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	ketoconazole	drug	50-61	midazolam	drug	171-179	mechanism	drugs such as erythromycin , diltiazem , verapamil , druga , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1	fluconazole	drug	64-74	itraconazole	drug	80-91	false	drugs such as erythromycin , diltiazem , verapamil , ketoconazole , druga and drugb were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1	fluconazole	drug	64-74	midazolam	drug	171-179	mechanism	drugs such as erythromycin , diltiazem , verapamil , ketoconazole , druga and itraconazole were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s1	itraconazole	drug	80-91	midazolam	drug	171-179	mechanism	drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and druga were shown to significantly increase the c max and auc of orally administered drugb .
DDI-DrugBank.d752.s3	ritonavir	drug	64-72	nelfinavir	drug	78-87	false	although not studied , the potent cytochrome p450 dg inhibitors druga and drugb may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam .
DDI-DrugBank.d752.s3	ritonavir	drug	64-72	midazolam	drug	198-206	mechanism	although not studied , the potent cytochrome p450 dg inhibitors druga and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of drugb .
DDI-DrugBank.d752.s3	nelfinavir	drug	78-87	midazolam	drug	198-206	mechanism	although not studied , the potent cytochrome p450 dg inhibitors ritonavir and druga may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of drugb .
DDI-DrugBank.d752.s6	rifampin	drug	63-70	carbamazepine	drug	73-85	false	inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as druga , drugb , and phenytoin , induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies .
DDI-DrugBank.d752.s6	rifampin	drug	63-70	phenytoin	drug	92-100	false	inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as druga , carbamazepine , and drugb , induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies .
DDI-DrugBank.d752.s6	rifampin	drug	63-70	midazolam	drug	175-183	mechanism	inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as druga , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased c max and auc of oral drugb in adult studies .
DDI-DrugBank.d752.s6	carbamazepine	drug	73-85	phenytoin	drug	92-100	false	inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as rifampin , druga , and drugb , induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies .
DDI-DrugBank.d752.s6	carbamazepine	drug	73-85	midazolam	drug	175-183	mechanism	inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as rifampin , druga , and phenytoin , induce metabolism and caused a markedly decreased c max and auc of oral drugb in adult studies .
DDI-DrugBank.d752.s6	phenytoin	drug	92-100	midazolam	drug	175-183	mechanism	inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as rifampin , carbamazepine , and druga , induce metabolism and caused a markedly decreased c max and auc of oral drugb in adult studies .
DDI-DrugBank.d752.s9	sedatives	group	102-110	methylphenidate	drug	178-192	false	the difficulty in achieving adequate sedation may have been the result of decreased absorption of the druga due to both the gastrointestinal effects and stimulant effects of drugb .
DDI-DrugBank.d752.s10	VERSED Syrup	brand	23-34	narcotics	group	153-161	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugb ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	VERSED Syrup	brand	23-34	morphine	drug	168-175	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , drugb , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	VERSED Syrup	brand	23-34	meperidine	drug	178-187	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , drugb and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	VERSED Syrup	brand	23-34	fentanyl	drug	193-200	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and drugb ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	VERSED Syrup	brand	23-34	propofol	drug	204-211	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , drugb , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	VERSED Syrup	brand	23-34	ketamine	drug	214-221	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , drugb , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	VERSED Syrup	brand	23-34	nitrous oxide	drug	224-236	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , drugb , secobarbital and droperidol .
DDI-DrugBank.d752.s10	VERSED Syrup	brand	23-34	secobarbital	drug	239-250	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , drugb and droperidol .
DDI-DrugBank.d752.s10	VERSED Syrup	brand	23-34	droperidol	drug	256-265	effect	the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and drugb .
DDI-DrugBank.d752.s10	narcotics	group	153-161	morphine	drug	168-175	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , drugb , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	narcotics	group	153-161	meperidine	drug	178-187	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , morphine , drugb and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	narcotics	group	153-161	fentanyl	drug	193-200	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , morphine , meperidine and drugb ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	narcotics	group	153-161	propofol	drug	204-211	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , morphine , meperidine and fentanyl ) , drugb , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	narcotics	group	153-161	ketamine	drug	214-221	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , morphine , meperidine and fentanyl ) , propofol , drugb , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	narcotics	group	153-161	nitrous oxide	drug	224-236	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , drugb , secobarbital and droperidol .
DDI-DrugBank.d752.s10	narcotics	group	153-161	secobarbital	drug	239-250	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , drugb and droperidol .
DDI-DrugBank.d752.s10	narcotics	group	153-161	droperidol	drug	256-265	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and drugb .
DDI-DrugBank.d752.s10	morphine	drug	168-175	meperidine	drug	178-187	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , druga , drugb and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	morphine	drug	168-175	fentanyl	drug	193-200	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , druga , meperidine and drugb ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	morphine	drug	168-175	propofol	drug	204-211	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , druga , meperidine and fentanyl ) , drugb , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	morphine	drug	168-175	ketamine	drug	214-221	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , druga , meperidine and fentanyl ) , propofol , drugb , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	morphine	drug	168-175	nitrous oxide	drug	224-236	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , druga , meperidine and fentanyl ) , propofol , ketamine , drugb , secobarbital and droperidol .
DDI-DrugBank.d752.s10	morphine	drug	168-175	secobarbital	drug	239-250	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , druga , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , drugb and droperidol .
DDI-DrugBank.d752.s10	morphine	drug	168-175	droperidol	drug	256-265	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , druga , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and drugb .
DDI-DrugBank.d752.s10	meperidine	drug	178-187	fentanyl	drug	193-200	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , druga and drugb ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	meperidine	drug	178-187	propofol	drug	204-211	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , druga and fentanyl ) , drugb , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	meperidine	drug	178-187	ketamine	drug	214-221	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , druga and fentanyl ) , propofol , drugb , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	meperidine	drug	178-187	nitrous oxide	drug	224-236	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , druga and fentanyl ) , propofol , ketamine , drugb , secobarbital and droperidol .
DDI-DrugBank.d752.s10	meperidine	drug	178-187	secobarbital	drug	239-250	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , druga and fentanyl ) , propofol , ketamine , nitrous oxide , drugb and droperidol .
DDI-DrugBank.d752.s10	meperidine	drug	178-187	droperidol	drug	256-265	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , druga and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and drugb .
DDI-DrugBank.d752.s10	fentanyl	drug	193-200	propofol	drug	204-211	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and druga ) , drugb , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	fentanyl	drug	193-200	ketamine	drug	214-221	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and druga ) , propofol , drugb , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	fentanyl	drug	193-200	nitrous oxide	drug	224-236	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and druga ) , propofol , ketamine , drugb , secobarbital and droperidol .
DDI-DrugBank.d752.s10	fentanyl	drug	193-200	secobarbital	drug	239-250	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and druga ) , propofol , ketamine , nitrous oxide , drugb and droperidol .
DDI-DrugBank.d752.s10	fentanyl	drug	193-200	droperidol	drug	256-265	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and druga ) , propofol , ketamine , nitrous oxide , secobarbital and drugb .
DDI-DrugBank.d752.s10	propofol	drug	204-211	ketamine	drug	214-221	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , druga , drugb , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10	propofol	drug	204-211	nitrous oxide	drug	224-236	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , druga , ketamine , drugb , secobarbital and droperidol .
DDI-DrugBank.d752.s10	propofol	drug	204-211	secobarbital	drug	239-250	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , druga , ketamine , nitrous oxide , drugb and droperidol .
DDI-DrugBank.d752.s10	propofol	drug	204-211	droperidol	drug	256-265	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , druga , ketamine , nitrous oxide , secobarbital and drugb .
DDI-DrugBank.d752.s10	ketamine	drug	214-221	nitrous oxide	drug	224-236	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , druga , drugb , secobarbital and droperidol .
DDI-DrugBank.d752.s10	ketamine	drug	214-221	secobarbital	drug	239-250	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , druga , nitrous oxide , drugb and droperidol .
DDI-DrugBank.d752.s10	ketamine	drug	214-221	droperidol	drug	256-265	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , druga , nitrous oxide , secobarbital and drugb .
DDI-DrugBank.d752.s10	nitrous oxide	drug	224-236	secobarbital	drug	239-250	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , druga , drugb and droperidol .
DDI-DrugBank.d752.s10	nitrous oxide	drug	224-236	droperidol	drug	256-265	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , druga , secobarbital and drugb .
DDI-DrugBank.d752.s10	secobarbital	drug	239-250	droperidol	drug	256-265	false	the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , druga and drugb .
DDI-DrugBank.d752.s12	atropine	drug	72-79	scopolamine	drug	82-92	false	no significant adverse interactions with common premedications ( such as druga , drugb , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	atropine	drug	72-79	glycopyrrolate	drug	95-108	false	no significant adverse interactions with common premedications ( such as druga , scopolamine , drugb , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	atropine	drug	72-79	diazepam	drug	111-118	false	no significant adverse interactions with common premedications ( such as druga , scopolamine , glycopyrrolate , drugb , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	atropine	drug	72-79	hydroxyzine	drug	121-131	false	no significant adverse interactions with common premedications ( such as druga , scopolamine , glycopyrrolate , diazepam , drugb , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	atropine	drug	72-79	muscle relaxants	group	144-159	false	no significant adverse interactions with common premedications ( such as druga , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other drugb ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	atropine	drug	72-79	anesthetics	group	171-181	false	no significant adverse interactions with common premedications ( such as druga , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local drugb have been observed .
DDI-DrugBank.d752.s12	scopolamine	drug	82-92	glycopyrrolate	drug	95-108	false	no significant adverse interactions with common premedications ( such as atropine , druga , drugb , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	scopolamine	drug	82-92	diazepam	drug	111-118	false	no significant adverse interactions with common premedications ( such as atropine , druga , glycopyrrolate , drugb , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	scopolamine	drug	82-92	hydroxyzine	drug	121-131	false	no significant adverse interactions with common premedications ( such as atropine , druga , glycopyrrolate , diazepam , drugb , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	scopolamine	drug	82-92	muscle relaxants	group	144-159	false	no significant adverse interactions with common premedications ( such as atropine , druga , glycopyrrolate , diazepam , hydroxyzine , and other drugb ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	scopolamine	drug	82-92	anesthetics	group	171-181	false	no significant adverse interactions with common premedications ( such as atropine , druga , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local drugb have been observed .
DDI-DrugBank.d752.s12	glycopyrrolate	drug	95-108	diazepam	drug	111-118	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , druga , drugb , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	glycopyrrolate	drug	95-108	hydroxyzine	drug	121-131	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , druga , diazepam , drugb , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	glycopyrrolate	drug	95-108	muscle relaxants	group	144-159	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , druga , diazepam , hydroxyzine , and other drugb ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	glycopyrrolate	drug	95-108	anesthetics	group	171-181	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , druga , diazepam , hydroxyzine , and other muscle relaxants ) or local drugb have been observed .
DDI-DrugBank.d752.s12	diazepam	drug	111-118	hydroxyzine	drug	121-131	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , druga , drugb , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	diazepam	drug	111-118	muscle relaxants	group	144-159	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , druga , hydroxyzine , and other drugb ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	diazepam	drug	111-118	anesthetics	group	171-181	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , druga , hydroxyzine , and other muscle relaxants ) or local drugb have been observed .
DDI-DrugBank.d752.s12	hydroxyzine	drug	121-131	muscle relaxants	group	144-159	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , druga , and other drugb ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12	hydroxyzine	drug	121-131	anesthetics	group	171-181	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , druga , and other muscle relaxants ) or local drugb have been observed .
DDI-DrugBank.d752.s12	muscle relaxants	group	144-159	anesthetics	group	171-181	false	no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other druga ) or local drugb have been observed .
DDI-DrugBank.d603.s0	ProAmatine	brand	37-46	cardiac glycosides	group	52-69	effect	when administered concomitantly with druga , drugb may enhance or precipitate bradycardia , a.v .
DDI-DrugBank.d603.s2	phenylephrine	drug	66-78	pseudoephedrine	drug	81-95	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , druga , drugb , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	phenylephrine	drug	66-78	ephedrine	drug	98-106	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , druga , pseudoephedrine , drugb , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	phenylephrine	drug	66-78	phenylpropanolamine	drug	109-127	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , druga , pseudoephedrine , ephedrine , drugb or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	phenylephrine	drug	66-78	dihydroergotamine	drug	132-148	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , druga , pseudoephedrine , ephedrine , phenylpropanolamine or drugb ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	phenylephrine	drug	66-78	ProAmatine	brand	200-209	effect	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , druga , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	phenylephrine	drug	66-78	ProAmatine	brand	254-263	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , druga , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	pseudoephedrine	drug	81-95	ephedrine	drug	98-106	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , druga , drugb , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	pseudoephedrine	drug	81-95	phenylpropanolamine	drug	109-127	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , druga , ephedrine , drugb or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	pseudoephedrine	drug	81-95	dihydroergotamine	drug	132-148	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , druga , ephedrine , phenylpropanolamine or drugb ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	pseudoephedrine	drug	81-95	ProAmatine	brand	200-209	effect	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , druga , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	pseudoephedrine	drug	81-95	ProAmatine	brand	254-263	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , druga , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	ephedrine	drug	98-106	phenylpropanolamine	drug	109-127	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , druga , drugb or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	ephedrine	drug	98-106	dihydroergotamine	drug	132-148	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , druga , phenylpropanolamine or drugb ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	ephedrine	drug	98-106	ProAmatine	brand	200-209	effect	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , druga , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	ephedrine	drug	98-106	ProAmatine	brand	254-263	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , druga , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	phenylpropanolamine	drug	109-127	dihydroergotamine	drug	132-148	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , druga or drugb ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	phenylpropanolamine	drug	109-127	ProAmatine	brand	200-209	effect	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , druga or dihydroergotamine ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	phenylpropanolamine	drug	109-127	ProAmatine	brand	254-263	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , druga or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	dihydroergotamine	drug	132-148	ProAmatine	brand	200-209	effect	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or druga ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when proamatine is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	dihydroergotamine	drug	132-148	ProAmatine	brand	254-263	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or druga ) may enhance or potentiate the pressor effects of proamatine . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s2	ProAmatine	brand	200-209	ProAmatine	brand	254-263	false	the use of drugs that stimulate alpha adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of druga . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
DDI-DrugBank.d603.s3	ProAmatine	brand	0-9	fludrocortisone acetate	drug	105-127	false	druga has been used in patients concomitantly treated with salt retaining steroid therapy ( i.e. , drugb ) , with or without salt supplementation .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	Alpha-adrenergic blocking agents	group	12-43	false	druga . drugb , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	prazosin	drug	54-61	false	druga . alpha adrenergic blocking agents , such as drugb , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	terazosin	drug	64-72	false	druga . alpha adrenergic blocking agents , such as prazosin , drugb , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	doxazosin	drug	79-87	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and drugb , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	ProAmatine	brand	120-129	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	desglymidodrine	drug_n	274-288	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	metformin	drug	415-423	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as drugb , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	cimetidine	drug	426-435	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , drugb , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	ranitidine	drug	438-447	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , drugb , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	procainamide	drug	450-461	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	triamterene	drug	464-474	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	flecainide	drug	477-486	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	0-9	quinidine	drug	493-501	false	druga . alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	prazosin	drug	54-61	false	proamatine. druga , such as drugb , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	terazosin	drug	64-72	false	proamatine. druga , such as prazosin , drugb , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	doxazosin	drug	79-87	false	proamatine. druga , such as prazosin , terazosin , and drugb , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	ProAmatine	brand	120-129	effect	proamatine. druga , such as prazosin , terazosin , and doxazosin , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	desglymidodrine	drug_n	274-288	false	proamatine. druga , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	metformin	drug	415-423	false	proamatine. druga , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as drugb , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	cimetidine	drug	426-435	false	proamatine. druga , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , drugb , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	ranitidine	drug	438-447	false	proamatine. druga , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , drugb , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	procainamide	drug	450-461	false	proamatine. druga , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	triamterene	drug	464-474	false	proamatine. druga , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	flecainide	drug	477-486	false	proamatine. druga , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	Alpha-adrenergic blocking agents	group	12-43	quinidine	drug	493-501	false	proamatine. druga , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	terazosin	drug	64-72	false	proamatine. alpha adrenergic blocking agents , such as druga , drugb , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	doxazosin	drug	79-87	false	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and drugb , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	ProAmatine	brand	120-129	effect	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and doxazosin , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	desglymidodrine	drug_n	274-288	false	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	metformin	drug	415-423	false	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as drugb , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	cimetidine	drug	426-435	false	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , drugb , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	ranitidine	drug	438-447	false	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , drugb , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	procainamide	drug	450-461	false	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	triamterene	drug	464-474	false	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	flecainide	drug	477-486	false	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	prazosin	drug	54-61	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as druga , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	doxazosin	drug	79-87	false	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and drugb , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	ProAmatine	brand	120-129	effect	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and doxazosin , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	desglymidodrine	drug_n	274-288	false	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	metformin	drug	415-423	false	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as drugb , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	cimetidine	drug	426-435	false	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , drugb , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	ranitidine	drug	438-447	false	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , drugb , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	procainamide	drug	450-461	false	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	triamterene	drug	464-474	false	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	flecainide	drug	477-486	false	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	terazosin	drug	64-72	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as prazosin , druga , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	doxazosin	drug	79-87	ProAmatine	brand	120-129	effect	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and druga , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	doxazosin	drug	79-87	desglymidodrine	drug_n	274-288	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and druga , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	doxazosin	drug	79-87	metformin	drug	415-423	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and druga , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as drugb , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	doxazosin	drug	79-87	cimetidine	drug	426-435	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and druga , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , drugb , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	doxazosin	drug	79-87	ranitidine	drug	438-447	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and druga , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , drugb , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	doxazosin	drug	79-87	procainamide	drug	450-461	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and druga , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	doxazosin	drug	79-87	triamterene	drug	464-474	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and druga , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	doxazosin	drug	79-87	flecainide	drug	477-486	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and druga , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	doxazosin	drug	79-87	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and druga , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	ProAmatine	brand	120-129	desglymidodrine	drug_n	274-288	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	120-129	metformin	drug	415-423	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as drugb , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	120-129	cimetidine	drug	426-435	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , drugb , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	120-129	ranitidine	drug	438-447	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , drugb , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	120-129	procainamide	drug	450-461	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	120-129	triamterene	drug	464-474	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	120-129	flecainide	drug	477-486	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	ProAmatine	brand	120-129	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	desglymidodrine	drug_n	274-288	metformin	drug	415-423	mechanism	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as drugb , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	desglymidodrine	drug_n	274-288	cimetidine	drug	426-435	mechanism	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , drugb , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	desglymidodrine	drug_n	274-288	ranitidine	drug	438-447	mechanism	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , drugb , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	desglymidodrine	drug_n	274-288	procainamide	drug	450-461	mechanism	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	desglymidodrine	drug_n	274-288	triamterene	drug	464-474	mechanism	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	desglymidodrine	drug_n	274-288	flecainide	drug	477-486	mechanism	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	desglymidodrine	drug_n	274-288	quinidine	drug	493-501	mechanism	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	metformin	drug	415-423	cimetidine	drug	426-435	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as druga , drugb , ranitidine , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	metformin	drug	415-423	ranitidine	drug	438-447	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as druga , cimetidine , drugb , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	metformin	drug	415-423	procainamide	drug	450-461	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as druga , cimetidine , ranitidine , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	metformin	drug	415-423	triamterene	drug	464-474	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as druga , cimetidine , ranitidine , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	metformin	drug	415-423	flecainide	drug	477-486	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as druga , cimetidine , ranitidine , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	metformin	drug	415-423	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as druga , cimetidine , ranitidine , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	cimetidine	drug	426-435	ranitidine	drug	438-447	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , druga , drugb , procainamide , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	cimetidine	drug	426-435	procainamide	drug	450-461	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , druga , ranitidine , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	cimetidine	drug	426-435	triamterene	drug	464-474	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , druga , ranitidine , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	cimetidine	drug	426-435	flecainide	drug	477-486	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , druga , ranitidine , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	cimetidine	drug	426-435	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , druga , ranitidine , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	ranitidine	drug	438-447	procainamide	drug	450-461	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , druga , drugb , triamterene , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ranitidine	drug	438-447	triamterene	drug	464-474	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , druga , procainamide , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	ranitidine	drug	438-447	flecainide	drug	477-486	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , druga , procainamide , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	ranitidine	drug	438-447	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , druga , procainamide , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	procainamide	drug	450-461	triamterene	drug	464-474	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , druga , drugb , flecainide , and quinidine .
DDI-DrugBank.d603.s5	procainamide	drug	450-461	flecainide	drug	477-486	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , druga , triamterene , drugb , and quinidine .
DDI-DrugBank.d603.s5	procainamide	drug	450-461	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , druga , triamterene , flecainide , and drugb .
DDI-DrugBank.d603.s5	triamterene	drug	464-474	flecainide	drug	477-486	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , druga , drugb , and quinidine .
DDI-DrugBank.d603.s5	triamterene	drug	464-474	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , druga , flecainide , and drugb .
DDI-DrugBank.d603.s5	flecainide	drug	477-486	quinidine	drug	493-501	false	proamatine. alpha adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine. potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , druga , and drugb .
DDI-DrugBank.d668.s0	mifepristone	drug	49-60	ketoconazole	drug	158-169	false	although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that drugb , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0	mifepristone	drug	49-60	itraconazole	drug	172-183	false	although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that ketoconazole , drugb , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0	mifepristone	drug	49-60	erythromycin	drug	186-197	false	although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that ketoconazole , itraconazole , drugb , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0	mifepristone	drug	49-60	mifepristone	drug	276-287	false	although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugb ) .
DDI-DrugBank.d668.s0	ketoconazole	drug	158-169	itraconazole	drug	172-183	false	although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that druga , drugb , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0	ketoconazole	drug	158-169	erythromycin	drug	186-197	false	although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that druga , itraconazole , drugb , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0	ketoconazole	drug	158-169	mifepristone	drug	276-287	mechanism	although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that druga , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugb ) .
DDI-DrugBank.d668.s0	itraconazole	drug	172-183	erythromycin	drug	186-197	false	although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that ketoconazole , druga , drugb , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0	itraconazole	drug	172-183	mifepristone	drug	276-287	mechanism	although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that ketoconazole , druga , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugb ) .
DDI-DrugBank.d668.s0	erythromycin	drug	186-197	mifepristone	drug	276-287	mechanism	although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp dg , it is possible that ketoconazole , itraconazole , druga , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugb ) .
DDI-DrugBank.d668.s1	rifampin	drug	13-20	dexamethasone	drug	23-35	false	furthermore , druga , drugb , st .
DDI-DrugBank.d668.s2	anticonvulsants	group	27-41	phenytoin	drug	44-52	false	john s wort , and certain druga ( drugb , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	anticonvulsants	group	27-41	phenobarbital	drug	55-67	false	john s wort , and certain druga ( phenytoin , drugb , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	anticonvulsants	group	27-41	carbamazepine	drug	70-82	false	john s wort , and certain druga ( phenytoin , phenobarbital , drugb ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	anticonvulsants	group	27-41	mifepristone	drug	96-107	mechanism	john s wort , and certain druga ( phenytoin , phenobarbital , carbamazepine ) may induce drugb metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	anticonvulsants	group	27-41	mifepristone	drug	146-157	false	john s wort , and certain druga ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of drugb ) .
DDI-DrugBank.d668.s2	phenytoin	drug	44-52	phenobarbital	drug	55-67	false	john s wort , and certain anticonvulsants ( druga , drugb , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	phenytoin	drug	44-52	carbamazepine	drug	70-82	false	john s wort , and certain anticonvulsants ( druga , phenobarbital , drugb ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	phenytoin	drug	44-52	mifepristone	drug	96-107	mechanism	john s wort , and certain anticonvulsants ( druga , phenobarbital , carbamazepine ) may induce drugb metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	phenytoin	drug	44-52	mifepristone	drug	146-157	false	john s wort , and certain anticonvulsants ( druga , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of drugb ) .
DDI-DrugBank.d668.s2	phenobarbital	drug	55-67	carbamazepine	drug	70-82	false	john s wort , and certain anticonvulsants ( phenytoin , druga , drugb ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	phenobarbital	drug	55-67	mifepristone	drug	96-107	mechanism	john s wort , and certain anticonvulsants ( phenytoin , druga , carbamazepine ) may induce drugb metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	phenobarbital	drug	55-67	mifepristone	drug	146-157	false	john s wort , and certain anticonvulsants ( phenytoin , druga , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of drugb ) .
DDI-DrugBank.d668.s2	carbamazepine	drug	70-82	mifepristone	drug	96-107	mechanism	john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , druga ) may induce drugb metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2	carbamazepine	drug	70-82	mifepristone	drug	146-157	false	john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , druga ) may induce mifepristone metabolism ( lowering serum levels of drugb ) .
DDI-DrugBank.d668.s2	mifepristone	drug	96-107	mifepristone	drug	146-157	false	john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce druga metabolism ( lowering serum levels of drugb ) .
DDI-DrugBank.d695.s0	ZAVESCA	brand	27-33	Cerezyme	brand	76-83	mechanism	while co administration of druga appeared to increase the clearance of drugb by dg % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of cerezyme .
DDI-DrugBank.d695.s0	ZAVESCA	brand	27-33	Cerezyme	brand	218-225	false	while co administration of druga appeared to increase the clearance of cerezyme by dg % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drugb .
DDI-DrugBank.d695.s0	Cerezyme	brand	76-83	Cerezyme	brand	218-225	false	while co administration of zavesca appeared to increase the clearance of druga by dg % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drugb .
DDI-DrugBank.d695.s1	Cerezyme	brand	25-32	imiglucerase	drug	38-49	false	combination therapy with druga ( drugb ) and zavesca is not indicated .
DDI-DrugBank.d695.s1	Cerezyme	brand	25-32	ZAVESCA	brand	56-62	advise	combination therapy with druga ( imiglucerase ) and drugb is not indicated .
DDI-DrugBank.d695.s1	imiglucerase	drug	38-49	ZAVESCA	brand	56-62	advise	combination therapy with cerezyme ( druga ) and drugb is not indicated .
DDI-DrugBank.d711.s0	tetracyclines	group	8-20	anticoagulant	group	98-110	advise	because druga have been shown to depress plasma prothrombin activity , patients who are on drugb therapy may require downward adjustment of their anticoagulant dosage .
DDI-DrugBank.d711.s0	tetracyclines	group	8-20	anticoagulant	group	161-173	false	because druga have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their drugb dosage .
DDI-DrugBank.d711.s0	anticoagulant	group	98-110	anticoagulant	group	161-173	false	because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on druga therapy may require downward adjustment of their drugb dosage .
DDI-DrugBank.d711.s1	penicillin	drug	73-82	tetracycline class drugs	group	117-140	false	since bacteriostatic drugs may interfere with the bactericidal action of druga , it is advisable to avoid giving drugb in conjunction with penicillin .
DDI-DrugBank.d711.s1	penicillin	drug	73-82	penicillin	drug	162-171	false	since bacteriostatic drugs may interfere with the bactericidal action of druga , it is advisable to avoid giving tetracycline class drugs in conjunction with drugb .
DDI-DrugBank.d711.s1	tetracycline class drugs	group	117-140	penicillin	drug	162-171	advise	since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving druga in conjunction with drugb .
DDI-DrugBank.d711.s2	tetracyclines	group	14-26	antacids	group	43-50	false	absorption of druga is impaired by drugb containing aluminum , calcium or magnesium , and iron containing preparations .
DDI-DrugBank.d711.s2	tetracyclines	group	14-26	aluminum	drug	63-70	mechanism	absorption of druga is impaired by antacids containing drugb , calcium or magnesium , and iron containing preparations .
DDI-DrugBank.d711.s2	tetracyclines	group	14-26	calcium	drug	73-79	mechanism	absorption of druga is impaired by antacids containing aluminum , drugb or magnesium , and iron containing preparations .
DDI-DrugBank.d711.s2	tetracyclines	group	14-26	magnesium	drug	84-92	mechanism	absorption of druga is impaired by antacids containing aluminum , calcium or drugb , and iron containing preparations .
DDI-DrugBank.d711.s2	tetracyclines	group	14-26	iron	drug	99-102	mechanism	absorption of druga is impaired by antacids containing aluminum , calcium or magnesium , and drugb containing preparations .
DDI-DrugBank.d711.s2	antacids	group	43-50	aluminum	drug	63-70	false	absorption of tetracyclines is impaired by druga containing drugb , calcium or magnesium , and iron containing preparations .
DDI-DrugBank.d711.s2	antacids	group	43-50	calcium	drug	73-79	false	absorption of tetracyclines is impaired by druga containing aluminum , drugb or magnesium , and iron containing preparations .
DDI-DrugBank.d711.s2	antacids	group	43-50	magnesium	drug	84-92	false	absorption of tetracyclines is impaired by druga containing aluminum , calcium or drugb , and iron containing preparations .
DDI-DrugBank.d711.s2	antacids	group	43-50	iron	drug	99-102	false	absorption of tetracyclines is impaired by druga containing aluminum , calcium or magnesium , and drugb containing preparations .
DDI-DrugBank.d711.s2	aluminum	drug	63-70	calcium	drug	73-79	false	absorption of tetracyclines is impaired by antacids containing druga , drugb or magnesium , and iron containing preparations .
DDI-DrugBank.d711.s2	aluminum	drug	63-70	magnesium	drug	84-92	false	absorption of tetracyclines is impaired by antacids containing druga , calcium or drugb , and iron containing preparations .
DDI-DrugBank.d711.s2	aluminum	drug	63-70	iron	drug	99-102	false	absorption of tetracyclines is impaired by antacids containing druga , calcium or magnesium , and drugb containing preparations .
DDI-DrugBank.d711.s2	calcium	drug	73-79	magnesium	drug	84-92	false	absorption of tetracyclines is impaired by antacids containing aluminum , druga or drugb , and iron containing preparations .
DDI-DrugBank.d711.s2	calcium	drug	73-79	iron	drug	99-102	false	absorption of tetracyclines is impaired by antacids containing aluminum , druga or magnesium , and drugb containing preparations .
DDI-DrugBank.d711.s2	magnesium	drug	84-92	iron	drug	99-102	false	absorption of tetracyclines is impaired by antacids containing aluminum , calcium or druga , and drugb containing preparations .
DDI-DrugBank.d711.s3	tetracycline	group	22-33	methoxyflurane	drug	39-52	effect	the concurrent use of druga and drugb has been reported to result in fatal renal toxicity .
DDI-DrugBank.d711.s4	tetracyclines	group	18-30	contraceptives	group	42-55	effect	concurrent use of druga with oral drugb may render oral contraceptives less effective .
DDI-DrugBank.d711.s4	tetracyclines	group	18-30	contraceptives	group	73-86	false	concurrent use of druga with oral contraceptives may render oral drugb less effective .
DDI-DrugBank.d711.s4	contraceptives	group	42-55	contraceptives	group	73-86	false	concurrent use of tetracyclines with oral druga may render oral drugb less effective .
DDI-DrugBank.d573.s0	Guanethidine	drug	17-28	minoxidil	drug	40-48	false	interaction with druga : although drugb does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects .
DDI-DrugBank.d573.s0	Guanethidine	drug	17-28	guanethidine	drug	146-157	false	interaction with druga : although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving drugb can result in profound orthostatic effects .
DDI-DrugBank.d573.s0	minoxidil	drug	40-48	guanethidine	drug	146-157	effect	interaction with guanethidine : although druga does not itself cause orthostatic hypotension , its administration to patients already receiving drugb can result in profound orthostatic effects .
DDI-DrugBank.d573.s1	guanethidine	drug	19-30	minoxidil	drug	67-75	advise	if at all possible druga should be discontinued well before drugb is begun .
DDI-DrugBank.d742.s2	REMERON SolTab	brand	74-87	mirtazapine	drug	93-103	false	drugs affecting hepatic metabolism the metabolism and pharmacokinetics of druga ( drugb ) orally disintegrating tablets may be affected by the induction or inhibition of drug metab olizing enzymes .
DDI-DrugBank.d742.s5	mirtazapine	drug	39-49	mirtazapine	drug	121-131	false	while in vitro studies have shown that druga is not a potent inhibitor of any of these enzymes , an indication that drugb is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes , the concomitant use of remeron soltab with most other drugs metabolized by these enzymes has not been formally studied .
DDI-DrugBank.d742.s5	mirtazapine	drug	39-49	REMERON SolTab	brand	309-322	false	while in vitro studies have shown that druga is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes , the concomitant use of drugb with most other drugs metabolized by these enzymes has not been formally studied .
DDI-DrugBank.d742.s5	mirtazapine	drug	121-131	REMERON SolTab	brand	309-322	false	while in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that druga is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes , the concomitant use of drugb with most other drugs metabolized by these enzymes has not been formally studied .
DDI-DrugBank.d742.s7	Alcohol	drug	0-6	alcohol	drug	39-45	false	druga : concomitant administration of drugb ( equivalent to dg g ) had a minimal effect on plasma levels of mirtazapine ( dg mg ) in dg healthy male subjects .
DDI-DrugBank.d742.s7	Alcohol	drug	0-6	mirtazapine	drug	109-119	false	druga : concomitant administration of alcohol ( equivalent to dg g ) had a minimal effect on plasma levels of drugb ( dg mg ) in dg healthy male subjects .
DDI-DrugBank.d742.s7	alcohol	drug	39-45	mirtazapine	drug	109-119	mechanism	alcohol : concomitant administration of druga ( equivalent to dg g ) had a minimal effect on plasma levels of drugb ( dg mg ) in dg healthy male subjects .
DDI-DrugBank.d742.s8	REMERON	brand	66-72	alcohol	drug	126-132	effect	however , the impairment of cognitive and motor skills produced by druga were shown to be additive with those produced by drugb .
DDI-DrugBank.d742.s9	alcohol	drug	49-55	REMERON SolTab	brand	70-83	advise	accordingly , patients should be advised to avoid druga while taking drugb . diazepam : concomitant administration of diazepam ( dg mg ) had a minimal effect on plasma levels of mirtazapine ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s9	alcohol	drug	49-55	Diazepam	drug	86-93	false	accordingly , patients should be advised to avoid druga while taking remeron soltab. drugb : concomitant administration of diazepam ( dg mg ) had a minimal effect on plasma levels of mirtazapine ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s9	alcohol	drug	49-55	diazepam	drug	126-133	false	accordingly , patients should be advised to avoid druga while taking remeron soltab. diazepam : concomitant administration of drugb ( dg mg ) had a minimal effect on plasma levels of mirtazapine ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s9	alcohol	drug	49-55	mirtazapine	drug	184-194	false	accordingly , patients should be advised to avoid druga while taking remeron soltab. diazepam : concomitant administration of diazepam ( dg mg ) had a minimal effect on plasma levels of drugb ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s9	REMERON SolTab	brand	70-83	Diazepam	drug	86-93	false	accordingly , patients should be advised to avoid alcohol while taking druga . drugb : concomitant administration of diazepam ( dg mg ) had a minimal effect on plasma levels of mirtazapine ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s9	REMERON SolTab	brand	70-83	diazepam	drug	126-133	false	accordingly , patients should be advised to avoid alcohol while taking druga . diazepam : concomitant administration of drugb ( dg mg ) had a minimal effect on plasma levels of mirtazapine ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s9	REMERON SolTab	brand	70-83	mirtazapine	drug	184-194	false	accordingly , patients should be advised to avoid alcohol while taking druga . diazepam : concomitant administration of diazepam ( dg mg ) had a minimal effect on plasma levels of drugb ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s9	Diazepam	drug	86-93	diazepam	drug	126-133	false	accordingly , patients should be advised to avoid alcohol while taking remeron soltab. druga : concomitant administration of drugb ( dg mg ) had a minimal effect on plasma levels of mirtazapine ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s9	Diazepam	drug	86-93	mirtazapine	drug	184-194	false	accordingly , patients should be advised to avoid alcohol while taking remeron soltab. druga : concomitant administration of diazepam ( dg mg ) had a minimal effect on plasma levels of drugb ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s9	diazepam	drug	126-133	mirtazapine	drug	184-194	mechanism	accordingly , patients should be advised to avoid alcohol while taking remeron soltab. diazepam : concomitant administration of druga ( dg mg ) had a minimal effect on plasma levels of drugb ( dg mg ) in dg healthy subjects .
DDI-DrugBank.d742.s10	REMERON	brand	52-58	diazepam	drug	111-118	effect	however , the impairment of motor skills produced by druga has been shown to be additive with those caused by drugb .
DDI-DrugBank.d742.s11	diazepam	drug	49-56	REMERON SolTab	brand	95-108	advise	accordingly , patients should be advised to avoid druga and other similar drugs while taking drugb .
DDI-DrugBank.d717.s0	Mitotane	drug	0-7	warfarin	drug	59-66	mechanism	druga has been reported to accelerate the metabolism of drugb by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for warfarin .
DDI-DrugBank.d717.s0	Mitotane	drug	0-7	warfarin	drug	175-182	false	druga has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for drugb .
DDI-DrugBank.d717.s0	warfarin	drug	59-66	warfarin	drug	175-182	false	mitotane has been reported to accelerate the metabolism of druga by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for drugb .
DDI-DrugBank.d717.s1	anticoagulant	group	70-82	Mitotane	drug	123-130	false	therefore , physicians should closely monitor patients for a change in druga dosage requirements when administering drugb to patients on coumarin type anticoagulants .
DDI-DrugBank.d717.s1	anticoagulant	group	70-82	coumarin-type anticoagulants	group	147-174	false	therefore , physicians should closely monitor patients for a change in druga dosage requirements when administering mitotane to patients on drugb .
DDI-DrugBank.d717.s1	Mitotane	drug	123-130	coumarin-type anticoagulants	group	147-174	advise	therefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering druga to patients on drugb .
DDI-DrugBank.d775.s0	MIVACRON	brand	9-16	MIVACRON	brand	165-172	false	although druga ( a mixture of three stereoisomers ) has been administered safely following succinylcholine facilitated tracheal intubation , the interaction between drugb and succinylcholine has not been systematically studied .
DDI-DrugBank.d775.s0	MIVACRON	brand	9-16	succinylcholine	drug	178-192	false	although druga ( a mixture of three stereoisomers ) has been administered safely following succinylcholine facilitated tracheal intubation , the interaction between mivacron and drugb has not been systematically studied .
DDI-DrugBank.d775.s0	MIVACRON	brand	165-172	succinylcholine	drug	178-192	false	although mivacron ( a mixture of three stereoisomers ) has been administered safely following succinylcholine facilitated tracheal intubation , the interaction between druga and drugb has not been systematically studied .
DDI-DrugBank.d775.s1	succinylcholine	drug	24-38	nondepolarizing agents	group	93-114	effect	prior administration of druga can potentiate the neuromuscular blocking effects of drugb .
DDI-DrugBank.d775.s2	succinylcholine	drug	38-52	MIVACRON	brand	102-109	advise	evidence of spontaneous recovery from druga should be observed before the administration of drugb .
DDI-DrugBank.d775.s3	MIVACRON	brand	11-18	succinylcholine	drug	27-41	false	the use of druga before drugb to attenuate some of the side effects of succinylcholine has not been studied .
DDI-DrugBank.d775.s3	MIVACRON	brand	11-18	succinylcholine	drug	84-98	false	the use of druga before succinylcholine to attenuate some of the side effects of drugb has not been studied .
DDI-DrugBank.d775.s3	succinylcholine	drug	27-41	succinylcholine	drug	84-98	false	the use of mivacron before druga to attenuate some of the side effects of drugb has not been studied .
DDI-DrugBank.d775.s4	MIVACRON	brand	41-48	nondepolarizing neuromuscular blocking agents	group	61-105	false	there are no clinical data on the use of druga with other drugb .
DDI-DrugBank.d775.s5	Isoflurane	drug	0-9	enflurane	drug	15-23	false	druga and drugb ( administered with nitrous oxide / oxygen to achieve dg m.c .
DDI-DrugBank.d775.s5	Isoflurane	drug	0-9	nitrous oxide	drug	44-56	false	druga and enflurane ( administered with drugb / oxygen to achieve dg m.c .
DDI-DrugBank.d775.s5	Isoflurane	drug	0-9	oxygen	drug	58-63	false	druga and enflurane ( administered with nitrous oxide / drugb to achieve dg m.c .
DDI-DrugBank.d775.s5	enflurane	drug	15-23	nitrous oxide	drug	44-56	false	isoflurane and druga ( administered with drugb / oxygen to achieve dg m.c .
DDI-DrugBank.d775.s5	enflurane	drug	15-23	oxygen	drug	58-63	false	isoflurane and druga ( administered with nitrous oxide / drugb to achieve dg m.c .
DDI-DrugBank.d775.s5	nitrous oxide	drug	44-56	oxygen	drug	58-63	false	isoflurane and enflurane ( administered with druga / drugb to achieve dg m.c .
DDI-DrugBank.d775.s8	MIVACRON	brand	64-71	enflurane	drug	119-127	false	a greater potentiation of the neuromuscular blocking effects of druga may be expected with higher concentrations of drugb or isoflurane .
DDI-DrugBank.d775.s8	MIVACRON	brand	64-71	isoflurane	drug	132-141	false	a greater potentiation of the neuromuscular blocking effects of druga may be expected with higher concentrations of enflurane or drugb .
DDI-DrugBank.d775.s8	enflurane	drug	119-127	isoflurane	drug	132-141	false	a greater potentiation of the neuromuscular blocking effects of mivacron may be expected with higher concentrations of druga or drugb .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	MIVACRON	brand	98-105	false	other drugs which may enhance the neuromuscular blocking action of druga such as drugb include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	antibiotics	group	123-133	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain drugb ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	aminoglycosides	group	142-156	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , drugb , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	tetracyclines	group	159-171	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , drugb , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	bacitracin	drug	174-183	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , drugb , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	polymyxins	group	186-195	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , drugb , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	lincomycin	drug	198-207	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , drugb , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	clindamycin	drug	210-220	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , drugb , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	colistin	drug	223-230	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , drugb , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	sodium colistimethate	drug	237-257	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	magnesium	group	261-269	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	lithium	drug	278-284	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	anesthetics	group	293-303	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	procainamide	drug	306-317	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	nondepolarizing agents	drug	67-88	quinidine	drug	324-332	int	other drugs which may enhance the neuromuscular blocking action of druga such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	antibiotics	group	123-133	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugb ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	aminoglycosides	group	142-156	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , drugb , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	tetracyclines	group	159-171	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , drugb , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	bacitracin	drug	174-183	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , drugb , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	polymyxins	group	186-195	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , drugb , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	lincomycin	drug	198-207	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , drugb , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	clindamycin	drug	210-220	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , drugb , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	colistin	drug	223-230	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , drugb , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	sodium colistimethate	drug	237-257	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	magnesium	group	261-269	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	lithium	drug	278-284	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	anesthetics	group	293-303	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	procainamide	drug	306-317	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	MIVACRON	brand	98-105	quinidine	drug	324-332	int	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	aminoglycosides	group	142-156	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , drugb , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	tetracyclines	group	159-171	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , drugb , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	bacitracin	drug	174-183	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , drugb , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	polymyxins	group	186-195	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , drugb , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	lincomycin	drug	198-207	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , drugb , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	clindamycin	drug	210-220	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , drugb , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	colistin	drug	223-230	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , drugb , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	sodium colistimethate	drug	237-257	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	magnesium	group	261-269	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	antibiotics	group	123-133	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain druga ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	tetracyclines	group	159-171	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , drugb , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	bacitracin	drug	174-183	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , drugb , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	polymyxins	group	186-195	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , drugb , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	lincomycin	drug	198-207	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , polymyxins , drugb , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	clindamycin	drug	210-220	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , polymyxins , lincomycin , drugb , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	colistin	drug	223-230	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , drugb , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	sodium colistimethate	drug	237-257	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	magnesium	group	261-269	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	aminoglycosides	group	142-156	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , druga , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	bacitracin	drug	174-183	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , drugb , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	polymyxins	group	186-195	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , drugb , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	lincomycin	drug	198-207	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , polymyxins , drugb , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	clindamycin	drug	210-220	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , polymyxins , lincomycin , drugb , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	colistin	drug	223-230	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , polymyxins , lincomycin , clindamycin , drugb , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	sodium colistimethate	drug	237-257	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	magnesium	group	261-269	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	tetracyclines	group	159-171	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , druga , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	polymyxins	group	186-195	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , drugb , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	lincomycin	drug	198-207	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , polymyxins , drugb , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	clindamycin	drug	210-220	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , polymyxins , lincomycin , drugb , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	colistin	drug	223-230	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , polymyxins , lincomycin , clindamycin , drugb , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	sodium colistimethate	drug	237-257	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , polymyxins , lincomycin , clindamycin , colistin , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	magnesium	group	261-269	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	bacitracin	drug	174-183	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , druga , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	polymyxins	group	186-195	lincomycin	drug	198-207	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , druga , drugb , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	polymyxins	group	186-195	clindamycin	drug	210-220	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , druga , lincomycin , drugb , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	polymyxins	group	186-195	colistin	drug	223-230	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , druga , lincomycin , clindamycin , drugb , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	polymyxins	group	186-195	sodium colistimethate	drug	237-257	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , druga , lincomycin , clindamycin , colistin , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	polymyxins	group	186-195	magnesium	group	261-269	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , druga , lincomycin , clindamycin , colistin , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	polymyxins	group	186-195	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , druga , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	polymyxins	group	186-195	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , druga , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	polymyxins	group	186-195	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , druga , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	polymyxins	group	186-195	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , druga , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	lincomycin	drug	198-207	clindamycin	drug	210-220	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , druga , drugb , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	lincomycin	drug	198-207	colistin	drug	223-230	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , druga , clindamycin , drugb , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	lincomycin	drug	198-207	sodium colistimethate	drug	237-257	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , druga , clindamycin , colistin , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	lincomycin	drug	198-207	magnesium	group	261-269	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , druga , clindamycin , colistin , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	lincomycin	drug	198-207	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , druga , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	lincomycin	drug	198-207	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , druga , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	lincomycin	drug	198-207	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , druga , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	lincomycin	drug	198-207	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , druga , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	clindamycin	drug	210-220	colistin	drug	223-230	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , druga , drugb , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	clindamycin	drug	210-220	sodium colistimethate	drug	237-257	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , druga , colistin , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	clindamycin	drug	210-220	magnesium	group	261-269	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , druga , colistin , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	clindamycin	drug	210-220	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , druga , colistin , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	clindamycin	drug	210-220	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , druga , colistin , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	clindamycin	drug	210-220	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , druga , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	clindamycin	drug	210-220	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , druga , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	colistin	drug	223-230	sodium colistimethate	drug	237-257	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , druga , and drugb ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	colistin	drug	223-230	magnesium	group	261-269	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , druga , and sodium colistimethate ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	colistin	drug	223-230	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , druga , and sodium colistimethate ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	colistin	drug	223-230	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , druga , and sodium colistimethate ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	colistin	drug	223-230	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , druga , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	colistin	drug	223-230	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , druga , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	sodium colistimethate	drug	237-257	magnesium	group	261-269	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and druga ) , drugb salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	sodium colistimethate	drug	237-257	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and druga ) , magnesium salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	sodium colistimethate	drug	237-257	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and druga ) , magnesium salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	sodium colistimethate	drug	237-257	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and druga ) , magnesium salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	sodium colistimethate	drug	237-257	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and druga ) , magnesium salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	magnesium	group	261-269	lithium	drug	278-284	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , druga salts , drugb , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10	magnesium	group	261-269	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , druga salts , lithium , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	magnesium	group	261-269	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , druga salts , lithium , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	magnesium	group	261-269	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , druga salts , lithium , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	lithium	drug	278-284	anesthetics	group	293-303	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , druga , local drugb , procainamide , and quinidine .
DDI-DrugBank.d775.s10	lithium	drug	278-284	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , druga , local anesthetics , drugb , and quinidine .
DDI-DrugBank.d775.s10	lithium	drug	278-284	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , druga , local anesthetics , procainamide , and drugb .
DDI-DrugBank.d775.s10	anesthetics	group	293-303	procainamide	drug	306-317	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local druga , drugb , and quinidine .
DDI-DrugBank.d775.s10	anesthetics	group	293-303	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local druga , procainamide , and drugb .
DDI-DrugBank.d775.s10	procainamide	drug	306-317	quinidine	drug	324-332	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , druga , and drugb .
DDI-DrugBank.d775.s11	MIVACRON	brand	37-44	contraceptives	group	151-164	effect	the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugb , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	MIVACRON	brand	37-44	glucocorticoids	group	167-181	effect	the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , drugb , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	MIVACRON	brand	37-44	monoamine oxidase inhibitors	group	195-222	effect	the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain drugb ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	MIVACRON	brand	37-44	neuromuscular blocking agents	group	354-382	false	the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugb has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	MIVACRON	brand	37-44	phenytoin	drug	443-451	false	the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered drugb or carbamazepine .
DDI-DrugBank.d775.s11	MIVACRON	brand	37-44	carbamazepine	drug	456-468	false	the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or drugb .
DDI-DrugBank.d775.s11	contraceptives	group	151-164	glucocorticoids	group	167-181	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , drugb , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	contraceptives	group	151-164	monoamine oxidase inhibitors	group	195-222	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , glucocorticoids , or certain drugb ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	contraceptives	group	151-164	neuromuscular blocking agents	group	354-382	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugb has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	contraceptives	group	151-164	phenytoin	drug	443-451	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered drugb or carbamazepine .
DDI-DrugBank.d775.s11	contraceptives	group	151-164	carbamazepine	drug	456-468	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or drugb .
DDI-DrugBank.d775.s11	glucocorticoids	group	167-181	monoamine oxidase inhibitors	group	195-222	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , druga , or certain drugb ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	glucocorticoids	group	167-181	neuromuscular blocking agents	group	354-382	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , druga , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugb has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	glucocorticoids	group	167-181	phenytoin	drug	443-451	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , druga , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered drugb or carbamazepine .
DDI-DrugBank.d775.s11	glucocorticoids	group	167-181	carbamazepine	drug	456-468	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , druga , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or drugb .
DDI-DrugBank.d775.s11	monoamine oxidase inhibitors	group	195-222	neuromuscular blocking agents	group	354-382	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain druga ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugb has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11	monoamine oxidase inhibitors	group	195-222	phenytoin	drug	443-451	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain druga ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered drugb or carbamazepine .
DDI-DrugBank.d775.s11	monoamine oxidase inhibitors	group	195-222	carbamazepine	drug	456-468	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain druga ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or drugb .
DDI-DrugBank.d775.s11	neuromuscular blocking agents	group	354-382	phenytoin	drug	443-451	effect	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing druga has been demonstrated in patients chronically administered drugb or carbamazepine .
DDI-DrugBank.d775.s11	neuromuscular blocking agents	group	354-382	carbamazepine	drug	456-468	effect	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing druga has been demonstrated in patients chronically administered phenytoin or drugb .
DDI-DrugBank.d775.s11	phenytoin	drug	443-451	carbamazepine	drug	456-468	false	the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered druga or drugb .
DDI-DrugBank.d775.s12	phenytoin	drug	29-37	carbamazepine	drug	42-54	false	while the effects of chronic druga or drugb therapy on the action of mivacron are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d775.s12	phenytoin	drug	29-37	MIVACRON	brand	81-88	effect	while the effects of chronic druga or carbamazepine therapy on the action of drugb are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d775.s12	carbamazepine	drug	42-54	MIVACRON	brand	81-88	effect	while the effects of chronic phenytoin or druga therapy on the action of drugb are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	phenytoin	drug	176-184	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as drugb or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	carbamazepine	drug	189-201	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or drugb certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	antibiotics	group	213-223	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain drugb given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	cisplatin	drug	246-254	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection drugb edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	edrophonium	drug	258-268	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin drugb neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	neostigmine	drug	272-282	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium drugb polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	polymyxin B	drug	286-296	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine drugb or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	bacitracin	drug	301-310	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or drugb local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	anesthetics	group	320-330	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local drugb such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	procaine	drug	340-347	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	anesthetics	group	359-369	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	corticosteroids	group	53-67	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills druga medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	carbamazepine	drug	189-201	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or drugb certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	antibiotics	group	213-223	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain drugb given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	cisplatin	drug	246-254	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection drugb edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	edrophonium	drug	258-268	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection cisplatin drugb neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	neostigmine	drug	272-282	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection cisplatin edrophonium drugb polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	polymyxin B	drug	286-296	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine drugb or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	bacitracin	drug	301-310	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or drugb local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	anesthetics	group	320-330	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local drugb such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	procaine	drug	340-347	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	phenytoin	drug	176-184	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as druga or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	antibiotics	group	213-223	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain drugb given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	cisplatin	drug	246-254	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection drugb edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	edrophonium	drug	258-268	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection cisplatin drugb neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	neostigmine	drug	272-282	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection cisplatin edrophonium drugb polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	polymyxin B	drug	286-296	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection cisplatin edrophonium neostigmine drugb or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	bacitracin	drug	301-310	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or drugb local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	anesthetics	group	320-330	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local drugb such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	procaine	drug	340-347	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	carbamazepine	drug	189-201	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or druga certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	antibiotics	group	213-223	cisplatin	drug	246-254	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection drugb edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	antibiotics	group	213-223	edrophonium	drug	258-268	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection cisplatin drugb neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	antibiotics	group	213-223	neostigmine	drug	272-282	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection cisplatin edrophonium drugb polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	antibiotics	group	213-223	polymyxin B	drug	286-296	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection cisplatin edrophonium neostigmine drugb or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	antibiotics	group	213-223	bacitracin	drug	301-310	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection cisplatin edrophonium neostigmine polymyxin b or drugb local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	antibiotics	group	213-223	anesthetics	group	320-330	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local drugb such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	antibiotics	group	213-223	procaine	drug	340-347	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	antibiotics	group	213-223	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	antibiotics	group	213-223	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	antibiotics	group	213-223	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain druga given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	cisplatin	drug	246-254	edrophonium	drug	258-268	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection druga drugb neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	cisplatin	drug	246-254	neostigmine	drug	272-282	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection druga edrophonium drugb polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	cisplatin	drug	246-254	polymyxin B	drug	286-296	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection druga edrophonium neostigmine drugb or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	cisplatin	drug	246-254	bacitracin	drug	301-310	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection druga edrophonium neostigmine polymyxin b or drugb local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	cisplatin	drug	246-254	anesthetics	group	320-330	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection druga edrophonium neostigmine polymyxin b or bacitracin local drugb such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	cisplatin	drug	246-254	procaine	drug	340-347	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection druga edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	cisplatin	drug	246-254	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection druga edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	cisplatin	drug	246-254	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection druga edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	cisplatin	drug	246-254	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection druga edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	edrophonium	drug	258-268	neostigmine	drug	272-282	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin druga drugb polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	edrophonium	drug	258-268	polymyxin B	drug	286-296	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin druga neostigmine drugb or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	edrophonium	drug	258-268	bacitracin	drug	301-310	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin druga neostigmine polymyxin b or drugb local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	edrophonium	drug	258-268	anesthetics	group	320-330	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin druga neostigmine polymyxin b or bacitracin local drugb such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	edrophonium	drug	258-268	procaine	drug	340-347	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin druga neostigmine polymyxin b or bacitracin local anesthetics such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	edrophonium	drug	258-268	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin druga neostigmine polymyxin b or bacitracin local anesthetics such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	edrophonium	drug	258-268	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin druga neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	edrophonium	drug	258-268	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin druga neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	neostigmine	drug	272-282	polymyxin B	drug	286-296	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium druga drugb or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	neostigmine	drug	272-282	bacitracin	drug	301-310	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium druga polymyxin b or drugb local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	neostigmine	drug	272-282	anesthetics	group	320-330	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium druga polymyxin b or bacitracin local drugb such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	neostigmine	drug	272-282	procaine	drug	340-347	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium druga polymyxin b or bacitracin local anesthetics such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	neostigmine	drug	272-282	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium druga polymyxin b or bacitracin local anesthetics such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	neostigmine	drug	272-282	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium druga polymyxin b or bacitracin local anesthetics such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	neostigmine	drug	272-282	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium druga polymyxin b or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	polymyxin B	drug	286-296	bacitracin	drug	301-310	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine druga or drugb local anesthetics such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	polymyxin B	drug	286-296	anesthetics	group	320-330	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine druga or bacitracin local drugb such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	polymyxin B	drug	286-296	procaine	drug	340-347	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine druga or bacitracin local anesthetics such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	polymyxin B	drug	286-296	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine druga or bacitracin local anesthetics such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	polymyxin B	drug	286-296	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine druga or bacitracin local anesthetics such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	polymyxin B	drug	286-296	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine druga or bacitracin local anesthetics such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	bacitracin	drug	301-310	anesthetics	group	320-330	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or druga local drugb such as procaine general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	bacitracin	drug	301-310	procaine	drug	340-347	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or druga local anesthetics such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	bacitracin	drug	301-310	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or druga local anesthetics such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	bacitracin	drug	301-310	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or druga local anesthetics such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	bacitracin	drug	301-310	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or druga local anesthetics such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	anesthetics	group	320-330	procaine	drug	340-347	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local druga such as drugb general anesthetics succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	anesthetics	group	320-330	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local druga such as procaine general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	anesthetics	group	320-330	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local druga such as procaine general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	anesthetics	group	320-330	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local druga such as procaine general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	procaine	drug	340-347	anesthetics	group	359-369	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as druga general drugb succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	procaine	drug	340-347	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as druga general anesthetics drugb or other muscle relaxants
DDI-DrugBank.d775.s13	procaine	drug	340-347	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as druga general anesthetics succinylcholine or other drugb
DDI-DrugBank.d775.s13	anesthetics	group	359-369	succinylcholine	drug	373-387	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general druga drugb or other muscle relaxants
DDI-DrugBank.d775.s13	anesthetics	group	359-369	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general druga succinylcholine or other drugb
DDI-DrugBank.d775.s13	succinylcholine	drug	373-387	muscle relaxants	group	398-413	false	some drug interactions are : birth control pills corticosteroids medicines for angina or high blood pressure medicines for pain medicines to control seizures such as phenytoin or carbamazepine certain antibiotics given by injection cisplatin edrophonium neostigmine polymyxin b or bacitracin local anesthetics such as procaine general anesthetics druga or other drugb
DDI-DrugBank.d640.s0	Diuretics	group	0-8	ACE inhibitors	group	97-110	false	druga : excessive reductions in blood pressure may occur in patients on diuretic therapy when drugb are started .
DDI-DrugBank.d640.s1	UNIVASC	brand	44-50	UNIVASC	brand	196-202	false	the possibility of hypotensive effects with druga can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with drugb . if this is not possible , the starting dose of moexpril should be reduced..
DDI-DrugBank.d640.s1	UNIVASC	brand	44-50	moexpril	drug	254-261	false	the possibility of hypotensive effects with druga can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with univasc . if this is not possible , the starting dose of drugb should be reduced..
DDI-DrugBank.d640.s1	UNIVASC	brand	196-202	moexpril	drug	254-261	false	the possibility of hypotensive effects with univasc can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with druga . if this is not possible , the starting dose of drugb should be reduced..
DDI-DrugBank.d640.s2	Potassium	drug	0-8	Potassium-Sparing Diuretics	group	26-52	false	druga supplements and drugb : univasc can increase serum potassium because it decreases aldosterone secretion .
DDI-DrugBank.d640.s2	Potassium	drug	0-8	UNIVASC	brand	55-61	false	druga supplements and potassium sparing diuretics : drugb can increase serum potassium because it decreases aldosterone secretion .
DDI-DrugBank.d640.s2	Potassium-Sparing Diuretics	group	26-52	UNIVASC	brand	55-61	false	potassium supplements and druga : drugb can increase serum potassium because it decreases aldosterone secretion .
DDI-DrugBank.d640.s3	potassium-sparing diuretics	group	7-33	spironolactone	drug	36-49	false	use of druga ( drugb , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	potassium-sparing diuretics	group	7-33	triamterene	drug	52-62	false	use of druga ( spironolactone , drugb , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	potassium-sparing diuretics	group	7-33	amiloride	drug	65-73	false	use of druga ( spironolactone , triamterene , drugb ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	potassium-sparing diuretics	group	7-33	potassium	drug	79-87	false	use of druga ( spironolactone , triamterene , amiloride ) or drugb supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	potassium-sparing diuretics	group	7-33	ACE inhibitors	group	120-133	effect	use of druga ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	spironolactone	drug	36-49	triamterene	drug	52-62	false	use of potassium sparing diuretics ( druga , drugb , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	spironolactone	drug	36-49	amiloride	drug	65-73	false	use of potassium sparing diuretics ( druga , triamterene , drugb ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	spironolactone	drug	36-49	potassium	drug	79-87	false	use of potassium sparing diuretics ( druga , triamterene , amiloride ) or drugb supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	spironolactone	drug	36-49	ACE inhibitors	group	120-133	effect	use of potassium sparing diuretics ( druga , triamterene , amiloride ) or potassium supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	triamterene	drug	52-62	amiloride	drug	65-73	false	use of potassium sparing diuretics ( spironolactone , druga , drugb ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	triamterene	drug	52-62	potassium	drug	79-87	false	use of potassium sparing diuretics ( spironolactone , druga , amiloride ) or drugb supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	triamterene	drug	52-62	ACE inhibitors	group	120-133	effect	use of potassium sparing diuretics ( spironolactone , druga , amiloride ) or potassium supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	amiloride	drug	65-73	potassium	drug	79-87	false	use of potassium sparing diuretics ( spironolactone , triamterene , druga ) or drugb supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	amiloride	drug	65-73	ACE inhibitors	group	120-133	effect	use of potassium sparing diuretics ( spironolactone , triamterene , druga ) or potassium supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3	potassium	drug	79-87	ACE inhibitors	group	120-133	effect	use of potassium sparing diuretics ( spironolactone , triamterene , amiloride ) or druga supplements concomitantly with drugb can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s5	Anticoagulants	group	5-18	warfarin	drug	46-53	false	oral druga : interaction studies with drugb failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect .
DDI-DrugBank.d640.s5	Anticoagulants	group	5-18	anticoagulant	group	141-153	false	oral druga : interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the drugb or on its anticoagulant effect .
DDI-DrugBank.d640.s5	warfarin	drug	46-53	anticoagulant	group	141-153	false	oral anticoagulants : interaction studies with druga failed to identify any clinically important effect on the serum concentrations of the drugb or on its anticoagulant effect .
DDI-DrugBank.d640.s6	Lithium	drug	0-6	lithium	drug	25-31	false	druga : increased serum drugb levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6	Lithium	drug	0-6	lithium	drug	56-62	false	druga : increased serum lithium levels and symptoms of drugb toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6	Lithium	drug	0-6	ACE inhibitors	group	114-127	false	druga : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving drugb during therapy with lithium .
DDI-DrugBank.d640.s6	Lithium	drug	0-6	lithium	drug	149-155	false	druga : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with drugb .
DDI-DrugBank.d640.s6	lithium	drug	25-31	lithium	drug	56-62	false	lithium : increased serum druga levels and symptoms of drugb toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6	lithium	drug	25-31	ACE inhibitors	group	114-127	false	lithium : increased serum druga levels and symptoms of lithium toxicity have been reported in patients receiving drugb during therapy with lithium .
DDI-DrugBank.d640.s6	lithium	drug	25-31	lithium	drug	149-155	false	lithium : increased serum druga levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with drugb .
DDI-DrugBank.d640.s6	lithium	drug	56-62	ACE inhibitors	group	114-127	false	lithium : increased serum lithium levels and symptoms of druga toxicity have been reported in patients receiving drugb during therapy with lithium .
DDI-DrugBank.d640.s6	lithium	drug	56-62	lithium	drug	149-155	false	lithium : increased serum lithium levels and symptoms of druga toxicity have been reported in patients receiving ace inhibitors during therapy with drugb .
DDI-DrugBank.d640.s6	ACE inhibitors	group	114-127	lithium	drug	149-155	effect	lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving druga during therapy with drugb .
DDI-DrugBank.d640.s8	diuretic	group	5-12	lithium	drug	40-46	effect	if a druga is also used , the risk of drugb toxicity may be increased .
DDI-DrugBank.d640.s9	UNIVASC	brand	81-87	hydrochlorothiazide	drug	128-146	false	other agents : no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugb , digoxin , or cimetidine .
DDI-DrugBank.d640.s9	UNIVASC	brand	81-87	digoxin	drug	149-155	false	other agents : no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with hydrochlorothiazide , drugb , or cimetidine .
DDI-DrugBank.d640.s9	UNIVASC	brand	81-87	cimetidine	drug	161-170	false	other agents : no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with hydrochlorothiazide , digoxin , or drugb .
DDI-DrugBank.d640.s9	hydrochlorothiazide	drug	128-146	digoxin	drug	149-155	false	other agents : no clinically important pharmacokinetic interactions occurred when univasc was administered concomitantly with druga , drugb , or cimetidine .
DDI-DrugBank.d640.s9	hydrochlorothiazide	drug	128-146	cimetidine	drug	161-170	false	other agents : no clinically important pharmacokinetic interactions occurred when univasc was administered concomitantly with druga , digoxin , or drugb .
DDI-DrugBank.d640.s9	digoxin	drug	149-155	cimetidine	drug	161-170	false	other agents : no clinically important pharmacokinetic interactions occurred when univasc was administered concomitantly with hydrochlorothiazide , druga , or drugb .
DDI-DrugBank.d640.s10	UNIVASC	brand	0-6	calcium-channel-blocking agents	group	63-93	false	druga has been used in clinical trials concomitantly with drugb , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	UNIVASC	brand	0-6	diuretics	group	96-104	false	druga has been used in clinical trials concomitantly with calcium channel blocking agents , drugb , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	UNIVASC	brand	0-6	H2 blockers	group	107-117	false	druga has been used in clinical trials concomitantly with calcium channel blocking agents , diuretics , drugb , digoxin , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	UNIVASC	brand	0-6	digoxin	drug	120-126	false	druga has been used in clinical trials concomitantly with calcium channel blocking agents , diuretics , h2 blockers , drugb , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	UNIVASC	brand	0-6	hypoglycemic agents	group	134-152	false	druga has been used in clinical trials concomitantly with calcium channel blocking agents , diuretics , h2 blockers , digoxin , oral drugb , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	calcium-channel-blocking agents	group	63-93	diuretics	group	96-104	false	univasc has been used in clinical trials concomitantly with druga , drugb , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	calcium-channel-blocking agents	group	63-93	H2 blockers	group	107-117	false	univasc has been used in clinical trials concomitantly with druga , diuretics , drugb , digoxin , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	calcium-channel-blocking agents	group	63-93	digoxin	drug	120-126	false	univasc has been used in clinical trials concomitantly with druga , diuretics , h2 blockers , drugb , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	calcium-channel-blocking agents	group	63-93	hypoglycemic agents	group	134-152	false	univasc has been used in clinical trials concomitantly with druga , diuretics , h2 blockers , digoxin , oral drugb , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	diuretics	group	96-104	H2 blockers	group	107-117	false	univasc has been used in clinical trials concomitantly with calcium channel blocking agents , druga , drugb , digoxin , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	diuretics	group	96-104	digoxin	drug	120-126	false	univasc has been used in clinical trials concomitantly with calcium channel blocking agents , druga , h2 blockers , drugb , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	diuretics	group	96-104	hypoglycemic agents	group	134-152	false	univasc has been used in clinical trials concomitantly with calcium channel blocking agents , druga , h2 blockers , digoxin , oral drugb , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	H2 blockers	group	107-117	digoxin	drug	120-126	false	univasc has been used in clinical trials concomitantly with calcium channel blocking agents , diuretics , druga , drugb , oral hypoglycemic agents , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	H2 blockers	group	107-117	hypoglycemic agents	group	134-152	false	univasc has been used in clinical trials concomitantly with calcium channel blocking agents , diuretics , druga , digoxin , oral drugb , and cholesterol lowering agents .
DDI-DrugBank.d640.s10	digoxin	drug	120-126	hypoglycemic agents	group	134-152	false	univasc has been used in clinical trials concomitantly with calcium channel blocking agents , diuretics , h2 blockers , druga , oral drugb , and cholesterol lowering agents .
DDI-DrugBank.d580.s1	ketoconazole	drug	9-20	mometasone furoate	drug	96-113	mechanism	however , druga , a potent inhibitor of cytochrome p450 dg , may increase plasma levels of drugb during concomitant dosing .
DDI-DrugBank.d739.s0	Montelukast	drug	0-10	theophylline	drug	176-187	false	druga at a dose of dg mg once daily dosed to pharmacokinetic steady state did not cause clinically significant changes in the kinetics of a single intravenous dose of drugb ( predominantly a cytochrome p450 dg substrate ) .
DDI-DrugBank.d739.s1	warfarin	drug	48-55	warfarin	drug	158-165	false	did not change the pharmacokinetic profile of druga ( a substrate of cytochromes p450 dg and dg ) or influence the effect of a single dg mg oral dose of drugb on prothrombin time or the inr ( international normalized ratio ) .
DDI-DrugBank.d739.s3	terfenadine	drug	53-63	fexofenadine	drug	105-116	false	did not change the plasma concentration profile of druga ( a substrate of cytochrome p450 dg ) or drugb , its carboxylated metabolite , and did not prolong the qtc interval following co administration with terfenadine dg mg twice daily .
DDI-DrugBank.d739.s3	terfenadine	drug	53-63	terfenadine	drug	218-228	false	did not change the plasma concentration profile of druga ( a substrate of cytochrome p450 dg ) or fexofenadine , its carboxylated metabolite , and did not prolong the qtc interval following co administration with drugb dg mg twice daily .
DDI-DrugBank.d739.s3	fexofenadine	drug	105-116	terfenadine	drug	218-228	false	did not change the plasma concentration profile of terfenadine ( a substrate of cytochrome p450 dg ) or druga , its carboxylated metabolite , and did not prolong the qtc interval following co administration with drugb dg mg twice daily .
DDI-DrugBank.d739.s4	Montelukast	drug	0-10	contraceptive	group	167-179	false	druga at doses of dg mg daily dosed to pharmacokinetic steady state : did not significantly alter the plasma concentrations of either component of an oral drugb containing norethindrone dg mg / ethinyl estradiol dg mcg .
DDI-DrugBank.d739.s4	Montelukast	drug	0-10	norethindrone	drug	192-204	false	druga at doses of dg mg daily dosed to pharmacokinetic steady state : did not significantly alter the plasma concentrations of either component of an oral contraceptive containing drugb dg mg / ethinyl estradiol dg mcg .
DDI-DrugBank.d739.s4	Montelukast	drug	0-10	estradiol	drug	219-227	false	druga at doses of dg mg daily dosed to pharmacokinetic steady state : did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone dg mg / ethinyl drugb dg mcg .
DDI-DrugBank.d739.s4	contraceptive	group	167-179	norethindrone	drug	192-204	false	montelukast at doses of dg mg daily dosed to pharmacokinetic steady state : did not significantly alter the plasma concentrations of either component of an oral druga containing drugb dg mg / ethinyl estradiol dg mcg .
DDI-DrugBank.d739.s4	contraceptive	group	167-179	estradiol	drug	219-227	false	montelukast at doses of dg mg daily dosed to pharmacokinetic steady state : did not significantly alter the plasma concentrations of either component of an oral druga containing norethindrone dg mg / ethinyl drugb dg mcg .
DDI-DrugBank.d739.s4	norethindrone	drug	192-204	estradiol	drug	219-227	false	montelukast at doses of dg mg daily dosed to pharmacokinetic steady state : did not significantly alter the plasma concentrations of either component of an oral contraceptive containing druga dg mg / ethinyl drugb dg mcg .
DDI-DrugBank.d739.s5	prednisone	drug	72-81	prednisolone	drug	86-97	false	did not cause any clinically significant change in plasma profiles of druga or drugb following administration of either oral prednisone or intravenous prednisolone .
DDI-DrugBank.d739.s5	prednisone	drug	72-81	prednisone	drug	139-148	false	did not cause any clinically significant change in plasma profiles of druga or prednisolone following administration of either oral drugb or intravenous prednisolone .
DDI-DrugBank.d739.s5	prednisone	drug	72-81	prednisolone	drug	165-176	false	did not cause any clinically significant change in plasma profiles of druga or prednisolone following administration of either oral prednisone or intravenous drugb .
DDI-DrugBank.d739.s5	prednisolone	drug	86-97	prednisone	drug	139-148	false	did not cause any clinically significant change in plasma profiles of prednisone or druga following administration of either oral drugb or intravenous prednisolone .
DDI-DrugBank.d739.s5	prednisolone	drug	86-97	prednisolone	drug	165-176	false	did not cause any clinically significant change in plasma profiles of prednisone or druga following administration of either oral prednisone or intravenous drugb .
DDI-DrugBank.d739.s5	prednisone	drug	139-148	prednisolone	drug	165-176	false	did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral druga or intravenous drugb .
DDI-DrugBank.d739.s6	Phenobarbital	drug	0-12	montelukast	drug	70-80	false	druga , which induces hepatic metabolism , decreased the auc of drugb approximately dg % following a single dg mg dose of montelukast .
DDI-DrugBank.d739.s6	Phenobarbital	drug	0-12	montelukast	drug	133-143	false	druga , which induces hepatic metabolism , decreased the auc of montelukast approximately dg % following a single dg mg dose of drugb .
DDI-DrugBank.d739.s6	montelukast	drug	70-80	montelukast	drug	133-143	false	phenobarbital , which induces hepatic metabolism , decreased the auc of druga approximately dg % following a single dg mg dose of drugb .
DDI-DrugBank.d739.s8	phenobarbital	drug	112-124	rifampin	drug	129-136	false	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugb , are co administered with montelukast .
DDI-DrugBank.d739.s8	phenobarbital	drug	112-124	montelukast	drug	164-174	advise	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or rifampin , are co administered with drugb .
DDI-DrugBank.d739.s8	rifampin	drug	129-136	montelukast	drug	164-174	advise	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as phenobarbital or druga , are co administered with drugb .
DDI-DrugBank.d739.s10	montelukast	drug	62-72	theophylline	drug	164-175	false	in drug interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugb , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	montelukast	drug	62-72	prednisone	drug	178-187	false	in drug interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , drugb , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	montelukast	drug	62-72	prednisolone	drug	190-201	false	in drug interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , drugb , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	montelukast	drug	62-72	contraceptives	group	209-222	false	in drug interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral drugb ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	montelukast	drug	62-72	norethindrone	drug	225-237	false	in drug interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( drugb dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	montelukast	drug	62-72	ethinyl estradiol	drug	244-260	false	in drug interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / drugb dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	montelukast	drug	62-72	terfenadine	drug	271-281	false	in drug interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , drugb , digoxin , and warfarin .
DDI-DrugBank.d739.s10	montelukast	drug	62-72	digoxin	drug	284-290	false	in drug interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , drugb , and warfarin .
DDI-DrugBank.d739.s10	montelukast	drug	62-72	warfarin	drug	297-304	false	in drug interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and drugb .
DDI-DrugBank.d739.s10	theophylline	drug	164-175	prednisone	drug	178-187	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugb , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	theophylline	drug	164-175	prednisolone	drug	190-201	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : druga , prednisone , drugb , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	theophylline	drug	164-175	contraceptives	group	209-222	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : druga , prednisone , prednisolone , oral drugb ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	theophylline	drug	164-175	norethindrone	drug	225-237	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : druga , prednisone , prednisolone , oral contraceptives ( drugb dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	theophylline	drug	164-175	ethinyl estradiol	drug	244-260	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : druga , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / drugb dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	theophylline	drug	164-175	terfenadine	drug	271-281	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : druga , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , drugb , digoxin , and warfarin .
DDI-DrugBank.d739.s10	theophylline	drug	164-175	digoxin	drug	284-290	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : druga , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , drugb , and warfarin .
DDI-DrugBank.d739.s10	theophylline	drug	164-175	warfarin	drug	297-304	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : druga , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and drugb .
DDI-DrugBank.d739.s10	prednisone	drug	178-187	prednisolone	drug	190-201	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , druga , drugb , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	prednisone	drug	178-187	contraceptives	group	209-222	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , druga , prednisolone , oral drugb ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	prednisone	drug	178-187	norethindrone	drug	225-237	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , druga , prednisolone , oral contraceptives ( drugb dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	prednisone	drug	178-187	ethinyl estradiol	drug	244-260	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , druga , prednisolone , oral contraceptives ( norethindrone dg mg / drugb dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	prednisone	drug	178-187	terfenadine	drug	271-281	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , druga , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , drugb , digoxin , and warfarin .
DDI-DrugBank.d739.s10	prednisone	drug	178-187	digoxin	drug	284-290	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , druga , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , drugb , and warfarin .
DDI-DrugBank.d739.s10	prednisone	drug	178-187	warfarin	drug	297-304	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , druga , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and drugb .
DDI-DrugBank.d739.s10	prednisolone	drug	190-201	contraceptives	group	209-222	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , druga , oral drugb ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	prednisolone	drug	190-201	norethindrone	drug	225-237	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , druga , oral contraceptives ( drugb dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	prednisolone	drug	190-201	ethinyl estradiol	drug	244-260	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , druga , oral contraceptives ( norethindrone dg mg / drugb dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	prednisolone	drug	190-201	terfenadine	drug	271-281	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , druga , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , drugb , digoxin , and warfarin .
DDI-DrugBank.d739.s10	prednisolone	drug	190-201	digoxin	drug	284-290	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , druga , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , drugb , and warfarin .
DDI-DrugBank.d739.s10	prednisolone	drug	190-201	warfarin	drug	297-304	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , druga , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and drugb .
DDI-DrugBank.d739.s10	contraceptives	group	209-222	norethindrone	drug	225-237	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral druga ( drugb dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	contraceptives	group	209-222	ethinyl estradiol	drug	244-260	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral druga ( norethindrone dg mg / drugb dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	contraceptives	group	209-222	terfenadine	drug	271-281	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral druga ( norethindrone dg mg / ethinyl estradiol dg mcg ) , drugb , digoxin , and warfarin .
DDI-DrugBank.d739.s10	contraceptives	group	209-222	digoxin	drug	284-290	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral druga ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , drugb , and warfarin .
DDI-DrugBank.d739.s10	contraceptives	group	209-222	warfarin	drug	297-304	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral druga ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and drugb .
DDI-DrugBank.d739.s10	norethindrone	drug	225-237	ethinyl estradiol	drug	244-260	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( druga dg mg / drugb dg mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10	norethindrone	drug	225-237	terfenadine	drug	271-281	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( druga dg mg / ethinyl estradiol dg mcg ) , drugb , digoxin , and warfarin .
DDI-DrugBank.d739.s10	norethindrone	drug	225-237	digoxin	drug	284-290	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( druga dg mg / ethinyl estradiol dg mcg ) , terfenadine , drugb , and warfarin .
DDI-DrugBank.d739.s10	norethindrone	drug	225-237	warfarin	drug	297-304	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( druga dg mg / ethinyl estradiol dg mcg ) , terfenadine , digoxin , and drugb .
DDI-DrugBank.d739.s10	ethinyl estradiol	drug	244-260	terfenadine	drug	271-281	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / druga dg mcg ) , drugb , digoxin , and warfarin .
DDI-DrugBank.d739.s10	ethinyl estradiol	drug	244-260	digoxin	drug	284-290	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / druga dg mcg ) , terfenadine , drugb , and warfarin .
DDI-DrugBank.d739.s10	ethinyl estradiol	drug	244-260	warfarin	drug	297-304	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / druga dg mcg ) , terfenadine , digoxin , and drugb .
DDI-DrugBank.d739.s10	terfenadine	drug	271-281	digoxin	drug	284-290	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , druga , drugb , and warfarin .
DDI-DrugBank.d739.s10	terfenadine	drug	271-281	warfarin	drug	297-304	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , druga , digoxin , and drugb .
DDI-DrugBank.d739.s10	digoxin	drug	284-290	warfarin	drug	297-304	false	in drug interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone dg mg / ethinyl estradiol dg mcg ) , terfenadine , druga , and drugb .
DDI-DrugBank.d739.s12	thyroid hormones	group	27-42	sedative hypnotics	group	45-62	false	these medications included druga , drugb , non steroidal anti inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12	thyroid hormones	group	27-42	non-steroidal anti-inflammatory agents	group	65-102	false	these medications included druga , sedative hypnotics , drugb , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12	thyroid hormones	group	27-42	benzodiazepines	group	105-119	false	these medications included druga , sedative hypnotics , non steroidal anti inflammatory agents , drugb , and decongestants .
DDI-DrugBank.d739.s12	thyroid hormones	group	27-42	decongestants	group	126-138	false	these medications included druga , sedative hypnotics , non steroidal anti inflammatory agents , benzodiazepines , and drugb .
DDI-DrugBank.d739.s12	sedative hypnotics	group	45-62	non-steroidal anti-inflammatory agents	group	65-102	false	these medications included thyroid hormones , druga , drugb , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12	sedative hypnotics	group	45-62	benzodiazepines	group	105-119	false	these medications included thyroid hormones , druga , non steroidal anti inflammatory agents , drugb , and decongestants .
DDI-DrugBank.d739.s12	sedative hypnotics	group	45-62	decongestants	group	126-138	false	these medications included thyroid hormones , druga , non steroidal anti inflammatory agents , benzodiazepines , and drugb .
DDI-DrugBank.d739.s12	non-steroidal anti-inflammatory agents	group	65-102	benzodiazepines	group	105-119	false	these medications included thyroid hormones , sedative hypnotics , druga , drugb , and decongestants .
DDI-DrugBank.d739.s12	non-steroidal anti-inflammatory agents	group	65-102	decongestants	group	126-138	false	these medications included thyroid hormones , sedative hypnotics , druga , benzodiazepines , and drugb .
DDI-DrugBank.d739.s12	benzodiazepines	group	105-119	decongestants	group	126-138	false	these medications included thyroid hormones , sedative hypnotics , non steroidal anti inflammatory agents , druga , and drugb .
DDI-DrugBank.d739.s13	Phenobarbital	drug	0-12	montelukast	drug	70-80	false	druga , which induces hepatic metabolism , decreased the auc of drugb approximately dg % following a single dg mg dose of montelukast .
DDI-DrugBank.d739.s13	Phenobarbital	drug	0-12	montelukast	drug	133-143	false	druga , which induces hepatic metabolism , decreased the auc of montelukast approximately dg % following a single dg mg dose of drugb .
DDI-DrugBank.d739.s13	montelukast	drug	70-80	montelukast	drug	133-143	false	phenobarbital , which induces hepatic metabolism , decreased the auc of druga approximately dg % following a single dg mg dose of drugb .
DDI-DrugBank.d739.s15	phenobarbital	drug	112-124	rifampin	drug	129-136	false	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugb , are co administered with montelukast .
DDI-DrugBank.d739.s15	phenobarbital	drug	112-124	montelukast	drug	164-174	advise	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or rifampin , are co administered with drugb .
DDI-DrugBank.d739.s15	rifampin	drug	129-136	montelukast	drug	164-174	advise	it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as phenobarbital or druga , are co administered with drugb .
DDI-DrugBank.d637.s0	Central Nervous System Depressants	group	15-48	morphine	drug	77-84	false	use with other druga : the depressant effects of drugb are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	Central Nervous System Depressants	group	15-48	CNS depressants	group	127-141	false	use with other druga : the depressant effects of morphine are potentiated by the presence of other drugb such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	Central Nervous System Depressants	group	15-48	alcohol	drug	151-157	false	use with other druga : the depressant effects of morphine are potentiated by the presence of other cns depressants such as drugb , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	Central Nervous System Depressants	group	15-48	sedatives	group	160-168	false	use with other druga : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , drugb , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	Central Nervous System Depressants	group	15-48	antihistaminics	group	171-185	false	use with other druga : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , drugb , or psychotropic drugs .
DDI-DrugBank.d637.s0	Central Nervous System Depressants	group	15-48	psychotropic drugs	group	191-208	false	use with other druga : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or drugb .
DDI-DrugBank.d637.s0	morphine	drug	77-84	CNS depressants	group	127-141	effect	use with other central nervous system depressants : the depressant effects of druga are potentiated by the presence of other drugb such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	morphine	drug	77-84	alcohol	drug	151-157	effect	use with other central nervous system depressants : the depressant effects of druga are potentiated by the presence of other cns depressants such as drugb , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	morphine	drug	77-84	sedatives	group	160-168	effect	use with other central nervous system depressants : the depressant effects of druga are potentiated by the presence of other cns depressants such as alcohol , drugb , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	morphine	drug	77-84	antihistaminics	group	171-185	effect	use with other central nervous system depressants : the depressant effects of druga are potentiated by the presence of other cns depressants such as alcohol , sedatives , drugb , or psychotropic drugs .
DDI-DrugBank.d637.s0	morphine	drug	77-84	psychotropic drugs	group	191-208	effect	use with other central nervous system depressants : the depressant effects of druga are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or drugb .
DDI-DrugBank.d637.s0	CNS depressants	group	127-141	alcohol	drug	151-157	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other druga such as drugb , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	CNS depressants	group	127-141	sedatives	group	160-168	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other druga such as alcohol , drugb , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	CNS depressants	group	127-141	antihistaminics	group	171-185	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other druga such as alcohol , sedatives , drugb , or psychotropic drugs .
DDI-DrugBank.d637.s0	CNS depressants	group	127-141	psychotropic drugs	group	191-208	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other druga such as alcohol , sedatives , antihistaminics , or drugb .
DDI-DrugBank.d637.s0	alcohol	drug	151-157	sedatives	group	160-168	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as druga , drugb , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0	alcohol	drug	151-157	antihistaminics	group	171-185	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as druga , sedatives , drugb , or psychotropic drugs .
DDI-DrugBank.d637.s0	alcohol	drug	151-157	psychotropic drugs	group	191-208	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as druga , sedatives , antihistaminics , or drugb .
DDI-DrugBank.d637.s0	sedatives	group	160-168	antihistaminics	group	171-185	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , druga , drugb , or psychotropic drugs .
DDI-DrugBank.d637.s0	sedatives	group	160-168	psychotropic drugs	group	191-208	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , druga , antihistaminics , or drugb .
DDI-DrugBank.d637.s0	antihistaminics	group	171-185	psychotropic drugs	group	191-208	false	use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , druga , or drugb .
DDI-DrugBank.d637.s1	neuroleptics	group	7-18	morphine	drug	45-52	effect	use of druga in conjunction with oral drugb may increase the risk of respiratory depression , hypotension and profound sedation or coma .
DDI-DrugBank.d637.s2	Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	Agonist/antagonist analgesics	group	61-89	false	interaction with druga : drugb ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	pentazocine	drug	98-108	false	interaction with druga : agonist / antagonist analgesics ( i.e. , drugb , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	nalbuphine	drug	111-120	false	interaction with druga : agonist / antagonist analgesics ( i.e. , pentazocine , drugb , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	butorphanol	drug	123-133	false	interaction with druga : agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , drugb , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	buprenorphine	drug	139-151	false	interaction with druga : agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	opioid agonist analgesic	group	261-284	false	interaction with druga : agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d637.s2	Agonist/antagonist analgesics	group	61-89	pentazocine	drug	98-108	false	interaction with mixed agonist / antagonist opioid analgesics : druga ( i.e. , drugb , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	Agonist/antagonist analgesics	group	61-89	nalbuphine	drug	111-120	false	interaction with mixed agonist / antagonist opioid analgesics : druga ( i.e. , pentazocine , drugb , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	Agonist/antagonist analgesics	group	61-89	butorphanol	drug	123-133	false	interaction with mixed agonist / antagonist opioid analgesics : druga ( i.e. , pentazocine , nalbuphine , drugb , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	Agonist/antagonist analgesics	group	61-89	buprenorphine	drug	139-151	false	interaction with mixed agonist / antagonist opioid analgesics : druga ( i.e. , pentazocine , nalbuphine , butorphanol , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	Agonist/antagonist analgesics	group	61-89	opioid agonist analgesic	group	261-284	advise	interaction with mixed agonist / antagonist opioid analgesics : druga ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d637.s2	pentazocine	drug	98-108	nalbuphine	drug	111-120	false	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , druga , drugb , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	pentazocine	drug	98-108	butorphanol	drug	123-133	false	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , druga , nalbuphine , drugb , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	pentazocine	drug	98-108	buprenorphine	drug	139-151	false	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , druga , nalbuphine , butorphanol , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	pentazocine	drug	98-108	opioid agonist analgesic	group	261-284	advise	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , druga , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d637.s2	nalbuphine	drug	111-120	butorphanol	drug	123-133	false	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , pentazocine , druga , drugb , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	nalbuphine	drug	111-120	buprenorphine	drug	139-151	false	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , pentazocine , druga , butorphanol , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	nalbuphine	drug	111-120	opioid agonist analgesic	group	261-284	advise	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , pentazocine , druga , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d637.s2	butorphanol	drug	123-133	buprenorphine	drug	139-151	false	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , druga , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2	butorphanol	drug	123-133	opioid agonist analgesic	group	261-284	advise	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , druga , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d637.s2	buprenorphine	drug	139-151	opioid agonist analgesic	group	261-284	advise	interaction with mixed agonist / antagonist opioid analgesics : agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or druga ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
DDI-DrugBank.d700.s0	Antacids	group	0-7	Myfortic	brand	41-48	false	druga : absorption of a single dose of drugb was decreased when administered to dg stable renal transplant patients also taking magnesium aluminum containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	Antacids	group	0-7	magnesium	drug	133-141	false	druga : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking drugb aluminum containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	Antacids	group	0-7	aluminum	drug	143-150	false	druga : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking magnesium drugb containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	Antacids	group	0-7	antacids	group	163-170	false	druga : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking magnesium aluminum containing drugb ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	Antacids	group	0-7	Myfortic	brand	271-278	false	druga : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking magnesium aluminum containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when drugb was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	Myfortic	brand	41-48	magnesium	drug	133-141	mechanism	antacids : absorption of a single dose of druga was decreased when administered to dg stable renal transplant patients also taking drugb aluminum containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	Myfortic	brand	41-48	aluminum	drug	143-150	mechanism	antacids : absorption of a single dose of druga was decreased when administered to dg stable renal transplant patients also taking magnesium drugb containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	Myfortic	brand	41-48	antacids	group	163-170	false	antacids : absorption of a single dose of druga was decreased when administered to dg stable renal transplant patients also taking magnesium aluminum containing drugb ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	Myfortic	brand	41-48	Myfortic	brand	271-278	false	antacids : absorption of a single dose of druga was decreased when administered to dg stable renal transplant patients also taking magnesium aluminum containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when drugb was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	magnesium	drug	133-141	aluminum	drug	143-150	false	antacids : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking druga drugb containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	magnesium	drug	133-141	antacids	group	163-170	false	antacids : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking druga aluminum containing drugb ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	magnesium	drug	133-141	Myfortic	brand	271-278	false	antacids : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking druga aluminum containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when drugb was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	aluminum	drug	143-150	antacids	group	163-170	false	antacids : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking magnesium druga containing drugb ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	aluminum	drug	143-150	Myfortic	brand	271-278	false	antacids : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking magnesium druga containing antacids ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when drugb was administered alone under fasting conditions .
DDI-DrugBank.d700.s0	antacids	group	163-170	Myfortic	brand	271-278	false	antacids : absorption of a single dose of myfortic was decreased when administered to dg stable renal transplant patients also taking magnesium aluminum containing druga ( dg ml ) : the mean cmax and auc ( dg t ) values for mpa were dg % and dg % lower , respectively , than when drugb was administered alone under fasting conditions .
DDI-DrugBank.d700.s1	Myfortic	drug	23-30	antacids	group	36-43	advise	it is recommended that druga and drugb not be administered simultaneously .
DDI-DrugBank.d700.s2	Cyclosporine	drug	0-11	cyclosporine	drug	64-75	false	druga : when studied in stable renal transplant patients , drugb , usp ( modified ) pharmacokinetics were unaffected by steady state dosing of myfortic .
DDI-DrugBank.d700.s2	Cyclosporine	drug	0-11	Myfortic	brand	152-159	false	druga : when studied in stable renal transplant patients , cyclosporine , usp ( modified ) pharmacokinetics were unaffected by steady state dosing of drugb .
DDI-DrugBank.d700.s2	cyclosporine	drug	64-75	Myfortic	brand	152-159	false	cyclosporine : when studied in stable renal transplant patients , druga , usp ( modified ) pharmacokinetics were unaffected by steady state dosing of drugb .
DDI-DrugBank.d700.s3	Acyclovir	drug	0-8	Ganciclovir	drug	10-20	false	druga / drugb : may be taken with myfortic ;
DDI-DrugBank.d700.s3	Acyclovir	drug	0-8	Myfortic	brand	41-48	false	druga / ganciclovir : may be taken with drugb ;
DDI-DrugBank.d700.s3	Ganciclovir	drug	10-20	Myfortic	brand	41-48	false	acyclovir / druga : may be taken with drugb ;
DDI-DrugBank.d700.s5	acyclovir	drug	5-13	ganciclovir	drug	15-25	false	both druga / drugb and mpag concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
DDI-DrugBank.d700.s5	acyclovir	drug	5-13	MPAG	drug_n	31-34	false	both druga / ganciclovir and drugb concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
DDI-DrugBank.d700.s5	ganciclovir	drug	15-25	MPAG	drug_n	31-34	false	both acyclovir / druga and drugb concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
DDI-DrugBank.d700.s6	Azathioprine	drug	0-11	Mycophenolate Mofetil	drug	13-33	false	druga / drugb : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Azathioprine	drug	0-11	azathioprine	drug	47-58	false	druga / mycophenolate mofetil : given that drugb and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Azathioprine	drug	0-11	mycophenolate mofetil	drug	64-84	false	druga / mycophenolate mofetil : given that azathioprine and drugb inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Azathioprine	drug	0-11	Myfortic	brand	136-143	false	druga / mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Azathioprine	drug	0-11	azathioprine	drug	184-195	false	druga / mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with drugb or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Azathioprine	drug	0-11	mycophenolate mofetil	drug	200-220	false	druga / mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or drugb .
DDI-DrugBank.d700.s6	Mycophenolate Mofetil	drug	13-33	azathioprine	drug	47-58	false	azathioprine / druga : given that drugb and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Mycophenolate Mofetil	drug	13-33	mycophenolate mofetil	drug	64-84	false	azathioprine / druga : given that azathioprine and drugb inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Mycophenolate Mofetil	drug	13-33	Myfortic	brand	136-143	false	azathioprine / druga : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Mycophenolate Mofetil	drug	13-33	azathioprine	drug	184-195	false	azathioprine / druga : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with drugb or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Mycophenolate Mofetil	drug	13-33	mycophenolate mofetil	drug	200-220	false	azathioprine / druga : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or drugb .
DDI-DrugBank.d700.s6	azathioprine	drug	47-58	mycophenolate mofetil	drug	64-84	false	azathioprine / mycophenolate mofetil : given that druga and drugb inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	azathioprine	drug	47-58	Myfortic	brand	136-143	false	azathioprine / mycophenolate mofetil : given that druga and mycophenolate mofetil inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	azathioprine	drug	47-58	azathioprine	drug	184-195	false	azathioprine / mycophenolate mofetil : given that druga and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with drugb or mycophenolate mofetil .
DDI-DrugBank.d700.s6	azathioprine	drug	47-58	mycophenolate mofetil	drug	200-220	false	azathioprine / mycophenolate mofetil : given that druga and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or drugb .
DDI-DrugBank.d700.s6	mycophenolate mofetil	drug	64-84	Myfortic	brand	136-143	false	azathioprine / mycophenolate mofetil : given that azathioprine and druga inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6	mycophenolate mofetil	drug	64-84	azathioprine	drug	184-195	false	azathioprine / mycophenolate mofetil : given that azathioprine and druga inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with drugb or mycophenolate mofetil .
DDI-DrugBank.d700.s6	mycophenolate mofetil	drug	64-84	mycophenolate mofetil	drug	200-220	false	azathioprine / mycophenolate mofetil : given that azathioprine and druga inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or drugb .
DDI-DrugBank.d700.s6	Myfortic	brand	136-143	azathioprine	drug	184-195	advise	azathioprine / mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that druga not be administered concomitantly with drugb or mycophenolate mofetil .
DDI-DrugBank.d700.s6	Myfortic	brand	136-143	mycophenolate mofetil	drug	200-220	advise	azathioprine / mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that druga not be administered concomitantly with azathioprine or drugb .
DDI-DrugBank.d700.s6	azathioprine	drug	184-195	mycophenolate mofetil	drug	200-220	false	azathioprine / mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with druga or drugb .
DDI-DrugBank.d700.s7	Cholestyramine	drug	0-13	MPA	drug_n	108-110	false	druga and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce drugb exposure when coadministered with mycophenolate mofetil .
DDI-DrugBank.d700.s7	Cholestyramine	drug	0-13	mycophenolate mofetil	drug	146-166	false	druga and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce mpa exposure when coadministered with drugb .
DDI-DrugBank.d700.s7	MPA	drug_n	108-110	mycophenolate mofetil	drug	146-166	false	cholestyramine and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce druga exposure when coadministered with drugb .
DDI-DrugBank.d700.s8	Myfortic	drug	29-36	cholestyramine	drug	43-56	advise	therefore , do not administer druga with drugb or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of myfortic .
DDI-DrugBank.d700.s8	Myfortic	drug	29-36	activated charcoal	drug	204-221	advise	therefore , do not administer druga with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral drugb , because of the potential to reduce the efficacy of myfortic .
DDI-DrugBank.d700.s8	Myfortic	drug	29-36	Myfortic	brand	275-282	false	therefore , do not administer druga with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of drugb .
DDI-DrugBank.d700.s8	cholestyramine	drug	43-56	activated charcoal	drug	204-221	false	therefore , do not administer myfortic with druga or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral drugb , because of the potential to reduce the efficacy of myfortic .
DDI-DrugBank.d700.s8	cholestyramine	drug	43-56	Myfortic	brand	275-282	false	therefore , do not administer myfortic with druga or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of drugb .
DDI-DrugBank.d700.s8	activated charcoal	drug	204-221	Myfortic	brand	275-282	false	therefore , do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral druga , because of the potential to reduce the efficacy of drugb .
DDI-DrugBank.d700.s9	Contraceptives	group	5-18	Myfortic	brand	55-62	false	oral druga : given the different metabolism of drugb and oral contraceptives , no drug interaction between these two classes of drug is expected .
DDI-DrugBank.d700.s9	Contraceptives	group	5-18	contraceptives	group	73-86	false	oral druga : given the different metabolism of myfortic and oral drugb , no drug interaction between these two classes of drug is expected .
DDI-DrugBank.d700.s9	Myfortic	brand	55-62	contraceptives	group	73-86	false	oral contraceptives : given the different metabolism of druga and oral drugb , no drug interaction between these two classes of drug is expected .
DDI-DrugBank.d700.s10	levonorgesterol	drug	48-62	mycophenolate mofetil	drug	114-134	mechanism	however , in a drug drug interaction study , mean druga auc was decreased by dg % when coadministered with drugb .
DDI-DrugBank.d700.s11	contraceptives	group	39-52	Myfortic	brand	80-87	advise	therefore , it is recommended that oral druga are co administered with drugb with caution and additional birth control methods be considered .
DDI-DrugBank.d700.s12	Live Vaccines	group	0-12	Myfortic	drug	37-44	false	druga : during treatment with drugb , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective .
DDI-DrugBank.d700.s12	Live Vaccines	group	0-12	live attenuated vaccines	group	58-81	false	druga : during treatment with myfortic , the use of drugb should be avoided and patients should be advised that vaccinations may be less effective .
DDI-DrugBank.d700.s12	Myfortic	drug	37-44	live attenuated vaccines	group	58-81	advise	live vaccines : during treatment with druga , the use of drugb should be avoided and patients should be advised that vaccinations may be less effective .
DDI-DrugBank.d700.s16	MPAG	drug_n	16-19	MPA	drug_n	49-51	false	interference of druga hydrolysis may lead to less drugb available for absorption .
DDI-DrugBank.d763.s1	ondansetron	drug	8-18	ondansetron	drug	209-219	false	because druga is metabolized by hepatic cytochrome p dg drug metabolizing enzymes ( cyp3a4 , cyp2d6 , cyp1a2 ) , inducers or inhibitors of these enzymes may change the clearance and , hence , the half life of drugb .
DDI-DrugBank.d763.s3	Phenytoin	drug	0-8	Carbamazepine	drug	11-23	false	druga , drugb , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Phenytoin	drug	0-8	Rifampicin	drug	30-39	false	druga , carbamazepine , and drugb : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Phenytoin	drug	0-8	phenytoin	drug	100-108	false	druga , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , drugb , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Phenytoin	drug	0-8	carbamazepine	drug	111-123	false	druga , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , drugb , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Phenytoin	drug	0-8	rifampicin	drug	130-139	false	druga , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and drugb ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Phenytoin	drug	0-8	ondansetron	drug	160-170	false	druga , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of drugb was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Phenytoin	drug	0-8	ondansetron	drug	204-214	false	druga , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s3	Carbamazepine	drug	11-23	Rifampicin	drug	30-39	false	phenytoin , druga , and drugb : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Carbamazepine	drug	11-23	phenytoin	drug	100-108	false	phenytoin , druga , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , drugb , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Carbamazepine	drug	11-23	carbamazepine	drug	111-123	false	phenytoin , druga , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , drugb , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Carbamazepine	drug	11-23	rifampicin	drug	130-139	false	phenytoin , druga , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and drugb ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Carbamazepine	drug	11-23	ondansetron	drug	160-170	false	phenytoin , druga , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of drugb was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Carbamazepine	drug	11-23	ondansetron	drug	204-214	false	phenytoin , druga , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s3	Rifampicin	drug	30-39	phenytoin	drug	100-108	false	phenytoin , carbamazepine , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , drugb , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Rifampicin	drug	30-39	carbamazepine	drug	111-123	false	phenytoin , carbamazepine , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , drugb , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Rifampicin	drug	30-39	rifampicin	drug	130-139	false	phenytoin , carbamazepine , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and drugb ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Rifampicin	drug	30-39	ondansetron	drug	160-170	false	phenytoin , carbamazepine , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of drugb was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	Rifampicin	drug	30-39	ondansetron	drug	204-214	false	phenytoin , carbamazepine , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s3	phenytoin	drug	100-108	carbamazepine	drug	111-123	false	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , druga , drugb , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	phenytoin	drug	100-108	rifampicin	drug	130-139	false	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , druga , carbamazepine , and drugb ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	phenytoin	drug	100-108	ondansetron	drug	160-170	mechanism	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , druga , carbamazepine , and rifampicin ) , the clearance of drugb was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	phenytoin	drug	100-108	ondansetron	drug	204-214	mechanism	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , druga , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s3	carbamazepine	drug	111-123	rifampicin	drug	130-139	false	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , druga , and drugb ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	carbamazepine	drug	111-123	ondansetron	drug	160-170	mechanism	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , druga , and rifampicin ) , the clearance of drugb was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	carbamazepine	drug	111-123	ondansetron	drug	204-214	mechanism	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , druga , and rifampicin ) , the clearance of ondansetron was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s3	rifampicin	drug	130-139	ondansetron	drug	160-170	mechanism	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and druga ) , the clearance of drugb was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3	rifampicin	drug	130-139	ondansetron	drug	204-214	mechanism	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and druga ) , the clearance of ondansetron was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s3	ondansetron	drug	160-170	ondansetron	drug	204-214	false	phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of druga was significantly increased and drugb blood concentrations were decreased .
DDI-DrugBank.d763.s4	ondansetron	drug	66-76	Tramadol	drug	126-133	false	however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1 , dg drugb : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	ondansetron	drug	66-76	ondansetron	drug	189-199	false	however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between drugb and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	ondansetron	drug	66-76	tramadol	drug	205-212	false	however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and drugb has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	ondansetron	drug	66-76	ondansetron	drug	273-283	false	however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that drugb may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	ondansetron	drug	66-76	tramadol	drug	360-367	false	however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of drugb .4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	ondansetron	drug	66-76	ondansetron	drug	472-482	false	however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by drugb .
DDI-DrugBank.d763.s4	Tramadol	drug	126-133	ondansetron	drug	189-199	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg druga : although no pharmacokinetic drug interaction between drugb and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	Tramadol	drug	126-133	tramadol	drug	205-212	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg druga : although no pharmacokinetic drug interaction between ondansetron and drugb has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	Tramadol	drug	126-133	ondansetron	drug	273-283	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg druga : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that drugb may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	Tramadol	drug	126-133	tramadol	drug	360-367	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg druga : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of drugb .4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	Tramadol	drug	126-133	ondansetron	drug	472-482	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg druga : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by drugb .
DDI-DrugBank.d763.s4	ondansetron	drug	189-199	tramadol	drug	205-212	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between druga and drugb has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	ondansetron	drug	189-199	ondansetron	drug	273-283	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between druga and tramadol has been observed , data from dg small studies indicate that drugb may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	ondansetron	drug	189-199	tramadol	drug	360-367	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between druga and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of drugb .4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	ondansetron	drug	189-199	ondansetron	drug	472-482	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between druga and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by drugb .
DDI-DrugBank.d763.s4	tramadol	drug	205-212	ondansetron	drug	273-283	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and druga has been observed , data from dg small studies indicate that drugb may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	tramadol	drug	205-212	tramadol	drug	360-367	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and druga has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of drugb .4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	tramadol	drug	205-212	ondansetron	drug	472-482	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and druga has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by drugb .
DDI-DrugBank.d763.s4	ondansetron	drug	273-283	tramadol	drug	360-367	effect	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that druga may be associated with an increase in patient controlled administration of drugb .4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4	ondansetron	drug	273-283	ondansetron	drug	472-482	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that druga may be associated with an increase in patient controlled administration of tramadol.4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by drugb .
DDI-DrugBank.d763.s4	tramadol	drug	360-367	ondansetron	drug	472-482	false	however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1 , dg tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from dg small studies indicate that ondansetron may be associated with an increase in patient controlled administration of druga .4 , dg chemotherapy : tumor response to chemotherapy in the p dg mouse leukemia model is not affected by drugb .
DDI-DrugBank.d763.s5	carmustine	drug	11-20	etoposide	drug	23-31	false	in humans , druga , drugb , and cisplatin do not affect the pharmacokinetics of ondansetron .
DDI-DrugBank.d763.s5	carmustine	drug	11-20	cisplatin	drug	38-46	false	in humans , druga , etoposide , and drugb do not affect the pharmacokinetics of ondansetron .
DDI-DrugBank.d763.s5	carmustine	drug	11-20	ondansetron	drug	86-96	false	in humans , druga , etoposide , and cisplatin do not affect the pharmacokinetics of drugb .
DDI-DrugBank.d763.s5	etoposide	drug	23-31	cisplatin	drug	38-46	false	in humans , carmustine , druga , and drugb do not affect the pharmacokinetics of ondansetron .
DDI-DrugBank.d763.s5	etoposide	drug	23-31	ondansetron	drug	86-96	false	in humans , carmustine , druga , and cisplatin do not affect the pharmacokinetics of drugb .
DDI-DrugBank.d763.s5	cisplatin	drug	38-46	ondansetron	drug	86-96	false	in humans , carmustine , etoposide , and druga do not affect the pharmacokinetics of drugb .
DDI-DrugBank.d763.s7	ondansetron	drug	0-10	methotrexate	drug	55-66	false	druga did not increase blood levels of high dose drugb .
DDI-DrugBank.d611.s0	beta adrenergic aerosol bronchodilators	group	6-44	Alupent	brand	84-90	advise	other druga should not be used concomitantly with drugb ( metaproterenol sulfate usp ) because they may have additive effects .
DDI-DrugBank.d611.s0	beta adrenergic aerosol bronchodilators	group	6-44	metaproterenol sulfate	drug	96-117	advise	other druga should not be used concomitantly with alupent ( drugb usp ) because they may have additive effects .
DDI-DrugBank.d611.s0	Alupent	brand	84-90	metaproterenol sulfate	drug	96-117	false	other beta adrenergic aerosol bronchodilators should not be used concomitantly with druga ( drugb usp ) because they may have additive effects .
DDI-DrugBank.d611.s1	Beta adrenergic agonists	group	0-23	monoamine oxidase inhibitors	group	92-119	advise	druga should be administered with caution to patients being treated with drugb or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated .
DDI-DrugBank.d611.s1	Beta adrenergic agonists	group	0-23	tricyclic antidepressants	group	124-148	advise	druga should be administered with caution to patients being treated with monoamine oxidase inhibitors or drugb , since the action of beta adrenergic agonists on the vascular system may be potentiated .
DDI-DrugBank.d611.s1	Beta adrenergic agonists	group	0-23	beta adrenergic agonists	group	171-194	false	druga should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of drugb on the vascular system may be potentiated .
DDI-DrugBank.d611.s1	monoamine oxidase inhibitors	group	92-119	tricyclic antidepressants	group	124-148	false	beta adrenergic agonists should be administered with caution to patients being treated with druga or drugb , since the action of beta adrenergic agonists on the vascular system may be potentiated .
DDI-DrugBank.d611.s1	monoamine oxidase inhibitors	group	92-119	beta adrenergic agonists	group	171-194	false	beta adrenergic agonists should be administered with caution to patients being treated with druga or tricyclic antidepressants , since the action of drugb on the vascular system may be potentiated .
DDI-DrugBank.d611.s1	tricyclic antidepressants	group	124-148	beta adrenergic agonists	group	171-194	false	beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or druga , since the action of drugb on the vascular system may be potentiated .
DDI-DrugBank.d761.s0	Alcohol	drug	0-6	XENICAL	brand	84-90	false	druga : in a multiple dose study in dg normal weight subjects , coadministration of drugb and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	Alcohol	drug	0-6	alcohol	drug	108-114	false	druga : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of drugb ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	Alcohol	drug	0-6	alcohol	drug	188-194	false	druga : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of drugb pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	Alcohol	drug	0-6	orlistat	drug	214-221	false	druga : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , drugb pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	Alcohol	drug	0-6	orlistat	drug	287-294	false	druga : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
DDI-DrugBank.d761.s0	XENICAL	brand	84-90	alcohol	drug	108-114	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of druga and dg grams of drugb ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	XENICAL	brand	84-90	alcohol	drug	188-194	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of druga and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of drugb pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	XENICAL	brand	84-90	orlistat	drug	214-221	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of druga and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , drugb pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	XENICAL	brand	84-90	orlistat	drug	287-294	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of druga and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
DDI-DrugBank.d761.s0	alcohol	drug	108-114	alcohol	drug	188-194	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of druga ( e.g. , approximately dg glasses of wine ) did not result in alteration of drugb pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	alcohol	drug	108-114	orlistat	drug	214-221	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of druga ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , drugb pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	alcohol	drug	108-114	orlistat	drug	287-294	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of druga ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
DDI-DrugBank.d761.s0	alcohol	drug	188-194	orlistat	drug	214-221	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of druga pharmacokinetics , drugb pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0	alcohol	drug	188-194	orlistat	drug	287-294	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of druga pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
DDI-DrugBank.d761.s0	orlistat	drug	214-221	orlistat	drug	287-294	false	alcohol : in a multiple dose study in dg normal weight subjects , coadministration of xenical and dg grams of alcohol ( e.g. , approximately dg glasses of wine ) did not result in alteration of alcohol pharmacokinetics , druga pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
DDI-DrugBank.d761.s1	Cyclosporine	drug	0-11	XENICAL	brand	38-44	false	druga : preliminary data from a drugb and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	Cyclosporine	drug	0-11	cyclosporine	drug	50-61	false	druga : preliminary data from a xenical and drugb drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	Cyclosporine	drug	0-11	cyclosporine	drug	110-121	false	druga : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in drugb plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	Cyclosporine	drug	0-11	XENICAL	brand	142-148	false	druga : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when drugb was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	Cyclosporine	drug	0-11	cyclosporine	drug	174-185	false	druga : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with drugb .
DDI-DrugBank.d761.s1	XENICAL	brand	38-44	cyclosporine	drug	50-61	false	cyclosporine : preliminary data from a druga and drugb drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	XENICAL	brand	38-44	cyclosporine	drug	110-121	false	cyclosporine : preliminary data from a druga and cyclosporine drug interaction study indicate a reduction in drugb plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	XENICAL	brand	38-44	XENICAL	brand	142-148	false	cyclosporine : preliminary data from a druga and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when drugb was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	XENICAL	brand	38-44	cyclosporine	drug	174-185	false	cyclosporine : preliminary data from a druga and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with drugb .
DDI-DrugBank.d761.s1	cyclosporine	drug	50-61	cyclosporine	drug	110-121	false	cyclosporine : preliminary data from a xenical and druga drug interaction study indicate a reduction in drugb plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	cyclosporine	drug	50-61	XENICAL	brand	142-148	false	cyclosporine : preliminary data from a xenical and druga drug interaction study indicate a reduction in cyclosporine plasma levels when drugb was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	cyclosporine	drug	50-61	cyclosporine	drug	174-185	false	cyclosporine : preliminary data from a xenical and druga drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with drugb .
DDI-DrugBank.d761.s1	cyclosporine	drug	110-121	XENICAL	brand	142-148	false	cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in druga plasma levels when drugb was coadministered with cyclosporine .
DDI-DrugBank.d761.s1	cyclosporine	drug	110-121	cyclosporine	drug	174-185	false	cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in druga plasma levels when xenical was coadministered with drugb .
DDI-DrugBank.d761.s1	XENICAL	brand	142-148	cyclosporine	drug	174-185	mechanism	cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when druga was coadministered with drugb .
DDI-DrugBank.d761.s2	Digoxin	drug	0-6	XENICAL	brand	48-54	false	druga : in dg normal weight subjects receiving drugb dg mg three times a day for dg days , xenical did not alter the pharmacokinetics of a single dose of digoxin .
DDI-DrugBank.d761.s2	Digoxin	drug	0-6	XENICAL	brand	93-99	false	druga : in dg normal weight subjects receiving xenical dg mg three times a day for dg days , drugb did not alter the pharmacokinetics of a single dose of digoxin .
DDI-DrugBank.d761.s2	Digoxin	drug	0-6	digoxin	drug	156-162	false	druga : in dg normal weight subjects receiving xenical dg mg three times a day for dg days , xenical did not alter the pharmacokinetics of a single dose of drugb .
DDI-DrugBank.d761.s2	XENICAL	brand	48-54	XENICAL	brand	93-99	false	digoxin : in dg normal weight subjects receiving druga dg mg three times a day for dg days , drugb did not alter the pharmacokinetics of a single dose of digoxin .
DDI-DrugBank.d761.s2	XENICAL	brand	48-54	digoxin	drug	156-162	false	digoxin : in dg normal weight subjects receiving druga dg mg three times a day for dg days , xenical did not alter the pharmacokinetics of a single dose of drugb .
DDI-DrugBank.d761.s2	XENICAL	brand	93-99	digoxin	drug	156-162	false	digoxin : in dg normal weight subjects receiving xenical dg mg three times a day for dg days , druga did not alter the pharmacokinetics of a single dose of drugb .
DDI-DrugBank.d761.s3	Fat-soluble Vitamin Supplements	group	0-30	beta-carotene	drug	109-121	false	druga and analogues : a pharmacokinetic interaction study showed a dg % reduction in drugb supplement absorption when concomitantly administered with xenical .
DDI-DrugBank.d761.s3	Fat-soluble Vitamin Supplements	group	0-30	XENICAL	brand	182-188	false	druga and analogues : a pharmacokinetic interaction study showed a dg % reduction in beta carotene supplement absorption when concomitantly administered with drugb .
DDI-DrugBank.d761.s3	beta-carotene	drug	109-121	XENICAL	brand	182-188	mechanism	fat soluble vitamin supplements and analogues : a pharmacokinetic interaction study showed a dg % reduction in druga supplement absorption when concomitantly administered with drugb .
DDI-DrugBank.d761.s4	XENICAL	brand	0-6	vitamin E acetate	drug	34-50	mechanism	druga inhibited absorption of a drugb supplement by approximately dg % .
DDI-DrugBank.d761.s5	orlistat	drug	14-21	vitamin D	group	57-65	false	the effect of druga on the absorption of supplemental drugb , vitamin a , and nutritionally derived vitamin k is not known at this time .
DDI-DrugBank.d761.s5	orlistat	drug	14-21	vitamin A	group	68-76	false	the effect of druga on the absorption of supplemental vitamin d , drugb , and nutritionally derived vitamin k is not known at this time .
DDI-DrugBank.d761.s5	orlistat	drug	14-21	vitamin K	group	105-113	false	the effect of druga on the absorption of supplemental vitamin d , vitamin a , and nutritionally derived drugb is not known at this time .
DDI-DrugBank.d761.s5	vitamin D	group	57-65	vitamin A	group	68-76	false	the effect of orlistat on the absorption of supplemental druga , drugb , and nutritionally derived vitamin k is not known at this time .
DDI-DrugBank.d761.s5	vitamin D	group	57-65	vitamin K	group	105-113	false	the effect of orlistat on the absorption of supplemental druga , vitamin a , and nutritionally derived drugb is not known at this time .
DDI-DrugBank.d761.s5	vitamin A	group	68-76	vitamin K	group	105-113	false	the effect of orlistat on the absorption of supplemental vitamin d , druga , and nutritionally derived drugb is not known at this time .
DDI-DrugBank.d761.s6	Glyburide	drug	0-8	orlistat	drug	50-57	false	druga : in dg normal weight subjects receiving drugb dg mg three times a day for dg days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose lowering ) of glyburide .
DDI-DrugBank.d761.s6	Glyburide	drug	0-8	orlistat	drug	95-102	false	druga : in dg normal weight subjects receiving orlistat dg mg three times a day for dg days , drugb did not alter the pharmacokinetics or pharmacodynamics ( blood glucose lowering ) of glyburide .
DDI-DrugBank.d761.s6	Glyburide	drug	0-8	glyburide	drug	187-195	false	druga : in dg normal weight subjects receiving orlistat dg mg three times a day for dg days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose lowering ) of drugb .
DDI-DrugBank.d761.s6	orlistat	drug	50-57	orlistat	drug	95-102	false	glyburide : in dg normal weight subjects receiving druga dg mg three times a day for dg days , drugb did not alter the pharmacokinetics or pharmacodynamics ( blood glucose lowering ) of glyburide .
DDI-DrugBank.d761.s6	orlistat	drug	50-57	glyburide	drug	187-195	false	glyburide : in dg normal weight subjects receiving druga dg mg three times a day for dg days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose lowering ) of drugb .
DDI-DrugBank.d761.s6	orlistat	drug	95-102	glyburide	drug	187-195	false	glyburide : in dg normal weight subjects receiving orlistat dg mg three times a day for dg days , druga did not alter the pharmacokinetics or pharmacodynamics ( blood glucose lowering ) of drugb .
DDI-DrugBank.d761.s7	Nifedipine	drug	0-9	XENICAL	brand	78-84	false	druga ( extended release tablets ) : in dg normal weight subjects receiving drugb dg mg three times a day for dg days , xenical did not alter the bioavailability of nifedipine ( extended release tablets ) .
DDI-DrugBank.d761.s7	Nifedipine	drug	0-9	XENICAL	brand	123-129	false	druga ( extended release tablets ) : in dg normal weight subjects receiving xenical dg mg three times a day for dg days , drugb did not alter the bioavailability of nifedipine ( extended release tablets ) .
DDI-DrugBank.d761.s7	Nifedipine	drug	0-9	nifedipine	drug	168-177	false	druga ( extended release tablets ) : in dg normal weight subjects receiving xenical dg mg three times a day for dg days , xenical did not alter the bioavailability of drugb ( extended release tablets ) .
DDI-DrugBank.d761.s7	XENICAL	brand	78-84	XENICAL	brand	123-129	false	nifedipine ( extended release tablets ) : in dg normal weight subjects receiving druga dg mg three times a day for dg days , drugb did not alter the bioavailability of nifedipine ( extended release tablets ) .
DDI-DrugBank.d761.s7	XENICAL	brand	78-84	nifedipine	drug	168-177	false	nifedipine ( extended release tablets ) : in dg normal weight subjects receiving druga dg mg three times a day for dg days , xenical did not alter the bioavailability of drugb ( extended release tablets ) .
DDI-DrugBank.d761.s7	XENICAL	brand	123-129	nifedipine	drug	168-177	false	nifedipine ( extended release tablets ) : in dg normal weight subjects receiving xenical dg mg three times a day for dg days , druga did not alter the bioavailability of drugb ( extended release tablets ) .
DDI-DrugBank.d761.s8	Contraceptives	group	5-18	XENICAL	brand	75-81	false	oral druga : in dg normal weight female subjects , the treatment of drugb dg mg three times a day for dg days resulted in no changes in the ovulation suppressing action of oral contraceptives .
DDI-DrugBank.d761.s8	Contraceptives	group	5-18	contraceptives	group	187-200	false	oral druga : in dg normal weight female subjects , the treatment of xenical dg mg three times a day for dg days resulted in no changes in the ovulation suppressing action of oral drugb .
DDI-DrugBank.d761.s8	XENICAL	brand	75-81	contraceptives	group	187-200	false	oral contraceptives : in dg normal weight female subjects , the treatment of druga dg mg three times a day for dg days resulted in no changes in the ovulation suppressing action of oral drugb .
DDI-DrugBank.d761.s9	Phenytoin	drug	0-8	XENICAL	brand	50-56	false	druga : in dg normal weight subjects receiving drugb dg mg three times a day for dg days , xenical did not alter the pharmacokinetics of a single dg mg dose of phenytoin .
DDI-DrugBank.d761.s9	Phenytoin	drug	0-8	XENICAL	brand	95-101	false	druga : in dg normal weight subjects receiving xenical dg mg three times a day for dg days , drugb did not alter the pharmacokinetics of a single dg mg dose of phenytoin .
DDI-DrugBank.d761.s9	Phenytoin	drug	0-8	phenytoin	drug	165-173	false	druga : in dg normal weight subjects receiving xenical dg mg three times a day for dg days , xenical did not alter the pharmacokinetics of a single dg mg dose of drugb .
DDI-DrugBank.d761.s9	XENICAL	brand	50-56	XENICAL	brand	95-101	false	phenytoin : in dg normal weight subjects receiving druga dg mg three times a day for dg days , drugb did not alter the pharmacokinetics of a single dg mg dose of phenytoin .
DDI-DrugBank.d761.s9	XENICAL	brand	50-56	phenytoin	drug	165-173	false	phenytoin : in dg normal weight subjects receiving druga dg mg three times a day for dg days , xenical did not alter the pharmacokinetics of a single dg mg dose of drugb .
DDI-DrugBank.d761.s9	XENICAL	brand	95-101	phenytoin	drug	165-173	false	phenytoin : in dg normal weight subjects receiving xenical dg mg three times a day for dg days , druga did not alter the pharmacokinetics of a single dg mg dose of drugb .
DDI-DrugBank.d761.s10	Pravastatin	drug	0-10	XENICAL	brand	108-114	false	druga : in a dg way crossover study of dg normal weight , mildly hypercholesterolemic patients receiving drugb dg mg three times a day for dg days , xenical did not affect the pharmacokinetics of pravastatin .
DDI-DrugBank.d761.s10	Pravastatin	drug	0-10	XENICAL	brand	153-159	false	druga : in a dg way crossover study of dg normal weight , mildly hypercholesterolemic patients receiving xenical dg mg three times a day for dg days , drugb did not affect the pharmacokinetics of pravastatin .
DDI-DrugBank.d761.s10	Pravastatin	drug	0-10	pravastatin	drug	200-210	false	druga : in a dg way crossover study of dg normal weight , mildly hypercholesterolemic patients receiving xenical dg mg three times a day for dg days , xenical did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d761.s10	XENICAL	brand	108-114	XENICAL	brand	153-159	false	pravastatin : in a dg way crossover study of dg normal weight , mildly hypercholesterolemic patients receiving druga dg mg three times a day for dg days , drugb did not affect the pharmacokinetics of pravastatin .
DDI-DrugBank.d761.s10	XENICAL	brand	108-114	pravastatin	drug	200-210	false	pravastatin : in a dg way crossover study of dg normal weight , mildly hypercholesterolemic patients receiving druga dg mg three times a day for dg days , xenical did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d761.s10	XENICAL	brand	153-159	pravastatin	drug	200-210	false	pravastatin : in a dg way crossover study of dg normal weight , mildly hypercholesterolemic patients receiving xenical dg mg three times a day for dg days , druga did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d761.s11	Warfarin	drug	0-7	XENICAL	brand	58-64	false	druga : in dg normal weight subjects , administration of drugb dg mg three times a day for dg days did not result in any change in either warfarin pharmacokinetics ( both r and s enantiomers ) or pharmacodynamics ( prothrombin time and serum factor vii ) .
DDI-DrugBank.d761.s11	Warfarin	drug	0-7	warfarin	drug	142-149	false	druga : in dg normal weight subjects , administration of xenical dg mg three times a day for dg days did not result in any change in either drugb pharmacokinetics ( both r and s enantiomers ) or pharmacodynamics ( prothrombin time and serum factor vii ) .
DDI-DrugBank.d761.s11	XENICAL	brand	58-64	warfarin	drug	142-149	false	warfarin : in dg normal weight subjects , administration of druga dg mg three times a day for dg days did not result in any change in either drugb pharmacokinetics ( both r and s enantiomers ) or pharmacodynamics ( prothrombin time and serum factor vii ) .
DDI-DrugBank.d761.s12	XENICAL	brand	101-107	XENICAL	brand	179-185	false	although undercarboxylated osteocalcin , a marker of vitamin k nutritional status , was unaltered with druga administration , vitamin k levels tended to decline in subjects taking drugb .
DDI-DrugBank.d761.s13	vitamin K	group	14-22	XENICAL	brand	57-63	mechanism	therefore , as druga absorption may be decreased with drugb , patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13	vitamin K	group	14-22	warfarin	drug	102-109	false	therefore , as druga absorption may be decreased with xenical , patients on chronic stable doses of drugb who are prescribed xenical should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13	vitamin K	group	14-22	XENICAL	brand	130-136	false	therefore , as druga absorption may be decreased with xenical , patients on chronic stable doses of warfarin who are prescribed drugb should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13	XENICAL	brand	57-63	warfarin	drug	102-109	false	therefore , as vitamin k absorption may be decreased with druga , patients on chronic stable doses of drugb who are prescribed xenical should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13	XENICAL	brand	57-63	XENICAL	brand	130-136	false	therefore , as vitamin k absorption may be decreased with druga , patients on chronic stable doses of warfarin who are prescribed drugb should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13	warfarin	drug	102-109	XENICAL	brand	130-136	advise	therefore , as vitamin k absorption may be decreased with xenical , patients on chronic stable doses of druga who are prescribed drugb should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d747.s0	Tetracycline	group	0-11	antibiotic	group	31-40	false	druga , a bacteriostatic drugb , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided .
DDI-DrugBank.d747.s0	Tetracycline	group	0-11	penicillin	drug	85-94	effect	druga , a bacteriostatic antibiotic , may antagonize the bactericidal effect of drugb and concurrent use of these drugs should be avoided .
DDI-DrugBank.d747.s0	antibiotic	group	31-40	penicillin	drug	85-94	false	tetracycline , a bacteriostatic druga , may antagonize the bactericidal effect of drugb and concurrent use of these drugs should be avoided .
DDI-DrugBank.d728.s1	ELOXATIN	brand	48-55	5-FU	drug	72-75	false	no pharmacokinetic interaction between dg mg / m2 druga and infusional drugb has been observed in patients treated every dg weeks .
DDI-DrugBank.d728.s2	5-FU	drug	13-16	ELOXATIN	brand	104-111	mechanism	increases of druga plasma concentrations by approximately dg % have been observed with doses of dg mg / m2 drugb dosed every dg weeks .
DDI-DrugBank.d584.s0	Anticoagulants	group	0-13	Anabolic steroids	group	15-31	false	druga drugb may increase sensitivity to oral anticoagulants .
DDI-DrugBank.d584.s0	Anticoagulants	group	0-13	anticoagulants	group	66-79	false	druga anabolic steroids may increase sensitivity to oral drugb .
DDI-DrugBank.d584.s0	Anabolic steroids	group	15-31	anticoagulants	group	66-79	effect	anticoagulants druga may increase sensitivity to oral drugb .
DDI-DrugBank.d584.s3	Warfarin	drug	0-7	oxandrolone	drug	31-41	false	druga : a multidose study of drugb , given as dg or dg mg bid in dg healthy subjects concurrently treated with warfarin , resulted in a mean increase in s warfarin half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in r warfarin half life and auc were also detected .
DDI-DrugBank.d584.s3	Warfarin	drug	0-7	warfarin	drug	117-124	false	druga : a multidose study of oxandrolone , given as dg or dg mg bid in dg healthy subjects concurrently treated with drugb , resulted in a mean increase in s warfarin half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in r warfarin half life and auc were also detected .
DDI-DrugBank.d584.s3	Warfarin	drug	0-7	S-warfarin	drug	158-167	false	druga : a multidose study of oxandrolone , given as dg or dg mg bid in dg healthy subjects concurrently treated with warfarin , resulted in a mean increase in drugb half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in r warfarin half life and auc were also detected .
DDI-DrugBank.d584.s3	Warfarin	drug	0-7	R-warfarin	drug	257-266	false	druga : a multidose study of oxandrolone , given as dg or dg mg bid in dg healthy subjects concurrently treated with warfarin , resulted in a mean increase in s warfarin half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in drugb half life and auc were also detected .
DDI-DrugBank.d584.s3	oxandrolone	drug	31-41	warfarin	drug	117-124	mechanism	warfarin : a multidose study of druga , given as dg or dg mg bid in dg healthy subjects concurrently treated with drugb , resulted in a mean increase in s warfarin half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in r warfarin half life and auc were also detected .
DDI-DrugBank.d584.s3	oxandrolone	drug	31-41	S-warfarin	drug	158-167	false	warfarin : a multidose study of druga , given as dg or dg mg bid in dg healthy subjects concurrently treated with warfarin , resulted in a mean increase in drugb half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in r warfarin half life and auc were also detected .
DDI-DrugBank.d584.s3	oxandrolone	drug	31-41	R-warfarin	drug	257-266	false	warfarin : a multidose study of druga , given as dg or dg mg bid in dg healthy subjects concurrently treated with warfarin , resulted in a mean increase in s warfarin half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in drugb half life and auc were also detected .
DDI-DrugBank.d584.s3	warfarin	drug	117-124	S-warfarin	drug	158-167	false	warfarin : a multidose study of oxandrolone , given as dg or dg mg bid in dg healthy subjects concurrently treated with druga , resulted in a mean increase in drugb half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in r warfarin half life and auc were also detected .
DDI-DrugBank.d584.s3	warfarin	drug	117-124	R-warfarin	drug	257-266	false	warfarin : a multidose study of oxandrolone , given as dg or dg mg bid in dg healthy subjects concurrently treated with druga , resulted in a mean increase in s warfarin half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in drugb half life and auc were also detected .
DDI-DrugBank.d584.s3	S-warfarin	drug	158-167	R-warfarin	drug	257-266	false	warfarin : a multidose study of oxandrolone , given as dg or dg mg bid in dg healthy subjects concurrently treated with warfarin , resulted in a mean increase in druga half life from dg to dg hours and auc from dg to dg ng*hr / ml : similar increases in drugb half life and auc were also detected .
DDI-DrugBank.d584.s5	warfarin	drug	32-39	warfarin	drug	113-120	false	a dg fold decrease in the mean druga dose from dg mg / day to dg mg / day ( approximately dg dg % reduction of drugb dose ) , was necessary to maintain a target inr of dg .
DDI-DrugBank.d584.s6	oxandrolone	drug	5-15	warfarin	drug	84-91	advise	when druga therapy is initiated in a patient already receiving treatment with drugb , the inr or prothrombin time ( pt ) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target inr or pt has been achieved .
DDI-DrugBank.d584.s6	oxandrolone	drug	5-15	warfarin	drug	171-178	false	when druga therapy is initiated in a patient already receiving treatment with warfarin , the inr or prothrombin time ( pt ) should be monitored closely and the dose of drugb adjusted as necessary until a stable target inr or pt has been achieved .
DDI-DrugBank.d584.s6	warfarin	drug	84-91	warfarin	drug	171-178	false	when oxandrolone therapy is initiated in a patient already receiving treatment with druga , the inr or prothrombin time ( pt ) should be monitored closely and the dose of drugb adjusted as necessary until a stable target inr or pt has been achieved .
DDI-DrugBank.d584.s7	warfarin	drug	106-113	oxandrolone	drug	160-170	advise	furthermore , in patients receiving both drugs , careful monitoring of the inr or pt , and adjustment of the druga dosage if indicated are recommended when the drugb dose is changed or discontinued .
DDI-DrugBank.d584.s9	hypoglycemic agents	group	5-23	Oxandrolone	drug	25-35	false	oral druga drugb may inhibit the metabolism of oral hypoglycemic agents .
DDI-DrugBank.d584.s9	hypoglycemic agents	group	5-23	hypoglycemic agents	group	72-90	false	oral druga oxandrolone may inhibit the metabolism of oral drugb .
DDI-DrugBank.d584.s9	Oxandrolone	drug	25-35	hypoglycemic agents	group	72-90	mechanism	oral hypoglycemic agents druga may inhibit the metabolism of oral drugb .
DDI-DrugBank.d584.s10	Adrenal steroids	group	0-15	ACTH	drug	20-23	false	druga or drugb in patients with edema , concomitant administration with adrenal cortical steroids or acth may increase the edema .
DDI-DrugBank.d584.s10	Adrenal steroids	group	0-15	adrenal cortical steroids	group	81-105	false	druga or acth in patients with edema , concomitant administration with drugb or acth may increase the edema .
DDI-DrugBank.d584.s10	Adrenal steroids	group	0-15	ACTH	drug	110-113	false	druga or acth in patients with edema , concomitant administration with adrenal cortical steroids or drugb may increase the edema .
DDI-DrugBank.d584.s10	ACTH	drug	20-23	adrenal cortical steroids	group	81-105	false	adrenal steroids or druga in patients with edema , concomitant administration with drugb or acth may increase the edema .
DDI-DrugBank.d584.s10	ACTH	drug	20-23	ACTH	drug	110-113	false	adrenal steroids or druga in patients with edema , concomitant administration with adrenal cortical steroids or drugb may increase the edema .
DDI-DrugBank.d584.s10	adrenal cortical steroids	group	81-105	ACTH	drug	110-113	false	adrenal steroids or acth in patients with edema , concomitant administration with druga or drugb may increase the edema .
DDI-DrugBank.d784.s0	oxybutynin	drug	23-32	anticholinergic drugs	group	45-65	effect	the concomitant use of druga with other drugb or with other agents which produce dry mouth , constipation , somnolence ( drowsiness ) , and / or other anticholinergic like effects may increase the frequency and / or severity of such effects .
DDI-DrugBank.d784.s3	oxybutynin chloride	drug	5-23	DITROPAN XL	brand	85-95	false	mean druga plasma concentrations were approximately dg fold higher when drugb was administered with ketoconazole , a potent cyp3a4 inhibitor .
DDI-DrugBank.d784.s3	oxybutynin chloride	drug	5-23	ketoconazole	drug	119-130	false	mean druga plasma concentrations were approximately dg fold higher when ditropan xl was administered with drugb , a potent cyp3a4 inhibitor .
DDI-DrugBank.d784.s3	DITROPAN XL	brand	85-95	ketoconazole	drug	119-130	mechanism	mean oxybutynin chloride plasma concentrations were approximately dg fold higher when druga was administered with drugb , a potent cyp3a4 inhibitor .
DDI-DrugBank.d784.s4	antimycotic agents	group	67-84	itraconazole	drug	93-104	false	other inhibitors of the cytochrome p450 dg enzyme system , such as druga ( e.g. , drugb and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	antimycotic agents	group	67-84	miconazole	drug	110-119	false	other inhibitors of the cytochrome p450 dg enzyme system , such as druga ( e.g. , itraconazole and drugb ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	antimycotic agents	group	67-84	macrolide antibiotics	group	125-145	false	other inhibitors of the cytochrome p450 dg enzyme system , such as druga ( e.g. , itraconazole and miconazole ) or drugb ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	antimycotic agents	group	67-84	erythromycin	drug	154-165	false	other inhibitors of the cytochrome p450 dg enzyme system , such as druga ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , drugb and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	antimycotic agents	group	67-84	clarithromycin	drug	171-184	false	other inhibitors of the cytochrome p450 dg enzyme system , such as druga ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and drugb ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	antimycotic agents	group	67-84	oxybutynin	drug	198-207	mechanism	other inhibitors of the cytochrome p450 dg enzyme system , such as druga ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	itraconazole	drug	93-104	miconazole	drug	110-119	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , druga and drugb ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	itraconazole	drug	93-104	macrolide antibiotics	group	125-145	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , druga and miconazole ) or drugb ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	itraconazole	drug	93-104	erythromycin	drug	154-165	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , druga and miconazole ) or macrolide antibiotics ( e.g. , drugb and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	itraconazole	drug	93-104	clarithromycin	drug	171-184	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , druga and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and drugb ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	itraconazole	drug	93-104	oxybutynin	drug	198-207	mechanism	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , druga and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	miconazole	drug	110-119	macrolide antibiotics	group	125-145	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and druga ) or drugb ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	miconazole	drug	110-119	erythromycin	drug	154-165	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and druga ) or macrolide antibiotics ( e.g. , drugb and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	miconazole	drug	110-119	clarithromycin	drug	171-184	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and druga ) or macrolide antibiotics ( e.g. , erythromycin and drugb ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	miconazole	drug	110-119	oxybutynin	drug	198-207	mechanism	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and druga ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	macrolide antibiotics	group	125-145	erythromycin	drug	154-165	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or druga ( e.g. , drugb and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	macrolide antibiotics	group	125-145	clarithromycin	drug	171-184	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or druga ( e.g. , erythromycin and drugb ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	macrolide antibiotics	group	125-145	oxybutynin	drug	198-207	mechanism	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or druga ( e.g. , erythromycin and clarithromycin ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	erythromycin	drug	154-165	clarithromycin	drug	171-184	false	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , druga and drugb ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	erythromycin	drug	154-165	oxybutynin	drug	198-207	mechanism	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , druga and clarithromycin ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4	clarithromycin	drug	171-184	oxybutynin	drug	198-207	mechanism	other inhibitors of the cytochrome p450 dg enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and druga ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s7	antacid	group	24-30	antacid	group	42-48	false	concurrent ingestion of druga ( dg ml of drugb containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	antacid	group	24-30	aluminum hydroxide	drug	61-78	false	concurrent ingestion of druga ( dg ml of antacid containing drugb , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	antacid	group	24-30	magnesium hydroxide	drug	81-99	false	concurrent ingestion of druga ( dg ml of antacid containing aluminum hydroxide , drugb , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	antacid	group	24-30	simethicone	drug	106-116	false	concurrent ingestion of druga ( dg ml of antacid containing aluminum hydroxide , magnesium hydroxide , and drugb ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	antacid	group	24-30	oxybutynin	drug	164-173	false	concurrent ingestion of druga ( dg ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of drugb or desethyloxybutynin .
DDI-DrugBank.d784.s7	antacid	group	24-30	desethyloxybutynin	drug_n	178-195	false	concurrent ingestion of druga ( dg ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or drugb .
DDI-DrugBank.d784.s7	antacid	group	42-48	aluminum hydroxide	drug	61-78	false	concurrent ingestion of antacid ( dg ml of druga containing drugb , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	antacid	group	42-48	magnesium hydroxide	drug	81-99	false	concurrent ingestion of antacid ( dg ml of druga containing aluminum hydroxide , drugb , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	antacid	group	42-48	simethicone	drug	106-116	false	concurrent ingestion of antacid ( dg ml of druga containing aluminum hydroxide , magnesium hydroxide , and drugb ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	antacid	group	42-48	oxybutynin	drug	164-173	false	concurrent ingestion of antacid ( dg ml of druga containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of drugb or desethyloxybutynin .
DDI-DrugBank.d784.s7	antacid	group	42-48	desethyloxybutynin	drug_n	178-195	false	concurrent ingestion of antacid ( dg ml of druga containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or drugb .
DDI-DrugBank.d784.s7	aluminum hydroxide	drug	61-78	magnesium hydroxide	drug	81-99	false	concurrent ingestion of antacid ( dg ml of antacid containing druga , drugb , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	aluminum hydroxide	drug	61-78	simethicone	drug	106-116	false	concurrent ingestion of antacid ( dg ml of antacid containing druga , magnesium hydroxide , and drugb ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	aluminum hydroxide	drug	61-78	oxybutynin	drug	164-173	false	concurrent ingestion of antacid ( dg ml of antacid containing druga , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of drugb or desethyloxybutynin .
DDI-DrugBank.d784.s7	aluminum hydroxide	drug	61-78	desethyloxybutynin	drug_n	178-195	false	concurrent ingestion of antacid ( dg ml of antacid containing druga , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or drugb .
DDI-DrugBank.d784.s7	magnesium hydroxide	drug	81-99	simethicone	drug	106-116	false	concurrent ingestion of antacid ( dg ml of antacid containing aluminum hydroxide , druga , and drugb ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7	magnesium hydroxide	drug	81-99	oxybutynin	drug	164-173	false	concurrent ingestion of antacid ( dg ml of antacid containing aluminum hydroxide , druga , and simethicone ) did not significantly affect the exposure of drugb or desethyloxybutynin .
DDI-DrugBank.d784.s7	magnesium hydroxide	drug	81-99	desethyloxybutynin	drug_n	178-195	false	concurrent ingestion of antacid ( dg ml of antacid containing aluminum hydroxide , druga , and simethicone ) did not significantly affect the exposure of oxybutynin or drugb .
DDI-DrugBank.d784.s7	simethicone	drug	106-116	oxybutynin	drug	164-173	false	concurrent ingestion of antacid ( dg ml of antacid containing aluminum hydroxide , magnesium hydroxide , and druga ) did not significantly affect the exposure of drugb or desethyloxybutynin .
DDI-DrugBank.d784.s7	simethicone	drug	106-116	desethyloxybutynin	drug_n	178-195	false	concurrent ingestion of antacid ( dg ml of antacid containing aluminum hydroxide , magnesium hydroxide , and druga ) did not significantly affect the exposure of oxybutynin or drugb .
DDI-DrugBank.d784.s7	oxybutynin	drug	164-173	desethyloxybutynin	drug_n	178-195	false	concurrent ingestion of antacid ( dg ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of druga or drugb .
DDI-DrugBank.d758.s0	oxycodone hydrochloride	drug	30-52	CNS depressants	group	89-103	effect	the cns depressant effects of druga may be additive with that of other drugb ..
DDI-DrugBank.d753.s0	CNS depressants	group	29-43	sedatives	group	55-63	false	the concomitant use of other druga including drugb , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	CNS depressants	group	29-43	hypnotics	group	66-74	false	the concomitant use of other druga including sedatives , drugb , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	CNS depressants	group	29-43	tranquilizers	group	77-89	false	the concomitant use of other druga including sedatives , hypnotics , drugb , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	CNS depressants	group	29-43	anesthetics	group	100-110	false	the concomitant use of other druga including sedatives , hypnotics , tranquilizers , general drugb , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	CNS depressants	group	29-43	phenothiazines	group	113-126	false	the concomitant use of other druga including sedatives , hypnotics , tranquilizers , general anesthetics , drugb , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	CNS depressants	group	29-43	opioids	group	135-141	false	the concomitant use of other druga including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other drugb , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	CNS depressants	group	29-43	tricyclic antidepressants	group	144-168	false	the concomitant use of other druga including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , drugb , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	CNS depressants	group	29-43	monoamine oxidase (MAO) inhibitors	group	171-204	false	the concomitant use of other druga including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , drugb , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	CNS depressants	group	29-43	alcohol	drug	211-217	false	the concomitant use of other druga including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	sedatives	group	55-63	hypnotics	group	66-74	false	the concomitant use of other cns depressants including druga , drugb , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	sedatives	group	55-63	tranquilizers	group	77-89	false	the concomitant use of other cns depressants including druga , hypnotics , drugb , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	sedatives	group	55-63	anesthetics	group	100-110	false	the concomitant use of other cns depressants including druga , hypnotics , tranquilizers , general drugb , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	sedatives	group	55-63	phenothiazines	group	113-126	false	the concomitant use of other cns depressants including druga , hypnotics , tranquilizers , general anesthetics , drugb , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	sedatives	group	55-63	opioids	group	135-141	false	the concomitant use of other cns depressants including druga , hypnotics , tranquilizers , general anesthetics , phenothiazines , other drugb , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	sedatives	group	55-63	tricyclic antidepressants	group	144-168	false	the concomitant use of other cns depressants including druga , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , drugb , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	sedatives	group	55-63	monoamine oxidase (MAO) inhibitors	group	171-204	false	the concomitant use of other cns depressants including druga , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , drugb , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	sedatives	group	55-63	alcohol	drug	211-217	false	the concomitant use of other cns depressants including druga , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	hypnotics	group	66-74	tranquilizers	group	77-89	false	the concomitant use of other cns depressants including sedatives , druga , drugb , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	hypnotics	group	66-74	anesthetics	group	100-110	false	the concomitant use of other cns depressants including sedatives , druga , tranquilizers , general drugb , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	hypnotics	group	66-74	phenothiazines	group	113-126	false	the concomitant use of other cns depressants including sedatives , druga , tranquilizers , general anesthetics , drugb , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	hypnotics	group	66-74	opioids	group	135-141	false	the concomitant use of other cns depressants including sedatives , druga , tranquilizers , general anesthetics , phenothiazines , other drugb , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	hypnotics	group	66-74	tricyclic antidepressants	group	144-168	false	the concomitant use of other cns depressants including sedatives , druga , tranquilizers , general anesthetics , phenothiazines , other opioids , drugb , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	hypnotics	group	66-74	monoamine oxidase (MAO) inhibitors	group	171-204	false	the concomitant use of other cns depressants including sedatives , druga , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , drugb , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	hypnotics	group	66-74	alcohol	drug	211-217	false	the concomitant use of other cns depressants including sedatives , druga , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	tranquilizers	group	77-89	anesthetics	group	100-110	false	the concomitant use of other cns depressants including sedatives , hypnotics , druga , general drugb , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	tranquilizers	group	77-89	phenothiazines	group	113-126	false	the concomitant use of other cns depressants including sedatives , hypnotics , druga , general anesthetics , drugb , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	tranquilizers	group	77-89	opioids	group	135-141	false	the concomitant use of other cns depressants including sedatives , hypnotics , druga , general anesthetics , phenothiazines , other drugb , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	tranquilizers	group	77-89	tricyclic antidepressants	group	144-168	false	the concomitant use of other cns depressants including sedatives , hypnotics , druga , general anesthetics , phenothiazines , other opioids , drugb , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	tranquilizers	group	77-89	monoamine oxidase (MAO) inhibitors	group	171-204	false	the concomitant use of other cns depressants including sedatives , hypnotics , druga , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , drugb , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	tranquilizers	group	77-89	alcohol	drug	211-217	false	the concomitant use of other cns depressants including sedatives , hypnotics , druga , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	anesthetics	group	100-110	phenothiazines	group	113-126	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general druga , drugb , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	anesthetics	group	100-110	opioids	group	135-141	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general druga , phenothiazines , other drugb , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	anesthetics	group	100-110	tricyclic antidepressants	group	144-168	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general druga , phenothiazines , other opioids , drugb , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	anesthetics	group	100-110	monoamine oxidase (MAO) inhibitors	group	171-204	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general druga , phenothiazines , other opioids , tricyclic antidepressants , drugb , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	anesthetics	group	100-110	alcohol	drug	211-217	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general druga , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	phenothiazines	group	113-126	opioids	group	135-141	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , druga , other drugb , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	phenothiazines	group	113-126	tricyclic antidepressants	group	144-168	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , druga , other opioids , drugb , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	phenothiazines	group	113-126	monoamine oxidase (MAO) inhibitors	group	171-204	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , druga , other opioids , tricyclic antidepressants , drugb , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	phenothiazines	group	113-126	alcohol	drug	211-217	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , druga , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	opioids	group	135-141	tricyclic antidepressants	group	144-168	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other druga , drugb , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	opioids	group	135-141	monoamine oxidase (MAO) inhibitors	group	171-204	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other druga , tricyclic antidepressants , drugb , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	opioids	group	135-141	alcohol	drug	211-217	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other druga , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	tricyclic antidepressants	group	144-168	monoamine oxidase (MAO) inhibitors	group	171-204	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , druga , drugb , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	tricyclic antidepressants	group	144-168	alcohol	drug	211-217	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , druga , monoamine oxidase ( mao ) inhibitors , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s0	monoamine oxidase (MAO) inhibitors	group	171-204	alcohol	drug	211-217	false	the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , druga , and drugb may produce additive cns depressant effects .
DDI-DrugBank.d753.s2	Anticholinergics	group	0-15	opioid analgesics	group	96-112	effect	druga or other medications with anticholinergic activity when used concurrently with drugb may result in increased risk of urinary retention and / or severe constipation , which may lead to paralytic ileus .
DDI-DrugBank.d753.s3	oxymorphone	drug	74-84	propofol	drug	104-111	effect	it has been reported that the incidence of bradycardia was increased when druga was combined with drugb for induction of anesthesia .
DDI-DrugBank.d753.s4	cimetidine	drug	143-152	opioid analgesics	group	159-175	effect	in addition , cns toxicity has been reported ( confusion , disorientation , respiratory depression , apnea , seizures ) following coadministration of druga with drugb ;
DDI-DrugBank.d670.s0	INVEGA	brand	14-19	Paliperidone	drug	46-57	false	potential for druga to affect other drugs drugb is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome p450 isozymes .
DDI-DrugBank.d670.s6	paliperidone	drug	33-44	INVEGA	brand	47-52	false	given the primary cns effects of druga , drugb should be used with caution in combination with other centrally acting drugs and alcohol .
DDI-DrugBank.d670.s6	paliperidone	drug	33-44	centrally acting drugs	group	111-132	advise	given the primary cns effects of druga , invega should be used with caution in combination with other drugb and alcohol .
DDI-DrugBank.d670.s6	paliperidone	drug	33-44	alcohol	drug	138-144	advise	given the primary cns effects of druga , invega should be used with caution in combination with other centrally acting drugs and drugb .
DDI-DrugBank.d670.s6	INVEGA	brand	47-52	centrally acting drugs	group	111-132	advise	given the primary cns effects of paliperidone , druga should be used with caution in combination with other drugb and alcohol .
DDI-DrugBank.d670.s6	INVEGA	brand	47-52	alcohol	drug	138-144	advise	given the primary cns effects of paliperidone , druga should be used with caution in combination with other centrally acting drugs and drugb .
DDI-DrugBank.d670.s6	centrally acting drugs	group	111-132	alcohol	drug	138-144	false	given the primary cns effects of paliperidone , invega should be used with caution in combination with other druga and drugb .
DDI-DrugBank.d670.s7	Paliperidone	drug	0-11	levodopa	drug	42-49	effect	druga may antagonize the effect of drugb and other dopamine agonists .
DDI-DrugBank.d670.s7	Paliperidone	drug	0-11	dopamine agonists	group	61-77	effect	druga may antagonize the effect of levodopa and other drugb .
DDI-DrugBank.d670.s7	levodopa	drug	42-49	dopamine agonists	group	61-77	false	paliperidone may antagonize the effect of druga and other drugb .
DDI-DrugBank.d670.s9	INVEGA	brand	36-41	Paliperidone	drug	46-57	false	potential for other drugs to affect druga drugb is not a substrate of cyp1a2 , cyp2a6 , cyp2c9 , and cyp2c19 , so that an interaction with inhibitors or inducers of these isozymes is unlikely .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	theophylline	drug	154-165	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugb , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	cisapride	drug	168-176	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , drugb , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	antipyrine	drug	179-188	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , drugb , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	caffeine	drug	191-198	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , drugb , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	carbamazepine	drug	201-213	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , drugb , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	diazepam	drug	216-223	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , drugb ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	desmethyldiazepam	drug_n	253-269	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , drugb ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	diclofenac	drug	273-282	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , drugb , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	naproxen	drug	285-292	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , drugb , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	digoxin	drug	306-312	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	ethanol	drug	315-321	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	glyburide	drug	324-332	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	contraceptive	group	343-355	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	warfarin	drug	428-435	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	midazolam	drug	438-446	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	pantoprazole	drug	53-64	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	cisapride	drug	168-176	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugb , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	antipyrine	drug	179-188	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , drugb , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	caffeine	drug	191-198	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , drugb , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	carbamazepine	drug	201-213	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , drugb , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	diazepam	drug	216-223	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , drugb ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	desmethyldiazepam	drug_n	253-269	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , drugb ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	diclofenac	drug	273-282	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , drugb , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	naproxen	drug	285-292	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , drugb , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	theophylline	drug	154-165	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	antipyrine	drug	179-188	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , drugb , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	caffeine	drug	191-198	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , drugb , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	carbamazepine	drug	201-213	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , drugb , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	diazepam	drug	216-223	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , drugb ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	desmethyldiazepam	drug_n	253-269	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , drugb ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	diclofenac	drug	273-282	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , drugb , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	naproxen	drug	285-292	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , drugb , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	cisapride	drug	168-176	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , druga , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	caffeine	drug	191-198	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , drugb , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	carbamazepine	drug	201-213	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , drugb , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	diazepam	drug	216-223	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , drugb ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	desmethyldiazepam	drug_n	253-269	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , drugb ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	diclofenac	drug	273-282	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , drugb , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	naproxen	drug	285-292	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , drugb , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	antipyrine	drug	179-188	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , druga , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	carbamazepine	drug	201-213	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , drugb , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	diazepam	drug	216-223	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , drugb ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	desmethyldiazepam	drug_n	253-269	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , drugb ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	diclofenac	drug	273-282	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , drugb , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	naproxen	drug	285-292	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , drugb , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	caffeine	drug	191-198	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , druga , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	diazepam	drug	216-223	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , drugb ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	desmethyldiazepam	drug_n	253-269	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , drugb ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	diclofenac	drug	273-282	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , drugb , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	naproxen	drug	285-292	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , drugb , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	carbamazepine	drug	201-213	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , druga , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	desmethyldiazepam	drug_n	253-269	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , drugb ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	diclofenac	drug	273-282	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , drugb , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	naproxen	drug	285-292	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , drugb , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	diazepam	drug	216-223	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , druga ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	diclofenac	drug	273-282	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , drugb , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	naproxen	drug	285-292	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , drugb , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	desmethyldiazepam	drug_n	253-269	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , druga ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	naproxen	drug	285-292	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , drugb , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	diclofenac	drug	273-282	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , druga , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	piroxicam	drug	295-303	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , drugb , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	naproxen	drug	285-292	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , druga , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	digoxin	drug	306-312	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , drugb , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	piroxicam	drug	295-303	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , druga , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	ethanol	drug	315-321	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , drugb , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	digoxin	drug	306-312	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , druga , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	glyburide	drug	324-332	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , drugb , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	ethanol	drug	315-321	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , druga , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	contraceptive	group	343-355	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral drugb ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	glyburide	drug	324-332	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , druga , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	levonorgestrel	drug	358-371	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( drugb / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( levonorgestrel / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( levonorgestrel / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( levonorgestrel / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	contraceptive	group	343-355	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral druga ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	levonorgestrel	drug	358-371	ethinyl estradiol	drug	373-389	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( druga / drugb ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	levonorgestrel	drug	358-371	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( druga / ethinyl estradiol ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	levonorgestrel	drug	358-371	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( druga / ethinyl estradiol ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	levonorgestrel	drug	358-371	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( druga / ethinyl estradiol ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	levonorgestrel	drug	358-371	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( druga / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	levonorgestrel	drug	358-371	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( druga / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	levonorgestrel	drug	358-371	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( druga / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	levonorgestrel	drug	358-371	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( druga / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	levonorgestrel	drug	358-371	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( druga / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	ethinyl estradiol	drug	373-389	metoprolol	drug	393-402	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / druga ) , drugb , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethinyl estradiol	drug	373-389	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / druga ) , metoprolol , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethinyl estradiol	drug	373-389	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / druga ) , metoprolol , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethinyl estradiol	drug	373-389	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / druga ) , metoprolol , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethinyl estradiol	drug	373-389	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / druga ) , metoprolol , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethinyl estradiol	drug	373-389	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / druga ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	ethinyl estradiol	drug	373-389	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / druga ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	ethinyl estradiol	drug	373-389	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / druga ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	metoprolol	drug	393-402	nifedipine	drug	405-414	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , druga , drugb , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	metoprolol	drug	393-402	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , druga , nifedipine , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	metoprolol	drug	393-402	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , druga , nifedipine , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	metoprolol	drug	393-402	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , druga , nifedipine , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	metoprolol	drug	393-402	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , druga , nifedipine , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	metoprolol	drug	393-402	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , druga , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	metoprolol	drug	393-402	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , druga , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	nifedipine	drug	405-414	phenytoin	drug	417-425	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , druga , drugb , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	nifedipine	drug	405-414	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , druga , phenytoin , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	nifedipine	drug	405-414	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , druga , phenytoin , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	nifedipine	drug	405-414	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , druga , phenytoin , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	nifedipine	drug	405-414	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , druga , phenytoin , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	nifedipine	drug	405-414	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , druga , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	phenytoin	drug	417-425	warfarin	drug	428-435	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , druga , drugb , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	phenytoin	drug	417-425	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , druga , warfarin , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	phenytoin	drug	417-425	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , druga , warfarin , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	phenytoin	drug	417-425	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , druga , warfarin , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	phenytoin	drug	417-425	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , druga , warfarin , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	warfarin	drug	428-435	midazolam	drug	438-446	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , druga , drugb , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	warfarin	drug	428-435	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , druga , midazolam , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	warfarin	drug	428-435	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , druga , midazolam , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	warfarin	drug	428-435	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , druga , midazolam , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	midazolam	drug	438-446	clarithromycin	drug	449-462	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , druga , drugb , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1	midazolam	drug	438-446	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , druga , clarithromycin , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	midazolam	drug	438-446	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , druga , clarithromycin , metronidazole , or drugb .
DDI-DrugBank.d680.s1	clarithromycin	drug	449-462	metronidazole	drug	465-477	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , druga , drugb , or amoxicillin .
DDI-DrugBank.d680.s1	clarithromycin	drug	449-462	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , druga , metronidazole , or drugb .
DDI-DrugBank.d680.s1	metronidazole	drug	465-477	amoxicillin	drug	483-493	false	based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , druga , or drugb .
DDI-DrugBank.d680.s3	pantoprazole	drug	36-47	pantoprazole	drug	78-89	false	therefore , when coadministered with druga , adjustment of the dosage of drugb or of such drugs may not be necessary .
DDI-DrugBank.d680.s5	proton pump inhibitors	group	98-119	pantoprazole	drug	132-143	false	there have been postmarketing reports of increased inr and prothrombin time in patients receiving druga , including drugb , and warfarin concomitantly .
DDI-DrugBank.d680.s5	proton pump inhibitors	group	98-119	warfarin	drug	150-157	effect	there have been postmarketing reports of increased inr and prothrombin time in patients receiving druga , including pantoprazole , and drugb concomitantly .
DDI-DrugBank.d680.s5	pantoprazole	drug	132-143	warfarin	drug	150-157	effect	there have been postmarketing reports of increased inr and prothrombin time in patients receiving proton pump inhibitors , including druga , and drugb concomitantly .
DDI-DrugBank.d680.s7	proton pump inhibitors	group	22-43	warfarin	drug	49-56	advise	patients treated with druga and drugb concomitantly should be monitored for increases in inr and prothrombin time .
DDI-DrugBank.d680.s8	pantoprazole	drug	75-86	ketoconazole	drug	202-213	mechanism	because of profound and long lasting inhibition of gastric acid secretion , druga may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , drugb , ampicillin esters , and iron salts ) .
DDI-DrugBank.d680.s8	pantoprazole	drug	75-86	ampicillin	drug	216-225	mechanism	because of profound and long lasting inhibition of gastric acid secretion , druga may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , ketoconazole , drugb esters , and iron salts ) .
DDI-DrugBank.d680.s8	pantoprazole	drug	75-86	iron	drug	239-242	mechanism	because of profound and long lasting inhibition of gastric acid secretion , druga may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , ketoconazole , ampicillin esters , and drugb salts ) .
DDI-DrugBank.d680.s8	ketoconazole	drug	202-213	ampicillin	drug	216-225	false	because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , druga , drugb esters , and iron salts ) .
DDI-DrugBank.d680.s8	ketoconazole	drug	202-213	iron	drug	239-242	false	because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , druga , ampicillin esters , and drugb salts ) .
DDI-DrugBank.d680.s8	ampicillin	drug	216-225	iron	drug	239-242	false	because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , ketoconazole , druga esters , and drugb salts ) .
DDI-DrugBank.d680.s9	tetrahydrocannabinol	drug	85-104	THC	drug	107-109	false	laboratory tests there have been reports of false positive urine screening tests for druga ( drugb ) in patients receiving most proton pump inhibitors , including pantoprazole .
DDI-DrugBank.d680.s9	tetrahydrocannabinol	drug	85-104	proton pump inhibitors	group	139-160	false	laboratory tests there have been reports of false positive urine screening tests for druga ( thc ) in patients receiving most drugb , including pantoprazole .
DDI-DrugBank.d680.s9	tetrahydrocannabinol	drug	85-104	pantoprazole	drug	173-184	false	laboratory tests there have been reports of false positive urine screening tests for druga ( thc ) in patients receiving most proton pump inhibitors , including drugb .
DDI-DrugBank.d680.s9	THC	drug	107-109	proton pump inhibitors	group	139-160	false	laboratory tests there have been reports of false positive urine screening tests for tetrahydrocannabinol ( druga ) in patients receiving most drugb , including pantoprazole .
DDI-DrugBank.d680.s9	THC	drug	107-109	pantoprazole	drug	173-184	false	laboratory tests there have been reports of false positive urine screening tests for tetrahydrocannabinol ( druga ) in patients receiving most proton pump inhibitors , including drugb .
DDI-DrugBank.d680.s9	proton pump inhibitors	group	139-160	pantoprazole	drug	173-184	false	laboratory tests there have been reports of false positive urine screening tests for tetrahydrocannabinol ( thc ) in patients receiving most druga , including drugb .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	paricalcitol	drug	97-108	mechanism	a multiple dose drug drug interaction study demonstrated that druga approximately doubled drugb auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	paricalcitol	drug	126-137	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since drugb is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	ketoconazole	drug	177-188	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and drugb le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	paricalcitol	drug	291-302	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugb with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	ketoconazole	drug	309-320	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with drugb and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	atazanavir	drug	368-377	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including drugb , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	clarithromycin	drug	380-393	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , drugb , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	indinavir	drug	396-404	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , drugb , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	itraconazole	drug	407-418	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	nefazodone	drug	421-430	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	62-73	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that druga approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	paricalcitol	drug	126-137	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since drugb is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	ketoconazole	drug	177-188	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and drugb le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	paricalcitol	drug	291-302	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugb with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	ketoconazole	drug	309-320	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with drugb and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	atazanavir	drug	368-377	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including drugb , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	clarithromycin	drug	380-393	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , drugb , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	indinavir	drug	396-404	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , drugb , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	itraconazole	drug	407-418	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	nefazodone	drug	421-430	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	97-108	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled druga auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	ketoconazole	drug	177-188	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and drugb le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	paricalcitol	drug	291-302	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugb with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	ketoconazole	drug	309-320	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with drugb and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	atazanavir	drug	368-377	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including drugb , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	clarithromycin	drug	380-393	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , drugb , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	indinavir	drug	396-404	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , drugb , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	itraconazole	drug	407-418	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	nefazodone	drug	421-430	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	126-137	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since druga is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	paricalcitol	drug	291-302	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugb with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	ketoconazole	drug	309-320	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with drugb and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	atazanavir	drug	368-377	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including drugb , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	clarithromycin	drug	380-393	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , drugb , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	indinavir	drug	396-404	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , drugb , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	itraconazole	drug	407-418	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	nefazodone	drug	421-430	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	177-188	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	ketoconazole	drug	309-320	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugb and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	atazanavir	drug	368-377	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including drugb , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	clarithromycin	drug	380-393	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including atazanavir , drugb , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	indinavir	drug	396-404	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , drugb , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	itraconazole	drug	407-418	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	nefazodone	drug	421-430	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	nelfinavir	drug	433-442	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	ritonavir	drug	445-453	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	saquinavir	drug	456-465	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	telithromycin	drug	468-480	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	paricalcitol	drug	291-302	voriconazole	drug	485-496	advise	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	atazanavir	drug	368-377	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including drugb , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	clarithromycin	drug	380-393	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including atazanavir , drugb , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	indinavir	drug	396-404	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including atazanavir , clarithromycin , drugb , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	itraconazole	drug	407-418	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	nefazodone	drug	421-430	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	ketoconazole	drug	309-320	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with druga and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	atazanavir	drug	368-377	clarithromycin	drug	380-393	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including druga , drugb , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	atazanavir	drug	368-377	indinavir	drug	396-404	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including druga , clarithromycin , drugb , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	atazanavir	drug	368-377	itraconazole	drug	407-418	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including druga , clarithromycin , indinavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	atazanavir	drug	368-377	nefazodone	drug	421-430	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including druga , clarithromycin , indinavir , itraconazole , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	atazanavir	drug	368-377	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including druga , clarithromycin , indinavir , itraconazole , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	atazanavir	drug	368-377	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including druga , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	atazanavir	drug	368-377	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including druga , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	atazanavir	drug	368-377	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including druga , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	atazanavir	drug	368-377	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including druga , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	clarithromycin	drug	380-393	indinavir	drug	396-404	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , druga , drugb , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	clarithromycin	drug	380-393	itraconazole	drug	407-418	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , druga , indinavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	clarithromycin	drug	380-393	nefazodone	drug	421-430	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , druga , indinavir , itraconazole , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	clarithromycin	drug	380-393	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , druga , indinavir , itraconazole , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	clarithromycin	drug	380-393	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , druga , indinavir , itraconazole , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	clarithromycin	drug	380-393	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , druga , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	clarithromycin	drug	380-393	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , druga , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	clarithromycin	drug	380-393	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , druga , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	indinavir	drug	396-404	itraconazole	drug	407-418	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , druga , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	indinavir	drug	396-404	nefazodone	drug	421-430	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , druga , itraconazole , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	indinavir	drug	396-404	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , druga , itraconazole , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	indinavir	drug	396-404	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , druga , itraconazole , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	indinavir	drug	396-404	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , druga , itraconazole , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	indinavir	drug	396-404	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , druga , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	indinavir	drug	396-404	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , druga , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	itraconazole	drug	407-418	nefazodone	drug	421-430	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , druga , drugb , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	itraconazole	drug	407-418	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , druga , nefazodone , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	itraconazole	drug	407-418	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , druga , nefazodone , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	itraconazole	drug	407-418	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , druga , nefazodone , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	itraconazole	drug	407-418	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , druga , nefazodone , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	itraconazole	drug	407-418	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , druga , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	nefazodone	drug	421-430	nelfinavir	drug	433-442	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , druga , drugb , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	nefazodone	drug	421-430	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , druga , nelfinavir , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	nefazodone	drug	421-430	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , druga , nelfinavir , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	nefazodone	drug	421-430	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , druga , nelfinavir , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	nefazodone	drug	421-430	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , druga , nelfinavir , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	nelfinavir	drug	433-442	ritonavir	drug	445-453	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , druga , drugb , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	nelfinavir	drug	433-442	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , druga , ritonavir , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	nelfinavir	drug	433-442	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , druga , ritonavir , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	nelfinavir	drug	433-442	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , druga , ritonavir , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	ritonavir	drug	445-453	saquinavir	drug	456-465	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , druga , drugb , telithromycin or voriconazole .
DDI-DrugBank.d726.s1	ritonavir	drug	445-453	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , druga , saquinavir , drugb or voriconazole .
DDI-DrugBank.d726.s1	ritonavir	drug	445-453	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , druga , saquinavir , telithromycin or drugb .
DDI-DrugBank.d726.s1	saquinavir	drug	456-465	telithromycin	drug	468-480	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , druga , drugb or voriconazole .
DDI-DrugBank.d726.s1	saquinavir	drug	456-465	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , druga , telithromycin or drugb .
DDI-DrugBank.d726.s1	telithromycin	drug	468-480	voriconazole	drug	485-496	false	a multiple dose drug drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0 . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , druga or drugb .
DDI-DrugBank.d726.s2	Zemplar	brand	19-25	ketoconazole	drug	209-220	advise	dose adjustment of druga capsules may be required , and ipth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor such as drugb .
DDI-DrugBank.d726.s3	fat-soluble vitamins	group	43-62	cholestyramine	drug	73-86	mechanism	drugs that impair intestinal absorption of druga , such as drugb , may interfere with the absorption of zemplar capsules .
DDI-DrugBank.d726.s3	fat-soluble vitamins	group	43-62	Zemplar	brand	126-132	false	drugs that impair intestinal absorption of druga , such as cholestyramine , may interfere with the absorption of drugb capsules .
DDI-DrugBank.d726.s3	cholestyramine	drug	73-86	Zemplar	brand	126-132	mechanism	drugs that impair intestinal absorption of fat soluble vitamins , such as druga , may interfere with the absorption of drugb capsules .
DDI-DrugBank.d581.s2	lithium	drug	19-25	Neulasta	brand	31-38	advise	patients receiving druga and drugb should have more frequent monitoring of neutrophil counts .
DDI-DrugBank.d741.s0	methadone	drug	86-94	PEG-Intron	brand	112-121	mechanism	in a pharmacokinetic study of dg chronic hepatitis c patients concomitantly receiving druga , treatment with drugb once weekly for dg weeks was associated with a mean increase of dg % in methadone auc ;
DDI-DrugBank.d741.s0	methadone	drug	86-94	methadone	drug	193-201	false	in a pharmacokinetic study of dg chronic hepatitis c patients concomitantly receiving druga , treatment with peg intron once weekly for dg weeks was associated with a mean increase of dg % in drugb auc ;
DDI-DrugBank.d741.s0	PEG-Intron	brand	112-121	methadone	drug	193-201	false	in a pharmacokinetic study of dg chronic hepatitis c patients concomitantly receiving methadone , treatment with druga once weekly for dg weeks was associated with a mean increase of dg % in drugb auc ;
DDI-DrugBank.d744.s0	insulin	drug	63-69	hypoglycemic	group	83-94	false	acromegalic patients with diabetes mellitus being treated with druga and / or oral drugb agents may require dose reductions of these therapeutic agents after the initiation of therapy with somavert .
DDI-DrugBank.d744.s0	insulin	drug	63-69	SOMAVERT	brand	196-203	advise	acromegalic patients with diabetes mellitus being treated with druga and / or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with drugb .
DDI-DrugBank.d744.s0	hypoglycemic	group	83-94	SOMAVERT	brand	196-203	advise	acromegalic patients with diabetes mellitus being treated with insulin and / or oral druga agents may require dose reductions of these therapeutic agents after the initiation of therapy with drugb .
DDI-DrugBank.d744.s1	opioids	group	33-39	pegvisomant	drug	67-77	mechanism	in clinical studies , patients on druga often needed higher serum drugb concentrations to achieve appropriate igf i suppression compared with patients not receiving opioids .
DDI-DrugBank.d744.s1	opioids	group	33-39	opioids	group	172-178	false	in clinical studies , patients on druga often needed higher serum pegvisomant concentrations to achieve appropriate igf i suppression compared with patients not receiving drugb .
DDI-DrugBank.d744.s1	pegvisomant	drug	67-77	opioids	group	172-178	false	in clinical studies , patients on opioids often needed higher serum druga concentrations to achieve appropriate igf i suppression compared with patients not receiving drugb .
DDI-DrugBank.d641.s2	probenecid	drug	81-90	ALIMTA	brand	142-147	mechanism	concomitant administration of substances that are also tubularly secreted ( e.g. , druga ) could potentially result in delayed clearance of drugb .
DDI-DrugBank.d641.s3	ibuprofen	drug	9-17	ALIMTA	brand	57-62	false	although druga ( dg mg qid ) can be administered with drugb in patients with normal renal function ( creatinine clearance dg ml / min ) , caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency ( creatinine clearance from dg to dg ml / min ) .
DDI-DrugBank.d641.s3	ibuprofen	drug	9-17	ibuprofen	drug	182-190	false	although druga ( dg mg qid ) can be administered with alimta in patients with normal renal function ( creatinine clearance dg ml / min ) , caution should be used when administering drugb concurrently with alimta to patients with mild to moderate renal insufficiency ( creatinine clearance from dg to dg ml / min ) .
DDI-DrugBank.d641.s3	ibuprofen	drug	9-17	ALIMTA	brand	210-215	false	although druga ( dg mg qid ) can be administered with alimta in patients with normal renal function ( creatinine clearance dg ml / min ) , caution should be used when administering ibuprofen concurrently with drugb to patients with mild to moderate renal insufficiency ( creatinine clearance from dg to dg ml / min ) .
DDI-DrugBank.d641.s3	ALIMTA	brand	57-62	ibuprofen	drug	182-190	false	although ibuprofen ( dg mg qid ) can be administered with druga in patients with normal renal function ( creatinine clearance dg ml / min ) , caution should be used when administering drugb concurrently with alimta to patients with mild to moderate renal insufficiency ( creatinine clearance from dg to dg ml / min ) .
DDI-DrugBank.d641.s3	ALIMTA	brand	57-62	ALIMTA	brand	210-215	false	although ibuprofen ( dg mg qid ) can be administered with druga in patients with normal renal function ( creatinine clearance dg ml / min ) , caution should be used when administering ibuprofen concurrently with drugb to patients with mild to moderate renal insufficiency ( creatinine clearance from dg to dg ml / min ) .
DDI-DrugBank.d641.s3	ibuprofen	drug	182-190	ALIMTA	brand	210-215	advise	although ibuprofen ( dg mg qid ) can be administered with alimta in patients with normal renal function ( creatinine clearance dg ml / min ) , caution should be used when administering druga concurrently with drugb to patients with mild to moderate renal insufficiency ( creatinine clearance from dg to dg ml / min ) .
DDI-DrugBank.d641.s4	NSAIDs	group	71-76	ALIMTA	brand	194-199	advise	patients with mild to moderate renal insufficiency should avoid taking druga with short elimination half lives for a period of dg days before , the day of , and dg days following administration of drugb .
DDI-DrugBank.d641.s5	ALIMTA	brand	63-68	NSAIDs	group	74-79	false	in the absence of data regarding potential interaction between druga and drugb with longer half lives , all patients taking these nsaids should interrupt dosing for at least dg days before , the day of , and dg days following alimta administration .
DDI-DrugBank.d641.s5	ALIMTA	brand	63-68	NSAIDs	group	131-136	false	in the absence of data regarding potential interaction between druga and nsaids with longer half lives , all patients taking these drugb should interrupt dosing for at least dg days before , the day of , and dg days following alimta administration .
DDI-DrugBank.d641.s5	ALIMTA	brand	63-68	ALIMTA	brand	223-228	false	in the absence of data regarding potential interaction between druga and nsaids with longer half lives , all patients taking these nsaids should interrupt dosing for at least dg days before , the day of , and dg days following drugb administration .
DDI-DrugBank.d641.s5	NSAIDs	group	74-79	NSAIDs	group	131-136	false	in the absence of data regarding potential interaction between alimta and druga with longer half lives , all patients taking these drugb should interrupt dosing for at least dg days before , the day of , and dg days following alimta administration .
DDI-DrugBank.d641.s5	NSAIDs	group	74-79	ALIMTA	brand	223-228	false	in the absence of data regarding potential interaction between alimta and druga with longer half lives , all patients taking these nsaids should interrupt dosing for at least dg days before , the day of , and dg days following drugb administration .
DDI-DrugBank.d641.s5	NSAIDs	group	131-136	ALIMTA	brand	223-228	advise	in the absence of data regarding potential interaction between alimta and nsaids with longer half lives , all patients taking these druga should interrupt dosing for at least dg days before , the day of , and dg days following drugb administration .
DDI-DrugBank.d671.s0	CYLERT	brand	19-24	pemoline	drug	27-34	false	the interaction of druga ( drugb ) with other drugs has not been studied in humans .
DDI-DrugBank.d671.s2	CYLERT	brand	68-73	antiepileptic medications	group	94-118	effect	decreased seizure threshold has been reported in patients receiving druga concomitantly with drugb .
DDI-DrugBank.d665.s0	bacteriostatic antibiotics	group	29-54	erythromycin	drug	63-74	false	concurrent administration of druga ( e.g. , drugb , tetracycline ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0	bacteriostatic antibiotics	group	29-54	tetracycline	drug	77-88	false	concurrent administration of druga ( e.g. , erythromycin , drugb ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0	bacteriostatic antibiotics	group	29-54	penicillins	group	132-142	effect	concurrent administration of druga ( e.g. , erythromycin , tetracycline ) may diminish the bactericidal effects of drugb by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0	erythromycin	drug	63-74	tetracycline	drug	77-88	false	concurrent administration of bacteriostatic antibiotics ( e.g. , druga , drugb ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0	erythromycin	drug	63-74	penicillins	group	132-142	effect	concurrent administration of bacteriostatic antibiotics ( e.g. , druga , tetracycline ) may diminish the bactericidal effects of drugb by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0	tetracycline	drug	77-88	penicillins	group	132-142	effect	concurrent administration of bacteriostatic antibiotics ( e.g. , erythromycin , druga ) may diminish the bactericidal effects of drugb by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s6	Penicillin	group	0-9	probenecid	drug	73-82	mechanism	druga blood levels may be prolonged by concurrent administration of drugb which blocks the renal tubular secretion of penicillins .
DDI-DrugBank.d665.s6	Penicillin	group	0-9	penicillins	group	128-138	false	druga blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of drugb .
DDI-DrugBank.d665.s6	probenecid	drug	73-82	penicillins	group	128-138	false	penicillin blood levels may be prolonged by concurrent administration of druga which blocks the renal tubular secretion of drugb .
DDI-DrugBank.d665.s7	penicillin	group	16-25	penicillin	group	92-101	false	displacement of druga from plasma protein binding sites will elevate the level of free drugb in the serum .
DDI-DrugBank.d757.s0	Alcohol	drug	11-17	alcohol	drug	80-86	false	usage with druga : due to the potential for increased cns depressants effects , drugb should be used with caution in patients who are currently receiving pentazocine .
DDI-DrugBank.d757.s0	Alcohol	drug	11-17	pentazocine	drug	156-166	false	usage with druga : due to the potential for increased cns depressants effects , alcohol should be used with caution in patients who are currently receiving drugb .
DDI-DrugBank.d757.s0	alcohol	drug	80-86	pentazocine	drug	156-166	advise	usage with alcohol : due to the potential for increased cns depressants effects , druga should be used with caution in patients who are currently receiving drugb .
DDI-DrugBank.d659.s0	TRENTAL	brand	152-158	anticoagulants	group	177-190	effect	although a causal relationship has not been established , there have been reports of bleeding and / or prolonged prothrombin time in patients treated with druga with and without drugb or platelet aggregation inhibitors .
DDI-DrugBank.d659.s0	TRENTAL	brand	152-158	platelet aggregation inhibitors	group	195-225	effect	although a causal relationship has not been established , there have been reports of bleeding and / or prolonged prothrombin time in patients treated with druga with and without anticoagulants or drugb .
DDI-DrugBank.d659.s0	anticoagulants	group	177-190	platelet aggregation inhibitors	group	195-225	false	although a causal relationship has not been established , there have been reports of bleeding and / or prolonged prothrombin time in patients treated with trental with and without druga or drugb .
DDI-DrugBank.d659.s2	TRENTAL	brand	30-36	theophylline	drug	42-53	mechanism	concomitant administration of druga and drugb containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals .
DDI-DrugBank.d659.s2	TRENTAL	brand	30-36	theophylline	drug	91-102	false	concomitant administration of druga and theophylline containing drugs leads to increased drugb levels and theophylline toxicity in some individuals .
DDI-DrugBank.d659.s2	TRENTAL	brand	30-36	theophylline	drug	115-126	false	concomitant administration of druga and theophylline containing drugs leads to increased theophylline levels and drugb toxicity in some individuals .
DDI-DrugBank.d659.s2	theophylline	drug	42-53	theophylline	drug	91-102	false	concomitant administration of trental and druga containing drugs leads to increased drugb levels and theophylline toxicity in some individuals .
DDI-DrugBank.d659.s2	theophylline	drug	42-53	theophylline	drug	115-126	false	concomitant administration of trental and druga containing drugs leads to increased theophylline levels and drugb toxicity in some individuals .
DDI-DrugBank.d659.s2	theophylline	drug	91-102	theophylline	drug	115-126	false	concomitant administration of trental and theophylline containing drugs leads to increased druga levels and drugb toxicity in some individuals .
DDI-DrugBank.d659.s4	TRENTAL	brand	0-6	antihypertensive drugs	group	40-61	false	druga has been used concurrently with drugb , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	TRENTAL	brand	0-6	beta blockers	group	64-76	false	druga has been used concurrently with antihypertensive drugs , drugb , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	TRENTAL	brand	0-6	digitalis	group	79-87	false	druga has been used concurrently with antihypertensive drugs , beta blockers , drugb , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	TRENTAL	brand	0-6	diuretics	group	90-98	false	druga has been used concurrently with antihypertensive drugs , beta blockers , digitalis , drugb , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	TRENTAL	brand	0-6	antidiabetic agents	group	101-119	false	druga has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , drugb , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	TRENTAL	brand	0-6	antiarrhythmics	group	126-140	false	druga has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and drugb , without observed problems .
DDI-DrugBank.d659.s4	antihypertensive drugs	group	40-61	beta blockers	group	64-76	false	trental has been used concurrently with druga , drugb , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	antihypertensive drugs	group	40-61	digitalis	group	79-87	false	trental has been used concurrently with druga , beta blockers , drugb , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	antihypertensive drugs	group	40-61	diuretics	group	90-98	false	trental has been used concurrently with druga , beta blockers , digitalis , drugb , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	antihypertensive drugs	group	40-61	antidiabetic agents	group	101-119	false	trental has been used concurrently with druga , beta blockers , digitalis , diuretics , drugb , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	antihypertensive drugs	group	40-61	antiarrhythmics	group	126-140	false	trental has been used concurrently with druga , beta blockers , digitalis , diuretics , antidiabetic agents , and drugb , without observed problems .
DDI-DrugBank.d659.s4	beta blockers	group	64-76	digitalis	group	79-87	false	trental has been used concurrently with antihypertensive drugs , druga , drugb , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	beta blockers	group	64-76	diuretics	group	90-98	false	trental has been used concurrently with antihypertensive drugs , druga , digitalis , drugb , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	beta blockers	group	64-76	antidiabetic agents	group	101-119	false	trental has been used concurrently with antihypertensive drugs , druga , digitalis , diuretics , drugb , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	beta blockers	group	64-76	antiarrhythmics	group	126-140	false	trental has been used concurrently with antihypertensive drugs , druga , digitalis , diuretics , antidiabetic agents , and drugb , without observed problems .
DDI-DrugBank.d659.s4	digitalis	group	79-87	diuretics	group	90-98	false	trental has been used concurrently with antihypertensive drugs , beta blockers , druga , drugb , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	digitalis	group	79-87	antidiabetic agents	group	101-119	false	trental has been used concurrently with antihypertensive drugs , beta blockers , druga , diuretics , drugb , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	digitalis	group	79-87	antiarrhythmics	group	126-140	false	trental has been used concurrently with antihypertensive drugs , beta blockers , druga , diuretics , antidiabetic agents , and drugb , without observed problems .
DDI-DrugBank.d659.s4	diuretics	group	90-98	antidiabetic agents	group	101-119	false	trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , druga , drugb , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4	diuretics	group	90-98	antiarrhythmics	group	126-140	false	trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , druga , antidiabetic agents , and drugb , without observed problems .
DDI-DrugBank.d659.s4	antidiabetic agents	group	101-119	antiarrhythmics	group	126-140	false	trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , druga , and drugb , without observed problems .
DDI-DrugBank.d650.s0	Dopamine antagonists	group	0-19	neuroleptics	group	34-45	false	druga , such as the drugb ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	Dopamine antagonists	group	0-19	phenothiazines	group	48-61	false	druga , such as the neuroleptics ( drugb , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	Dopamine antagonists	group	0-19	butyrophenones	group	64-77	false	druga , such as the neuroleptics ( phenothiazines , drugb , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	Dopamine antagonists	group	0-19	thioxanthines	group	80-92	false	druga , such as the neuroleptics ( phenothiazines , butyrophenones , drugb ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	Dopamine antagonists	group	0-19	metoclopramide	drug	99-112	false	druga , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or drugb , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	Dopamine antagonists	group	0-19	Permax	brand	171-176	advise	druga , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with drugb ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	Dopamine antagonists	group	0-19	dopamine agonist	group	181-196	false	druga , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a drugb ) ;
DDI-DrugBank.d650.s0	neuroleptics	group	34-45	phenothiazines	group	48-61	false	dopamine antagonists , such as the druga ( drugb , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	neuroleptics	group	34-45	butyrophenones	group	64-77	false	dopamine antagonists , such as the druga ( phenothiazines , drugb , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	neuroleptics	group	34-45	thioxanthines	group	80-92	false	dopamine antagonists , such as the druga ( phenothiazines , butyrophenones , drugb ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	neuroleptics	group	34-45	metoclopramide	drug	99-112	false	dopamine antagonists , such as the druga ( phenothiazines , butyrophenones , thioxanthines ) or drugb , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	neuroleptics	group	34-45	Permax	brand	171-176	advise	dopamine antagonists , such as the druga ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with drugb ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	neuroleptics	group	34-45	dopamine agonist	group	181-196	false	dopamine antagonists , such as the druga ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a drugb ) ;
DDI-DrugBank.d650.s0	phenothiazines	group	48-61	butyrophenones	group	64-77	false	dopamine antagonists , such as the neuroleptics ( druga , drugb , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	phenothiazines	group	48-61	thioxanthines	group	80-92	false	dopamine antagonists , such as the neuroleptics ( druga , butyrophenones , drugb ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	phenothiazines	group	48-61	metoclopramide	drug	99-112	false	dopamine antagonists , such as the neuroleptics ( druga , butyrophenones , thioxanthines ) or drugb , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	phenothiazines	group	48-61	Permax	brand	171-176	advise	dopamine antagonists , such as the neuroleptics ( druga , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with drugb ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	phenothiazines	group	48-61	dopamine agonist	group	181-196	false	dopamine antagonists , such as the neuroleptics ( druga , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a drugb ) ;
DDI-DrugBank.d650.s0	butyrophenones	group	64-77	thioxanthines	group	80-92	false	dopamine antagonists , such as the neuroleptics ( phenothiazines , druga , drugb ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	butyrophenones	group	64-77	metoclopramide	drug	99-112	false	dopamine antagonists , such as the neuroleptics ( phenothiazines , druga , thioxanthines ) or drugb , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	butyrophenones	group	64-77	Permax	brand	171-176	advise	dopamine antagonists , such as the neuroleptics ( phenothiazines , druga , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with drugb ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	butyrophenones	group	64-77	dopamine agonist	group	181-196	false	dopamine antagonists , such as the neuroleptics ( phenothiazines , druga , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a drugb ) ;
DDI-DrugBank.d650.s0	thioxanthines	group	80-92	metoclopramide	drug	99-112	false	dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , druga ) or drugb , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	thioxanthines	group	80-92	Permax	brand	171-176	advise	dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , druga ) or metoclopramide , ordinarily should not be administered concurrently with drugb ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	thioxanthines	group	80-92	dopamine agonist	group	181-196	false	dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , druga ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a drugb ) ;
DDI-DrugBank.d650.s0	metoclopramide	drug	99-112	Permax	brand	171-176	advise	dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or druga , ordinarily should not be administered concurrently with drugb ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0	metoclopramide	drug	99-112	dopamine agonist	group	181-196	false	dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or druga , ordinarily should not be administered concurrently with permax ( a drugb ) ;
DDI-DrugBank.d650.s0	Permax	brand	171-176	dopamine agonist	group	181-196	false	dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with druga ( a drugb ) ;
DDI-DrugBank.d650.s2	pergolide mesylate	drug	8-25	pergolide mesylate	drug	105-122	false	because druga is approximately dg % bound to plasma proteins , caution should be exercised if drugb is coadministered with other drugs known to affect protein binding .
DDI-DrugBank.d781.s0	Diuretics	group	0-8	diuretics	group	23-31	false	druga : patients on drugb , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of aceon tablets therapy .
DDI-DrugBank.d781.s0	Diuretics	group	0-8	ACEON	brand	162-166	false	druga : patients on diuretics , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of drugb tablets therapy .
DDI-DrugBank.d781.s0	diuretics	group	23-31	ACEON	brand	162-166	effect	diuretics : patients on druga , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of drugb tablets therapy .
DDI-DrugBank.d781.s1	diuretic	group	84-91	perindopril	drug	161-171	effect	the possibility of hypotensive effects can be minimized by either discontinuing the druga or increasing the salt intake prior to initiation of treatment with drugb .
DDI-DrugBank.d781.s2	diuretics	group	3-11	ACEON	brand	104-108	advise	if druga can not be interrupted , close medical supervision should be provided with the first dose of drugb tablets , for at least two hours and until blood pressure has stabilized for another hour .
DDI-DrugBank.d781.s3	perindopril	drug	23-33	diuretics	group	94-102	false	the rate and extent of druga absorption and elimination are not affected by concomitant drugb .
DDI-DrugBank.d781.s4	perindoprilat	drug_n	23-35	diuretics	group	52-60	false	the bioavailability of druga was reduced by drugb , however , and this was associated with a decrease in plasma ace inhibition .
DDI-DrugBank.d781.s5	Potassium	drug	0-8	Potassium-Sparing Diuretics	group	26-52	false	druga supplements and drugb : aceon tablets may increase serum potassium because of its potential to decrease aldosterone production .
DDI-DrugBank.d781.s5	Potassium	drug	0-8	ACEON	brand	55-59	false	druga supplements and potassium sparing diuretics : drugb tablets may increase serum potassium because of its potential to decrease aldosterone production .
DDI-DrugBank.d781.s5	Potassium-Sparing Diuretics	group	26-52	ACEON	brand	55-59	false	potassium supplements and druga : drugb tablets may increase serum potassium because of its potential to decrease aldosterone production .
DDI-DrugBank.d781.s6	potassium-sparing diuretics	group	7-33	spironolactone	drug	36-49	false	use of druga ( drugb , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	potassium-sparing diuretics	group	7-33	amiloride	drug	52-60	false	use of druga ( spironolactone , drugb , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	potassium-sparing diuretics	group	7-33	triamterene	drug	63-73	false	use of druga ( spironolactone , amiloride , drugb and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	potassium-sparing diuretics	group	7-33	potassium	drug	88-96	false	use of druga ( spironolactone , amiloride , triamterene and others ) , drugb supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	potassium-sparing diuretics	group	7-33	indomethacin	drug	164-175	false	use of druga ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( drugb , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	potassium-sparing diuretics	group	7-33	heparin	drug	178-184	false	use of druga ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , drugb , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	potassium-sparing diuretics	group	7-33	cyclosporine	drug	187-198	false	use of druga ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , drugb and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	spironolactone	drug	36-49	amiloride	drug	52-60	false	use of potassium sparing diuretics ( druga , drugb , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	spironolactone	drug	36-49	triamterene	drug	63-73	false	use of potassium sparing diuretics ( druga , amiloride , drugb and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	spironolactone	drug	36-49	potassium	drug	88-96	false	use of potassium sparing diuretics ( druga , amiloride , triamterene and others ) , drugb supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	spironolactone	drug	36-49	indomethacin	drug	164-175	false	use of potassium sparing diuretics ( druga , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( drugb , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	spironolactone	drug	36-49	heparin	drug	178-184	false	use of potassium sparing diuretics ( druga , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , drugb , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	spironolactone	drug	36-49	cyclosporine	drug	187-198	false	use of potassium sparing diuretics ( druga , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , drugb and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	amiloride	drug	52-60	triamterene	drug	63-73	false	use of potassium sparing diuretics ( spironolactone , druga , drugb and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	amiloride	drug	52-60	potassium	drug	88-96	false	use of potassium sparing diuretics ( spironolactone , druga , triamterene and others ) , drugb supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	amiloride	drug	52-60	indomethacin	drug	164-175	false	use of potassium sparing diuretics ( spironolactone , druga , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( drugb , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	amiloride	drug	52-60	heparin	drug	178-184	false	use of potassium sparing diuretics ( spironolactone , druga , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , drugb , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	amiloride	drug	52-60	cyclosporine	drug	187-198	false	use of potassium sparing diuretics ( spironolactone , druga , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , drugb and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	triamterene	drug	63-73	potassium	drug	88-96	false	use of potassium sparing diuretics ( spironolactone , amiloride , druga and others ) , drugb supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	triamterene	drug	63-73	indomethacin	drug	164-175	false	use of potassium sparing diuretics ( spironolactone , amiloride , druga and others ) , potassium supplements or other drugs capable of increasing serum potassium ( drugb , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	triamterene	drug	63-73	heparin	drug	178-184	false	use of potassium sparing diuretics ( spironolactone , amiloride , druga and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , drugb , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	triamterene	drug	63-73	cyclosporine	drug	187-198	false	use of potassium sparing diuretics ( spironolactone , amiloride , druga and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , drugb and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	potassium	drug	88-96	indomethacin	drug	164-175	false	use of potassium sparing diuretics ( spironolactone , amiloride , triamterene and others ) , druga supplements or other drugs capable of increasing serum potassium ( drugb , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	potassium	drug	88-96	heparin	drug	178-184	false	use of potassium sparing diuretics ( spironolactone , amiloride , triamterene and others ) , druga supplements or other drugs capable of increasing serum potassium ( indomethacin , drugb , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	potassium	drug	88-96	cyclosporine	drug	187-198	false	use of potassium sparing diuretics ( spironolactone , amiloride , triamterene and others ) , druga supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , drugb and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	indomethacin	drug	164-175	heparin	drug	178-184	false	use of potassium sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( druga , drugb , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	indomethacin	drug	164-175	cyclosporine	drug	187-198	false	use of potassium sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( druga , heparin , drugb and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6	heparin	drug	178-184	cyclosporine	drug	187-198	false	use of potassium sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , druga , drugb and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s8	Lithium	drug	0-6	lithium	drug	25-31	false	druga : increased serum drugb and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy .
DDI-DrugBank.d781.s8	Lithium	drug	0-6	lithium	drug	49-55	false	druga : increased serum lithium and symptoms of drugb toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy .
DDI-DrugBank.d781.s8	Lithium	drug	0-6	lithium	drug	119-125	false	druga : increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant drugb and ace inhibitor therapy .
DDI-DrugBank.d781.s8	lithium	drug	25-31	lithium	drug	49-55	false	lithium : increased serum druga and symptoms of drugb toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy .
DDI-DrugBank.d781.s8	lithium	drug	25-31	lithium	drug	119-125	false	lithium : increased serum druga and symptoms of lithium toxicity have been reported in patients receiving concomitant drugb and ace inhibitor therapy .
DDI-DrugBank.d781.s8	lithium	drug	49-55	lithium	drug	119-125	false	lithium : increased serum lithium and symptoms of druga toxicity have been reported in patients receiving concomitant drugb and ace inhibitor therapy .
DDI-DrugBank.d781.s10	diuretic	group	9-16	lithium	drug	51-57	false	use of a druga may further increase the risk of drugb toxicity .
DDI-DrugBank.d781.s11	Digoxin	drug	0-6	digoxin	drug	74-80	false	druga : a controlled pharmacokinetic study has shown no effect on plasma drugb concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	Digoxin	drug	0-6	ACEON	brand	122-126	false	druga : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with drugb tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	Digoxin	drug	0-6	digoxin	drug	157-163	false	druga : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of drugb on the plasma concentration of perindopril / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	Digoxin	drug	0-6	perindopril	drug	196-206	false	druga : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of drugb / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	Digoxin	drug	0-6	perindoprilat	drug_n	208-220	false	druga : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril / drugb has not been excluded .
DDI-DrugBank.d781.s11	digoxin	drug	74-80	ACEON	brand	122-126	false	digoxin : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with drugb tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	digoxin	drug	74-80	digoxin	drug	157-163	false	digoxin : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with aceon tablets , but an effect of drugb on the plasma concentration of perindopril / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	digoxin	drug	74-80	perindopril	drug	196-206	false	digoxin : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of drugb / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	digoxin	drug	74-80	perindoprilat	drug_n	208-220	false	digoxin : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril / drugb has not been excluded .
DDI-DrugBank.d781.s11	ACEON	brand	122-126	digoxin	drug	157-163	false	digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with druga tablets , but an effect of drugb on the plasma concentration of perindopril / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	ACEON	brand	122-126	perindopril	drug	196-206	false	digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with druga tablets , but an effect of digoxin on the plasma concentration of drugb / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	ACEON	brand	122-126	perindoprilat	drug_n	208-220	false	digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with druga tablets , but an effect of digoxin on the plasma concentration of perindopril / drugb has not been excluded .
DDI-DrugBank.d781.s11	digoxin	drug	157-163	perindopril	drug	196-206	mechanism	digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of druga on the plasma concentration of drugb / perindoprilat has not been excluded .
DDI-DrugBank.d781.s11	digoxin	drug	157-163	perindoprilat	drug_n	208-220	mechanism	digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of druga on the plasma concentration of perindopril / drugb has not been excluded .
DDI-DrugBank.d781.s11	perindopril	drug	196-206	perindoprilat	drug_n	208-220	false	digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of druga / drugb has not been excluded .
DDI-DrugBank.d781.s12	Gentamicin	drug	0-9	perindopril	drug	78-88	false	druga : animal data have suggested the possibility of interaction between drugb and gentamicin .
DDI-DrugBank.d781.s12	Gentamicin	drug	0-9	gentamicin	drug	94-103	false	druga : animal data have suggested the possibility of interaction between perindopril and drugb .
DDI-DrugBank.d781.s12	perindopril	drug	78-88	gentamicin	drug	94-103	int	gentamicin : animal data have suggested the possibility of interaction between druga and drugb .
DDI-DrugBank.d781.s15	ACEON	brand	41-45	perindopril	drug	119-129	false	food interaction : oral administration of druga tablets with food does not significantly lower the rate or extent of drugb absorption relative to the fasted state .
DDI-DrugBank.d781.s16	perindopril	drug	44-54	perindoprilat	drug_n	82-94	false	however , the extent of biotransformation of druga to the active metabolite , drugb , is reduced approximately dg % , resulting in a reduction in the plasma ace inhibition curve of approximately dg % , probably clinically insignificant .
DDI-DrugBank.d750.s0	alcohol	drug	19-25	phentermine hydrochloride	drug	32-56	int	concomitant use of druga with drugb may result in an adverse drug interaction .
DDI-DrugBank.d725.s0	Vasopressors	group	0-11	metaraminol	drug	27-37	false	druga , particularly drugb , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d725.s0	Vasopressors	group	0-11	halothane	drug	85-93	effect	druga , particularly metaraminol , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d725.s0	metaraminol	drug	27-37	halothane	drug	85-93	effect	vasopressors , particularly druga , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d725.s1	MAO Inhibitors	group	0-13	sympathomimetic pressor amines	group	38-67	false	druga : the pressor effect of drugb is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d725.s1	MAO Inhibitors	group	0-13	monoamine oxidase inhibitors	group	115-142	false	druga : the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving drugb ( maoi ) .
DDI-DrugBank.d725.s1	MAO Inhibitors	group	0-13	MAOI	group	145-148	false	druga : the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( drugb ) .
DDI-DrugBank.d725.s1	sympathomimetic pressor amines	group	38-67	monoamine oxidase inhibitors	group	115-142	effect	mao inhibitors : the pressor effect of druga is markedly potentiated in patients receiving drugb ( maoi ) .
DDI-DrugBank.d725.s1	sympathomimetic pressor amines	group	38-67	MAOI	group	145-148	effect	mao inhibitors : the pressor effect of druga is markedly potentiated in patients receiving monoamine oxidase inhibitors ( drugb ) .
DDI-DrugBank.d725.s1	monoamine oxidase inhibitors	group	115-142	MAOI	group	145-148	false	mao inhibitors : the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving druga ( drugb ) .
DDI-DrugBank.d725.s3	adrenergic agents	group	24-40	tricyclic antidepressants	group	69-93	effect	the pressor response of druga may also be potentiated by drugb .
DDI-DrugBank.d689.s0	Vasopressors	group	0-11	metaraminol	drug	27-37	false	druga , particularly drugb , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d689.s0	Vasopressors	group	0-11	halothane	drug	85-93	effect	druga , particularly metaraminol , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d689.s0	metaraminol	drug	27-37	halothane	drug	85-93	effect	vasopressors , particularly druga , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d689.s1	MAO Inhibitors	group	0-13	sympathomimetic pressor amines	group	39-68	false	druga the pressor effect of drugb is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d689.s1	MAO Inhibitors	group	0-13	monoamine oxidase inhibitors	group	116-143	false	druga the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving drugb ( maoi ) .
DDI-DrugBank.d689.s1	MAO Inhibitors	group	0-13	MAOI	group	146-149	false	druga the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( drugb ) .
DDI-DrugBank.d689.s1	sympathomimetic pressor amines	group	39-68	monoamine oxidase inhibitors	group	116-143	effect	mao inhibitors the pressor effect of druga is markedly potentiated in patients receiving drugb ( maoi ) .
DDI-DrugBank.d689.s1	sympathomimetic pressor amines	group	39-68	MAOI	group	146-149	effect	mao inhibitors the pressor effect of druga is markedly potentiated in patients receiving monoamine oxidase inhibitors ( drugb ) .
DDI-DrugBank.d689.s1	monoamine oxidase inhibitors	group	116-143	MAOI	group	146-149	false	mao inhibitors the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving druga ( drugb ) .
DDI-DrugBank.d689.s3	adrenergic agents	group	24-40	tricyclic antidepressants	group	69-93	effect	the pressor response of druga may also be potentiated by drugb .
DDI-DrugBank.d627.s0	Pilocarpine	drug	0-10	beta adrenergic antagonists	group	67-93	advise	druga should be administered with caution to patients taking drugb because of the possibility of conduction disturbances .
DDI-DrugBank.d627.s3	atropine	drug	146-153	ipratropium	drug	164-174	false	these effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication ( e.g. , druga , inhaled drugb ) .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	calcium	drug	219-225	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugb , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	conjugated estrogens	drug	228-247	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , drugb , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	hydroxychloroquine sulfate	drug	250-275	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , drugb , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	ibuprofen	drug	278-286	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , drugb , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	levothyroxine sodium	drug	289-308	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , drugb , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	medroxyprogesterone acetate	drug	311-337	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , drugb , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	methotrexate	drug	340-351	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , drugb , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	multivitamins	group	354-366	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , drugb , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	naproxen	drug	369-376	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , drugb , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	acetylsalicylic acid	drug	179-198	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : druga , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	calcium	drug	219-225	conjugated estrogens	drug	228-247	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , drugb , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	hydroxychloroquine sulfate	drug	250-275	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , drugb , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	ibuprofen	drug	278-286	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , hydroxychloroquine sulfate , drugb , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	levothyroxine sodium	drug	289-308	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , drugb , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	medroxyprogesterone acetate	drug	311-337	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , drugb , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	methotrexate	drug	340-351	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , drugb , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	multivitamins	group	354-366	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , drugb , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	naproxen	drug	369-376	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , drugb , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	calcium	drug	219-225	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , druga , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	hydroxychloroquine sulfate	drug	250-275	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , drugb , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	ibuprofen	drug	278-286	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , hydroxychloroquine sulfate , drugb , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	levothyroxine sodium	drug	289-308	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , hydroxychloroquine sulfate , ibuprofen , drugb , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	medroxyprogesterone acetate	drug	311-337	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , drugb , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	methotrexate	drug	340-351	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , drugb , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	multivitamins	group	354-366	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , drugb , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	naproxen	drug	369-376	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , drugb , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	conjugated estrogens	drug	228-247	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , druga , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	hydroxychloroquine sulfate	drug	250-275	ibuprofen	drug	278-286	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , druga , drugb , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	hydroxychloroquine sulfate	drug	250-275	levothyroxine sodium	drug	289-308	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , druga , ibuprofen , drugb , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	hydroxychloroquine sulfate	drug	250-275	medroxyprogesterone acetate	drug	311-337	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , druga , ibuprofen , levothyroxine sodium , drugb , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	hydroxychloroquine sulfate	drug	250-275	methotrexate	drug	340-351	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , druga , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , drugb , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	hydroxychloroquine sulfate	drug	250-275	multivitamins	group	354-366	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , druga , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , drugb , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	hydroxychloroquine sulfate	drug	250-275	naproxen	drug	369-376	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , druga , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , drugb , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	hydroxychloroquine sulfate	drug	250-275	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , druga , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	hydroxychloroquine sulfate	drug	250-275	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , druga , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	hydroxychloroquine sulfate	drug	250-275	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , druga , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	ibuprofen	drug	278-286	levothyroxine sodium	drug	289-308	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , druga , drugb , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	ibuprofen	drug	278-286	medroxyprogesterone acetate	drug	311-337	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , druga , levothyroxine sodium , drugb , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	ibuprofen	drug	278-286	methotrexate	drug	340-351	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , druga , levothyroxine sodium , medroxyprogesterone acetate , drugb , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	ibuprofen	drug	278-286	multivitamins	group	354-366	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , druga , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , drugb , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	ibuprofen	drug	278-286	naproxen	drug	369-376	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , druga , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , drugb , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	ibuprofen	drug	278-286	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , druga , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	ibuprofen	drug	278-286	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , druga , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	ibuprofen	drug	278-286	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , druga , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	levothyroxine sodium	drug	289-308	medroxyprogesterone acetate	drug	311-337	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , druga , drugb , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	levothyroxine sodium	drug	289-308	methotrexate	drug	340-351	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , druga , medroxyprogesterone acetate , drugb , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	levothyroxine sodium	drug	289-308	multivitamins	group	354-366	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , druga , medroxyprogesterone acetate , methotrexate , drugb , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	levothyroxine sodium	drug	289-308	naproxen	drug	369-376	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , druga , medroxyprogesterone acetate , methotrexate , multivitamins , drugb , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	levothyroxine sodium	drug	289-308	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , druga , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	levothyroxine sodium	drug	289-308	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , druga , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	levothyroxine sodium	drug	289-308	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , druga , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	medroxyprogesterone acetate	drug	311-337	methotrexate	drug	340-351	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , druga , drugb , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	medroxyprogesterone acetate	drug	311-337	multivitamins	group	354-366	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , druga , methotrexate , drugb , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	medroxyprogesterone acetate	drug	311-337	naproxen	drug	369-376	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , druga , methotrexate , multivitamins , drugb , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	medroxyprogesterone acetate	drug	311-337	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , druga , methotrexate , multivitamins , naproxen , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	medroxyprogesterone acetate	drug	311-337	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , druga , methotrexate , multivitamins , naproxen , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	medroxyprogesterone acetate	drug	311-337	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , druga , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	methotrexate	drug	340-351	multivitamins	group	354-366	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , druga , drugb , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	methotrexate	drug	340-351	naproxen	drug	369-376	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , druga , multivitamins , drugb , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	methotrexate	drug	340-351	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , druga , multivitamins , naproxen , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	methotrexate	drug	340-351	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , druga , multivitamins , naproxen , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	methotrexate	drug	340-351	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , druga , multivitamins , naproxen , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	multivitamins	group	354-366	naproxen	drug	369-376	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , druga , drugb , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	multivitamins	group	354-366	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , druga , naproxen , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	multivitamins	group	354-366	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , druga , naproxen , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	multivitamins	group	354-366	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , druga , naproxen , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	naproxen	drug	369-376	omeprazole	drug	379-388	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , druga , drugb , paracetamol , and prednisone .
DDI-DrugBank.d627.s4	naproxen	drug	369-376	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , druga , omeprazole , drugb , and prednisone .
DDI-DrugBank.d627.s4	naproxen	drug	369-376	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , druga , omeprazole , paracetamol , and drugb .
DDI-DrugBank.d627.s4	omeprazole	drug	379-388	paracetamol	drug	391-401	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , druga , drugb , and prednisone .
DDI-DrugBank.d627.s4	omeprazole	drug	379-388	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , druga , paracetamol , and drugb .
DDI-DrugBank.d627.s4	paracetamol	drug	391-401	prednisone	drug	408-417	false	while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least dg % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , druga , and drugb .
DDI-DrugBank.d666.s0	reserpine	drug	37-45	beta-blocking agents	group	92-111	effect	catecholamine depleting drugs ( e.g. , druga ) may have an additive effect when given with drugb .
DDI-DrugBank.d666.s2	Pindolol	drug	0-7	antihypertensive agents	group	41-63	false	druga has been used with a variety of drugb , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2	Pindolol	drug	0-7	hydrochlorothiazide	drug	76-94	false	druga has been used with a variety of antihypertensive agents , including drugb , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2	Pindolol	drug	0-7	hydralazine	drug	97-107	false	druga has been used with a variety of antihypertensive agents , including hydrochlorothiazide , drugb , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2	Pindolol	drug	0-7	guanethidine	drug	114-125	false	druga has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and drugb without unexpected adverse interactions .
DDI-DrugBank.d666.s2	antihypertensive agents	group	41-63	hydrochlorothiazide	drug	76-94	false	pindolol has been used with a variety of druga , including drugb , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2	antihypertensive agents	group	41-63	hydralazine	drug	97-107	false	pindolol has been used with a variety of druga , including hydrochlorothiazide , drugb , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2	antihypertensive agents	group	41-63	guanethidine	drug	114-125	false	pindolol has been used with a variety of druga , including hydrochlorothiazide , hydralazine , and drugb without unexpected adverse interactions .
DDI-DrugBank.d666.s2	hydrochlorothiazide	drug	76-94	hydralazine	drug	97-107	false	pindolol has been used with a variety of antihypertensive agents , including druga , drugb , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2	hydrochlorothiazide	drug	76-94	guanethidine	drug	114-125	false	pindolol has been used with a variety of antihypertensive agents , including druga , hydralazine , and drugb without unexpected adverse interactions .
DDI-DrugBank.d666.s2	hydralazine	drug	97-107	guanethidine	drug	114-125	false	pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , druga , and drugb without unexpected adverse interactions .
DDI-DrugBank.d666.s3	Pindolol	drug	0-7	thioridazine	drug	42-53	mechanism	druga has been shown to increase serum drugb levels when both drugs are co administered .
DDI-DrugBank.d635.s0	short-acting beta adrenergic aerosol bronchodilators	group	6-57	MAXAIR AUTOHALER	brand	97-112	advise	other druga should not be used concomitantly with drugb because they may have additive effects .
DDI-DrugBank.d656.s1	coumarin-type anticoagulants	group	56-83	coumarin-type anticoagulants	group	104-131	false	although this has not occurred in in vitro studies with druga , interactions with drugb have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin type anticoagulants and other highly protein bound drugs .
DDI-DrugBank.d656.s1	coumarin-type anticoagulants	group	56-83	FELDENE	brand	157-163	false	although this has not occurred in in vitro studies with druga , interactions with coumarin type anticoagulants have been reported with drugb since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin type anticoagulants and other highly protein bound drugs .
DDI-DrugBank.d656.s1	coumarin-type anticoagulants	group	56-83	FELDENE	brand	291-297	false	although this has not occurred in in vitro studies with druga , interactions with coumarin type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugb to patients on coumarin type anticoagulants and other highly protein bound drugs .
DDI-DrugBank.d656.s1	coumarin-type anticoagulants	group	56-83	coumarin-type anticoagulants	group	314-341	false	although this has not occurred in in vitro studies with druga , interactions with coumarin type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on drugb and other highly protein bound drugs .
DDI-DrugBank.d656.s1	coumarin-type anticoagulants	group	104-131	FELDENE	brand	157-163	int	although this has not occurred in in vitro studies with coumarin type anticoagulants , interactions with druga have been reported with drugb since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin type anticoagulants and other highly protein bound drugs .
DDI-DrugBank.d656.s1	coumarin-type anticoagulants	group	104-131	FELDENE	brand	291-297	false	although this has not occurred in in vitro studies with coumarin type anticoagulants , interactions with druga have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugb to patients on coumarin type anticoagulants and other highly protein bound drugs .
DDI-DrugBank.d656.s1	coumarin-type anticoagulants	group	104-131	coumarin-type anticoagulants	group	314-341	false	although this has not occurred in in vitro studies with coumarin type anticoagulants , interactions with druga have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on drugb and other highly protein bound drugs .
DDI-DrugBank.d656.s1	FELDENE	brand	157-163	FELDENE	brand	291-297	false	although this has not occurred in in vitro studies with coumarin type anticoagulants , interactions with coumarin type anticoagulants have been reported with druga since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugb to patients on coumarin type anticoagulants and other highly protein bound drugs .
DDI-DrugBank.d656.s1	FELDENE	brand	157-163	coumarin-type anticoagulants	group	314-341	false	although this has not occurred in in vitro studies with coumarin type anticoagulants , interactions with coumarin type anticoagulants have been reported with druga since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on drugb and other highly protein bound drugs .
DDI-DrugBank.d656.s1	FELDENE	brand	291-297	coumarin-type anticoagulants	group	314-341	advise	although this has not occurred in in vitro studies with coumarin type anticoagulants , interactions with coumarin type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering druga to patients on drugb and other highly protein bound drugs .
DDI-DrugBank.d656.s2	piroxicam	drug	17-25	FELDENE	brand	90-96	false	plasma levels of druga are depressed to approximately dg % of their normal values when drugb is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	piroxicam	drug	17-25	aspirin	brand	134-140	false	plasma levels of druga are depressed to approximately dg % of their normal values when feldene is administered in conjunction with drugb ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	piroxicam	drug	17-25	antacids	group	191-198	false	plasma levels of druga are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of drugb has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	piroxicam	drug	17-25	piroxicam	drug	217-225	false	plasma levels of druga are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on drugb plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	piroxicam	drug	17-25	Nonsteroidal anti-inflammatory agents	group	243-279	false	plasma levels of druga are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . drugb , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	piroxicam	drug	17-25	FELDENE	brand	292-298	false	plasma levels of druga are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including drugb , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	piroxicam	drug	17-25	lithium	drug	352-358	false	plasma levels of druga are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2	FELDENE	brand	90-96	aspirin	brand	134-140	mechanism	plasma levels of piroxicam are depressed to approximately dg % of their normal values when druga is administered in conjunction with drugb ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	FELDENE	brand	90-96	antacids	group	191-198	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when druga is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of drugb has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	FELDENE	brand	90-96	piroxicam	drug	217-225	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when druga is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on drugb plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	FELDENE	brand	90-96	Nonsteroidal anti-inflammatory agents	group	243-279	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when druga is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . drugb , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	FELDENE	brand	90-96	FELDENE	brand	292-298	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when druga is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including drugb , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	FELDENE	brand	90-96	lithium	drug	352-358	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when druga is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2	aspirin	brand	134-140	antacids	group	191-198	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with druga ( dg mg / day ) , but concomitant administration of drugb has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	aspirin	brand	134-140	piroxicam	drug	217-225	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with druga ( dg mg / day ) , but concomitant administration of antacids has no effect on drugb plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	aspirin	brand	134-140	Nonsteroidal anti-inflammatory agents	group	243-279	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with druga ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . drugb , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	aspirin	brand	134-140	FELDENE	brand	292-298	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with druga ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including drugb , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	aspirin	brand	134-140	lithium	drug	352-358	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with druga ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2	antacids	group	191-198	piroxicam	drug	217-225	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of druga has no effect on drugb plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	antacids	group	191-198	Nonsteroidal anti-inflammatory agents	group	243-279	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of druga has no effect on piroxicam plasma levels . drugb , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	antacids	group	191-198	FELDENE	brand	292-298	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of druga has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including drugb , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	antacids	group	191-198	lithium	drug	352-358	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of druga has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2	piroxicam	drug	217-225	Nonsteroidal anti-inflammatory agents	group	243-279	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on druga plasma levels . drugb , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	piroxicam	drug	217-225	FELDENE	brand	292-298	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on druga plasma levels . nonsteroidal anti inflammatory agents , including drugb , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	piroxicam	drug	217-225	lithium	drug	352-358	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on druga plasma levels . nonsteroidal anti inflammatory agents , including feldene , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2	Nonsteroidal anti-inflammatory agents	group	243-279	FELDENE	brand	292-298	false	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . druga , including drugb , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2	Nonsteroidal anti-inflammatory agents	group	243-279	lithium	drug	352-358	mechanism	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . druga , including feldene , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s2	FELDENE	brand	292-298	lithium	drug	352-358	mechanism	plasma levels of piroxicam are depressed to approximately dg % of their normal values when feldene is administered in conjunction with aspirin ( dg mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti inflammatory agents , including druga , have been reported to increase steady state plasma drugb levels .
DDI-DrugBank.d656.s3	lithium	drug	30-36	FELDENE	brand	103-109	advise	it is recommended that plasma druga levels be monitored when initiating , adjusting and discontinuing drugb .
DDI-DrugBank.d622.s0	atropine	drug	5-12	pralidoxime	drug	18-28	effect	when druga and drugb are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when atropine is used alone .
DDI-DrugBank.d622.s0	atropine	drug	5-12	atropine	drug	189-196	false	when druga and pralidoxime are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when drugb is used alone .
DDI-DrugBank.d622.s0	pralidoxime	drug	18-28	atropine	drug	189-196	false	when atropine and druga are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when drugb is used alone .
DDI-DrugBank.d622.s1	atropine	drug	45-52	pralidoxime	drug	95-105	false	this is especially true if the total dose of druga has been large and the administration of drugb has been delayed .
DDI-DrugBank.d622.s2	pralidoxime	drug	154-164	barbiturates	group	173-184	false	dg dg the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of druga : since drugb are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions ;
DDI-DrugBank.d622.s2	pralidoxime	drug	154-164	anticholinesterases	group	209-227	false	dg dg the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of druga : since barbiturates are potentiated by the drugb , they should be used cautiously in the treatment of convulsions ;
DDI-DrugBank.d622.s2	barbiturates	group	173-184	anticholinesterases	group	209-227	effect	dg dg the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of pralidoxime : since druga are potentiated by the drugb , they should be used cautiously in the treatment of convulsions ;
DDI-DrugBank.d622.s3	morphine	drug	0-7	theophylline	drug	10-21	false	druga , drugb , aminophylline , succinylcholine , reserpine , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	morphine	drug	0-7	aminophylline	drug	24-36	false	druga , theophylline , drugb , succinylcholine , reserpine , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	morphine	drug	0-7	succinylcholine	drug	39-53	false	druga , theophylline , aminophylline , drugb , reserpine , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	morphine	drug	0-7	reserpine	drug	56-64	false	druga , theophylline , aminophylline , succinylcholine , drugb , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	morphine	drug	0-7	phenothiazine-type tranquilizers	group	71-102	false	druga , theophylline , aminophylline , succinylcholine , reserpine , and drugb should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	theophylline	drug	10-21	aminophylline	drug	24-36	false	morphine , druga , drugb , succinylcholine , reserpine , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	theophylline	drug	10-21	succinylcholine	drug	39-53	false	morphine , druga , aminophylline , drugb , reserpine , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	theophylline	drug	10-21	reserpine	drug	56-64	false	morphine , druga , aminophylline , succinylcholine , drugb , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	theophylline	drug	10-21	phenothiazine-type tranquilizers	group	71-102	false	morphine , druga , aminophylline , succinylcholine , reserpine , and drugb should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	aminophylline	drug	24-36	succinylcholine	drug	39-53	false	morphine , theophylline , druga , drugb , reserpine , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	aminophylline	drug	24-36	reserpine	drug	56-64	false	morphine , theophylline , druga , succinylcholine , drugb , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	aminophylline	drug	24-36	phenothiazine-type tranquilizers	group	71-102	false	morphine , theophylline , druga , succinylcholine , reserpine , and drugb should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	succinylcholine	drug	39-53	reserpine	drug	56-64	false	morphine , theophylline , aminophylline , druga , drugb , and phenothiazine type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	succinylcholine	drug	39-53	phenothiazine-type tranquilizers	group	71-102	false	morphine , theophylline , aminophylline , druga , reserpine , and drugb should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3	reserpine	drug	56-64	phenothiazine-type tranquilizers	group	71-102	false	morphine , theophylline , aminophylline , succinylcholine , druga , and drugb should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d737.s0	Carbidopa	drug	0-8	Levodopa	drug	10-17	false	druga / drugb : carbidopa / levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s0	Carbidopa	drug	0-8	Carbidopa	drug	20-28	false	druga / levodopa : drugb / levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s0	Carbidopa	drug	0-8	Levodopa	drug	30-37	false	druga / levodopa : carbidopa / drugb does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s0	Carbidopa	drug	0-8	pramipexole	drug	82-92	false	druga / levodopa : carbidopa / levodopa does not influence the pharmacokinetics of drugb in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s0	Levodopa	drug	10-17	Carbidopa	drug	20-28	false	carbidopa / druga : drugb / levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s0	Levodopa	drug	10-17	Levodopa	drug	30-37	false	carbidopa / druga : carbidopa / drugb does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s0	Levodopa	drug	10-17	pramipexole	drug	82-92	false	carbidopa / druga : carbidopa / levodopa does not influence the pharmacokinetics of drugb in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s0	Carbidopa	drug	20-28	Levodopa	drug	30-37	false	carbidopa / levodopa : druga / drugb does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s0	Carbidopa	drug	20-28	pramipexole	drug	82-92	false	carbidopa / levodopa : druga / levodopa does not influence the pharmacokinetics of drugb in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s0	Levodopa	drug	30-37	pramipexole	drug	82-92	false	carbidopa / levodopa : carbidopa / druga does not influence the pharmacokinetics of drugb in healthy volunteers ( n= dg ) .
DDI-DrugBank.d737.s2	Selegiline	drug	0-9	selegiline	drug	43-52	false	druga : in healthy volunteers ( n= dg ) , drugb did not influence the pharmacokinetics of pramipexole .
DDI-DrugBank.d737.s2	Selegiline	drug	0-9	pramipexole	drug	96-106	false	druga : in healthy volunteers ( n= dg ) , selegiline did not influence the pharmacokinetics of drugb .
DDI-DrugBank.d737.s2	selegiline	drug	43-52	pramipexole	drug	96-106	false	selegiline : in healthy volunteers ( n= dg ) , druga did not influence the pharmacokinetics of drugb .
DDI-DrugBank.d737.s3	Amantadine	drug	0-9	amantadine	drug	62-71	false	druga : population pharmacokinetic analysis suggests that drugb is unlikely to alter the oral clearance of pramipexole ( n= dg ) .
DDI-DrugBank.d737.s3	Amantadine	drug	0-9	pramipexole	drug	116-126	false	druga : population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of drugb ( n= dg ) .
DDI-DrugBank.d737.s3	amantadine	drug	62-71	pramipexole	drug	116-126	false	amantadine : population pharmacokinetic analysis suggests that druga is unlikely to alter the oral clearance of drugb ( n= dg ) .
DDI-DrugBank.d737.s4	Cimetidine	drug	0-9	Cimetidine	drug	12-21	false	druga : drugb , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a dg % increase in pramipexole auc and a dg % increase in half life ( n= dg ) .
DDI-DrugBank.d737.s4	Cimetidine	drug	0-9	pramipexole	drug	146-156	false	druga : cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a dg % increase in drugb auc and a dg % increase in half life ( n= dg ) .
DDI-DrugBank.d737.s4	Cimetidine	drug	12-21	pramipexole	drug	146-156	mechanism	cimetidine : druga , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a dg % increase in drugb auc and a dg % increase in half life ( n= dg ) .
DDI-DrugBank.d737.s5	Probenecid	drug	0-9	Probenecid	drug	12-21	false	druga : drugb , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence pramipexole pharmacokinetics ( n= dg ) .
DDI-DrugBank.d737.s5	Probenecid	drug	0-9	pramipexole	drug	144-154	false	druga : probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence drugb pharmacokinetics ( n= dg ) .
DDI-DrugBank.d737.s5	Probenecid	drug	12-21	pramipexole	drug	144-154	false	probenecid : druga , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence drugb pharmacokinetics ( n= dg ) .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	ranitidine	drug	190-199	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugb , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	diltiazem	drug	202-210	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , drugb , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	triamterene	drug	213-223	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , drugb , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	verapamil	drug	226-234	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , drugb , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	quinidine	drug	237-245	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , verapamil , drugb , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	quinine	drug	252-258	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , verapamil , quinidine , and drugb ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	pramipexole	drug	293-303	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of drugb by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	cephalosporins	group	379-392	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , drugb , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	penicillins	group	395-405	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , drugb , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cimetidine	drug	178-187	pramipexole	drug	521-531	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	diltiazem	drug	202-210	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , drugb , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	triamterene	drug	213-223	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , drugb , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	verapamil	drug	226-234	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , drugb , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	quinidine	drug	237-245	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , verapamil , drugb , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	quinine	drug	252-258	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , verapamil , quinidine , and drugb ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	pramipexole	drug	293-303	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of drugb by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	cephalosporins	group	379-392	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , drugb , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	penicillins	group	395-405	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , drugb , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	ranitidine	drug	190-199	pramipexole	drug	521-531	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , druga , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	triamterene	drug	213-223	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , drugb , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	verapamil	drug	226-234	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , drugb , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	quinidine	drug	237-245	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , verapamil , drugb , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	quinine	drug	252-258	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , verapamil , quinidine , and drugb ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	pramipexole	drug	293-303	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of drugb by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	cephalosporins	group	379-392	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , drugb , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	penicillins	group	395-405	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , drugb , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	diltiazem	drug	202-210	pramipexole	drug	521-531	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , druga , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	verapamil	drug	226-234	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , drugb , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	quinidine	drug	237-245	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , verapamil , drugb , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	quinine	drug	252-258	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , verapamil , quinidine , and drugb ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	pramipexole	drug	293-303	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , verapamil , quinidine , and quinine ) decreases the oral clearance of drugb by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	cephalosporins	group	379-392	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , drugb , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	penicillins	group	395-405	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , drugb , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	triamterene	drug	213-223	pramipexole	drug	521-531	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , druga , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	verapamil	drug	226-234	quinidine	drug	237-245	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , druga , drugb , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	verapamil	drug	226-234	quinine	drug	252-258	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , druga , quinidine , and drugb ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	verapamil	drug	226-234	pramipexole	drug	293-303	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , druga , quinidine , and quinine ) decreases the oral clearance of drugb by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	verapamil	drug	226-234	cephalosporins	group	379-392	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , druga , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , drugb , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	verapamil	drug	226-234	penicillins	group	395-405	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , druga , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , drugb , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	verapamil	drug	226-234	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , druga , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	verapamil	drug	226-234	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , druga , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	verapamil	drug	226-234	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , druga , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	verapamil	drug	226-234	pramipexole	drug	521-531	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , druga , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	quinidine	drug	237-245	quinine	drug	252-258	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , druga , and drugb ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinidine	drug	237-245	pramipexole	drug	293-303	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , druga , and quinine ) decreases the oral clearance of drugb by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinidine	drug	237-245	cephalosporins	group	379-392	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , druga , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , drugb , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinidine	drug	237-245	penicillins	group	395-405	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , druga , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , drugb , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinidine	drug	237-245	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , druga , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinidine	drug	237-245	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , druga , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinidine	drug	237-245	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , druga , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinidine	drug	237-245	pramipexole	drug	521-531	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , druga , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	quinine	drug	252-258	pramipexole	drug	293-303	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and druga ) decreases the oral clearance of drugb by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinine	drug	252-258	cephalosporins	group	379-392	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and druga ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , drugb , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinine	drug	252-258	penicillins	group	395-405	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and druga ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , drugb , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinine	drug	252-258	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and druga ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinine	drug	252-258	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and druga ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinine	drug	252-258	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and druga ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	quinine	drug	252-258	pramipexole	drug	521-531	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and druga ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	pramipexole	drug	293-303	cephalosporins	group	379-392	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of druga by about dg % , while those secreted by the anionic transport system ( e.g. , drugb , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	pramipexole	drug	293-303	penicillins	group	395-405	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of druga by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , drugb , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	pramipexole	drug	293-303	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of druga by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	pramipexole	drug	293-303	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of druga by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	pramipexole	drug	293-303	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of druga by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	pramipexole	drug	293-303	pramipexole	drug	521-531	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of druga by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	cephalosporins	group	379-392	penicillins	group	395-405	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , druga , drugb , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cephalosporins	group	379-392	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , druga , penicillins , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cephalosporins	group	379-392	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , druga , penicillins , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cephalosporins	group	379-392	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , druga , penicillins , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	cephalosporins	group	379-392	pramipexole	drug	521-531	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , druga , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	penicillins	group	395-405	indomethacin	drug	408-419	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , druga , drugb , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	penicillins	group	395-405	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , druga , indomethacin , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	penicillins	group	395-405	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , druga , indomethacin , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	penicillins	group	395-405	pramipexole	drug	521-531	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , druga , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	indomethacin	drug	408-419	hydrochlorothiazide	drug	422-440	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , druga , drugb , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	indomethacin	drug	408-419	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , druga , hydrochlorothiazide , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	indomethacin	drug	408-419	pramipexole	drug	521-531	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , druga , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	hydrochlorothiazide	drug	422-440	chlorpropamide	drug	447-460	false	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , druga , and drugb ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6	hydrochlorothiazide	drug	422-440	pramipexole	drug	521-531	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , druga , and chlorpropamide ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s6	chlorpropamide	drug	447-460	pramipexole	drug	521-531	mechanism	other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about dg % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and druga ) are likely to have little effect on the oral clearance of drugb .
DDI-DrugBank.d737.s7	pramipexole	drug	88-98	pramipexole	drug	120-130	false	cyp interactions : inhibitors of cytochrome p450 enzymes would not be expected to affect druga elimination because drugb is not appreciably metabolized by these enzymes in vivo or in vitro .
DDI-DrugBank.d737.s10	Dopamine antagonists	group	0-19	pramipexole	drug	28-38	false	druga : since drugb is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	Dopamine antagonists	group	0-19	dopamine agonist	group	45-60	false	druga : since pramipexole is a drugb , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	Dopamine antagonists	group	0-19	dopamine antagonists	group	83-102	false	druga : since pramipexole is a dopamine agonist , it is possible that drugb , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	Dopamine antagonists	group	0-19	neuroleptics	group	117-128	false	druga : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the drugb ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	Dopamine antagonists	group	0-19	phenothiazines	group	131-144	false	druga : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( drugb , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	Dopamine antagonists	group	0-19	butyrophenones	group	147-160	false	druga : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , drugb , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	Dopamine antagonists	group	0-19	thioxanthenes	group	163-175	false	druga : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , drugb ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	Dopamine antagonists	group	0-19	metoclopramide	group	181-194	false	druga : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or drugb , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	Dopamine antagonists	group	0-19	MIRAPEX	brand	231-237	false	druga : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10	pramipexole	drug	28-38	dopamine agonist	group	45-60	false	dopamine antagonists : since druga is a drugb , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	pramipexole	drug	28-38	dopamine antagonists	group	83-102	false	dopamine antagonists : since druga is a dopamine agonist , it is possible that drugb , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	pramipexole	drug	28-38	neuroleptics	group	117-128	false	dopamine antagonists : since druga is a dopamine agonist , it is possible that dopamine antagonists , such as the drugb ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	pramipexole	drug	28-38	phenothiazines	group	131-144	false	dopamine antagonists : since druga is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( drugb , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	pramipexole	drug	28-38	butyrophenones	group	147-160	false	dopamine antagonists : since druga is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , drugb , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	pramipexole	drug	28-38	thioxanthenes	group	163-175	false	dopamine antagonists : since druga is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , drugb ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	pramipexole	drug	28-38	metoclopramide	group	181-194	false	dopamine antagonists : since druga is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or drugb , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	pramipexole	drug	28-38	MIRAPEX	brand	231-237	false	dopamine antagonists : since druga is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10	dopamine agonist	group	45-60	dopamine antagonists	group	83-102	false	dopamine antagonists : since pramipexole is a druga , it is possible that drugb , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine agonist	group	45-60	neuroleptics	group	117-128	false	dopamine antagonists : since pramipexole is a druga , it is possible that dopamine antagonists , such as the drugb ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine agonist	group	45-60	phenothiazines	group	131-144	false	dopamine antagonists : since pramipexole is a druga , it is possible that dopamine antagonists , such as the neuroleptics ( drugb , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine agonist	group	45-60	butyrophenones	group	147-160	false	dopamine antagonists : since pramipexole is a druga , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , drugb , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine agonist	group	45-60	thioxanthenes	group	163-175	false	dopamine antagonists : since pramipexole is a druga , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , drugb ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine agonist	group	45-60	metoclopramide	group	181-194	false	dopamine antagonists : since pramipexole is a druga , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or drugb , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine agonist	group	45-60	MIRAPEX	brand	231-237	false	dopamine antagonists : since pramipexole is a druga , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10	dopamine antagonists	group	83-102	neuroleptics	group	117-128	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that druga , such as the drugb ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine antagonists	group	83-102	phenothiazines	group	131-144	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that druga , such as the neuroleptics ( drugb , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine antagonists	group	83-102	butyrophenones	group	147-160	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that druga , such as the neuroleptics ( phenothiazines , drugb , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine antagonists	group	83-102	thioxanthenes	group	163-175	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that druga , such as the neuroleptics ( phenothiazines , butyrophenones , drugb ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine antagonists	group	83-102	metoclopramide	group	181-194	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that druga , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or drugb , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	dopamine antagonists	group	83-102	MIRAPEX	brand	231-237	effect	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that druga , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10	neuroleptics	group	117-128	phenothiazines	group	131-144	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the druga ( drugb , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	neuroleptics	group	117-128	butyrophenones	group	147-160	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the druga ( phenothiazines , drugb , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	neuroleptics	group	117-128	thioxanthenes	group	163-175	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the druga ( phenothiazines , butyrophenones , drugb ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	neuroleptics	group	117-128	metoclopramide	group	181-194	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the druga ( phenothiazines , butyrophenones , thioxanthenes ) or drugb , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	neuroleptics	group	117-128	MIRAPEX	brand	231-237	effect	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the druga ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10	phenothiazines	group	131-144	butyrophenones	group	147-160	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( druga , drugb , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	phenothiazines	group	131-144	thioxanthenes	group	163-175	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( druga , butyrophenones , drugb ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	phenothiazines	group	131-144	metoclopramide	group	181-194	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( druga , butyrophenones , thioxanthenes ) or drugb , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	phenothiazines	group	131-144	MIRAPEX	brand	231-237	effect	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( druga , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10	butyrophenones	group	147-160	thioxanthenes	group	163-175	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , druga , drugb ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	butyrophenones	group	147-160	metoclopramide	group	181-194	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , druga , thioxanthenes ) or drugb , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	butyrophenones	group	147-160	MIRAPEX	brand	231-237	effect	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , druga , thioxanthenes ) or metoclopramide , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10	thioxanthenes	group	163-175	metoclopramide	group	181-194	false	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , druga ) or drugb , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10	thioxanthenes	group	163-175	MIRAPEX	brand	231-237	effect	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , druga ) or metoclopramide , may diminish the effectiveness of drugb .
DDI-DrugBank.d737.s10	metoclopramide	group	181-194	MIRAPEX	brand	231-237	effect	dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or druga , may diminish the effectiveness of drugb .
DDI-DrugBank.d632.s0	SYMLIN	brand	40-45	anticholinergic agents	group	150-171	advise	due to its effects on gastric emptying , druga therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , drugb such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) .
DDI-DrugBank.d632.s0	SYMLIN	brand	40-45	atropine	drug	181-188	advise	due to its effects on gastric emptying , druga therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as drugb ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) .
DDI-DrugBank.d632.s0	SYMLIN	brand	40-45	alpha glucosidase inhibitors	group	258-285	advise	due to its effects on gastric emptying , druga therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , drugb ) .
DDI-DrugBank.d632.s0	anticholinergic agents	group	150-171	atropine	drug	181-188	false	due to its effects on gastric emptying , symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , druga such as drugb ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) .
DDI-DrugBank.d632.s0	anticholinergic agents	group	150-171	alpha glucosidase inhibitors	group	258-285	false	due to its effects on gastric emptying , symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , druga such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , drugb ) .
DDI-DrugBank.d632.s0	atropine	drug	181-188	alpha glucosidase inhibitors	group	258-285	false	due to its effects on gastric emptying , symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as druga ) and agents that slow the intestinal absorption of nutrients ( e.g. , drugb ) .
DDI-DrugBank.d632.s3	analgesics	group	116-125	SYMLIN	brand	204-209	advise	when the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness ( such as druga ) , the agent should be administered at least dg hour prior to or dg hours after drugb injection .
DDI-DrugBank.d632.s4	sulfonylureas	group	43-55	biguanides	group	60-69	false	in clinical trials , the concomitant use of druga or drugb did not alter the adverse event profile of symlin .
DDI-DrugBank.d632.s4	sulfonylureas	group	43-55	SYMLIN	brand	114-119	false	in clinical trials , the concomitant use of druga or biguanides did not alter the adverse event profile of drugb .
DDI-DrugBank.d632.s4	biguanides	group	60-69	SYMLIN	brand	114-119	false	in clinical trials , the concomitant use of sulfonylureas or druga did not alter the adverse event profile of drugb .
DDI-DrugBank.d632.s5	SYMLIN	brand	74-79	antidiabetic agents	group	105-123	false	no formal interaction studies have been performed to assess the effect of druga on the kinetics of oral drugb .
DDI-DrugBank.d632.s6	SYMLIN	brand	7-12	Insulin	drug	18-24	false	mixing druga and drugb the pharmacokinetic parameters of symlin were altered when mixed with regular , nph , and dg / dg premixed formulations of recombinant human insulin immediately prior to injection .
DDI-DrugBank.d632.s6	SYMLIN	brand	7-12	SYMLIN	brand	60-65	false	mixing druga and insulin the pharmacokinetic parameters of drugb were altered when mixed with regular , nph , and dg / dg premixed formulations of recombinant human insulin immediately prior to injection .
DDI-DrugBank.d632.s6	SYMLIN	brand	7-12	human insulin	drug	157-169	false	mixing druga and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular , nph , and dg / dg premixed formulations of recombinant drugb immediately prior to injection .
DDI-DrugBank.d632.s6	Insulin	drug	18-24	SYMLIN	brand	60-65	false	mixing symlin and druga the pharmacokinetic parameters of drugb were altered when mixed with regular , nph , and dg / dg premixed formulations of recombinant human insulin immediately prior to injection .
DDI-DrugBank.d632.s6	Insulin	drug	18-24	human insulin	drug	157-169	false	mixing symlin and druga the pharmacokinetic parameters of symlin were altered when mixed with regular , nph , and dg / dg premixed formulations of recombinant drugb immediately prior to injection .
DDI-DrugBank.d632.s6	SYMLIN	brand	60-65	human insulin	drug	157-169	mechanism	mixing symlin and insulin the pharmacokinetic parameters of druga were altered when mixed with regular , nph , and dg / dg premixed formulations of recombinant drugb immediately prior to injection .
DDI-DrugBank.d632.s7	SYMLIN	brand	6-11	insulin	drug	17-23	false	thus , druga and drugb should not be mixed and must be administered separately .
DDI-DrugBank.d653.s1	phenobarbital	drug	42-54	phenytoin	drug	57-65	false	drugs that induce hepatic enzymes such as druga , drugb and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1	phenobarbital	drug	42-54	rifampin	drug	71-78	false	drugs that induce hepatic enzymes such as druga , phenytoin and drugb may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1	phenobarbital	drug	42-54	corticosteroids	group	110-124	mechanism	drugs that induce hepatic enzymes such as druga , phenytoin and rifampin may increase the clearance of drugb and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1	phenobarbital	drug	42-54	corticosteroid	group	155-168	mechanism	drugs that induce hepatic enzymes such as druga , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d653.s1	phenytoin	drug	57-65	rifampin	drug	71-78	false	drugs that induce hepatic enzymes such as phenobarbital , druga and drugb may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1	phenytoin	drug	57-65	corticosteroids	group	110-124	mechanism	drugs that induce hepatic enzymes such as phenobarbital , druga and rifampin may increase the clearance of drugb and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1	phenytoin	drug	57-65	corticosteroid	group	155-168	mechanism	drugs that induce hepatic enzymes such as phenobarbital , druga and rifampin may increase the clearance of corticosteroids and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d653.s1	rifampin	drug	71-78	corticosteroids	group	110-124	mechanism	drugs that induce hepatic enzymes such as phenobarbital , phenytoin and druga may increase the clearance of drugb and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1	rifampin	drug	71-78	corticosteroid	group	155-168	mechanism	drugs that induce hepatic enzymes such as phenobarbital , phenytoin and druga may increase the clearance of corticosteroids and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d653.s1	corticosteroids	group	110-124	corticosteroid	group	155-168	false	drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of druga and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d653.s2	troleandomycin	drug	14-27	ketoconazole	drug	33-44	false	drugs such as druga and drugb may inhibit the metabolism of corticosteroids and thus decrease their clearance .
DDI-DrugBank.d653.s2	troleandomycin	drug	14-27	corticosteroids	group	76-90	mechanism	drugs such as druga and ketoconazole may inhibit the metabolism of drugb and thus decrease their clearance .
DDI-DrugBank.d653.s2	ketoconazole	drug	33-44	corticosteroids	group	76-90	mechanism	drugs such as troleandomycin and druga may inhibit the metabolism of drugb and thus decrease their clearance .
DDI-DrugBank.d653.s4	Corticosteroids	group	0-14	aspirin	brand	64-70	mechanism	druga may increase the clearance of chronic high dose drugb .
DDI-DrugBank.d653.s5	salicylate	group	29-38	salicylate	group	77-86	false	this could lead to decreased druga serum levels or increase the risk of drugb toxicity when corticosteroid is withdrawn .
DDI-DrugBank.d653.s5	salicylate	group	29-38	corticosteroid	group	102-115	false	this could lead to decreased druga serum levels or increase the risk of salicylate toxicity when drugb is withdrawn .
DDI-DrugBank.d653.s5	salicylate	group	77-86	corticosteroid	group	102-115	effect	this could lead to decreased salicylate serum levels or increase the risk of druga toxicity when drugb is withdrawn .
DDI-DrugBank.d653.s6	Aspirin	brand	0-6	corticosteroids	group	54-68	advise	druga should be used cautiously in conjunction with drugb in patients suffering from hypoprothrombinemia .
DDI-DrugBank.d653.s7	corticosteroids	group	14-28	anticoagulants	group	38-51	effect	the effect of druga on oral drugb is variable .
DDI-DrugBank.d653.s8	anticoagulants	group	63-76	corticosteroids	group	107-121	effect	there are reports of enhanced as well as diminished effects of druga when given concurrently with drugb .
DDI-DrugBank.d780.s0	Anticholinesterases	group	0-18	procaine hydrochloride	drug	39-60	false	druga : concurrent use of drugb and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0	Anticholinesterases	group	0-18	anticholinesterase agents	group	66-90	false	druga : concurrent use of procaine hydrochloride and drugb may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0	Anticholinesterases	group	0-18	anticholinesterases	group	140-158	false	druga : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since drugb inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0	Anticholinesterases	group	0-18	procaine hydrochloride	drug	185-206	false	druga : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of drugb .
DDI-DrugBank.d780.s0	procaine hydrochloride	drug	39-60	anticholinesterase agents	group	66-90	effect	anticholinesterases : concurrent use of druga and drugb may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0	procaine hydrochloride	drug	39-60	anticholinesterases	group	140-158	false	anticholinesterases : concurrent use of druga and anticholinesterase agents may result in increased systemic toxicity since drugb inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0	procaine hydrochloride	drug	39-60	procaine hydrochloride	drug	185-206	false	anticholinesterases : concurrent use of druga and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of drugb .
DDI-DrugBank.d780.s0	anticholinesterase agents	group	66-90	anticholinesterases	group	140-158	false	anticholinesterases : concurrent use of procaine hydrochloride and druga may result in increased systemic toxicity since drugb inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0	anticholinesterase agents	group	66-90	procaine hydrochloride	drug	185-206	false	anticholinesterases : concurrent use of procaine hydrochloride and druga may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of drugb .
DDI-DrugBank.d780.s0	anticholinesterases	group	140-158	procaine hydrochloride	drug	185-206	mechanism	anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since druga inhibit the breakdown of drugb .
DDI-DrugBank.d780.s4	CNS depressant	group	0-13	procaine hydrochloride	drug	46-67	false	druga medications : concurrent use of drugb and cns depressant medications may result in additive depressant effects .
DDI-DrugBank.d780.s4	CNS depressant	group	0-13	CNS depressant medications	group	73-98	false	druga medications : concurrent use of procaine hydrochloride and drugb may result in additive depressant effects .
DDI-DrugBank.d780.s4	procaine hydrochloride	drug	46-67	CNS depressant medications	group	73-98	effect	cns depressant medications : concurrent use of druga and drugb may result in additive depressant effects .
DDI-DrugBank.d780.s5	Hyaluronidase	drug	0-12	Hyaluronidase	drug	15-27	false	druga : drugb may increase the diffusion rate of procaine hydrochloride , resulting in a decreased time of onset , but an increase in systemic toxicity .
DDI-DrugBank.d780.s5	Hyaluronidase	drug	0-12	procaine hydrochloride	drug	64-85	false	druga : hyaluronidase may increase the diffusion rate of drugb , resulting in a decreased time of onset , but an increase in systemic toxicity .
DDI-DrugBank.d780.s5	Hyaluronidase	drug	15-27	procaine hydrochloride	drug	64-85	mechanism	hyaluronidase : druga may increase the diffusion rate of drugb , resulting in a decreased time of onset , but an increase in systemic toxicity .
DDI-DrugBank.d780.s6	Neuromuscular blocking agents	group	0-28	suxamethonium chloride	drug	39-60	false	druga ( such as drugb ) : concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6	Neuromuscular blocking agents	group	0-28	procaine hydrochloride	drug	82-103	false	druga ( such as suxamethonium chloride ) : concurrent use of drugb and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6	Neuromuscular blocking agents	group	0-28	neuromuscular blocking agents	group	109-137	false	druga ( such as suxamethonium chloride ) : concurrent use of procaine hydrochloride and drugb may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6	suxamethonium chloride	drug	39-60	procaine hydrochloride	drug	82-103	false	neuromuscular blocking agents ( such as druga ) : concurrent use of drugb and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6	suxamethonium chloride	drug	39-60	neuromuscular blocking agents	group	109-137	false	neuromuscular blocking agents ( such as druga ) : concurrent use of procaine hydrochloride and drugb may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6	procaine hydrochloride	drug	82-103	neuromuscular blocking agents	group	109-137	effect	neuromuscular blocking agents ( such as suxamethonium chloride ) : concurrent use of druga and drugb may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s7	Sulfonamides	group	0-11	procaine hydrochloride	drug	32-53	false	druga : concurrent use of drugb and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide .
DDI-DrugBank.d780.s7	Sulfonamides	group	0-11	sulfonamides	group	59-70	false	druga : concurrent use of procaine hydrochloride and drugb may result in a reduction of the antibacterial action of the sulfonamide .
DDI-DrugBank.d780.s7	Sulfonamides	group	0-11	sulfonamide	group	133-143	false	druga : concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the drugb .
DDI-DrugBank.d780.s7	procaine hydrochloride	drug	32-53	sulfonamides	group	59-70	effect	sulfonamides : concurrent use of druga and drugb may result in a reduction of the antibacterial action of the sulfonamide .
DDI-DrugBank.d780.s7	procaine hydrochloride	drug	32-53	sulfonamide	group	133-143	false	sulfonamides : concurrent use of druga and sulfonamides may result in a reduction of the antibacterial action of the drugb .
DDI-DrugBank.d780.s7	sulfonamides	group	59-70	sulfonamide	group	133-143	false	sulfonamides : concurrent use of procaine hydrochloride and druga may result in a reduction of the antibacterial action of the drugb .
DDI-DrugBank.d780.s8	Acetazolamide	drug	0-12	acetazolamide	drug	33-45	false	druga : concurrent use of drugb and procaine hydrochloride may extend the plasma half life of procaine .
DDI-DrugBank.d780.s8	Acetazolamide	drug	0-12	procaine hydrochloride	drug	51-72	false	druga : concurrent use of acetazolamide and drugb may extend the plasma half life of procaine .
DDI-DrugBank.d780.s8	Acetazolamide	drug	0-12	procaine	drug	109-116	false	druga : concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half life of drugb .
DDI-DrugBank.d780.s8	acetazolamide	drug	33-45	procaine hydrochloride	drug	51-72	mechanism	acetazolamide : concurrent use of druga and drugb may extend the plasma half life of procaine .
DDI-DrugBank.d780.s8	acetazolamide	drug	33-45	procaine	drug	109-116	false	acetazolamide : concurrent use of druga and procaine hydrochloride may extend the plasma half life of drugb .
DDI-DrugBank.d780.s8	procaine hydrochloride	drug	51-72	procaine	drug	109-116	false	acetazolamide : concurrent use of acetazolamide and druga may extend the plasma half life of drugb .
DDI-DrugBank.d676.s0	barbiturates	group	54-65	antihistamines	group	68-81	false	to minimize cns depression and possible potentiation , druga , drugb , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0	barbiturates	group	54-65	narcotics	group	84-92	false	to minimize cns depression and possible potentiation , druga , antihistamines , drugb , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0	barbiturates	group	54-65	hypotensive agents	group	95-112	false	to minimize cns depression and possible potentiation , druga , antihistamines , narcotics , drugb or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0	barbiturates	group	54-65	phenothiazines	group	117-130	false	to minimize cns depression and possible potentiation , druga , antihistamines , narcotics , hypotensive agents or drugb should be used with caution .
DDI-DrugBank.d676.s0	antihistamines	group	68-81	narcotics	group	84-92	false	to minimize cns depression and possible potentiation , barbiturates , druga , drugb , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0	antihistamines	group	68-81	hypotensive agents	group	95-112	false	to minimize cns depression and possible potentiation , barbiturates , druga , narcotics , drugb or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0	antihistamines	group	68-81	phenothiazines	group	117-130	false	to minimize cns depression and possible potentiation , barbiturates , druga , narcotics , hypotensive agents or drugb should be used with caution .
DDI-DrugBank.d676.s0	narcotics	group	84-92	hypotensive agents	group	95-112	false	to minimize cns depression and possible potentiation , barbiturates , antihistamines , druga , drugb or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0	narcotics	group	84-92	phenothiazines	group	117-130	false	to minimize cns depression and possible potentiation , barbiturates , antihistamines , druga , hypotensive agents or drugb should be used with caution .
DDI-DrugBank.d676.s0	hypotensive agents	group	95-112	phenothiazines	group	117-130	false	to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , druga or drugb should be used with caution .
DDI-DrugBank.d676.s2	Matulane	brand	8-15	sympathomimetic drugs	group	70-90	advise	because druga exhibits some monoamine oxidase inhibitory activity , drugb , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	Matulane	brand	8-15	tricyclic antidepressant	group	93-116	advise	because druga exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , drugb drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	Matulane	brand	8-15	amitriptyline HCl	drug	131-147	advise	because druga exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , drugb , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	Matulane	brand	8-15	imipramine HCl	drug	150-163	advise	because druga exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , drugb ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	Matulane	brand	8-15	tyramine	drug_n	208-215	advise	because druga exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	sympathomimetic drugs	group	70-90	tricyclic antidepressant	group	93-116	false	because matulane exhibits some monoamine oxidase inhibitory activity , druga , drugb drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	sympathomimetic drugs	group	70-90	amitriptyline HCl	drug	131-147	false	because matulane exhibits some monoamine oxidase inhibitory activity , druga , tricyclic antidepressant drugs ( e.g. , drugb , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	sympathomimetic drugs	group	70-90	imipramine HCl	drug	150-163	false	because matulane exhibits some monoamine oxidase inhibitory activity , druga , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , drugb ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	sympathomimetic drugs	group	70-90	tyramine	drug_n	208-215	false	because matulane exhibits some monoamine oxidase inhibitory activity , druga , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	tricyclic antidepressant	group	93-116	amitriptyline HCl	drug	131-147	false	because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , druga drugs ( e.g. , drugb , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	tricyclic antidepressant	group	93-116	imipramine HCl	drug	150-163	false	because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , druga drugs ( e.g. , amitriptyline hcl , drugb ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	tricyclic antidepressant	group	93-116	tyramine	drug_n	208-215	false	because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , druga drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	amitriptyline HCl	drug	131-147	imipramine HCl	drug	150-163	false	because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , druga , drugb ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	amitriptyline HCl	drug	131-147	tyramine	drug_n	208-215	false	because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , druga , imipramine hcl ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2	imipramine HCl	drug	150-163	tyramine	drug_n	208-215	false	because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , druga ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s4	chemotherapeutic agents	group	31-53	steroids	group	72-79	false	no cross resistance with other druga , radiotherapy or drugb has been demonstrated .
DDI-DrugBank.d734.s0	Thiazide diuretics	group	0-17	phenothiazines	group	82-95	effect	druga may accentuate the orthostatic hypotension that may occur with drugb .
DDI-DrugBank.d734.s1	guanethidine	drug	28-39	phenothiazines	group	88-101	effect	antihypertensive effects of druga and related compounds may be counteracted when drugb are used concomitantly .
DDI-DrugBank.d734.s2	propranolol	drug	30-40	phenothiazines	group	47-60	mechanism	concomitant administration of druga with drugb results in increased plasma levels of both drugs .
DDI-DrugBank.d628.s0	DIPRIVAN	brand	35-42	narcotics	group	158-166	effect	the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugb ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0	DIPRIVAN	brand	35-42	morphine	drug	173-180	effect	the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , drugb , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0	DIPRIVAN	brand	35-42	meperidine	drug	183-192	effect	the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , drugb , and fentanyl , etc . )
DDI-DrugBank.d628.s0	DIPRIVAN	brand	35-42	fentanyl	drug	199-206	effect	the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and drugb , etc . )
DDI-DrugBank.d628.s0	narcotics	group	158-166	morphine	drug	173-180	false	the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with druga ( eg , drugb , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0	narcotics	group	158-166	meperidine	drug	183-192	false	the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with druga ( eg , morphine , drugb , and fentanyl , etc . )
DDI-DrugBank.d628.s0	narcotics	group	158-166	fentanyl	drug	199-206	false	the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with druga ( eg , morphine , meperidine , and drugb , etc . )
DDI-DrugBank.d628.s0	morphine	drug	173-180	meperidine	drug	183-192	false	the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , druga , drugb , and fentanyl , etc . )
DDI-DrugBank.d628.s0	morphine	drug	173-180	fentanyl	drug	199-206	false	the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , druga , meperidine , and drugb , etc . )
DDI-DrugBank.d628.s0	meperidine	drug	183-192	fentanyl	drug	199-206	false	the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , druga , and drugb , etc . )
DDI-DrugBank.d628.s1	opioids	group	20-26	sedatives	group	32-40	false	and combinations of druga and drugb ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc. ) .
DDI-DrugBank.d628.s1	opioids	group	20-26	benzodiazepines	group	47-61	false	and combinations of druga and sedatives ( eg , drugb , barbiturates , chloral hydrate , droperidol , etc. ) .
DDI-DrugBank.d628.s1	opioids	group	20-26	barbiturates	group	64-75	false	and combinations of druga and sedatives ( eg , benzodiazepines , drugb , chloral hydrate , droperidol , etc. ) .
DDI-DrugBank.d628.s1	opioids	group	20-26	chloral hydrate	drug	78-92	false	and combinations of druga and sedatives ( eg , benzodiazepines , barbiturates , drugb , droperidol , etc. ) .
DDI-DrugBank.d628.s1	opioids	group	20-26	droperidol	drug	95-104	false	and combinations of druga and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , drugb , etc. ) .
DDI-DrugBank.d628.s1	sedatives	group	32-40	benzodiazepines	group	47-61	false	and combinations of opioids and druga ( eg , drugb , barbiturates , chloral hydrate , droperidol , etc. ) .
DDI-DrugBank.d628.s1	sedatives	group	32-40	barbiturates	group	64-75	false	and combinations of opioids and druga ( eg , benzodiazepines , drugb , chloral hydrate , droperidol , etc. ) .
DDI-DrugBank.d628.s1	sedatives	group	32-40	chloral hydrate	drug	78-92	false	and combinations of opioids and druga ( eg , benzodiazepines , barbiturates , drugb , droperidol , etc. ) .
DDI-DrugBank.d628.s1	sedatives	group	32-40	droperidol	drug	95-104	false	and combinations of opioids and druga ( eg , benzodiazepines , barbiturates , chloral hydrate , drugb , etc. ) .
DDI-DrugBank.d628.s1	benzodiazepines	group	47-61	barbiturates	group	64-75	false	and combinations of opioids and sedatives ( eg , druga , drugb , chloral hydrate , droperidol , etc. ) .
DDI-DrugBank.d628.s1	benzodiazepines	group	47-61	chloral hydrate	drug	78-92	false	and combinations of opioids and sedatives ( eg , druga , barbiturates , drugb , droperidol , etc. ) .
DDI-DrugBank.d628.s1	benzodiazepines	group	47-61	droperidol	drug	95-104	false	and combinations of opioids and sedatives ( eg , druga , barbiturates , chloral hydrate , drugb , etc. ) .
DDI-DrugBank.d628.s1	barbiturates	group	64-75	chloral hydrate	drug	78-92	false	and combinations of opioids and sedatives ( eg , benzodiazepines , druga , drugb , droperidol , etc. ) .
DDI-DrugBank.d628.s1	barbiturates	group	64-75	droperidol	drug	95-104	false	and combinations of opioids and sedatives ( eg , benzodiazepines , druga , chloral hydrate , drugb , etc. ) .
DDI-DrugBank.d628.s1	chloral hydrate	drug	78-92	droperidol	drug	95-104	false	and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , druga , drugb , etc. ) .
DDI-DrugBank.d628.s3	DIPRIVAN	brand	58-65	analgesic agents	group	229-244	advise	during maintenance of anesthesia or sedation , the rate of druga injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drugb ( eg , nitrous oxide or opioids ) .
DDI-DrugBank.d628.s3	DIPRIVAN	brand	58-65	nitrous oxide	drug	251-263	advise	during maintenance of anesthesia or sedation , the rate of druga injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , drugb or opioids ) .
DDI-DrugBank.d628.s3	DIPRIVAN	brand	58-65	opioids	group	268-274	advise	during maintenance of anesthesia or sedation , the rate of druga injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , nitrous oxide or drugb ) .
DDI-DrugBank.d628.s3	analgesic agents	group	229-244	nitrous oxide	drug	251-263	false	during maintenance of anesthesia or sedation , the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental druga ( eg , drugb or opioids ) .
DDI-DrugBank.d628.s3	analgesic agents	group	229-244	opioids	group	268-274	false	during maintenance of anesthesia or sedation , the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental druga ( eg , nitrous oxide or drugb ) .
DDI-DrugBank.d628.s3	nitrous oxide	drug	251-263	opioids	group	268-274	false	during maintenance of anesthesia or sedation , the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , druga or drugb ) .
DDI-DrugBank.d628.s4	isoflurane	drug	65-74	enflurane	drug	77-85	false	the concurrent administration of potent inhalational agents ( eg , druga , drugb , and halothane ) during maintenance with diprivan injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4	isoflurane	drug	65-74	halothane	drug	92-100	false	the concurrent administration of potent inhalational agents ( eg , druga , enflurane , and drugb ) during maintenance with diprivan injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4	isoflurane	drug	65-74	DIPRIVAN	brand	127-134	false	the concurrent administration of potent inhalational agents ( eg , druga , enflurane , and halothane ) during maintenance with drugb injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4	enflurane	drug	77-85	halothane	drug	92-100	false	the concurrent administration of potent inhalational agents ( eg , isoflurane , druga , and drugb ) during maintenance with diprivan injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4	enflurane	drug	77-85	DIPRIVAN	brand	127-134	false	the concurrent administration of potent inhalational agents ( eg , isoflurane , druga , and halothane ) during maintenance with drugb injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4	halothane	drug	92-100	DIPRIVAN	brand	127-134	false	the concurrent administration of potent inhalational agents ( eg , isoflurane , enflurane , and druga ) during maintenance with drugb injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s6	DIPRIVAN	brand	0-7	neuromuscular blocking agents	group	140-168	false	druga injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used drugb ( eg , succinylcholine and nondepolarizing muscle relaxants ) .
DDI-DrugBank.d628.s6	DIPRIVAN	brand	0-7	succinylcholine	drug	175-189	false	druga injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , drugb and nondepolarizing muscle relaxants ) .
DDI-DrugBank.d628.s6	DIPRIVAN	brand	0-7	nondepolarizing muscle relaxants	group	195-226	false	druga injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and drugb ) .
DDI-DrugBank.d628.s6	neuromuscular blocking agents	group	140-168	succinylcholine	drug	175-189	false	diprivan injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used druga ( eg , drugb and nondepolarizing muscle relaxants ) .
DDI-DrugBank.d628.s6	neuromuscular blocking agents	group	140-168	nondepolarizing muscle relaxants	group	195-226	false	diprivan injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used druga ( eg , succinylcholine and drugb ) .
DDI-DrugBank.d628.s6	succinylcholine	drug	175-189	nondepolarizing muscle relaxants	group	195-226	false	diprivan injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , druga and drugb ) .
DDI-DrugBank.d628.s7	muscle relaxants	group	136-151	analgesic agents	group	175-190	false	no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of druga , inhalational agents , drugb , and local anesthetic agents ) have been observed .
DDI-DrugBank.d628.s7	muscle relaxants	group	136-151	anesthetic agents	group	203-219	false	no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of druga , inhalational agents , analgesic agents , and local drugb ) have been observed .
DDI-DrugBank.d628.s7	analgesic agents	group	175-190	anesthetic agents	group	203-219	false	no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of muscle relaxants , inhalational agents , druga , and local drugb ) have been observed .
DDI-DrugBank.d690.s0	propoxyphene	drug	29-40	CNS depressants	group	73-87	effect	the cns depressant effect of druga is additive with that of other drugb , including alcohol .
DDI-DrugBank.d690.s0	propoxyphene	drug	29-40	alcohol	drug	100-106	effect	the cns depressant effect of druga is additive with that of other cns depressants , including drugb .
DDI-DrugBank.d690.s0	CNS depressants	group	73-87	alcohol	drug	100-106	false	the cns depressant effect of propoxyphene is additive with that of other druga , including drugb .
DDI-DrugBank.d690.s3	propoxyphene	drug	41-52	antidepressants	group	86-100	false	such occurrences have been reported when druga was administered to patients on drugb , anticonvulsants , or warfarin like drugs .
DDI-DrugBank.d690.s3	propoxyphene	drug	41-52	anticonvulsants	group	103-117	false	such occurrences have been reported when druga was administered to patients on antidepressants , drugb , or warfarin like drugs .
DDI-DrugBank.d690.s3	propoxyphene	drug	41-52	warfarin	drug	123-130	false	such occurrences have been reported when druga was administered to patients on antidepressants , anticonvulsants , or drugb like drugs .
DDI-DrugBank.d690.s3	antidepressants	group	86-100	anticonvulsants	group	103-117	false	such occurrences have been reported when propoxyphene was administered to patients on druga , drugb , or warfarin like drugs .
DDI-DrugBank.d690.s3	antidepressants	group	86-100	warfarin	drug	123-130	false	such occurrences have been reported when propoxyphene was administered to patients on druga , anticonvulsants , or drugb like drugs .
DDI-DrugBank.d690.s3	anticonvulsants	group	103-117	warfarin	drug	123-130	false	such occurrences have been reported when propoxyphene was administered to patients on antidepressants , druga , or drugb like drugs .
DDI-DrugBank.d606.s0	MAO inhibitors	group	0-13	beta adrenergic blockers	group	19-42	false	druga and drugb increase the effects of pseudoephedrine .
DDI-DrugBank.d606.s0	MAO inhibitors	group	0-13	pseudoephedrine	drug	68-82	effect	druga and beta adrenergic blockers increase the effects of drugb .
DDI-DrugBank.d606.s0	beta adrenergic blockers	group	19-42	pseudoephedrine	drug	68-82	effect	mao inhibitors and druga increase the effects of drugb .
DDI-DrugBank.d606.s1	Sympathomimetics	group	0-15	methyldopa	drug	60-69	effect	druga may reduce the antihypertensive effects of drugb , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1	Sympathomimetics	group	0-15	mecamylamine	drug	72-83	effect	druga may reduce the antihypertensive effects of methyldopa , drugb , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1	Sympathomimetics	group	0-15	reserpine	drug	86-94	effect	druga may reduce the antihypertensive effects of methyldopa , mecamylamine , drugb and veratrum alkaloids .
DDI-DrugBank.d606.s1	Sympathomimetics	group	0-15	veratrum alkaloids	group	100-117	effect	druga may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and drugb .
DDI-DrugBank.d606.s1	methyldopa	drug	60-69	mecamylamine	drug	72-83	false	sympathomimetics may reduce the antihypertensive effects of druga , drugb , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1	methyldopa	drug	60-69	reserpine	drug	86-94	false	sympathomimetics may reduce the antihypertensive effects of druga , mecamylamine , drugb and veratrum alkaloids .
DDI-DrugBank.d606.s1	methyldopa	drug	60-69	veratrum alkaloids	group	100-117	false	sympathomimetics may reduce the antihypertensive effects of druga , mecamylamine , reserpine and drugb .
DDI-DrugBank.d606.s1	mecamylamine	drug	72-83	reserpine	drug	86-94	false	sympathomimetics may reduce the antihypertensive effects of methyldopa , druga , drugb and veratrum alkaloids .
DDI-DrugBank.d606.s1	mecamylamine	drug	72-83	veratrum alkaloids	group	100-117	false	sympathomimetics may reduce the antihypertensive effects of methyldopa , druga , reserpine and drugb .
DDI-DrugBank.d606.s1	reserpine	drug	86-94	veratrum alkaloids	group	100-117	false	sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , druga and drugb .
DDI-DrugBank.d631.s0	Pyrimethamine	drug	0-12	sulfonamides	group	31-42	false	druga may be used with drugb , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0	Pyrimethamine	drug	0-12	quinine	drug	45-51	false	druga may be used with sulfonamides , drugb and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0	Pyrimethamine	drug	0-12	antimalarials	group	63-75	false	druga may be used with sulfonamides , quinine and other drugb , and with other antibiotics .
DDI-DrugBank.d631.s0	Pyrimethamine	drug	0-12	antibiotics	group	93-103	false	druga may be used with sulfonamides , quinine and other antimalarials , and with other drugb .
DDI-DrugBank.d631.s0	sulfonamides	group	31-42	quinine	drug	45-51	false	pyrimethamine may be used with druga , drugb and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0	sulfonamides	group	31-42	antimalarials	group	63-75	false	pyrimethamine may be used with druga , quinine and other drugb , and with other antibiotics .
DDI-DrugBank.d631.s0	sulfonamides	group	31-42	antibiotics	group	93-103	false	pyrimethamine may be used with druga , quinine and other antimalarials , and with other drugb .
DDI-DrugBank.d631.s0	quinine	drug	45-51	antimalarials	group	63-75	false	pyrimethamine may be used with sulfonamides , druga and other drugb , and with other antibiotics .
DDI-DrugBank.d631.s0	quinine	drug	45-51	antibiotics	group	93-103	false	pyrimethamine may be used with sulfonamides , druga and other antimalarials , and with other drugb .
DDI-DrugBank.d631.s0	antimalarials	group	63-75	antibiotics	group	93-103	false	pyrimethamine may be used with sulfonamides , quinine and other druga , and with other drugb .
DDI-DrugBank.d631.s2	Folinic acid	drug	0-11	leucovorin	drug	14-23	false	druga ( drugb ) should be administered until normal hematopoiesis is restored .
DDI-DrugBank.d631.s3	lorazepam	drug	60-68	pyrimethamine	drug	74-86	effect	mild hepatotoxicity has been reported in some patients when druga and drugb were administered concomitantly .
DDI-DrugBank.d648.s0	Cholestyramine	drug	0-13	Cholestyramine	drug	16-29	false	druga : drugb causes a dg % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista .
DDI-DrugBank.d648.s0	Cholestyramine	drug	0-13	raloxifene	drug	101-110	false	druga : cholestyramine causes a dg % reduction in the absorption and enterohepatic cycling of drugb and should not be coadministered with evista .
DDI-DrugBank.d648.s0	Cholestyramine	drug	0-13	EVISTA	brand	150-155	false	druga : cholestyramine causes a dg % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with drugb .
DDI-DrugBank.d648.s0	Cholestyramine	drug	16-29	raloxifene	drug	101-110	mechanism	cholestyramine : druga causes a dg % reduction in the absorption and enterohepatic cycling of drugb and should not be coadministered with evista .
DDI-DrugBank.d648.s0	Cholestyramine	drug	16-29	EVISTA	brand	150-155	advise	cholestyramine : druga causes a dg % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with drugb .
DDI-DrugBank.d648.s0	raloxifene	drug	101-110	EVISTA	brand	150-155	false	cholestyramine : cholestyramine causes a dg % reduction in the absorption and enterohepatic cycling of druga and should not be coadministered with drugb .
DDI-DrugBank.d648.s1	Warfarin	drug	0-7	EVISTA	brand	34-39	false	druga : the coadministration of drugb and warfarin has not been assessed under chronic conditions .
DDI-DrugBank.d648.s1	Warfarin	drug	0-7	warfarin	drug	45-52	false	druga : the coadministration of evista and drugb has not been assessed under chronic conditions .
DDI-DrugBank.d648.s1	EVISTA	brand	34-39	warfarin	drug	45-52	false	warfarin : the coadministration of druga and drugb has not been assessed under chronic conditions .
DDI-DrugBank.d648.s3	EVISTA	brand	3-8	warfarin	drug	37-44	advise	if druga is given concurrently with drugb , prothrombin time should be monitored .
DDI-DrugBank.d648.s5	raloxifene	drug	10-19	warfarin	drug	51-58	false	in vitro , druga did not affect the binding of drugb , phenytoin , or tamoxifen .
DDI-DrugBank.d648.s5	raloxifene	drug	10-19	phenytoin	drug	61-69	false	in vitro , druga did not affect the binding of warfarin , drugb , or tamoxifen .
DDI-DrugBank.d648.s5	raloxifene	drug	10-19	tamoxifen	drug	75-83	false	in vitro , druga did not affect the binding of warfarin , phenytoin , or drugb .
DDI-DrugBank.d648.s5	warfarin	drug	51-58	phenytoin	drug	61-69	false	in vitro , raloxifene did not affect the binding of druga , drugb , or tamoxifen .
DDI-DrugBank.d648.s5	warfarin	drug	51-58	tamoxifen	drug	75-83	false	in vitro , raloxifene did not affect the binding of druga , phenytoin , or drugb .
DDI-DrugBank.d648.s5	phenytoin	drug	61-69	tamoxifen	drug	75-83	false	in vitro , raloxifene did not affect the binding of warfarin , druga , or drugb .
DDI-DrugBank.d648.s6	EVISTA	brand	28-33	clofibrate	drug	100-109	advise	caution should be used when druga is coadministered with other highly protein bound drugs , such as drugb , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	EVISTA	brand	28-33	indomethacin	drug	112-123	advise	caution should be used when druga is coadministered with other highly protein bound drugs , such as clofibrate , drugb , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	EVISTA	brand	28-33	naproxen	drug	126-133	advise	caution should be used when druga is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , drugb , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	EVISTA	brand	28-33	ibuprofen	drug	136-144	advise	caution should be used when druga is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , naproxen , drugb , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	EVISTA	brand	28-33	diazepam	drug	147-154	advise	caution should be used when druga is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , drugb , and diazoxide .
DDI-DrugBank.d648.s6	EVISTA	brand	28-33	diazoxide	drug	161-169	advise	caution should be used when druga is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and drugb .
DDI-DrugBank.d648.s6	clofibrate	drug	100-109	indomethacin	drug	112-123	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as druga , drugb , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	clofibrate	drug	100-109	naproxen	drug	126-133	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as druga , indomethacin , drugb , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	clofibrate	drug	100-109	ibuprofen	drug	136-144	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as druga , indomethacin , naproxen , drugb , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	clofibrate	drug	100-109	diazepam	drug	147-154	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as druga , indomethacin , naproxen , ibuprofen , drugb , and diazoxide .
DDI-DrugBank.d648.s6	clofibrate	drug	100-109	diazoxide	drug	161-169	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as druga , indomethacin , naproxen , ibuprofen , diazepam , and drugb .
DDI-DrugBank.d648.s6	indomethacin	drug	112-123	naproxen	drug	126-133	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , druga , drugb , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	indomethacin	drug	112-123	ibuprofen	drug	136-144	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , druga , naproxen , drugb , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	indomethacin	drug	112-123	diazepam	drug	147-154	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , druga , naproxen , ibuprofen , drugb , and diazoxide .
DDI-DrugBank.d648.s6	indomethacin	drug	112-123	diazoxide	drug	161-169	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , druga , naproxen , ibuprofen , diazepam , and drugb .
DDI-DrugBank.d648.s6	naproxen	drug	126-133	ibuprofen	drug	136-144	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , druga , drugb , diazepam , and diazoxide .
DDI-DrugBank.d648.s6	naproxen	drug	126-133	diazepam	drug	147-154	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , druga , ibuprofen , drugb , and diazoxide .
DDI-DrugBank.d648.s6	naproxen	drug	126-133	diazoxide	drug	161-169	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , druga , ibuprofen , diazepam , and drugb .
DDI-DrugBank.d648.s6	ibuprofen	drug	136-144	diazepam	drug	147-154	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , naproxen , druga , drugb , and diazoxide .
DDI-DrugBank.d648.s6	ibuprofen	drug	136-144	diazoxide	drug	161-169	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , naproxen , druga , diazepam , and drugb .
DDI-DrugBank.d648.s6	diazepam	drug	147-154	diazoxide	drug	161-169	false	caution should be used when evista is coadministered with other highly protein bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , druga , and drugb .
DDI-DrugBank.d590.s0	TRITEC	brand	20-25	clarithromycin	drug	32-45	mechanism	coadministration of druga with drugb resulted in increased plasma ranitidine concentrations ( dg % ) , increased plasma bismuth trough concentrations ( dg % ) , and increased dg hydroxy clarithromycin plasma concentrations ( dg % ) .
DDI-DrugBank.d590.s0	TRITEC	brand	20-25	ranitidine	drug	76-85	false	coadministration of druga with clarithromycin resulted in increased plasma drugb concentrations ( dg % ) , increased plasma bismuth trough concentrations ( dg % ) , and increased dg hydroxy clarithromycin plasma concentrations ( dg % ) .
DDI-DrugBank.d590.s0	TRITEC	brand	20-25	14- hydroxy- clarithromycin	drug_n	177-203	false	coadministration of druga with clarithromycin resulted in increased plasma ranitidine concentrations ( dg % ) , increased plasma bismuth trough concentrations ( dg % ) , and increased drugb plasma concentrations ( dg % ) .
DDI-DrugBank.d590.s0	clarithromycin	drug	32-45	ranitidine	drug	76-85	false	coadministration of tritec with druga resulted in increased plasma drugb concentrations ( dg % ) , increased plasma bismuth trough concentrations ( dg % ) , and increased dg hydroxy clarithromycin plasma concentrations ( dg % ) .
DDI-DrugBank.d590.s0	clarithromycin	drug	32-45	14- hydroxy- clarithromycin	drug_n	177-203	false	coadministration of tritec with druga resulted in increased plasma ranitidine concentrations ( dg % ) , increased plasma bismuth trough concentrations ( dg % ) , and increased drugb plasma concentrations ( dg % ) .
DDI-DrugBank.d590.s0	ranitidine	drug	76-85	14- hydroxy- clarithromycin	drug_n	177-203	false	coadministration of tritec with clarithromycin resulted in increased plasma druga concentrations ( dg % ) , increased plasma bismuth trough concentrations ( dg % ) , and increased drugb plasma concentrations ( dg % ) .
DDI-DrugBank.d590.s1	aspirin	brand	22-28	salicylate	group	74-83	false	coadministration with druga results in a slight decrease in the rate of drugb absorption that is clinically unimportant .
DDI-DrugBank.d590.s2	antacid	group	37-43	ranitidine	drug	109-118	mechanism	coadministration with a high dose of druga ( dg meq ) results in a dg % decrease in plasma concentrations of drugb and may decrease plasma concentrations of bismuth from tritec .
DDI-DrugBank.d590.s2	antacid	group	37-43	TRITEC	brand	175-180	mechanism	coadministration with a high dose of druga ( dg meq ) results in a dg % decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from drugb .
DDI-DrugBank.d590.s2	ranitidine	drug	109-118	TRITEC	brand	175-180	false	coadministration with a high dose of antacid ( dg meq ) results in a dg % decrease in plasma concentrations of druga and may decrease plasma concentrations of bismuth from drugb .
DDI-DrugBank.d590.s4	ranitidine	drug	53-62	ZANTAC	brand	78-83	false	for information on drug interactions associated with druga , refer to the drugb package insert .
DDI-DrugBank.d654.s0	ketoconazole	drug	26-37	retapamulin	drug	68-78	false	co administration of oral druga dg mg twice daily increased drugb geometric mean auc ( dg dg ) and cmax by dg % after topical application of retapamulin ointment , dg % on the abraded skin of healthy adult males .
DDI-DrugBank.d654.s0	ketoconazole	drug	26-37	retapamulin	drug	150-160	mechanism	co administration of oral druga dg mg twice daily increased retapamulin geometric mean auc ( dg dg ) and cmax by dg % after topical application of drugb ointment , dg % on the abraded skin of healthy adult males .
DDI-DrugBank.d654.s0	retapamulin	drug	68-78	retapamulin	drug	150-160	false	co administration of oral ketoconazole dg mg twice daily increased druga geometric mean auc ( dg dg ) and cmax by dg % after topical application of drugb ointment , dg % on the abraded skin of healthy adult males .
DDI-DrugBank.d654.s1	retapamulin	drug	32-42	retapamulin	drug	110-120	false	due to low systemic exposure to druga following topical application in patients , dosage adjustments for drugb are unnecessary when co administered with cyp3a4 inhibitors , such as ketoconazole .
DDI-DrugBank.d654.s1	retapamulin	drug	32-42	ketoconazole	drug	191-202	false	due to low systemic exposure to druga following topical application in patients , dosage adjustments for retapamulin are unnecessary when co administered with cyp3a4 inhibitors , such as drugb .
DDI-DrugBank.d654.s1	retapamulin	drug	110-120	ketoconazole	drug	191-202	false	due to low systemic exposure to retapamulin following topical application in patients , dosage adjustments for druga are unnecessary when co administered with cyp3a4 inhibitors , such as drugb .
DDI-DrugBank.d654.s2	ALTABAX	brand	114-120	retapamulin	drug	123-133	false	based on in vitro p450 inhibition studies and the low systemic exposure observed following topical application of druga , drugb is unlikely to affect the metabolism of other p450 substrates .
DDI-DrugBank.d618.s1	heparin	drug	40-46	vitamin K antagonists	group	52-72	false	in addition to bleeding associated with druga and drugb , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	heparin	drug	40-46	aspirin	brand	119-125	false	in addition to bleeding associated with druga and vitamin k antagonists , drugs that alter platelet function ( such as drugb , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	heparin	drug	40-46	dipyridamole	drug	128-139	false	in addition to bleeding associated with druga and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , drugb , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	heparin	drug	40-46	abciximab	drug	146-154	false	in addition to bleeding associated with druga and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and drugb ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	heparin	drug	40-46	Retavase	brand	225-232	effect	in addition to bleeding associated with druga and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d618.s1	vitamin K antagonists	group	52-72	aspirin	brand	119-125	false	in addition to bleeding associated with heparin and druga , drugs that alter platelet function ( such as drugb , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	vitamin K antagonists	group	52-72	dipyridamole	drug	128-139	false	in addition to bleeding associated with heparin and druga , drugs that alter platelet function ( such as aspirin , drugb , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	vitamin K antagonists	group	52-72	abciximab	drug	146-154	false	in addition to bleeding associated with heparin and druga , drugs that alter platelet function ( such as aspirin , dipyridamole , and drugb ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	vitamin K antagonists	group	52-72	Retavase	brand	225-232	effect	in addition to bleeding associated with heparin and druga , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d618.s1	aspirin	brand	119-125	dipyridamole	drug	128-139	false	in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as druga , drugb , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	aspirin	brand	119-125	abciximab	drug	146-154	false	in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as druga , dipyridamole , and drugb ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	aspirin	brand	119-125	Retavase	brand	225-232	effect	in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as druga , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d618.s1	dipyridamole	drug	128-139	abciximab	drug	146-154	false	in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , druga , and drugb ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1	dipyridamole	drug	128-139	Retavase	brand	225-232	effect	in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , druga , and abciximab ) may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d618.s1	abciximab	drug	146-154	Retavase	brand	225-232	effect	in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and druga ) may increase the risk of bleeding if administered prior to or after drugb therapy .
DDI-DrugBank.d698.s0	Vitamin B2	drug	17-26	Riboflavin	drug	29-38	false	interactions for druga ( drugb ) : alcohol impairs the intestinal absorption of riboflavin
DDI-DrugBank.d698.s0	Vitamin B2	drug	17-26	Alcohol	drug	43-49	false	interactions for druga ( riboflavin ) : drugb impairs the intestinal absorption of riboflavin
DDI-DrugBank.d698.s0	Vitamin B2	drug	17-26	riboflavin	drug	90-99	false	interactions for druga ( riboflavin ) : alcohol impairs the intestinal absorption of drugb
DDI-DrugBank.d698.s0	Riboflavin	drug	29-38	Alcohol	drug	43-49	false	interactions for vitamin b2 ( druga ) : drugb impairs the intestinal absorption of riboflavin
DDI-DrugBank.d698.s0	Riboflavin	drug	29-38	riboflavin	drug	90-99	false	interactions for vitamin b2 ( druga ) : alcohol impairs the intestinal absorption of drugb
DDI-DrugBank.d698.s0	Alcohol	drug	43-49	riboflavin	drug	90-99	mechanism	interactions for vitamin b2 ( riboflavin ) : druga impairs the intestinal absorption of drugb
DDI-DrugBank.d698.s1	Probenecid	drug	0-9	riboflavin	drug	69-78	mechanism	druga concurrent use decreases gastrointestinal absorption of drugb ;
DDI-DrugBank.d698.s2	riboflavin	drug	17-26	probenecid	drug	67-76	effect	requirements for druga may be increased in patients receiving drugb .
DDI-DrugBank.d710.s0	Cimetidine	drug	0-9	cimetidine	drug	35-44	false	druga : the effects of chronic drugb use on the metabolism of rimantadine are not known .
DDI-DrugBank.d710.s0	Cimetidine	drug	0-9	rimantadine	drug	71-81	false	druga : the effects of chronic cimetidine use on the metabolism of drugb are not known .
DDI-DrugBank.d710.s0	cimetidine	drug	35-44	rimantadine	drug	71-81	false	cimetidine : the effects of chronic druga use on the metabolism of drugb are not known .
DDI-DrugBank.d710.s1	rimantadine HCl	drug	29-43	Cimetidine	drug	95-104	mechanism	when a single dg mg dose of druga was administered one hour after the initiation of drugb ( dg mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1	rimantadine HCl	drug	29-43	rimantadine	drug	152-162	false	when a single dg mg dose of druga was administered one hour after the initiation of cimetidine ( dg mg four times a day ) , the apparent total drugb clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1	rimantadine HCl	drug	29-43	rimantadine	drug	270-280	false	when a single dg mg dose of druga was administered one hour after the initiation of cimetidine ( dg mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total drugb clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1	rimantadine HCl	drug	29-43	cimetidine	drug	331-340	false	when a single dg mg dose of druga was administered one hour after the initiation of cimetidine ( dg mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of drugb ) .
DDI-DrugBank.d710.s1	Cimetidine	drug	95-104	rimantadine	drug	152-162	false	when a single dg mg dose of rimantadine hcl was administered one hour after the initiation of druga ( dg mg four times a day ) , the apparent total drugb clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1	Cimetidine	drug	95-104	rimantadine	drug	270-280	false	when a single dg mg dose of rimantadine hcl was administered one hour after the initiation of druga ( dg mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total drugb clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1	Cimetidine	drug	95-104	cimetidine	drug	331-340	false	when a single dg mg dose of rimantadine hcl was administered one hour after the initiation of druga ( dg mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of drugb ) .
DDI-DrugBank.d710.s1	rimantadine	drug	152-162	rimantadine	drug	270-280	false	when a single dg mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( dg mg four times a day ) , the apparent total druga clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total drugb clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1	rimantadine	drug	152-162	cimetidine	drug	331-340	false	when a single dg mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( dg mg four times a day ) , the apparent total druga clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of drugb ) .
DDI-DrugBank.d710.s1	rimantadine	drug	270-280	cimetidine	drug	331-340	false	when a single dg mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( dg mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by dg % ( compared to the apparent total druga clearance in the same subjects in the absence of drugb ) .
DDI-DrugBank.d710.s2	Acetaminophen	drug	0-12	Rimantadine HCl	drug	15-29	false	druga : drugb , dg mg , was given twice daily for dg days to dg healthy volunteers .
DDI-DrugBank.d710.s5	acetaminophen	drug	22-34	rimantadine	drug	86-96	mechanism	coadministration with druga reduced the peak concentration and auc values for drugb by approximately dg % .
DDI-DrugBank.d710.s6	Aspirin	brand	0-6	Rimantadine HCl	drug	9-23	false	druga : drugb , dg mg , was given twice daily fro dg days to dg healthy volunteers .
DDI-DrugBank.d710.s9	rimantadine	drug	38-48	aspirin	brand	100-106	mechanism	peak plasma concentrations and auc of druga were reduced approximately dg % in the presence of drugb .
DDI-DrugBank.d596.s0	Exelon	brand	33-38	rivastigmine tartrate	drug	44-64	false	drug drug interactions effect of druga ( drugb ) on the metabolism of other drugs : rivastigmine is primarily metabolized through hydrolysis by esterases .
DDI-DrugBank.d596.s0	Exelon	brand	33-38	Rivastigmine	drug	101-112	false	drug drug interactions effect of druga ( rivastigmine tartrate ) on the metabolism of other drugs : drugb is primarily metabolized through hydrolysis by esterases .
DDI-DrugBank.d596.s0	rivastigmine tartrate	drug	44-64	Rivastigmine	drug	101-112	false	drug drug interactions effect of exelon ( druga ) on the metabolism of other drugs : drugb is primarily metabolized through hydrolysis by esterases .
DDI-DrugBank.d596.s3	rivastigmine	drug	52-63	digoxin	drug	69-75	false	no pharmacokinetic interaction was observed between druga and drugb , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3	rivastigmine	drug	52-63	warfarin	drug	78-85	false	no pharmacokinetic interaction was observed between druga and digoxin , drugb , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3	rivastigmine	drug	52-63	diazepam	drug	88-95	false	no pharmacokinetic interaction was observed between druga and digoxin , warfarin , drugb , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3	rivastigmine	drug	52-63	fluoxetine	drug	101-110	false	no pharmacokinetic interaction was observed between druga and digoxin , warfarin , diazepam , or drugb in studies in healthy volunteers .
DDI-DrugBank.d596.s3	digoxin	drug	69-75	warfarin	drug	78-85	false	no pharmacokinetic interaction was observed between rivastigmine and druga , drugb , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3	digoxin	drug	69-75	diazepam	drug	88-95	false	no pharmacokinetic interaction was observed between rivastigmine and druga , warfarin , drugb , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3	digoxin	drug	69-75	fluoxetine	drug	101-110	false	no pharmacokinetic interaction was observed between rivastigmine and druga , warfarin , diazepam , or drugb in studies in healthy volunteers .
DDI-DrugBank.d596.s3	warfarin	drug	78-85	diazepam	drug	88-95	false	no pharmacokinetic interaction was observed between rivastigmine and digoxin , druga , drugb , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3	warfarin	drug	78-85	fluoxetine	drug	101-110	false	no pharmacokinetic interaction was observed between rivastigmine and digoxin , druga , diazepam , or drugb in studies in healthy volunteers .
DDI-DrugBank.d596.s3	diazepam	drug	88-95	fluoxetine	drug	101-110	false	no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , druga , or drugb in studies in healthy volunteers .
DDI-DrugBank.d596.s4	warfarin	drug	45-52	Exelon	brand	91-96	false	the elevation of prothrombin time induced by druga is not affected by administration of drugb .
DDI-DrugBank.d596.s5	Exelon	brand	43-48	rivastigmine	drug	142-153	false	effect of other drugs on the metabolism of druga : drugs that induce or inhibit cyp450 metabolism are not expected to alter the metabolism of drugb .
DDI-DrugBank.d596.s6	rivastigmine	drug	72-83	digoxin	drug	147-153	false	single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of drugb , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6	rivastigmine	drug	72-83	warfarin	drug	156-163	false	single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of digoxin , drugb , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6	rivastigmine	drug	72-83	diazepam	drug	166-173	false	single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of digoxin , warfarin , drugb , or fluoxetine .
DDI-DrugBank.d596.s6	rivastigmine	drug	72-83	fluoxetine	drug	179-188	false	single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or drugb .
DDI-DrugBank.d596.s6	digoxin	drug	147-153	warfarin	drug	156-163	false	single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of druga , drugb , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6	digoxin	drug	147-153	diazepam	drug	166-173	false	single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of druga , warfarin , drugb , or fluoxetine .
DDI-DrugBank.d596.s6	digoxin	drug	147-153	fluoxetine	drug	179-188	false	single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of druga , warfarin , diazepam , or drugb .
DDI-DrugBank.d596.s6	warfarin	drug	156-163	diazepam	drug	166-173	false	single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , druga , drugb , or fluoxetine .
DDI-DrugBank.d596.s6	warfarin	drug	156-163	fluoxetine	drug	179-188	false	single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , druga , diazepam , or drugb .
DDI-DrugBank.d596.s6	diazepam	drug	166-173	fluoxetine	drug	179-188	false	single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , druga , or drugb .
DDI-DrugBank.d596.s7	rivastigmine	drug	91-102	antacids	group	167-174	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugb ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	rivastigmine	drug	91-102	antihypertensives	group	184-200	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as antacids ( n=77 ) , drugb ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	rivastigmine	drug	91-102	calcium channel blockers	group	210-233	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , drugb ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	rivastigmine	drug	91-102	antidiabetics	group	243-255	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , drugb ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	rivastigmine	drug	91-102	nonsteroidal anti-inflammatory drugs	group	265-300	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , drugb ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	rivastigmine	drug	91-102	estrogens	group	310-318	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , drugb ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	rivastigmine	drug	91-102	salicylate analgesics	group	328-348	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , drugb ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	rivastigmine	drug	91-102	antianginals	group	359-370	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , drugb ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	rivastigmine	drug	91-102	antihistamines	group	384-397	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and drugb ( n=15 ) .
DDI-DrugBank.d596.s7	antacids	group	167-174	antihypertensives	group	184-200	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as druga ( n=77 ) , drugb ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antacids	group	167-174	calcium channel blockers	group	210-233	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as druga ( n=77 ) , antihypertensives ( n=72 ) , drugb ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antacids	group	167-174	antidiabetics	group	243-255	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as druga ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , drugb ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antacids	group	167-174	nonsteroidal anti-inflammatory drugs	group	265-300	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as druga ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , drugb ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antacids	group	167-174	estrogens	group	310-318	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as druga ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , drugb ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antacids	group	167-174	salicylate analgesics	group	328-348	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as druga ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , drugb ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antacids	group	167-174	antianginals	group	359-370	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as druga ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , drugb ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antacids	group	167-174	antihistamines	group	384-397	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as druga ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and drugb ( n=15 ) .
DDI-DrugBank.d596.s7	antihypertensives	group	184-200	calcium channel blockers	group	210-233	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , druga ( n=72 ) , drugb ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antihypertensives	group	184-200	antidiabetics	group	243-255	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , druga ( n=72 ) , calcium channel blockers ( n=75 ) , drugb ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antihypertensives	group	184-200	nonsteroidal anti-inflammatory drugs	group	265-300	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , druga ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , drugb ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antihypertensives	group	184-200	estrogens	group	310-318	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , druga ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , drugb ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antihypertensives	group	184-200	salicylate analgesics	group	328-348	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , druga ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , drugb ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antihypertensives	group	184-200	antianginals	group	359-370	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , druga ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , drugb ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antihypertensives	group	184-200	antihistamines	group	384-397	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , druga ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and drugb ( n=15 ) .
DDI-DrugBank.d596.s7	calcium channel blockers	group	210-233	antidiabetics	group	243-255	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , druga ( n=75 ) , drugb ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	calcium channel blockers	group	210-233	nonsteroidal anti-inflammatory drugs	group	265-300	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , druga ( n=75 ) , antidiabetics ( n=21 ) , drugb ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	calcium channel blockers	group	210-233	estrogens	group	310-318	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , druga ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , drugb ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	calcium channel blockers	group	210-233	salicylate analgesics	group	328-348	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , druga ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , drugb ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	calcium channel blockers	group	210-233	antianginals	group	359-370	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , druga ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , drugb ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	calcium channel blockers	group	210-233	antihistamines	group	384-397	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , druga ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and drugb ( n=15 ) .
DDI-DrugBank.d596.s7	antidiabetics	group	243-255	nonsteroidal anti-inflammatory drugs	group	265-300	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , druga ( n=21 ) , drugb ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antidiabetics	group	243-255	estrogens	group	310-318	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , druga ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , drugb ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antidiabetics	group	243-255	salicylate analgesics	group	328-348	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , druga ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , drugb ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antidiabetics	group	243-255	antianginals	group	359-370	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , druga ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , drugb ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	antidiabetics	group	243-255	antihistamines	group	384-397	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , druga ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and drugb ( n=15 ) .
DDI-DrugBank.d596.s7	nonsteroidal anti-inflammatory drugs	group	265-300	estrogens	group	310-318	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , druga ( n=79 ) , drugb ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	nonsteroidal anti-inflammatory drugs	group	265-300	salicylate analgesics	group	328-348	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , druga ( n=79 ) , estrogens ( n=70 ) , drugb ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	nonsteroidal anti-inflammatory drugs	group	265-300	antianginals	group	359-370	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , druga ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , drugb ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	nonsteroidal anti-inflammatory drugs	group	265-300	antihistamines	group	384-397	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , druga ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and drugb ( n=15 ) .
DDI-DrugBank.d596.s7	estrogens	group	310-318	salicylate analgesics	group	328-348	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , druga ( n=70 ) , drugb ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	estrogens	group	310-318	antianginals	group	359-370	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , druga ( n=70 ) , salicylate analgesics ( n=177 ) , drugb ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	estrogens	group	310-318	antihistamines	group	384-397	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , druga ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and drugb ( n=15 ) .
DDI-DrugBank.d596.s7	salicylate analgesics	group	328-348	antianginals	group	359-370	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , druga ( n=177 ) , drugb ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7	salicylate analgesics	group	328-348	antihistamines	group	384-397	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , druga ( n=177 ) , antianginals ( n=35 ) , and drugb ( n=15 ) .
DDI-DrugBank.d596.s7	antianginals	group	359-370	antihistamines	group	384-397	false	population pk analysis with a database of dg patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , druga ( n=35 ) , and drugb ( n=15 ) .
DDI-DrugBank.d596.s8	Anticholinergics	group	9-24	cholinesterase inhibitors	group	65-89	false	use with druga : because of their mechanism of action , drugb have the potential to interfere with the activity of anticholinergic medications .
DDI-DrugBank.d596.s8	Anticholinergics	group	9-24	anticholinergic medications	group	144-170	false	use with druga : because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of drugb .
DDI-DrugBank.d596.s8	cholinesterase inhibitors	group	65-89	anticholinergic medications	group	144-170	int	use with anticholinergics : because of their mechanism of action , druga have the potential to interfere with the activity of drugb .
DDI-DrugBank.d596.s9	Cholinomimetics	group	9-23	Cholinesterase Inhibitors	group	35-59	false	use with druga and other drugb : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	Cholinomimetics	group	9-23	cholinesterase inhibitors	group	104-128	false	use with druga and other cholinesterase inhibitors : a synergistic effect may be expected when drugb are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	Cholinomimetics	group	9-23	succinylcholine	drug	158-172	false	use with druga and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with drugb , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	Cholinomimetics	group	9-23	neuromuscular blocking agents	group	183-211	false	use with druga and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar drugb or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	Cholinomimetics	group	9-23	cholinergic agonists	group	216-235	false	use with druga and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or drugb such as bethanechol .
DDI-DrugBank.d596.s9	Cholinomimetics	group	9-23	bethanechol	drug	245-255	false	use with druga and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as drugb .
DDI-DrugBank.d596.s9	Cholinesterase Inhibitors	group	35-59	cholinesterase inhibitors	group	104-128	false	use with cholinomimetics and other druga : a synergistic effect may be expected when drugb are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	Cholinesterase Inhibitors	group	35-59	succinylcholine	drug	158-172	false	use with cholinomimetics and other druga : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with drugb , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	Cholinesterase Inhibitors	group	35-59	neuromuscular blocking agents	group	183-211	false	use with cholinomimetics and other druga : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar drugb or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	Cholinesterase Inhibitors	group	35-59	cholinergic agonists	group	216-235	false	use with cholinomimetics and other druga : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or drugb such as bethanechol .
DDI-DrugBank.d596.s9	Cholinesterase Inhibitors	group	35-59	bethanechol	drug	245-255	false	use with cholinomimetics and other druga : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as drugb .
DDI-DrugBank.d596.s9	cholinesterase inhibitors	group	104-128	succinylcholine	drug	158-172	effect	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when druga are given concurrently with drugb , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	cholinesterase inhibitors	group	104-128	neuromuscular blocking agents	group	183-211	effect	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when druga are given concurrently with succinylcholine , similar drugb or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	cholinesterase inhibitors	group	104-128	cholinergic agonists	group	216-235	effect	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when druga are given concurrently with succinylcholine , similar neuromuscular blocking agents or drugb such as bethanechol .
DDI-DrugBank.d596.s9	cholinesterase inhibitors	group	104-128	bethanechol	drug	245-255	effect	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when druga are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as drugb .
DDI-DrugBank.d596.s9	succinylcholine	drug	158-172	neuromuscular blocking agents	group	183-211	false	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with druga , similar drugb or cholinergic agonists such as bethanechol .
DDI-DrugBank.d596.s9	succinylcholine	drug	158-172	cholinergic agonists	group	216-235	false	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with druga , similar neuromuscular blocking agents or drugb such as bethanechol .
DDI-DrugBank.d596.s9	succinylcholine	drug	158-172	bethanechol	drug	245-255	false	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with druga , similar neuromuscular blocking agents or cholinergic agonists such as drugb .
DDI-DrugBank.d596.s9	neuromuscular blocking agents	group	183-211	cholinergic agonists	group	216-235	false	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar druga or drugb such as bethanechol .
DDI-DrugBank.d596.s9	neuromuscular blocking agents	group	183-211	bethanechol	drug	245-255	false	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar druga or cholinergic agonists such as drugb .
DDI-DrugBank.d596.s9	cholinergic agonists	group	216-235	bethanechol	drug	245-255	false	use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or druga such as drugb .
DDI-DrugBank.d661.s0	ZEMURON	brand	30-36	rocuronium bromide	drug	42-59	false	drug interactions : the use of druga ( drugb ) injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied .
DDI-DrugBank.d661.s0	ZEMURON	brand	30-36	succinylcholine	drug	79-93	false	drug interactions : the use of druga ( rocuronium bromide ) injection before drugb , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied .
DDI-DrugBank.d661.s0	ZEMURON	brand	30-36	succinylcholine	drug	155-169	false	drug interactions : the use of druga ( rocuronium bromide ) injection before succinylcholine , for the purpose of attenuating some of the side effects of drugb , has not been studied .
DDI-DrugBank.d661.s0	rocuronium bromide	drug	42-59	succinylcholine	drug	79-93	false	drug interactions : the use of zemuron ( druga ) injection before drugb , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied .
DDI-DrugBank.d661.s0	rocuronium bromide	drug	42-59	succinylcholine	drug	155-169	false	drug interactions : the use of zemuron ( druga ) injection before succinylcholine , for the purpose of attenuating some of the side effects of drugb , has not been studied .
DDI-DrugBank.d661.s0	succinylcholine	drug	79-93	succinylcholine	drug	155-169	false	drug interactions : the use of zemuron ( rocuronium bromide ) injection before druga , for the purpose of attenuating some of the side effects of drugb , has not been studied .
DDI-DrugBank.d661.s1	ZEMURON	brand	3-9	succinylcholine	drug	58-72	advise	if druga is administered following administration of drugb , it should not be given until recovery from succinylcholine has been observed .
DDI-DrugBank.d661.s1	ZEMURON	brand	3-9	succinylcholine	drug	118-132	false	if druga is administered following administration of succinylcholine , it should not be given until recovery from drugb has been observed .
DDI-DrugBank.d661.s1	succinylcholine	drug	58-72	succinylcholine	drug	118-132	false	if zemuron is administered following administration of druga , it should not be given until recovery from drugb has been observed .
DDI-DrugBank.d661.s2	ZEMURON	brand	33-39	succinylcholine	drug	91-105	false	the median duration of action of druga dg mg / kg administered after a dg mg / kg dose of drugb when t dg returned to dg % of control was dg minutes ( range dg dg , n=12 ) vs .
DDI-DrugBank.d661.s4	ZEMURON	brand	55-61	nondepolarizing muscle relaxants	group	88-119	false	there are no controlled studies documenting the use of druga before or after other drugb .
DDI-DrugBank.d591.s0	Ropivacaine	drug	0-10	anesthetics	group	74-84	advise	druga should be used with caution in patients receiving other local drugb or agents structurally related to amide type local anesthetics , since the toxic effects of these drugs are additive .
DDI-DrugBank.d591.s0	Ropivacaine	drug	0-10	amide-type local anesthetics	group	120-147	false	druga should be used with caution in patients receiving other local anesthetics or agents structurally related to drugb , since the toxic effects of these drugs are additive .
DDI-DrugBank.d591.s0	anesthetics	group	74-84	amide-type local anesthetics	group	120-147	false	ropivacaine should be used with caution in patients receiving other local druga or agents structurally related to drugb , since the toxic effects of these drugs are additive .
DDI-DrugBank.d591.s2	ropivacaine	drug	33-43	fluvoxamine	drug	91-101	mechanism	in vivo , the plasma clearance of druga was reduced by dg % during coadministration of drugb ( dg mg bid for dg days ) , a selective and potent cyp1a2 inhibitor .
DDI-DrugBank.d591.s3	fluvoxamine	drug	54-64	Ropivacaine	drug	112-122	int	thus strong inhibitors of cytochrome p4501a2 , such as druga , given concomitantly during administration of drugb , can interact with ropivacaine leading to increased ropivacaine plasma levels .
DDI-DrugBank.d591.s3	fluvoxamine	drug	54-64	Ropivacaine	drug	143-153	false	thus strong inhibitors of cytochrome p4501a2 , such as druga , given concomitantly during administration of ropivacaine , can interact with drugb leading to increased ropivacaine plasma levels .
DDI-DrugBank.d591.s3	fluvoxamine	drug	54-64	ropivacaine	drug	176-186	false	thus strong inhibitors of cytochrome p4501a2 , such as druga , given concomitantly during administration of ropivacaine , can interact with ropivacaine leading to increased drugb plasma levels .
DDI-DrugBank.d591.s3	Ropivacaine	drug	112-122	Ropivacaine	drug	143-153	false	thus strong inhibitors of cytochrome p4501a2 , such as fluvoxamine , given concomitantly during administration of druga , can interact with drugb leading to increased ropivacaine plasma levels .
DDI-DrugBank.d591.s3	Ropivacaine	drug	112-122	ropivacaine	drug	176-186	false	thus strong inhibitors of cytochrome p4501a2 , such as fluvoxamine , given concomitantly during administration of druga , can interact with ropivacaine leading to increased drugb plasma levels .
DDI-DrugBank.d591.s3	Ropivacaine	drug	143-153	ropivacaine	drug	176-186	false	thus strong inhibitors of cytochrome p4501a2 , such as fluvoxamine , given concomitantly during administration of ropivacaine , can interact with druga leading to increased drugb plasma levels .
DDI-DrugBank.d591.s5	theophylline	drug	102-113	imipramine	drug	119-128	false	possible interactions with drugs known to be metabolized by cyp1a2 via competitive inhibition such as druga and drugb may also occur .
DDI-DrugBank.d591.s6	ketoconazole	drug	64-75	ropivacaine	drug	105-115	false	coadministration of a selective and potent inhibitor of cyp3a4 , druga ( dg mg bid for dg days with drugb infusion administered dg hour after ketoconazole ) caused a dg % reduction in in vivo plasma clearance of ropivacaine .
DDI-DrugBank.d591.s6	ketoconazole	drug	64-75	ketoconazole	drug	152-163	false	coadministration of a selective and potent inhibitor of cyp3a4 , druga ( dg mg bid for dg days with ropivacaine infusion administered dg hour after drugb ) caused a dg % reduction in in vivo plasma clearance of ropivacaine .
DDI-DrugBank.d591.s6	ketoconazole	drug	64-75	ropivacaine	drug	220-230	mechanism	coadministration of a selective and potent inhibitor of cyp3a4 , druga ( dg mg bid for dg days with ropivacaine infusion administered dg hour after ketoconazole ) caused a dg % reduction in in vivo plasma clearance of drugb .
DDI-DrugBank.d591.s6	ropivacaine	drug	105-115	ketoconazole	drug	152-163	false	coadministration of a selective and potent inhibitor of cyp3a4 , ketoconazole ( dg mg bid for dg days with druga infusion administered dg hour after drugb ) caused a dg % reduction in in vivo plasma clearance of ropivacaine .
DDI-DrugBank.d591.s6	ropivacaine	drug	105-115	ropivacaine	drug	220-230	false	coadministration of a selective and potent inhibitor of cyp3a4 , ketoconazole ( dg mg bid for dg days with druga infusion administered dg hour after ketoconazole ) caused a dg % reduction in in vivo plasma clearance of drugb .
DDI-DrugBank.d591.s6	ketoconazole	drug	152-163	ropivacaine	drug	220-230	false	coadministration of a selective and potent inhibitor of cyp3a4 , ketoconazole ( dg mg bid for dg days with ropivacaine infusion administered dg hour after druga ) caused a dg % reduction in in vivo plasma clearance of drugb .
DDI-DrugBank.d609.s0	gemfibrozil	drug	32-42	rosiglitazone	drug	69-81	mechanism	an inhibitor of cyp2c8 ( such as druga ) may increase the auc of drugb and an inducer of cyp2c8 ( such as rifampin ) may decrease the auc of rosiglitazone .
DDI-DrugBank.d609.s0	gemfibrozil	drug	32-42	rifampin	drug	117-124	false	an inhibitor of cyp2c8 ( such as druga ) may increase the auc of rosiglitazone and an inducer of cyp2c8 ( such as drugb ) may decrease the auc of rosiglitazone .
DDI-DrugBank.d609.s0	gemfibrozil	drug	32-42	rosiglitazone	drug	151-163	false	an inhibitor of cyp2c8 ( such as druga ) may increase the auc of rosiglitazone and an inducer of cyp2c8 ( such as rifampin ) may decrease the auc of drugb .
DDI-DrugBank.d609.s0	rosiglitazone	drug	69-81	rifampin	drug	117-124	false	an inhibitor of cyp2c8 ( such as gemfibrozil ) may increase the auc of druga and an inducer of cyp2c8 ( such as drugb ) may decrease the auc of rosiglitazone .
DDI-DrugBank.d609.s0	rosiglitazone	drug	69-81	rosiglitazone	drug	151-163	false	an inhibitor of cyp2c8 ( such as gemfibrozil ) may increase the auc of druga and an inducer of cyp2c8 ( such as rifampin ) may decrease the auc of drugb .
DDI-DrugBank.d609.s0	rifampin	drug	117-124	rosiglitazone	drug	151-163	mechanism	an inhibitor of cyp2c8 ( such as gemfibrozil ) may increase the auc of rosiglitazone and an inducer of cyp2c8 ( such as druga ) may decrease the auc of drugb .
DDI-DrugBank.d709.s1	Terfenadine	drug	48-58	astemizole	drug	64-73	false	concomitant administrations not recommended : druga and drugb : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1	Terfenadine	drug	48-58	macrolides	group	84-93	false	concomitant administrations not recommended : druga and astemizole : certain drugb interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1	Terfenadine	drug	48-58	terfenadine	drug	109-119	false	concomitant administrations not recommended : druga and astemizole : certain macrolides interact with drugb and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1	Terfenadine	drug	48-58	astemizole	drug	125-134	false	concomitant administrations not recommended : druga and astemizole : certain macrolides interact with terfenadine and drugb leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1	astemizole	drug	64-73	macrolides	group	84-93	false	concomitant administrations not recommended : terfenadine and druga : certain drugb interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1	astemizole	drug	64-73	terfenadine	drug	109-119	false	concomitant administrations not recommended : terfenadine and druga : certain macrolides interact with drugb and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1	astemizole	drug	64-73	astemizole	drug	125-134	false	concomitant administrations not recommended : terfenadine and druga : certain macrolides interact with terfenadine and drugb leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1	macrolides	group	84-93	terfenadine	drug	109-119	int	concomitant administrations not recommended : terfenadine and astemizole : certain druga interact with drugb and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1	macrolides	group	84-93	astemizole	drug	125-134	int	concomitant administrations not recommended : terfenadine and astemizole : certain druga interact with terfenadine and drugb leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1	terfenadine	drug	109-119	astemizole	drug	125-134	false	concomitant administrations not recommended : terfenadine and astemizole : certain macrolides interact with druga and drugb leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s3	roxithromycin	drug	56-68	roxithromycin	drug	101-113	false	although such a reaction has not been demonstrated with druga , concomitant administration of drugb with terfenadine or astemizole is not recommended .
DDI-DrugBank.d709.s3	roxithromycin	drug	56-68	terfenadine	drug	120-130	false	although such a reaction has not been demonstrated with druga , concomitant administration of roxithromycin with drugb or astemizole is not recommended .
DDI-DrugBank.d709.s3	roxithromycin	drug	56-68	astemizole	drug	135-144	false	although such a reaction has not been demonstrated with druga , concomitant administration of roxithromycin with terfenadine or drugb is not recommended .
DDI-DrugBank.d709.s3	roxithromycin	drug	101-113	terfenadine	drug	120-130	advise	although such a reaction has not been demonstrated with roxithromycin , concomitant administration of druga with drugb or astemizole is not recommended .
DDI-DrugBank.d709.s3	roxithromycin	drug	101-113	astemizole	drug	135-144	advise	although such a reaction has not been demonstrated with roxithromycin , concomitant administration of druga with terfenadine or drugb is not recommended .
DDI-DrugBank.d709.s3	terfenadine	drug	120-130	astemizole	drug	135-144	false	although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with druga or drugb is not recommended .
DDI-DrugBank.d709.s4	Cisapride	drug	2-10	pimozide	drug	13-20	false	druga , drugb : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials .
DDI-DrugBank.d709.s4	Cisapride	drug	2-10	cisapride	drug	43-51	false	druga , pimozide : other drugs such as drugb or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials .
DDI-DrugBank.d709.s4	Cisapride	drug	2-10	pimozide	drug	56-63	false	druga , pimozide : other drugs such as cisapride or drugb , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials .
DDI-DrugBank.d709.s4	Cisapride	drug	2-10	macrolide antibacterials	group	352-375	false	druga , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
DDI-DrugBank.d709.s4	pimozide	drug	13-20	cisapride	drug	43-51	false	cisapride , druga : other drugs such as drugb or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials .
DDI-DrugBank.d709.s4	pimozide	drug	13-20	pimozide	drug	56-63	false	cisapride , druga : other drugs such as cisapride or drugb , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials .
DDI-DrugBank.d709.s4	pimozide	drug	13-20	macrolide antibacterials	group	352-375	mechanism	cisapride , druga : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
DDI-DrugBank.d709.s4	cisapride	drug	43-51	pimozide	drug	56-63	false	cisapride , pimozide : other drugs such as druga or drugb , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials .
DDI-DrugBank.d709.s4	cisapride	drug	43-51	macrolide antibacterials	group	352-375	mechanism	cisapride , pimozide : other drugs such as druga or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
DDI-DrugBank.d709.s4	pimozide	drug	56-63	macrolide antibacterials	group	352-375	false	cisapride , pimozide : other drugs such as cisapride or druga , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
DDI-DrugBank.d709.s5	roxithromycin	drug	41-53	roxithromycin	drug	71-83	false	although such a risk is not verified for druga , combination of drugb with such drugs is not recommended .
DDI-DrugBank.d770.s4	diphosphonate	group	48-60	Calcitonin (salmon)	drug	116-134	effect	however , in patients with paget 's disease prior druga use appears to reduce the anti resorptive response to drugb nasal spray .
DDI-DrugBank.d576.s1	ASPIRIN	brand	0-6	SALICYLATE DRUGS	group	18-33	false	druga and other drugb will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels .
DDI-DrugBank.d576.s1	ASPIRIN	brand	0-6	DISALCID	brand	55-62	effect	druga and other salicylate drugs will be additive to drugb and may increase plasma concentrations of salicylic acid to toxic levels .
DDI-DrugBank.d576.s1	ASPIRIN	brand	0-6	SALICYLIC ACID	drug	106-119	false	druga and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of drugb to toxic levels .
DDI-DrugBank.d576.s1	SALICYLATE DRUGS	group	18-33	DISALCID	brand	55-62	effect	aspirin and other druga will be additive to drugb and may increase plasma concentrations of salicylic acid to toxic levels .
DDI-DrugBank.d576.s1	SALICYLATE DRUGS	group	18-33	SALICYLIC ACID	drug	106-119	false	aspirin and other druga will be additive to disalcid and may increase plasma concentrations of drugb to toxic levels .
DDI-DrugBank.d576.s1	DISALCID	brand	55-62	SALICYLIC ACID	drug	106-119	false	aspirin and other salicylate drugs will be additive to druga and may increase plasma concentrations of drugb to toxic levels .
DDI-DrugBank.d576.s4	Salicylates	group	0-10	anticoagulant drugs	group	37-55	effect	druga given concomitantly with drugb may predispose to systemic bleeding .
DDI-DrugBank.d576.s5	Salicylates	group	0-10	antidiabetic drugs	group	56-73	effect	druga may enhance the hypoglycemic effect of oral drugb of the sulfonylurea class .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	penicillin	drug	78-87	mechanism	druga competes with a number of drugs for protein binding sites , notably drugb , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	thiopental	drug	90-99	mechanism	druga competes with a number of drugs for protein binding sites , notably penicillin , drugb , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	thyroxine	drug	102-110	mechanism	druga competes with a number of drugs for protein binding sites , notably penicillin , thiopental , drugb , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	triiodothyronine	drug	113-128	mechanism	druga competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , drugb , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	phenytoin	drug	131-139	mechanism	druga competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , drugb , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	sulfinpyrazone	drug	142-155	mechanism	druga competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , drugb , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	naproxen	drug	158-165	mechanism	druga competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , drugb , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	warfarin	drug	168-175	mechanism	druga competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , drugb , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	methotrexate	drug	178-189	mechanism	druga competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , drugb , and possibly corticosteroids .
DDI-DrugBank.d576.s6	Salicylate	group	0-9	corticosteroids	group	205-219	mechanism	druga competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly drugb .
DDI-DrugBank.d576.s6	penicillin	drug	78-87	thiopental	drug	90-99	false	salicylate competes with a number of drugs for protein binding sites , notably druga , drugb , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	penicillin	drug	78-87	thyroxine	drug	102-110	false	salicylate competes with a number of drugs for protein binding sites , notably druga , thiopental , drugb , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	penicillin	drug	78-87	triiodothyronine	drug	113-128	false	salicylate competes with a number of drugs for protein binding sites , notably druga , thiopental , thyroxine , drugb , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	penicillin	drug	78-87	phenytoin	drug	131-139	false	salicylate competes with a number of drugs for protein binding sites , notably druga , thiopental , thyroxine , triiodothyronine , drugb , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	penicillin	drug	78-87	sulfinpyrazone	drug	142-155	false	salicylate competes with a number of drugs for protein binding sites , notably druga , thiopental , thyroxine , triiodothyronine , phenytoin , drugb , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	penicillin	drug	78-87	naproxen	drug	158-165	false	salicylate competes with a number of drugs for protein binding sites , notably druga , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , drugb , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	penicillin	drug	78-87	warfarin	drug	168-175	false	salicylate competes with a number of drugs for protein binding sites , notably druga , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , drugb , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	penicillin	drug	78-87	methotrexate	drug	178-189	false	salicylate competes with a number of drugs for protein binding sites , notably druga , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , drugb , and possibly corticosteroids .
DDI-DrugBank.d576.s6	penicillin	drug	78-87	corticosteroids	group	205-219	false	salicylate competes with a number of drugs for protein binding sites , notably druga , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly drugb .
DDI-DrugBank.d576.s6	thiopental	drug	90-99	thyroxine	drug	102-110	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , druga , drugb , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thiopental	drug	90-99	triiodothyronine	drug	113-128	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , druga , thyroxine , drugb , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thiopental	drug	90-99	phenytoin	drug	131-139	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , druga , thyroxine , triiodothyronine , drugb , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thiopental	drug	90-99	sulfinpyrazone	drug	142-155	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , druga , thyroxine , triiodothyronine , phenytoin , drugb , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thiopental	drug	90-99	naproxen	drug	158-165	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , druga , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , drugb , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thiopental	drug	90-99	warfarin	drug	168-175	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , druga , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , drugb , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thiopental	drug	90-99	methotrexate	drug	178-189	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , druga , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , drugb , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thiopental	drug	90-99	corticosteroids	group	205-219	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , druga , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly drugb .
DDI-DrugBank.d576.s6	thyroxine	drug	102-110	triiodothyronine	drug	113-128	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , druga , drugb , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thyroxine	drug	102-110	phenytoin	drug	131-139	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , druga , triiodothyronine , drugb , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thyroxine	drug	102-110	sulfinpyrazone	drug	142-155	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , druga , triiodothyronine , phenytoin , drugb , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thyroxine	drug	102-110	naproxen	drug	158-165	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , druga , triiodothyronine , phenytoin , sulfinpyrazone , drugb , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thyroxine	drug	102-110	warfarin	drug	168-175	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , druga , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , drugb , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thyroxine	drug	102-110	methotrexate	drug	178-189	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , druga , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , drugb , and possibly corticosteroids .
DDI-DrugBank.d576.s6	thyroxine	drug	102-110	corticosteroids	group	205-219	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , druga , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly drugb .
DDI-DrugBank.d576.s6	triiodothyronine	drug	113-128	phenytoin	drug	131-139	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , druga , drugb , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	triiodothyronine	drug	113-128	sulfinpyrazone	drug	142-155	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , druga , phenytoin , drugb , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	triiodothyronine	drug	113-128	naproxen	drug	158-165	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , druga , phenytoin , sulfinpyrazone , drugb , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	triiodothyronine	drug	113-128	warfarin	drug	168-175	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , druga , phenytoin , sulfinpyrazone , naproxen , drugb , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	triiodothyronine	drug	113-128	methotrexate	drug	178-189	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , druga , phenytoin , sulfinpyrazone , naproxen , warfarin , drugb , and possibly corticosteroids .
DDI-DrugBank.d576.s6	triiodothyronine	drug	113-128	corticosteroids	group	205-219	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , druga , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly drugb .
DDI-DrugBank.d576.s6	phenytoin	drug	131-139	sulfinpyrazone	drug	142-155	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , druga , drugb , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	phenytoin	drug	131-139	naproxen	drug	158-165	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , druga , sulfinpyrazone , drugb , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	phenytoin	drug	131-139	warfarin	drug	168-175	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , druga , sulfinpyrazone , naproxen , drugb , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	phenytoin	drug	131-139	methotrexate	drug	178-189	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , druga , sulfinpyrazone , naproxen , warfarin , drugb , and possibly corticosteroids .
DDI-DrugBank.d576.s6	phenytoin	drug	131-139	corticosteroids	group	205-219	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , druga , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly drugb .
DDI-DrugBank.d576.s6	sulfinpyrazone	drug	142-155	naproxen	drug	158-165	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , druga , drugb , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	sulfinpyrazone	drug	142-155	warfarin	drug	168-175	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , druga , naproxen , drugb , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	sulfinpyrazone	drug	142-155	methotrexate	drug	178-189	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , druga , naproxen , warfarin , drugb , and possibly corticosteroids .
DDI-DrugBank.d576.s6	sulfinpyrazone	drug	142-155	corticosteroids	group	205-219	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , druga , naproxen , warfarin , methotrexate , and possibly drugb .
DDI-DrugBank.d576.s6	naproxen	drug	158-165	warfarin	drug	168-175	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , druga , drugb , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6	naproxen	drug	158-165	methotrexate	drug	178-189	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , druga , warfarin , drugb , and possibly corticosteroids .
DDI-DrugBank.d576.s6	naproxen	drug	158-165	corticosteroids	group	205-219	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , druga , warfarin , methotrexate , and possibly drugb .
DDI-DrugBank.d576.s6	warfarin	drug	168-175	methotrexate	drug	178-189	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , druga , drugb , and possibly corticosteroids .
DDI-DrugBank.d576.s6	warfarin	drug	168-175	corticosteroids	group	205-219	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , druga , methotrexate , and possibly drugb .
DDI-DrugBank.d576.s6	methotrexate	drug	178-189	corticosteroids	group	205-219	false	salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , druga , and possibly drugb .
DDI-DrugBank.d607.s1	Leukine	brand	61-67	lithium	drug	78-84	effect	drugs which may potentiate the myeloproliferative effects of druga , such as drugb and corticosteroids , should be used with caution .
DDI-DrugBank.d607.s1	Leukine	brand	61-67	corticosteroids	group	90-104	effect	drugs which may potentiate the myeloproliferative effects of druga , such as lithium and drugb , should be used with caution .
DDI-DrugBank.d607.s1	lithium	drug	78-84	corticosteroids	group	90-104	false	drugs which may potentiate the myeloproliferative effects of leukine , such as druga and drugb , should be used with caution .
DDI-DrugBank.d771.s1	Scopolamine	drug	0-10	sedatives	group	116-124	advise	druga should be used with care in patients taking other drugs that are capable of causing cns effects such as drugb , tranquilizers , or alcohol .
DDI-DrugBank.d771.s1	Scopolamine	drug	0-10	tranquilizers	group	127-139	advise	druga should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives , drugb , or alcohol .
DDI-DrugBank.d771.s1	Scopolamine	drug	0-10	alcohol	drug	145-151	advise	druga should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives , tranquilizers , or drugb .
DDI-DrugBank.d771.s1	sedatives	group	116-124	tranquilizers	group	127-139	false	scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as druga , drugb , or alcohol .
DDI-DrugBank.d771.s1	sedatives	group	116-124	alcohol	drug	145-151	false	scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as druga , tranquilizers , or drugb .
DDI-DrugBank.d771.s1	tranquilizers	group	127-139	alcohol	drug	145-151	false	scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives , druga , or drugb .
DDI-DrugBank.d771.s3	belladonna alkaloids	group	12-31	antihistamines	group	34-47	false	e.g. , other druga , drugb ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3	belladonna alkaloids	group	12-31	meclizine	drug	60-68	false	e.g. , other druga , antihistamines ( including drugb ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3	belladonna alkaloids	group	12-31	tricyclic antidepressants	group	72-96	false	e.g. , other druga , antihistamines ( including meclizine ) , drugb , and muscle relaxants .
DDI-DrugBank.d771.s3	belladonna alkaloids	group	12-31	muscle relaxants	group	103-118	false	e.g. , other druga , antihistamines ( including meclizine ) , tricyclic antidepressants , and drugb .
DDI-DrugBank.d771.s3	antihistamines	group	34-47	meclizine	drug	60-68	false	e.g. , other belladonna alkaloids , druga ( including drugb ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3	antihistamines	group	34-47	tricyclic antidepressants	group	72-96	false	e.g. , other belladonna alkaloids , druga ( including meclizine ) , drugb , and muscle relaxants .
DDI-DrugBank.d771.s3	antihistamines	group	34-47	muscle relaxants	group	103-118	false	e.g. , other belladonna alkaloids , druga ( including meclizine ) , tricyclic antidepressants , and drugb .
DDI-DrugBank.d771.s3	meclizine	drug	60-68	tricyclic antidepressants	group	72-96	false	e.g. , other belladonna alkaloids , antihistamines ( including druga ) , drugb , and muscle relaxants .
DDI-DrugBank.d771.s3	meclizine	drug	60-68	muscle relaxants	group	103-118	false	e.g. , other belladonna alkaloids , antihistamines ( including druga ) , tricyclic antidepressants , and drugb .
DDI-DrugBank.d771.s3	tricyclic antidepressants	group	72-96	muscle relaxants	group	103-118	false	e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , druga , and drugb .
DDI-DrugBank.d601.s0	Barbiturates	group	0-11	contraceptives	group	52-65	int	druga may decrease the effectiveness of oral drugb , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	Barbiturates	group	0-11	antibiotics	group	76-86	int	druga may decrease the effectiveness of oral contraceptives , certain drugb , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	Barbiturates	group	0-11	quinidine	group	89-97	int	druga may decrease the effectiveness of oral contraceptives , certain antibiotics , drugb , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	Barbiturates	group	0-11	theophylline	drug	100-111	int	druga may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , drugb , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	Barbiturates	group	0-11	corticosteroids	group	114-128	int	druga may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , drugb , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	Barbiturates	group	0-11	anticoagulants	group	131-144	int	druga may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , drugb , and beta blockers .
DDI-DrugBank.d601.s0	Barbiturates	group	0-11	beta blockers	group	151-163	int	druga may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and drugb .
DDI-DrugBank.d601.s0	contraceptives	group	52-65	antibiotics	group	76-86	false	barbiturates may decrease the effectiveness of oral druga , certain drugb , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	contraceptives	group	52-65	quinidine	group	89-97	false	barbiturates may decrease the effectiveness of oral druga , certain antibiotics , drugb , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	contraceptives	group	52-65	theophylline	drug	100-111	false	barbiturates may decrease the effectiveness of oral druga , certain antibiotics , quinidine , drugb , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	contraceptives	group	52-65	corticosteroids	group	114-128	false	barbiturates may decrease the effectiveness of oral druga , certain antibiotics , quinidine , theophylline , drugb , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	contraceptives	group	52-65	anticoagulants	group	131-144	false	barbiturates may decrease the effectiveness of oral druga , certain antibiotics , quinidine , theophylline , corticosteroids , drugb , and beta blockers .
DDI-DrugBank.d601.s0	contraceptives	group	52-65	beta blockers	group	151-163	false	barbiturates may decrease the effectiveness of oral druga , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and drugb .
DDI-DrugBank.d601.s0	antibiotics	group	76-86	quinidine	group	89-97	false	barbiturates may decrease the effectiveness of oral contraceptives , certain druga , drugb , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	antibiotics	group	76-86	theophylline	drug	100-111	false	barbiturates may decrease the effectiveness of oral contraceptives , certain druga , quinidine , drugb , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	antibiotics	group	76-86	corticosteroids	group	114-128	false	barbiturates may decrease the effectiveness of oral contraceptives , certain druga , quinidine , theophylline , drugb , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	antibiotics	group	76-86	anticoagulants	group	131-144	false	barbiturates may decrease the effectiveness of oral contraceptives , certain druga , quinidine , theophylline , corticosteroids , drugb , and beta blockers .
DDI-DrugBank.d601.s0	antibiotics	group	76-86	beta blockers	group	151-163	false	barbiturates may decrease the effectiveness of oral contraceptives , certain druga , quinidine , theophylline , corticosteroids , anticoagulants , and drugb .
DDI-DrugBank.d601.s0	quinidine	group	89-97	theophylline	drug	100-111	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , druga , drugb , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	quinidine	group	89-97	corticosteroids	group	114-128	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , druga , theophylline , drugb , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	quinidine	group	89-97	anticoagulants	group	131-144	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , druga , theophylline , corticosteroids , drugb , and beta blockers .
DDI-DrugBank.d601.s0	quinidine	group	89-97	beta blockers	group	151-163	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , druga , theophylline , corticosteroids , anticoagulants , and drugb .
DDI-DrugBank.d601.s0	theophylline	drug	100-111	corticosteroids	group	114-128	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , druga , drugb , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0	theophylline	drug	100-111	anticoagulants	group	131-144	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , druga , corticosteroids , drugb , and beta blockers .
DDI-DrugBank.d601.s0	theophylline	drug	100-111	beta blockers	group	151-163	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , druga , corticosteroids , anticoagulants , and drugb .
DDI-DrugBank.d601.s0	corticosteroids	group	114-128	anticoagulants	group	131-144	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , druga , drugb , and beta blockers .
DDI-DrugBank.d601.s0	corticosteroids	group	114-128	beta blockers	group	151-163	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , druga , anticoagulants , and drugb .
DDI-DrugBank.d601.s0	anticoagulants	group	131-144	beta blockers	group	151-163	false	barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , druga , and drugb .
DDI-DrugBank.d619.s0	selegiline	drug	152-161	meperidine	drug	167-176	effect	the occurrence of stupor , muscular rigidity , severe agitation , and elevated temperature has been reported in some patients receiving the combination of druga and drugb .
DDI-DrugBank.d619.s2	meperidine	drug	38-47	MAOIs	group	53-57	int	this is typical of the interaction of druga and drugb .
DDI-DrugBank.d619.s4	tricyclic antidepressants	group	80-104	ELDEPRYL	brand	110-117	effect	severe toxicity has also been reported in patients receiving the combination of druga and drugb and selective serotonin reuptake inhibitors and eldepryl .
DDI-DrugBank.d619.s4	tricyclic antidepressants	group	80-104	selective serotonin reuptake inhibitors	group	123-161	false	severe toxicity has also been reported in patients receiving the combination of druga and eldepryl and drugb and eldepryl .
DDI-DrugBank.d619.s4	tricyclic antidepressants	group	80-104	ELDEPRYL	brand	167-174	false	severe toxicity has also been reported in patients receiving the combination of druga and eldepryl and selective serotonin reuptake inhibitors and drugb .
DDI-DrugBank.d619.s4	ELDEPRYL	brand	110-117	selective serotonin reuptake inhibitors	group	123-161	false	severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and druga and drugb and eldepryl .
DDI-DrugBank.d619.s4	ELDEPRYL	brand	110-117	ELDEPRYL	brand	167-174	false	severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and druga and selective serotonin reuptake inhibitors and drugb .
DDI-DrugBank.d619.s4	selective serotonin reuptake inhibitors	group	123-161	ELDEPRYL	brand	167-174	effect	severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and druga and drugb .
DDI-DrugBank.d619.s5	selegiline	drug	95-104	sympathomimetic medication	group	112-137	effect	one case of hypertensive crisis has been reported in a patient taking the recommended doses of druga and a drugb ( ephedrine ) .
DDI-DrugBank.d619.s5	selegiline	drug	95-104	ephedrine	drug	140-148	effect	one case of hypertensive crisis has been reported in a patient taking the recommended doses of druga and a sympathomimetic medication ( drugb ) .
DDI-DrugBank.d619.s5	sympathomimetic medication	group	112-137	ephedrine	drug	140-148	false	one case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a druga ( drugb ) .
DDI-DrugBank.d694.s0	Digoxin	drug	0-6	digoxin	drug	124-130	false	druga : there was a slight increase in the area under the curve ( auc , dg % ) and mean peak drug concentration ( cmax , dg % ) of drugb with the co administration of dg mg sitagliptin for dg days .
DDI-DrugBank.d694.s0	Digoxin	drug	0-6	sitagliptin	drug	169-179	false	druga : there was a slight increase in the area under the curve ( auc , dg % ) and mean peak drug concentration ( cmax , dg % ) of digoxin with the co administration of dg mg drugb for dg days .
DDI-DrugBank.d694.s0	digoxin	drug	124-130	sitagliptin	drug	169-179	mechanism	digoxin : there was a slight increase in the area under the curve ( auc , dg % ) and mean peak drug concentration ( cmax , dg % ) of druga with the co administration of dg mg drugb for dg days .
DDI-DrugBank.d694.s2	digoxin	drug	24-30	JANUVIA	brand	35-41	false	no dosage adjustment of druga or drugb is recommended .
DDI-DrugBank.d595.s1	norepinephrine	drug	0-13	dobutamine	drug	19-28	false	druga and drugb are incompatible with sodium bicarbonate solution .
DDI-DrugBank.d595.s1	norepinephrine	drug	0-13	sodium bicarbonate	drug	52-69	int	druga and dobutamine are incompatible with drugb solution .
DDI-DrugBank.d595.s1	dobutamine	drug	19-28	sodium bicarbonate	drug	52-69	int	norepinephrine and druga are incompatible with drugb solution .
DDI-DrugBank.d595.s2	sodium bicarbonate	drug	16-33	calcium	drug	70-76	false	the addition of druga to parenteral solutions containing drugb should be avoided , except where compatibility has been previously established .
DDI-DrugBank.d738.s0	VESIcare	brand	35-42	ketoconazole	drug	88-99	advise	do not exceed a dg mg daily dose of druga when administered with therapeutic doses of drugb or other potent cyp3a4 inhibitors .
DDI-DrugBank.d738.s1	solifenacin	drug	81-91	solifenacin	drug	177-187	false	patients with congenital or acquired qt prolongation in a study of the effect of druga on the qt interval in dg healthy women , the qt prolonging effect appeared less with drugb dg mg than with dg mg ( three times the maximum recommended dose ) , and the effect of solifenacin dg mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose .
DDI-DrugBank.d738.s1	solifenacin	drug	81-91	solifenacin	drug	273-283	false	patients with congenital or acquired qt prolongation in a study of the effect of druga on the qt interval in dg healthy women , the qt prolonging effect appeared less with solifenacin dg mg than with dg mg ( three times the maximum recommended dose ) , and the effect of drugb dg mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose .
DDI-DrugBank.d738.s1	solifenacin	drug	81-91	moxifloxacin	drug	347-358	false	patients with congenital or acquired qt prolongation in a study of the effect of druga on the qt interval in dg healthy women , the qt prolonging effect appeared less with solifenacin dg mg than with dg mg ( three times the maximum recommended dose ) , and the effect of solifenacin dg mg did not appear as large as that of the positive control drugb at its therapeutic dose .
DDI-DrugBank.d738.s1	solifenacin	drug	177-187	solifenacin	drug	273-283	false	patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in dg healthy women , the qt prolonging effect appeared less with druga dg mg than with dg mg ( three times the maximum recommended dose ) , and the effect of drugb dg mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose .
DDI-DrugBank.d738.s1	solifenacin	drug	177-187	moxifloxacin	drug	347-358	false	patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in dg healthy women , the qt prolonging effect appeared less with druga dg mg than with dg mg ( three times the maximum recommended dose ) , and the effect of solifenacin dg mg did not appear as large as that of the positive control drugb at its therapeutic dose .
DDI-DrugBank.d738.s1	solifenacin	drug	273-283	moxifloxacin	drug	347-358	false	patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in dg healthy women , the qt prolonging effect appeared less with solifenacin dg mg than with dg mg ( three times the maximum recommended dose ) , and the effect of druga dg mg did not appear as large as that of the positive control drugb at its therapeutic dose .
DDI-DrugBank.d599.s4	glucocorticoid	group	3-16	glucocorticoid	group	47-60	false	if druga replacement is required , the drugb dose should be carefully adjusted .
DDI-DrugBank.d599.s6	GH	drug	37-38	antipyrine	drug	93-102	mechanism	limited published data indicate that druga treatment increases cytochrome p450 ( cp450 ) mediated drugb clearance in man .
DDI-DrugBank.d599.s7	GH	drug	24-25	corticosteroids	group	133-147	mechanism	these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , drugb , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7	GH	drug	24-25	sex steroids	group	150-161	mechanism	these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , drugb , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7	GH	drug	24-25	anticonvulsants	group	164-178	mechanism	these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , drugb , cyclosporin ) .
DDI-DrugBank.d599.s7	GH	drug	24-25	cyclosporin	drug	181-191	mechanism	these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , drugb ) .
DDI-DrugBank.d599.s7	corticosteroids	group	133-147	sex steroids	group	150-161	false	these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , druga , drugb , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7	corticosteroids	group	133-147	anticonvulsants	group	164-178	false	these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , druga , sex steroids , drugb , cyclosporin ) .
DDI-DrugBank.d599.s7	corticosteroids	group	133-147	cyclosporin	drug	181-191	false	these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , druga , sex steroids , anticonvulsants , drugb ) .
DDI-DrugBank.d599.s7	sex steroids	group	150-161	anticonvulsants	group	164-178	false	these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , druga , drugb , cyclosporin ) .
DDI-DrugBank.d599.s7	sex steroids	group	150-161	cyclosporin	drug	181-191	false	these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , druga , anticonvulsants , drugb ) .
DDI-DrugBank.d599.s7	anticonvulsants	group	164-178	cyclosporin	drug	181-191	false	these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , druga , drugb ) .
DDI-DrugBank.d602.s0	NEXAVAR	brand	42-48	irinotecan	drug	139-148	advise	caution is recommended when administering druga with compounds that are metabolized / eliminated predominantly by the ugt1a1 pathway ( e.g. drugb ) .
DDI-DrugBank.d602.s1	NEXAVAR	brand	27-33	doxorubicin	drug	76-86	mechanism	concomitant treatment with druga resulted in a dg % increase in the auc of drugb .
DDI-DrugBank.d602.s2	doxorubicin	drug	42-52	NEXAVAR	brand	59-65	advise	caution is recommended when administering druga with drugb .
DDI-DrugBank.d727.s0	Zidovudine	drug	0-9	stavudine	drug	71-79	effect	druga competitively inhibits the intracellular phosphorylation of drugb .
DDI-DrugBank.d727.s1	zidovudine	drug	18-27	ZERIT	brand	49-53	advise	therefore , use of druga in combination with drugb should be avoided .
DDI-DrugBank.d727.s2	stavudine	drug	51-59	doxorubicin	drug	109-119	effect	in vitro data indicate that the phosphorylation of druga is also inhibited at relevant concentrations by drugb and ribavirin .
DDI-DrugBank.d727.s2	stavudine	drug	51-59	ribavirin	drug	125-133	effect	in vitro data indicate that the phosphorylation of druga is also inhibited at relevant concentrations by doxorubicin and drugb .
DDI-DrugBank.d727.s2	doxorubicin	drug	109-119	ribavirin	drug	125-133	false	in vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by druga and drugb .
DDI-DrugBank.d777.s0	Streptase	brand	19-27	Streptokinase	drug	30-42	false	the interaction of druga , drugb , with other drugs has not been well studied .
DDI-DrugBank.d777.s1	Anticoagulants	group	7-20	Antiplatelet Agents	group	26-44	false	use of druga and drugb streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Anticoagulants	group	7-20	Streptase	brand	49-57	false	use of druga and antiplatelet agents drugb , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Anticoagulants	group	7-20	Streptokinase	drug	60-72	false	use of druga and antiplatelet agents streptase , drugb , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Anticoagulants	group	7-20	antiplatelet agents	group	104-122	false	use of druga and antiplatelet agents streptase , streptokinase , alone or in combination with drugb and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Anticoagulants	group	7-20	anticoagulants	group	128-141	false	use of druga and antiplatelet agents streptase , streptokinase , alone or in combination with antiplatelet agents and drugb , may cause bleeding complications .
DDI-DrugBank.d777.s1	Antiplatelet Agents	group	26-44	Streptase	brand	49-57	false	use of anticoagulants and druga drugb , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Antiplatelet Agents	group	26-44	Streptokinase	drug	60-72	false	use of anticoagulants and druga streptase , drugb , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Antiplatelet Agents	group	26-44	antiplatelet agents	group	104-122	false	use of anticoagulants and druga streptase , streptokinase , alone or in combination with drugb and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Antiplatelet Agents	group	26-44	anticoagulants	group	128-141	false	use of anticoagulants and druga streptase , streptokinase , alone or in combination with antiplatelet agents and drugb , may cause bleeding complications .
DDI-DrugBank.d777.s1	Streptase	brand	49-57	Streptokinase	drug	60-72	false	use of anticoagulants and antiplatelet agents druga , drugb , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Streptase	brand	49-57	antiplatelet agents	group	104-122	effect	use of anticoagulants and antiplatelet agents druga , streptokinase , alone or in combination with drugb and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Streptase	brand	49-57	anticoagulants	group	128-141	effect	use of anticoagulants and antiplatelet agents druga , streptokinase , alone or in combination with antiplatelet agents and drugb , may cause bleeding complications .
DDI-DrugBank.d777.s1	Streptokinase	drug	60-72	antiplatelet agents	group	104-122	effect	use of anticoagulants and antiplatelet agents streptase , druga , alone or in combination with drugb and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1	Streptokinase	drug	60-72	anticoagulants	group	128-141	effect	use of anticoagulants and antiplatelet agents streptase , druga , alone or in combination with antiplatelet agents and drugb , may cause bleeding complications .
DDI-DrugBank.d777.s1	antiplatelet agents	group	104-122	anticoagulants	group	128-141	false	use of anticoagulants and antiplatelet agents streptase , streptokinase , alone or in combination with druga and drugb , may cause bleeding complications .
DDI-DrugBank.d777.s3	aspirin	brand	30-36	Streptokinase	drug	103-115	false	in the treatment of acute mi , druga , when not otherwise contraindicated , should be administered with drugb ( see below ) .
DDI-DrugBank.d777.s4	Antiplatelets	group	20-32	aspirin	brand	139-145	false	anticoagulation and druga after treatment for myocardial infarction in the treatment of acute myocardial infarction , the use of drugb has been shown to reduce the incidence of reinfarction and stroke .
DDI-DrugBank.d777.s5	aspirin	brand	16-22	Streptokinase	drug	27-39	effect	the addition of druga to drugb causes a minimal increase in the risk of minor bleeding ( dg % vs. dg % ) , but does not appear to increase the incidence of major bleeding ( see
DDI-DrugBank.d647.s1	Streptozocin	drug	0-11	doxorubicin	drug	71-81	mechanism	druga has been reported to prolong the elimination half life of drugb and may lead to severe bone marrow suppression ;
DDI-DrugBank.d647.s2	doxorubicin	drug	19-29	ZANOSAR	brand	81-87	advise	a reduction of the druga dosage should be considered in patients receiving drugb concurrently .
DDI-DrugBank.d647.s3	streptozocin	drug	22-33	phenytoin	drug	39-47	effect	the concurrent use of druga and drugb has been reported in one case to result in reduced streptozocin cytotoxicity .
DDI-DrugBank.d647.s3	streptozocin	drug	22-33	streptozocin	drug	100-111	false	the concurrent use of druga and phenytoin has been reported in one case to result in reduced drugb cytotoxicity .
DDI-DrugBank.d647.s3	phenytoin	drug	39-47	streptozocin	drug	100-111	false	the concurrent use of streptozocin and druga has been reported in one case to result in reduced drugb cytotoxicity .
DDI-DrugBank.d732.s0	CHEMET	brand	0-5	iron	drug	59-62	false	druga is not known to interact with other drugs including drugb supplements ;
DDI-DrugBank.d732.s2	CHEMET	brand	30-35	CaNa 2 EDTA	drug	75-85	advise	concomitant administration of druga with other chelation therapy , such as drugb is not recommended .
DDI-DrugBank.d649.s0	Sulfamethizole	drug	0-13	barbiturates	group	43-54	effect	druga may increase the effects of drugb , tolbutamide , and uricosurics .
DDI-DrugBank.d649.s0	Sulfamethizole	drug	0-13	tolbutamide	drug	57-67	effect	druga may increase the effects of barbiturates , drugb , and uricosurics .
DDI-DrugBank.d649.s0	Sulfamethizole	drug	0-13	uricosurics	group	74-84	effect	druga may increase the effects of barbiturates , tolbutamide , and drugb .
DDI-DrugBank.d649.s0	barbiturates	group	43-54	tolbutamide	drug	57-67	false	sulfamethizole may increase the effects of druga , drugb , and uricosurics .
DDI-DrugBank.d649.s0	barbiturates	group	43-54	uricosurics	group	74-84	false	sulfamethizole may increase the effects of druga , tolbutamide , and drugb .
DDI-DrugBank.d649.s0	tolbutamide	drug	57-67	uricosurics	group	74-84	false	sulfamethizole may increase the effects of barbiturates , druga , and drugb .
DDI-DrugBank.d649.s1	thiazides	group	26-34	cyclosporine	drug	66-77	false	it may also interact with druga ( increased thrombocytopenia ) , drugb ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	thiazides	group	26-34	sulfonylurea agents	group	107-125	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , drugb ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	thiazides	group	26-34	warfarin	drug	162-169	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	thiazides	group	26-34	methotrexate	drug	205-216	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , drugb ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	thiazides	group	26-34	methotrexate	drug	248-259	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	thiazides	group	26-34	phenytoin	drug	263-271	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	thiazides	group	26-34	phenytoin	drug	305-313	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d649.s1	cyclosporine	drug	66-77	sulfonylurea agents	group	107-125	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugb ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	cyclosporine	drug	66-77	warfarin	drug	162-169	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	cyclosporine	drug	66-77	methotrexate	drug	205-216	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , drugb ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	cyclosporine	drug	66-77	methotrexate	drug	248-259	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	cyclosporine	drug	66-77	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	cyclosporine	drug	66-77	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d649.s1	sulfonylurea agents	group	107-125	warfarin	drug	162-169	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	sulfonylurea agents	group	107-125	methotrexate	drug	205-216	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , drugb ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	sulfonylurea agents	group	107-125	methotrexate	drug	248-259	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	sulfonylurea agents	group	107-125	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	sulfonylurea agents	group	107-125	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d649.s1	warfarin	drug	162-169	methotrexate	drug	205-216	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugb ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	warfarin	drug	162-169	methotrexate	drug	248-259	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	warfarin	drug	162-169	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	warfarin	drug	162-169	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d649.s1	methotrexate	drug	205-216	methotrexate	drug	248-259	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , druga ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	methotrexate	drug	205-216	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , druga ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	methotrexate	drug	205-216	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , druga ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d649.s1	methotrexate	drug	248-259	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of druga ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1	methotrexate	drug	248-259	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of druga ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d649.s1	phenytoin	drug	263-271	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , druga ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d577.s0	diuretics	group	51-59	thiazides	group	72-80	false	in elderly patients concurrently receiving certain druga , primarily drugb , an increased incidence of thrombopenia with purpura has been reported .
DDI-DrugBank.d577.s1	sulfamethoxazole	drug	26-41	anticoagulant	group	110-122	false	it has been reported that druga may prolong the prothrombin time in patients who are receiving the drugb warfarin .
DDI-DrugBank.d577.s1	sulfamethoxazole	drug	26-41	warfarin	drug	124-131	effect	it has been reported that druga may prolong the prothrombin time in patients who are receiving the anticoagulant drugb .
DDI-DrugBank.d577.s1	anticoagulant	group	110-122	warfarin	drug	124-131	false	it has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the druga drugb .
DDI-DrugBank.d577.s3	Sulfamethoxazole	drug	0-15	phenytoin	drug	55-63	mechanism	druga may inhibit the hepatic metabolism of drugb .
DDI-DrugBank.d577.s4	sulfamethoxazole	drug	17-32	phenytoin	drug	97-105	mechanism	at a dg g dose , druga produced a slight but significant increase in the half life of drugb but did not produce a corresponding decrease in the metabolic clearance rate .
DDI-DrugBank.d577.s6	Sulfonamides	group	0-11	methotrexate	drug	31-42	mechanism	druga can also displace drugb from plasma protein binding sites , thus increasing free methotrexate concentrations .
DDI-DrugBank.d577.s6	Sulfonamides	group	0-11	methotrexate	drug	100-111	false	druga can also displace methotrexate from plasma protein binding sites , thus increasing free drugb concentrations .
DDI-DrugBank.d577.s6	methotrexate	drug	31-42	methotrexate	drug	100-111	false	sulfonamides can also displace druga from plasma protein binding sites , thus increasing free drugb concentrations .
DDI-DrugBank.d693.s0	folic acid	drug	22-31	digoxin	drug	37-43	false	reduced absorption of druga and drugb have been reported when those agents were administered concomitantly with sulfasalazine .
DDI-DrugBank.d693.s0	folic acid	drug	22-31	sulfasalazine	drug	119-131	mechanism	reduced absorption of druga and digoxin have been reported when those agents were administered concomitantly with drugb .
DDI-DrugBank.d693.s0	digoxin	drug	37-43	sulfasalazine	drug	119-131	mechanism	reduced absorption of folic acid and druga have been reported when those agents were administered concomitantly with drugb .
DDI-DrugBank.d693.s1	sulfasalazine	drug	20-32	methotrexate	drug	58-69	false	when daily doses of druga dg g and weekly doses of drugb dg mg were coadministered to dg rheumatoid arthritis patients in a drug drug interaction study , the pharmacokinetic disposition of the drugs was not altered .
DDI-DrugBank.d693.s2	sulfasalazine	drug	15-27	methotrexate	drug	67-78	false	daily doses of druga dg g ( maximum dg g ) and weekly doses of drugb dg mg ( maximum dg mg ) were administered alone or in combination to dg rheumatoid arthritis patients in two controlled dg week clinical studies .
DDI-DrugBank.d682.s0	Sulfoxone	drug	0-8	barbiturates	group	38-49	effect	druga may increase the effects of drugb , tolbutamide , and uricosurics .
DDI-DrugBank.d682.s0	Sulfoxone	drug	0-8	tolbutamide	drug	52-62	effect	druga may increase the effects of barbiturates , drugb , and uricosurics .
DDI-DrugBank.d682.s0	Sulfoxone	drug	0-8	uricosurics	group	69-79	effect	druga may increase the effects of barbiturates , tolbutamide , and drugb .
DDI-DrugBank.d682.s0	barbiturates	group	38-49	tolbutamide	drug	52-62	false	sulfoxone may increase the effects of druga , drugb , and uricosurics .
DDI-DrugBank.d682.s0	barbiturates	group	38-49	uricosurics	group	69-79	false	sulfoxone may increase the effects of druga , tolbutamide , and drugb .
DDI-DrugBank.d682.s0	tolbutamide	drug	52-62	uricosurics	group	69-79	false	sulfoxone may increase the effects of barbiturates , druga , and drugb .
DDI-DrugBank.d682.s1	thiazides	group	26-34	cyclosporine	drug	66-77	false	it may also interact with druga ( increased thrombocytopenia ) , drugb ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	thiazides	group	26-34	sulfonylurea agents	group	107-125	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , drugb ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	thiazides	group	26-34	warfarin	drug	162-169	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	thiazides	group	26-34	methotrexate	drug	205-216	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , drugb ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	thiazides	group	26-34	methotrexate	drug	248-259	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	thiazides	group	26-34	phenytoin	drug	263-271	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	thiazides	group	26-34	phenytoin	drug	305-313	false	it may also interact with druga ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d682.s1	cyclosporine	drug	66-77	sulfonylurea agents	group	107-125	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugb ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	cyclosporine	drug	66-77	warfarin	drug	162-169	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	cyclosporine	drug	66-77	methotrexate	drug	205-216	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , drugb ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	cyclosporine	drug	66-77	methotrexate	drug	248-259	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	cyclosporine	drug	66-77	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	cyclosporine	drug	66-77	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d682.s1	sulfonylurea agents	group	107-125	warfarin	drug	162-169	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	sulfonylurea agents	group	107-125	methotrexate	drug	205-216	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , drugb ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	sulfonylurea agents	group	107-125	methotrexate	drug	248-259	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	sulfonylurea agents	group	107-125	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	sulfonylurea agents	group	107-125	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d682.s1	warfarin	drug	162-169	methotrexate	drug	205-216	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugb ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	warfarin	drug	162-169	methotrexate	drug	248-259	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	warfarin	drug	162-169	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	warfarin	drug	162-169	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d682.s1	methotrexate	drug	205-216	methotrexate	drug	248-259	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , druga ( decreased renal excretion of drugb ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	methotrexate	drug	205-216	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , druga ( decreased renal excretion of methotrexate ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	methotrexate	drug	205-216	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , druga ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d682.s1	methotrexate	drug	248-259	phenytoin	drug	263-271	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of druga ) , drugb ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1	methotrexate	drug	248-259	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of druga ) , phenytoin ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d682.s1	phenytoin	drug	263-271	phenytoin	drug	305-313	false	it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , druga ( decreased hepatic clearance of drugb ) .
DDI-DrugBank.d720.s1	ergotamine	drug	80-89	ergot-type medications	group	105-126	false	because there is a theoretical basis that these effects may be additive , use of druga containing or drugb ( like dihydroergotamine or methysergide ) and sumatriptan within dg hours of each other should be avoided .
DDI-DrugBank.d720.s1	ergotamine	drug	80-89	dihydroergotamine	drug	134-150	false	because there is a theoretical basis that these effects may be additive , use of druga containing or ergot type medications ( like drugb or methysergide ) and sumatriptan within dg hours of each other should be avoided .
DDI-DrugBank.d720.s1	ergotamine	drug	80-89	methysergide	drug	155-166	false	because there is a theoretical basis that these effects may be additive , use of druga containing or ergot type medications ( like dihydroergotamine or drugb ) and sumatriptan within dg hours of each other should be avoided .
DDI-DrugBank.d720.s1	ergotamine	drug	80-89	sumatriptan	drug	173-183	advise	because there is a theoretical basis that these effects may be additive , use of druga containing or ergot type medications ( like dihydroergotamine or methysergide ) and drugb within dg hours of each other should be avoided .
DDI-DrugBank.d720.s1	ergot-type medications	group	105-126	dihydroergotamine	drug	134-150	false	because there is a theoretical basis that these effects may be additive , use of ergotamine containing or druga ( like drugb or methysergide ) and sumatriptan within dg hours of each other should be avoided .
DDI-DrugBank.d720.s1	ergot-type medications	group	105-126	methysergide	drug	155-166	false	because there is a theoretical basis that these effects may be additive , use of ergotamine containing or druga ( like dihydroergotamine or drugb ) and sumatriptan within dg hours of each other should be avoided .
DDI-DrugBank.d720.s1	ergot-type medications	group	105-126	sumatriptan	drug	173-183	advise	because there is a theoretical basis that these effects may be additive , use of ergotamine containing or druga ( like dihydroergotamine or methysergide ) and drugb within dg hours of each other should be avoided .
DDI-DrugBank.d720.s1	dihydroergotamine	drug	134-150	methysergide	drug	155-166	false	because there is a theoretical basis that these effects may be additive , use of ergotamine containing or ergot type medications ( like druga or drugb ) and sumatriptan within dg hours of each other should be avoided .
DDI-DrugBank.d720.s1	dihydroergotamine	drug	134-150	sumatriptan	drug	173-183	advise	because there is a theoretical basis that these effects may be additive , use of ergotamine containing or ergot type medications ( like druga or methysergide ) and drugb within dg hours of each other should be avoided .
DDI-DrugBank.d720.s1	methysergide	drug	155-166	sumatriptan	drug	173-183	advise	because there is a theoretical basis that these effects may be additive , use of ergotamine containing or ergot type medications ( like dihydroergotamine or druga ) and drugb within dg hours of each other should be avoided .
DDI-DrugBank.d720.s2	MAO-A inhibitors	group	0-15	sumatriptan	drug	24-34	mechanism	druga reduce drugb clearance , significantly increasing systemic exposure .
DDI-DrugBank.d720.s3	sumatriptan succinate	drug	22-42	MAO-A inhibitors	group	74-89	advise	therefore , the use of druga tablets in patients receiving drugb is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	sumatriptan succinate	drug	22-42	Selective serotonin reuptake inhibitors	group	112-150	false	therefore , the use of druga tablets in patients receiving mao a inhibitors is contraindicated . drugb ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	sumatriptan succinate	drug	22-42	SSRIs	group	153-157	false	therefore , the use of druga tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( drugb ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	sumatriptan succinate	drug	22-42	fluoxetine	drug	167-176	false	therefore , the use of druga tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , drugb , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	sumatriptan succinate	drug	22-42	fluvoxamine	drug	179-189	false	therefore , the use of druga tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , drugb , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	sumatriptan succinate	drug	22-42	paroxetine	drug	192-201	false	therefore , the use of druga tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , drugb , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	sumatriptan succinate	drug	22-42	sertraline	drug	204-213	false	therefore , the use of druga tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	sumatriptan succinate	drug	22-42	sumatriptan	drug	322-332	false	therefore , the use of druga tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3	MAO-A inhibitors	group	74-89	Selective serotonin reuptake inhibitors	group	112-150	false	therefore , the use of sumatriptan succinate tablets in patients receiving druga is contraindicated . drugb ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	MAO-A inhibitors	group	74-89	SSRIs	group	153-157	false	therefore , the use of sumatriptan succinate tablets in patients receiving druga is contraindicated . selective serotonin reuptake inhibitors ( drugb ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	MAO-A inhibitors	group	74-89	fluoxetine	drug	167-176	false	therefore , the use of sumatriptan succinate tablets in patients receiving druga is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , drugb , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	MAO-A inhibitors	group	74-89	fluvoxamine	drug	179-189	false	therefore , the use of sumatriptan succinate tablets in patients receiving druga is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , drugb , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	MAO-A inhibitors	group	74-89	paroxetine	drug	192-201	false	therefore , the use of sumatriptan succinate tablets in patients receiving druga is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , drugb , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	MAO-A inhibitors	group	74-89	sertraline	drug	204-213	false	therefore , the use of sumatriptan succinate tablets in patients receiving druga is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	MAO-A inhibitors	group	74-89	sumatriptan	drug	322-332	false	therefore , the use of sumatriptan succinate tablets in patients receiving druga is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3	Selective serotonin reuptake inhibitors	group	112-150	SSRIs	group	153-157	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . druga ( drugb ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	Selective serotonin reuptake inhibitors	group	112-150	fluoxetine	drug	167-176	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . druga ( ssris ) ( e.g. , drugb , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	Selective serotonin reuptake inhibitors	group	112-150	fluvoxamine	drug	179-189	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . druga ( ssris ) ( e.g. , fluoxetine , drugb , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	Selective serotonin reuptake inhibitors	group	112-150	paroxetine	drug	192-201	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . druga ( ssris ) ( e.g. , fluoxetine , fluvoxamine , drugb , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	Selective serotonin reuptake inhibitors	group	112-150	sertraline	drug	204-213	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . druga ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	Selective serotonin reuptake inhibitors	group	112-150	sumatriptan	drug	322-332	effect	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . druga ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3	SSRIs	group	153-157	fluoxetine	drug	167-176	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( druga ) ( e.g. , drugb , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	SSRIs	group	153-157	fluvoxamine	drug	179-189	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( druga ) ( e.g. , fluoxetine , drugb , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	SSRIs	group	153-157	paroxetine	drug	192-201	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( druga ) ( e.g. , fluoxetine , fluvoxamine , drugb , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	SSRIs	group	153-157	sertraline	drug	204-213	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( druga ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	SSRIs	group	153-157	sumatriptan	drug	322-332	effect	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( druga ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3	fluoxetine	drug	167-176	fluvoxamine	drug	179-189	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , druga , drugb , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	fluoxetine	drug	167-176	paroxetine	drug	192-201	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , druga , fluvoxamine , drugb , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	fluoxetine	drug	167-176	sertraline	drug	204-213	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , druga , fluvoxamine , paroxetine , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	fluoxetine	drug	167-176	sumatriptan	drug	322-332	effect	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , druga , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3	fluvoxamine	drug	179-189	paroxetine	drug	192-201	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , druga , drugb , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	fluvoxamine	drug	179-189	sertraline	drug	204-213	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , druga , paroxetine , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	fluvoxamine	drug	179-189	sumatriptan	drug	322-332	effect	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , druga , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3	paroxetine	drug	192-201	sertraline	drug	204-213	false	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , druga , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3	paroxetine	drug	192-201	sumatriptan	drug	322-332	effect	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , druga , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s3	sertraline	drug	204-213	sumatriptan	drug	322-332	effect	therefore , the use of sumatriptan succinate tablets in patients receiving mao a inhibitors is contraindicated . selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , druga ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d720.s4	sumatriptan	drug	30-40	SSRI	group	49-52	advise	if concomitant treatment with druga and an drugb is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	ketoconazole	drug	79-90	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugb , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	itraconazole	drug	93-104	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , drugb , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	clarithromycin	drug	107-120	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , drugb , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	atazanavir	drug	123-132	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , drugb , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	indinavir	drug	135-143	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	nefazodone	drug	146-155	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , drugb , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	nelfinavir	drug	158-167	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , drugb , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	ritonavir	drug	170-178	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , drugb , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	saquinavir	drug	181-190	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , drugb , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	telithromycin	drug	193-205	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	voriconizole	drug	208-219	mechanism	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	SUTENT	brand	21-26	sunitinib	drug	236-244	false	co administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	itraconazole	drug	93-104	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugb , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	clarithromycin	drug	107-120	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , drugb , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	atazanavir	drug	123-132	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , clarithromycin , drugb , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	indinavir	drug	135-143	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , clarithromycin , atazanavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	nefazodone	drug	146-155	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , clarithromycin , atazanavir , indinavir , drugb , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	nelfinavir	drug	158-167	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , drugb , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	ritonavir	drug	170-178	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , drugb , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	saquinavir	drug	181-190	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , drugb , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	telithromycin	drug	193-205	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ketoconazole	drug	79-90	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , druga , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	clarithromycin	drug	107-120	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , drugb , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	atazanavir	drug	123-132	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , clarithromycin , drugb , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	indinavir	drug	135-143	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , clarithromycin , atazanavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	nefazodone	drug	146-155	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , clarithromycin , atazanavir , indinavir , drugb , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	nelfinavir	drug	158-167	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , clarithromycin , atazanavir , indinavir , nefazodone , drugb , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	ritonavir	drug	170-178	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , drugb , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	saquinavir	drug	181-190	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , drugb , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	telithromycin	drug	193-205	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	itraconazole	drug	93-104	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , druga , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	clarithromycin	drug	107-120	atazanavir	drug	123-132	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , druga , drugb , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	clarithromycin	drug	107-120	indinavir	drug	135-143	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , druga , atazanavir , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	clarithromycin	drug	107-120	nefazodone	drug	146-155	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , druga , atazanavir , indinavir , drugb , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	clarithromycin	drug	107-120	nelfinavir	drug	158-167	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , druga , atazanavir , indinavir , nefazodone , drugb , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	clarithromycin	drug	107-120	ritonavir	drug	170-178	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , druga , atazanavir , indinavir , nefazodone , nelfinavir , drugb , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	clarithromycin	drug	107-120	saquinavir	drug	181-190	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , druga , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , drugb , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	clarithromycin	drug	107-120	telithromycin	drug	193-205	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , druga , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	clarithromycin	drug	107-120	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , druga , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	clarithromycin	drug	107-120	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , druga , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	atazanavir	drug	123-132	indinavir	drug	135-143	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , druga , drugb , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	atazanavir	drug	123-132	nefazodone	drug	146-155	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , druga , indinavir , drugb , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	atazanavir	drug	123-132	nelfinavir	drug	158-167	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , druga , indinavir , nefazodone , drugb , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	atazanavir	drug	123-132	ritonavir	drug	170-178	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , druga , indinavir , nefazodone , nelfinavir , drugb , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	atazanavir	drug	123-132	saquinavir	drug	181-190	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , druga , indinavir , nefazodone , nelfinavir , ritonavir , drugb , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	atazanavir	drug	123-132	telithromycin	drug	193-205	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , druga , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	atazanavir	drug	123-132	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , druga , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	atazanavir	drug	123-132	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , druga , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	indinavir	drug	135-143	nefazodone	drug	146-155	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , druga , drugb , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	indinavir	drug	135-143	nelfinavir	drug	158-167	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , druga , nefazodone , drugb , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	indinavir	drug	135-143	ritonavir	drug	170-178	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , druga , nefazodone , nelfinavir , drugb , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	indinavir	drug	135-143	saquinavir	drug	181-190	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , druga , nefazodone , nelfinavir , ritonavir , drugb , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	indinavir	drug	135-143	telithromycin	drug	193-205	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , druga , nefazodone , nelfinavir , ritonavir , saquinavir , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	indinavir	drug	135-143	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , druga , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	indinavir	drug	135-143	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , druga , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	nefazodone	drug	146-155	nelfinavir	drug	158-167	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , druga , drugb , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	nefazodone	drug	146-155	ritonavir	drug	170-178	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , druga , nelfinavir , drugb , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	nefazodone	drug	146-155	saquinavir	drug	181-190	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , druga , nelfinavir , ritonavir , drugb , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	nefazodone	drug	146-155	telithromycin	drug	193-205	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , druga , nelfinavir , ritonavir , saquinavir , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	nefazodone	drug	146-155	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , druga , nelfinavir , ritonavir , saquinavir , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	nefazodone	drug	146-155	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , druga , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	nelfinavir	drug	158-167	ritonavir	drug	170-178	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , druga , drugb , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	nelfinavir	drug	158-167	saquinavir	drug	181-190	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , druga , ritonavir , drugb , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	nelfinavir	drug	158-167	telithromycin	drug	193-205	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , druga , ritonavir , saquinavir , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	nelfinavir	drug	158-167	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , druga , ritonavir , saquinavir , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	nelfinavir	drug	158-167	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , druga , ritonavir , saquinavir , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	ritonavir	drug	170-178	saquinavir	drug	181-190	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , druga , drugb , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ritonavir	drug	170-178	telithromycin	drug	193-205	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , druga , saquinavir , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ritonavir	drug	170-178	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , druga , saquinavir , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	ritonavir	drug	170-178	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , druga , saquinavir , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	saquinavir	drug	181-190	telithromycin	drug	193-205	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , druga , drugb , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	saquinavir	drug	181-190	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , druga , telithromycin , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	saquinavir	drug	181-190	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , druga , telithromycin , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	telithromycin	drug	193-205	voriconizole	drug	208-219	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , druga , drugb ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0	telithromycin	drug	193-205	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , druga , voriconizole ) may increases drugb concentrations .
DDI-DrugBank.d639.s0	voriconizole	drug	208-219	sunitinib	drug	236-244	false	co administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , druga ) may increases drugb concentrations .
DDI-DrugBank.d639.s2	SUTENT	brand	21-26	dexamethasone	drug	70-82	mechanism	co administration of druga with inducers of the cyp3a4 family ( e.g. , drugb , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	SUTENT	brand	21-26	phenytoin	drug	85-93	mechanism	co administration of druga with inducers of the cyp3a4 family ( e.g. , dexamethasone , drugb , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	SUTENT	brand	21-26	carbamazepine	drug	96-108	mechanism	co administration of druga with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , drugb , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	SUTENT	brand	21-26	rifampin	drug	111-118	mechanism	co administration of druga with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , drugb , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	SUTENT	brand	21-26	rifabutin	drug	121-129	mechanism	co administration of druga with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , drugb , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	SUTENT	brand	21-26	rifapentin	drug	132-141	mechanism	co administration of druga with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , drugb , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	SUTENT	brand	21-26	phenobarbital	drug	144-156	mechanism	co administration of druga with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , drugb , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	SUTENT	brand	21-26	sunitinib	drug	188-196	false	co administration of druga with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease drugb concentrations .
DDI-DrugBank.d639.s2	dexamethasone	drug	70-82	phenytoin	drug	85-93	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , druga , drugb , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	dexamethasone	drug	70-82	carbamazepine	drug	96-108	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , druga , phenytoin , drugb , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	dexamethasone	drug	70-82	rifampin	drug	111-118	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , druga , phenytoin , carbamazepine , drugb , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	dexamethasone	drug	70-82	rifabutin	drug	121-129	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , druga , phenytoin , carbamazepine , rifampin , drugb , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	dexamethasone	drug	70-82	rifapentin	drug	132-141	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , druga , phenytoin , carbamazepine , rifampin , rifabutin , drugb , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	dexamethasone	drug	70-82	phenobarbital	drug	144-156	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , druga , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , drugb , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	dexamethasone	drug	70-82	sunitinib	drug	188-196	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , druga , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease drugb concentrations .
DDI-DrugBank.d639.s2	phenytoin	drug	85-93	carbamazepine	drug	96-108	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , druga , drugb , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	phenytoin	drug	85-93	rifampin	drug	111-118	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , druga , carbamazepine , drugb , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	phenytoin	drug	85-93	rifabutin	drug	121-129	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , druga , carbamazepine , rifampin , drugb , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	phenytoin	drug	85-93	rifapentin	drug	132-141	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , druga , carbamazepine , rifampin , rifabutin , drugb , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	phenytoin	drug	85-93	phenobarbital	drug	144-156	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , druga , carbamazepine , rifampin , rifabutin , rifapentin , drugb , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	phenytoin	drug	85-93	sunitinib	drug	188-196	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , druga , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease drugb concentrations .
DDI-DrugBank.d639.s2	carbamazepine	drug	96-108	rifampin	drug	111-118	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , druga , drugb , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	carbamazepine	drug	96-108	rifabutin	drug	121-129	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , druga , rifampin , drugb , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	carbamazepine	drug	96-108	rifapentin	drug	132-141	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , druga , rifampin , rifabutin , drugb , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	carbamazepine	drug	96-108	phenobarbital	drug	144-156	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , druga , rifampin , rifabutin , rifapentin , drugb , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	carbamazepine	drug	96-108	sunitinib	drug	188-196	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , druga , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease drugb concentrations .
DDI-DrugBank.d639.s2	rifampin	drug	111-118	rifabutin	drug	121-129	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , druga , drugb , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	rifampin	drug	111-118	rifapentin	drug	132-141	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , druga , rifabutin , drugb , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	rifampin	drug	111-118	phenobarbital	drug	144-156	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , druga , rifabutin , rifapentin , drugb , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	rifampin	drug	111-118	sunitinib	drug	188-196	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , druga , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease drugb concentrations .
DDI-DrugBank.d639.s2	rifabutin	drug	121-129	rifapentin	drug	132-141	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , druga , drugb , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	rifabutin	drug	121-129	phenobarbital	drug	144-156	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , druga , rifapentin , drugb , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	rifabutin	drug	121-129	sunitinib	drug	188-196	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , druga , rifapentin , phenobarbital , st. johns wort ) may decrease drugb concentrations .
DDI-DrugBank.d639.s2	rifapentin	drug	132-141	phenobarbital	drug	144-156	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , druga , drugb , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2	rifapentin	drug	132-141	sunitinib	drug	188-196	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , druga , phenobarbital , st. johns wort ) may decrease drugb concentrations .
DDI-DrugBank.d639.s2	phenobarbital	drug	144-156	sunitinib	drug	188-196	false	co administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , druga , st. johns wort ) may decrease drugb concentrations .
DDI-DrugBank.d723.s0	acetylcholine chloride	drug	39-60	Miochol	brand	63-69	false	other eye drops or medications such as druga ( drugb ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	acetylcholine chloride	drug	39-60	carbachol	drug	76-84	false	other eye drops or medications such as druga ( miochol ) and drugb ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	acetylcholine chloride	drug	39-60	Carboptic	brand	87-95	false	other eye drops or medications such as druga ( miochol ) and carbachol ( drugb , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	acetylcholine chloride	drug	39-60	Isopto Carbachol	brand	98-113	false	other eye drops or medications such as druga ( miochol ) and carbachol ( carboptic , drugb ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	acetylcholine chloride	drug	39-60	suprofen	drug	144-151	effect	other eye drops or medications such as druga ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d723.s0	Miochol	brand	63-69	carbachol	drug	76-84	false	other eye drops or medications such as acetylcholine chloride ( druga ) and drugb ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	Miochol	brand	63-69	Carboptic	brand	87-95	false	other eye drops or medications such as acetylcholine chloride ( druga ) and carbachol ( drugb , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	Miochol	brand	63-69	Isopto Carbachol	brand	98-113	false	other eye drops or medications such as acetylcholine chloride ( druga ) and carbachol ( carboptic , drugb ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	Miochol	brand	63-69	suprofen	drug	144-151	effect	other eye drops or medications such as acetylcholine chloride ( druga ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d723.s0	carbachol	drug	76-84	Carboptic	brand	87-95	false	other eye drops or medications such as acetylcholine chloride ( miochol ) and druga ( drugb , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	carbachol	drug	76-84	Isopto Carbachol	brand	98-113	false	other eye drops or medications such as acetylcholine chloride ( miochol ) and druga ( carboptic , drugb ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	carbachol	drug	76-84	suprofen	drug	144-151	effect	other eye drops or medications such as acetylcholine chloride ( miochol ) and druga ( carboptic , isopto carbachol ) may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d723.s0	Carboptic	brand	87-95	Isopto Carbachol	brand	98-113	false	other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( druga , drugb ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0	Carboptic	brand	87-95	suprofen	drug	144-151	effect	other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( druga , isopto carbachol ) may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d723.s0	Isopto Carbachol	brand	98-113	suprofen	drug	144-151	effect	other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , druga ) may decrease the effects of drugb ophthalmic .
DDI-DrugBank.d704.s0	FLOMAX	brand	85-90	alpha-adrenergic blocking agents	group	111-142	false	drug drug interactions : the pharmacokinetic and pharmacodynamic interactions between druga capsules and other drugb have not been determined .
DDI-DrugBank.d704.s1	FLOMAX	brand	42-47	alpha-adrenergic blocking agents	group	103-134	advise	however , interactions may be expected and druga capsules should not be used in combination with other drugb .
DDI-DrugBank.d704.s2	cimetidine	drug	40-49	FLOMAX	brand	55-60	false	the pharmacokinetic interaction between druga and drugb capsules was investigated .
DDI-DrugBank.d704.s4	FLOMAX	brand	11-16	cimetidine	drug	75-84	advise	therefore , druga capsules should be used with caution in combination with drugb , particularly at doses higher than dg mg .
DDI-DrugBank.d704.s5	tamsulosin HCI	drug	80-93	warfarin	drug	99-106	false	results from limited in vitro and in vivo drug drug interaction studies between druga and drugb are inconclusive .
DDI-DrugBank.d704.s6	warfarin	drug	74-81	FLOMAX	brand	87-92	advise	therefore , caution should be exercised with concomitant administration of druga and drugb capsules .
DDI-DrugBank.d687.s0	valproic acid	drug	18-30	temozolomide	drug	60-71	mechanism	administration of druga decreases oral clearance of drugb by about dg % .
DDI-DrugBank.d773.s1	TNKase	brand	39-44	heparin	drug	74-80	false	patients studied in clinical trials of druga were routinely treated with drugb and aspirin .
DDI-DrugBank.d773.s1	TNKase	brand	39-44	aspirin	brand	86-92	false	patients studied in clinical trials of druga were routinely treated with heparin and drugb .
DDI-DrugBank.d773.s1	heparin	drug	74-80	aspirin	brand	86-92	false	patients studied in clinical trials of tnkase were routinely treated with druga and drugb .
DDI-DrugBank.d773.s2	Anticoagulants	group	0-13	heparin	drug	24-30	false	druga ( such as drugb and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	Anticoagulants	group	0-13	vitamin K antagonists	group	36-56	false	druga ( such as heparin and drugb ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	Anticoagulants	group	0-13	acetylsalicylic acid	drug	107-126	false	druga ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as drugb , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	Anticoagulants	group	0-13	dipyridamole	drug	129-140	false	druga ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , drugb , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	Anticoagulants	group	0-13	TNKase	brand	248-253	effect	druga ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d773.s2	heparin	drug	24-30	vitamin K antagonists	group	36-56	false	anticoagulants ( such as druga and drugb ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	heparin	drug	24-30	acetylsalicylic acid	drug	107-126	false	anticoagulants ( such as druga and vitamin k antagonists ) and drugs that alter platelet function ( such as drugb , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	heparin	drug	24-30	dipyridamole	drug	129-140	false	anticoagulants ( such as druga and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , drugb , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	heparin	drug	24-30	TNKase	brand	248-253	effect	anticoagulants ( such as druga and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d773.s2	vitamin K antagonists	group	36-56	acetylsalicylic acid	drug	107-126	false	anticoagulants ( such as heparin and druga ) and drugs that alter platelet function ( such as drugb , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	vitamin K antagonists	group	36-56	dipyridamole	drug	129-140	false	anticoagulants ( such as heparin and druga ) and drugs that alter platelet function ( such as acetylsalicylic acid , drugb , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	vitamin K antagonists	group	36-56	TNKase	brand	248-253	effect	anticoagulants ( such as heparin and druga ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d773.s2	acetylsalicylic acid	drug	107-126	dipyridamole	drug	129-140	false	anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as druga , drugb , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2	acetylsalicylic acid	drug	107-126	TNKase	brand	248-253	effect	anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as druga , dipyridamole , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d773.s2	dipyridamole	drug	129-140	TNKase	brand	248-253	effect	anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , druga , and gp iib / iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d575.s0	tolbutamide	drug	95-105	sodium salicylate	drug	108-124	false	in a study in which dg different drugs were tested , therapeutically relevant concentrations of druga , drugb and sulfamethizole displaced protein bound teniposide in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0	tolbutamide	drug	95-105	sulfamethizole	drug	130-143	false	in a study in which dg different drugs were tested , therapeutically relevant concentrations of druga , sodium salicylate and drugb displaced protein bound teniposide in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0	tolbutamide	drug	95-105	teniposide	drug	169-178	mechanism	in a study in which dg different drugs were tested , therapeutically relevant concentrations of druga , sodium salicylate and sulfamethizole displaced protein bound drugb in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0	sodium salicylate	drug	108-124	sulfamethizole	drug	130-143	false	in a study in which dg different drugs were tested , therapeutically relevant concentrations of tolbutamide , druga and drugb displaced protein bound teniposide in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0	sodium salicylate	drug	108-124	teniposide	drug	169-178	mechanism	in a study in which dg different drugs were tested , therapeutically relevant concentrations of tolbutamide , druga and sulfamethizole displaced protein bound drugb in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0	sulfamethizole	drug	130-143	teniposide	drug	169-178	mechanism	in a study in which dg different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and druga displaced protein bound drugb in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s2	VUMON	brand	51-55	teniposide	drug	58-67	false	therefore , caution should be used in administering druga ( drugb injection ) to patients receiving these other agents .
DDI-DrugBank.d575.s3	teniposide	drug	46-55	methotrexate	drug	82-93	false	there was no change in the plasma kinetics of druga when coadministered with drugb .
DDI-DrugBank.d575.s5	methotrexate	drug	39-50	teniposide	drug	93-102	mechanism	an increase in intracellular levels of druga was observed in vitro in the presence of drugb .
DDI-DrugBank.d645.s0	terbinafine	drug	57-67	tolbutamide	drug	104-114	false	in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of drugb , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0	terbinafine	drug	57-67	ethinylestradiol	drug	117-132	false	in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of tolbutamide , drugb , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0	terbinafine	drug	57-67	ethoxycoumarin	drug_n	135-148	false	in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of tolbutamide , ethinylestradiol , drugb , and cyclosporine .
DDI-DrugBank.d645.s0	terbinafine	drug	57-67	cyclosporine	drug	155-166	false	in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and drugb .
DDI-DrugBank.d645.s0	tolbutamide	drug	104-114	ethinylestradiol	drug	117-132	false	in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of druga , drugb , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0	tolbutamide	drug	104-114	ethoxycoumarin	drug_n	135-148	false	in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of druga , ethinylestradiol , drugb , and cyclosporine .
DDI-DrugBank.d645.s0	tolbutamide	drug	104-114	cyclosporine	drug	155-166	false	in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of druga , ethinylestradiol , ethoxycoumarin , and drugb .
DDI-DrugBank.d645.s0	ethinylestradiol	drug	117-132	ethoxycoumarin	drug_n	135-148	false	in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , druga , drugb , and cyclosporine .
DDI-DrugBank.d645.s0	ethinylestradiol	drug	117-132	cyclosporine	drug	155-166	false	in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , druga , ethoxycoumarin , and drugb .
DDI-DrugBank.d645.s0	ethoxycoumarin	drug_n	135-148	cyclosporine	drug	155-166	false	in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , druga , and drugb .
DDI-DrugBank.d645.s2	tricyclic antidepressants	group	98-122	selective serotonin reuptake inhibitors	group	139-177	false	this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as druga , blockers , drugb ( ssris ) , and monoamine oxidase inhibitors ( mao is ) type b , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2	tricyclic antidepressants	group	98-122	SSRIs	group	180-184	false	this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as druga , blockers , selective serotonin reuptake inhibitors ( drugb ) , and monoamine oxidase inhibitors ( mao is ) type b , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2	tricyclic antidepressants	group	98-122	monoamine oxidase inhibitors (MAO-Is) Type B	group	192-235	false	this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as druga , blockers , selective serotonin reuptake inhibitors ( ssris ) , and drugb , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2	selective serotonin reuptake inhibitors	group	139-177	SSRIs	group	180-184	false	this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , blockers , druga ( drugb ) , and monoamine oxidase inhibitors ( mao is ) type b , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2	selective serotonin reuptake inhibitors	group	139-177	monoamine oxidase inhibitors (MAO-Is) Type B	group	192-235	false	this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , blockers , druga ( ssris ) , and drugb , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2	SSRIs	group	180-184	monoamine oxidase inhibitors (MAO-Is) Type B	group	192-235	false	this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , blockers , selective serotonin reuptake inhibitors ( druga ) , and drugb , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s3	terbinafine	drug	89-99	antipyrine	drug	134-143	false	in vivo drug drug interaction studies conducted in normal volunteer subjects showed that druga does not affect the clearance of drugb or digoxin .
DDI-DrugBank.d645.s3	terbinafine	drug	89-99	digoxin	drug	148-154	false	in vivo drug drug interaction studies conducted in normal volunteer subjects showed that druga does not affect the clearance of antipyrine or drugb .
DDI-DrugBank.d645.s3	antipyrine	drug	134-143	digoxin	drug	148-154	false	in vivo drug drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of druga or drugb .
DDI-DrugBank.d645.s4	Terbinafine	drug	0-10	caffeine	drug	39-46	mechanism	druga decreases the clearance of drugb by dg % .
DDI-DrugBank.d645.s5	Terbinafine	drug	0-10	cyclosporine	drug	39-50	mechanism	druga increases the clearance of drugb by dg % .
DDI-DrugBank.d645.s6	terbinafine	drug	119-129	warfarin	drug	135-142	effect	there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral druga and drugb , however , a causal relationship between lamisil tablets and these changes has not been established .
DDI-DrugBank.d645.s6	terbinafine	drug	119-129	LAMISIL	brand	184-190	false	there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral druga and warfarin , however , a causal relationship between drugb tablets and these changes has not been established .
DDI-DrugBank.d645.s6	warfarin	drug	135-142	LAMISIL	brand	184-190	false	there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and druga , however , a causal relationship between drugb tablets and these changes has not been established .
DDI-DrugBank.d645.s7	Terbinafine	drug	0-10	rifampin	drug	43-50	mechanism	druga clearance is increased dg % by drugb , a cyp450 enzyme inducer , and decreased dg % by cimetidine , a cyp450 enzyme inhibitor .
DDI-DrugBank.d645.s7	Terbinafine	drug	0-10	cimetidine	drug	99-108	mechanism	druga clearance is increased dg % by rifampin , a cyp450 enzyme inducer , and decreased dg % by drugb , a cyp450 enzyme inhibitor .
DDI-DrugBank.d645.s7	rifampin	drug	43-50	cimetidine	drug	99-108	false	terbinafine clearance is increased dg % by druga , a cyp450 enzyme inducer , and decreased dg % by drugb , a cyp450 enzyme inhibitor .
DDI-DrugBank.d645.s8	Terbinafine	drug	0-10	cyclosporine	drug	39-50	false	druga clearance is unaffected by drugb .
DDI-DrugBank.d645.s9	contraceptives	group	120-133	hypoglycemics	group	167-179	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugb , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	contraceptives	group	120-133	theophyllines	drug	182-194	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , hypoglycemics , drugb , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	contraceptives	group	120-133	phenytoins	drug	197-206	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , hypoglycemics , theophyllines , drugb , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	contraceptives	group	120-133	thiazide diuretics	group	209-226	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , drugb , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	contraceptives	group	120-133	beta blockers	group	229-241	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , drugb , and calcium channel blockers .
DDI-DrugBank.d645.s9	contraceptives	group	120-133	calcium channel blockers	group	248-271	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and drugb .
DDI-DrugBank.d645.s9	hypoglycemics	group	167-179	theophyllines	drug	182-194	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , druga , drugb , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	hypoglycemics	group	167-179	phenytoins	drug	197-206	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , druga , theophyllines , drugb , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	hypoglycemics	group	167-179	thiazide diuretics	group	209-226	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , druga , theophyllines , phenytoins , drugb , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	hypoglycemics	group	167-179	beta blockers	group	229-241	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , druga , theophyllines , phenytoins , thiazide diuretics , drugb , and calcium channel blockers .
DDI-DrugBank.d645.s9	hypoglycemics	group	167-179	calcium channel blockers	group	248-271	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , druga , theophyllines , phenytoins , thiazide diuretics , beta blockers , and drugb .
DDI-DrugBank.d645.s9	theophyllines	drug	182-194	phenytoins	drug	197-206	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , druga , drugb , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	theophyllines	drug	182-194	thiazide diuretics	group	209-226	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , druga , phenytoins , drugb , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	theophyllines	drug	182-194	beta blockers	group	229-241	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , druga , phenytoins , thiazide diuretics , drugb , and calcium channel blockers .
DDI-DrugBank.d645.s9	theophyllines	drug	182-194	calcium channel blockers	group	248-271	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , druga , phenytoins , thiazide diuretics , beta blockers , and drugb .
DDI-DrugBank.d645.s9	phenytoins	drug	197-206	thiazide diuretics	group	209-226	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , druga , drugb , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9	phenytoins	drug	197-206	beta blockers	group	229-241	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , druga , thiazide diuretics , drugb , and calcium channel blockers .
DDI-DrugBank.d645.s9	phenytoins	drug	197-206	calcium channel blockers	group	248-271	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , druga , thiazide diuretics , beta blockers , and drugb .
DDI-DrugBank.d645.s9	thiazide diuretics	group	209-226	beta blockers	group	229-241	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , druga , drugb , and calcium channel blockers .
DDI-DrugBank.d645.s9	thiazide diuretics	group	209-226	calcium channel blockers	group	248-271	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , druga , beta blockers , and drugb .
DDI-DrugBank.d645.s9	beta blockers	group	229-241	calcium channel blockers	group	248-271	false	there is no information available from adequate drug drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , druga , and drugb .
DDI-DrugBank.d743.s0	Ketoconazole	drug	0-11	ketoconazole	drug	82-93	false	druga : spontaneous adverse reaction reports of patients taking concomitant drugb with recommended doses of terfenadine demonstrate qt interval prolongation and rare serious cardiac events , e.g .
DDI-DrugBank.d743.s0	Ketoconazole	drug	0-11	terfenadine	drug	121-131	false	druga : spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of drugb demonstrate qt interval prolongation and rare serious cardiac events , e.g .
DDI-DrugBank.d743.s0	ketoconazole	drug	82-93	terfenadine	drug	121-131	effect	ketoconazole : spontaneous adverse reaction reports of patients taking concomitant druga with recommended doses of drugb demonstrate qt interval prolongation and rare serious cardiac events , e.g .
DDI-DrugBank.d743.s2	ketoconazole	drug	35-46	terfenadine	drug	84-94	mechanism	pharmacokinetic data indicate that druga markedly inhibits the metabolism of drugb , resulting in elevated plasma terfenadine levels .
DDI-DrugBank.d743.s2	ketoconazole	drug	35-46	terfenadine	drug	126-136	false	pharmacokinetic data indicate that druga markedly inhibits the metabolism of terfenadine , resulting in elevated plasma drugb levels .
DDI-DrugBank.d743.s2	terfenadine	drug	84-94	terfenadine	drug	126-136	false	pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of druga , resulting in elevated plasma drugb levels .
DDI-DrugBank.d743.s4	ketoconazole	drug	30-41	terfenadine	drug	47-57	advise	concomitant administration of druga and drugb is contraindicated .
DDI-DrugBank.d743.s5	Itraconazole	drug	0-11	terfenadine	drug	54-64	false	druga : torsades de pointes and elevated parent drugb levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post marketing sources .
DDI-DrugBank.d743.s5	Itraconazole	drug	0-11	terfenadine	drug	118-128	false	druga : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of drugb and itraconazole in clinical trials of itraconazole and from foreign post marketing sources .
DDI-DrugBank.d743.s5	Itraconazole	drug	0-11	itraconazole	drug	134-145	false	druga : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and drugb in clinical trials of itraconazole and from foreign post marketing sources .
DDI-DrugBank.d743.s5	Itraconazole	drug	0-11	itraconazole	drug	169-180	false	druga : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of drugb and from foreign post marketing sources .
DDI-DrugBank.d743.s5	terfenadine	drug	54-64	terfenadine	drug	118-128	false	itraconazole : torsades de pointes and elevated parent druga levels have been reported during concomitant use of drugb and itraconazole in clinical trials of itraconazole and from foreign post marketing sources .
DDI-DrugBank.d743.s5	terfenadine	drug	54-64	itraconazole	drug	134-145	false	itraconazole : torsades de pointes and elevated parent druga levels have been reported during concomitant use of terfenadine and drugb in clinical trials of itraconazole and from foreign post marketing sources .
DDI-DrugBank.d743.s5	terfenadine	drug	54-64	itraconazole	drug	169-180	false	itraconazole : torsades de pointes and elevated parent druga levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of drugb and from foreign post marketing sources .
DDI-DrugBank.d743.s5	terfenadine	drug	118-128	itraconazole	drug	134-145	mechanism	itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of druga and drugb in clinical trials of itraconazole and from foreign post marketing sources .
DDI-DrugBank.d743.s5	terfenadine	drug	118-128	itraconazole	drug	169-180	false	itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of druga and itraconazole in clinical trials of drugb and from foreign post marketing sources .
DDI-DrugBank.d743.s5	itraconazole	drug	134-145	itraconazole	drug	169-180	false	itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and druga in clinical trials of drugb and from foreign post marketing sources .
DDI-DrugBank.d743.s7	itraconazole	drug	30-41	terfenadine	drug	47-57	advise	concomitant administration of druga and drugb is contraindicated .
DDI-DrugBank.d743.s8	azole-type antifungal agents	group	40-67	fluconazole	drug	80-90	false	due to the chemical similarity of other druga ( including drugb , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	azole-type antifungal agents	group	40-67	metronidazole	drug	93-105	false	due to the chemical similarity of other druga ( including fluconazole , drugb , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	azole-type antifungal agents	group	40-67	miconazole	drug	112-121	false	due to the chemical similarity of other druga ( including fluconazole , metronidazole , and drugb ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	azole-type antifungal agents	group	40-67	ketoconazole	drug	127-138	false	due to the chemical similarity of other druga ( including fluconazole , metronidazole , and miconazole ) to drugb , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	azole-type antifungal agents	group	40-67	itraconazole	drug	145-156	false	due to the chemical similarity of other druga ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and drugb , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	azole-type antifungal agents	group	40-67	terfenadine	drug	198-208	advise	due to the chemical similarity of other druga ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	fluconazole	drug	80-90	metronidazole	drug	93-105	false	due to the chemical similarity of other azole type antifungal agents ( including druga , drugb , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	fluconazole	drug	80-90	miconazole	drug	112-121	false	due to the chemical similarity of other azole type antifungal agents ( including druga , metronidazole , and drugb ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	fluconazole	drug	80-90	ketoconazole	drug	127-138	false	due to the chemical similarity of other azole type antifungal agents ( including druga , metronidazole , and miconazole ) to drugb , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	fluconazole	drug	80-90	itraconazole	drug	145-156	false	due to the chemical similarity of other azole type antifungal agents ( including druga , metronidazole , and miconazole ) to ketoconazole , and drugb , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	fluconazole	drug	80-90	terfenadine	drug	198-208	advise	due to the chemical similarity of other azole type antifungal agents ( including druga , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	metronidazole	drug	93-105	miconazole	drug	112-121	false	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , druga , and drugb ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	metronidazole	drug	93-105	ketoconazole	drug	127-138	false	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , druga , and miconazole ) to drugb , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	metronidazole	drug	93-105	itraconazole	drug	145-156	false	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , druga , and miconazole ) to ketoconazole , and drugb , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	metronidazole	drug	93-105	terfenadine	drug	198-208	advise	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , druga , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	miconazole	drug	112-121	ketoconazole	drug	127-138	false	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , metronidazole , and druga ) to drugb , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	miconazole	drug	112-121	itraconazole	drug	145-156	false	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , metronidazole , and druga ) to ketoconazole , and drugb , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	miconazole	drug	112-121	terfenadine	drug	198-208	advise	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , metronidazole , and druga ) to ketoconazole , and itraconazole , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	ketoconazole	drug	127-138	itraconazole	drug	145-156	false	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to druga , and drugb , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	ketoconazole	drug	127-138	terfenadine	drug	198-208	false	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to druga , and itraconazole , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8	itraconazole	drug	145-156	terfenadine	drug	198-208	false	due to the chemical similarity of other azole type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and druga , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s9	Macrolides	group	0-9	erythromycin	drug	60-71	false	druga : clinical drug interaction studies indicate that drugb and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9	Macrolides	group	0-9	clarithromycin	drug	77-90	false	druga : clinical drug interaction studies indicate that erythromycin and drugb can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9	Macrolides	group	0-9	terfenadine	drug	115-125	false	druga : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on drugb metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9	Macrolides	group	0-9	ketoconazole	drug	185-196	false	druga : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
DDI-DrugBank.d743.s9	erythromycin	drug	60-71	clarithromycin	drug	77-90	false	macrolides : clinical drug interaction studies indicate that druga and drugb can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9	erythromycin	drug	60-71	terfenadine	drug	115-125	mechanism	macrolides : clinical drug interaction studies indicate that druga and clarithromycin can exert an effect on drugb metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9	erythromycin	drug	60-71	ketoconazole	drug	185-196	false	macrolides : clinical drug interaction studies indicate that druga and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
DDI-DrugBank.d743.s9	clarithromycin	drug	77-90	terfenadine	drug	115-125	mechanism	macrolides : clinical drug interaction studies indicate that erythromycin and druga can exert an effect on drugb metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9	clarithromycin	drug	77-90	ketoconazole	drug	185-196	false	macrolides : clinical drug interaction studies indicate that erythromycin and druga can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
DDI-DrugBank.d743.s9	terfenadine	drug	115-125	ketoconazole	drug	185-196	false	macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on druga metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
DDI-DrugBank.d743.s11	erythromycin	drug	155-166	troleandomycin	drug	171-184	false	a few spontaneous accounts of qt interval prolongation with ventricular arrhythmia including torsades de pointes , have been reported in patients receiving druga or drugb .
DDI-DrugBank.d743.s12	terfenadine	drug	30-40	clarithromycin	drug	47-60	advise	concomitant administration of druga with drugb , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	terfenadine	drug	30-40	erythromycin	drug	63-74	advise	concomitant administration of druga with clarithromycin , drugb , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	terfenadine	drug	30-40	troleandomycin	drug	80-93	advise	concomitant administration of druga with clarithromycin , erythromycin , or drugb is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	terfenadine	drug	30-40	terfenadine	drug	202-212	false	concomitant administration of druga with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of drugb with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	terfenadine	drug	30-40	macrolide antibiotics	group	225-245	false	concomitant administration of druga with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other drugb , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	terfenadine	drug	30-40	azithromycin	drug	258-269	false	concomitant administration of druga with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including drugb , is not recommended .
DDI-DrugBank.d743.s12	clarithromycin	drug	47-60	erythromycin	drug	63-74	false	concomitant administration of terfenadine with druga , drugb , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	clarithromycin	drug	47-60	troleandomycin	drug	80-93	false	concomitant administration of terfenadine with druga , erythromycin , or drugb is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	clarithromycin	drug	47-60	terfenadine	drug	202-212	false	concomitant administration of terfenadine with druga , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of drugb with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	clarithromycin	drug	47-60	macrolide antibiotics	group	225-245	false	concomitant administration of terfenadine with druga , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other drugb , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	clarithromycin	drug	47-60	azithromycin	drug	258-269	false	concomitant administration of terfenadine with druga , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including drugb , is not recommended .
DDI-DrugBank.d743.s12	erythromycin	drug	63-74	troleandomycin	drug	80-93	false	concomitant administration of terfenadine with clarithromycin , druga , or drugb is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	erythromycin	drug	63-74	terfenadine	drug	202-212	false	concomitant administration of terfenadine with clarithromycin , druga , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of drugb with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	erythromycin	drug	63-74	macrolide antibiotics	group	225-245	false	concomitant administration of terfenadine with clarithromycin , druga , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other drugb , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	erythromycin	drug	63-74	azithromycin	drug	258-269	false	concomitant administration of terfenadine with clarithromycin , druga , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including drugb , is not recommended .
DDI-DrugBank.d743.s12	troleandomycin	drug	80-93	terfenadine	drug	202-212	false	concomitant administration of terfenadine with clarithromycin , erythromycin , or druga is contraindicated : pending full characterization of potential interactions , concomitant administration of drugb with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	troleandomycin	drug	80-93	macrolide antibiotics	group	225-245	false	concomitant administration of terfenadine with clarithromycin , erythromycin , or druga is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other drugb , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	troleandomycin	drug	80-93	azithromycin	drug	258-269	false	concomitant administration of terfenadine with clarithromycin , erythromycin , or druga is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including drugb , is not recommended .
DDI-DrugBank.d743.s12	terfenadine	drug	202-212	macrolide antibiotics	group	225-245	advise	concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of druga with other drugb , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12	terfenadine	drug	202-212	azithromycin	drug	258-269	advise	concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of druga with other macrolide antibiotics , including drugb , is not recommended .
DDI-DrugBank.d743.s12	macrolide antibiotics	group	225-245	azithromycin	drug	258-269	false	concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other druga , including drugb , is not recommended .
DDI-DrugBank.d743.s13	terfenadine	drug	46-56	azithromycin	drug	63-74	false	studies to evaluate potential interactions of druga with drugb are in progress .
DDI-DrugBank.d658.s0	testolactone	drug	32-43	anticoagulants	group	78-91	effect	when administered concurrently , druga may increase the effects of oral drugb ;
DDI-DrugBank.d604.s0	Thalidomide	drug	0-10	barbiturates	group	66-77	effect	druga has been reported to enhance the sedative activity of drugb , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0	Thalidomide	drug	0-10	alcohol	drug	80-86	false	druga has been reported to enhance the sedative activity of barbiturates , drugb , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0	Thalidomide	drug	0-10	chlorpromazine	drug	89-102	false	druga has been reported to enhance the sedative activity of barbiturates , alcohol , drugb , and reserpine .
DDI-DrugBank.d604.s0	Thalidomide	drug	0-10	reserpine	drug	109-117	false	druga has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and drugb .
DDI-DrugBank.d604.s0	barbiturates	group	66-77	alcohol	drug	80-86	false	thalidomide has been reported to enhance the sedative activity of druga , drugb , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0	barbiturates	group	66-77	chlorpromazine	drug	89-102	false	thalidomide has been reported to enhance the sedative activity of druga , alcohol , drugb , and reserpine .
DDI-DrugBank.d604.s0	barbiturates	group	66-77	reserpine	drug	109-117	false	thalidomide has been reported to enhance the sedative activity of druga , alcohol , chlorpromazine , and drugb .
DDI-DrugBank.d604.s0	alcohol	drug	80-86	chlorpromazine	drug	89-102	false	thalidomide has been reported to enhance the sedative activity of barbiturates , druga , drugb , and reserpine .
DDI-DrugBank.d604.s0	alcohol	drug	80-86	reserpine	drug	109-117	false	thalidomide has been reported to enhance the sedative activity of barbiturates , druga , chlorpromazine , and drugb .
DDI-DrugBank.d604.s0	chlorpromazine	drug	89-102	reserpine	drug	109-117	false	thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , druga , and drugb .
DDI-DrugBank.d604.s2	Contraceptives	group	5-18	norethindrone	drug	74-86	false	oral druga : in dg healthy women , the pharmacokinetic profiles of drugb and ethinyl estradiol following administration of a single dose containing dg mg of norethindrone acetate and dg g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2	Contraceptives	group	5-18	ethinyl estradiol	drug	92-108	false	oral druga : in dg healthy women , the pharmacokinetic profiles of norethindrone and drugb following administration of a single dose containing dg mg of norethindrone acetate and dg g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2	Contraceptives	group	5-18	norethindrone acetate	drug	173-193	false	oral druga : in dg healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing dg mg of drugb and dg g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2	Contraceptives	group	5-18	ethinyl estradiol	drug	210-226	false	oral druga : in dg healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing dg mg of norethindrone acetate and dg g of drugb were studied .
DDI-DrugBank.d604.s2	norethindrone	drug	74-86	ethinyl estradiol	drug	92-108	false	oral contraceptives : in dg healthy women , the pharmacokinetic profiles of druga and drugb following administration of a single dose containing dg mg of norethindrone acetate and dg g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2	norethindrone	drug	74-86	norethindrone acetate	drug	173-193	false	oral contraceptives : in dg healthy women , the pharmacokinetic profiles of druga and ethinyl estradiol following administration of a single dose containing dg mg of drugb and dg g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2	norethindrone	drug	74-86	ethinyl estradiol	drug	210-226	false	oral contraceptives : in dg healthy women , the pharmacokinetic profiles of druga and ethinyl estradiol following administration of a single dose containing dg mg of norethindrone acetate and dg g of drugb were studied .
DDI-DrugBank.d604.s2	ethinyl estradiol	drug	92-108	norethindrone acetate	drug	173-193	false	oral contraceptives : in dg healthy women , the pharmacokinetic profiles of norethindrone and druga following administration of a single dose containing dg mg of drugb and dg g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2	ethinyl estradiol	drug	92-108	ethinyl estradiol	drug	210-226	false	oral contraceptives : in dg healthy women , the pharmacokinetic profiles of norethindrone and druga following administration of a single dose containing dg mg of norethindrone acetate and dg g of drugb were studied .
DDI-DrugBank.d604.s2	norethindrone acetate	drug	173-193	ethinyl estradiol	drug	210-226	false	oral contraceptives : in dg healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing dg mg of druga and dg g of drugb were studied .
DDI-DrugBank.d604.s4	Thalidomide	drug	14-24	Hormonal Contraceptives	group	70-92	false	important non druga drug interactions drugs that interfere with drugb : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Thalidomide	drug	14-24	HIV-protease inhibitors	group	114-136	false	important non druga drug interactions drugs that interfere with hormonal contraceptives : concomitant use of drugb , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Thalidomide	drug	14-24	griseofulvin	drug	139-150	false	important non druga drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , drugb , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Thalidomide	drug	14-24	modafinil	drug	153-161	false	important non druga drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , drugb , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Thalidomide	drug	14-24	penicillins	group	164-174	false	important non druga drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , drugb , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Thalidomide	drug	14-24	rifampin	drug	177-184	false	important non druga drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , drugb , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Thalidomide	drug	14-24	rifabutin	drug	187-195	false	important non druga drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , drugb , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Thalidomide	drug	14-24	phenytoin	drug	198-206	false	important non druga drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , drugb , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Thalidomide	drug	14-24	carbamazepine	drug	209-221	false	important non druga drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , drugb , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Hormonal Contraceptives	group	70-92	HIV-protease inhibitors	group	114-136	false	important non thalidomide drug interactions drugs that interfere with druga : concomitant use of drugb , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Hormonal Contraceptives	group	70-92	griseofulvin	drug	139-150	false	important non thalidomide drug interactions drugs that interfere with druga : concomitant use of hiv protease inhibitors , drugb , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Hormonal Contraceptives	group	70-92	modafinil	drug	153-161	false	important non thalidomide drug interactions drugs that interfere with druga : concomitant use of hiv protease inhibitors , griseofulvin , drugb , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Hormonal Contraceptives	group	70-92	penicillins	group	164-174	false	important non thalidomide drug interactions drugs that interfere with druga : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , drugb , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Hormonal Contraceptives	group	70-92	rifampin	drug	177-184	false	important non thalidomide drug interactions drugs that interfere with druga : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , drugb , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Hormonal Contraceptives	group	70-92	rifabutin	drug	187-195	false	important non thalidomide drug interactions drugs that interfere with druga : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , drugb , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Hormonal Contraceptives	group	70-92	phenytoin	drug	198-206	false	important non thalidomide drug interactions drugs that interfere with druga : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , drugb , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	Hormonal Contraceptives	group	70-92	carbamazepine	drug	209-221	false	important non thalidomide drug interactions drugs that interfere with druga : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , drugb , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	HIV-protease inhibitors	group	114-136	griseofulvin	drug	139-150	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of druga , drugb , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	HIV-protease inhibitors	group	114-136	modafinil	drug	153-161	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of druga , griseofulvin , drugb , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	HIV-protease inhibitors	group	114-136	penicillins	group	164-174	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of druga , griseofulvin , modafinil , drugb , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	HIV-protease inhibitors	group	114-136	rifampin	drug	177-184	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of druga , griseofulvin , modafinil , penicillins , drugb , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	HIV-protease inhibitors	group	114-136	rifabutin	drug	187-195	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of druga , griseofulvin , modafinil , penicillins , rifampin , drugb , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	HIV-protease inhibitors	group	114-136	phenytoin	drug	198-206	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of druga , griseofulvin , modafinil , penicillins , rifampin , rifabutin , drugb , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	HIV-protease inhibitors	group	114-136	carbamazepine	drug	209-221	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of druga , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , drugb , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	griseofulvin	drug	139-150	modafinil	drug	153-161	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , druga , drugb , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	griseofulvin	drug	139-150	penicillins	group	164-174	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , druga , modafinil , drugb , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	griseofulvin	drug	139-150	rifampin	drug	177-184	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , druga , modafinil , penicillins , drugb , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	griseofulvin	drug	139-150	rifabutin	drug	187-195	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , druga , modafinil , penicillins , rifampin , drugb , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	griseofulvin	drug	139-150	phenytoin	drug	198-206	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , druga , modafinil , penicillins , rifampin , rifabutin , drugb , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	griseofulvin	drug	139-150	carbamazepine	drug	209-221	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , druga , modafinil , penicillins , rifampin , rifabutin , phenytoin , drugb , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	modafinil	drug	153-161	penicillins	group	164-174	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , druga , drugb , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	modafinil	drug	153-161	rifampin	drug	177-184	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , druga , penicillins , drugb , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	modafinil	drug	153-161	rifabutin	drug	187-195	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , druga , penicillins , rifampin , drugb , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	modafinil	drug	153-161	phenytoin	drug	198-206	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , druga , penicillins , rifampin , rifabutin , drugb , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	modafinil	drug	153-161	carbamazepine	drug	209-221	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , druga , penicillins , rifampin , rifabutin , phenytoin , drugb , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	penicillins	group	164-174	rifampin	drug	177-184	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , druga , drugb , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	penicillins	group	164-174	rifabutin	drug	187-195	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , druga , rifampin , drugb , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	penicillins	group	164-174	phenytoin	drug	198-206	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , druga , rifampin , rifabutin , drugb , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	penicillins	group	164-174	carbamazepine	drug	209-221	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , druga , rifampin , rifabutin , phenytoin , drugb , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	rifampin	drug	177-184	rifabutin	drug	187-195	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , druga , drugb , phenytoin , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	rifampin	drug	177-184	phenytoin	drug	198-206	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , druga , rifabutin , drugb , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	rifampin	drug	177-184	carbamazepine	drug	209-221	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , druga , rifabutin , phenytoin , drugb , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	rifabutin	drug	187-195	phenytoin	drug	198-206	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , druga , drugb , carbamazepine , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	rifabutin	drug	187-195	carbamazepine	drug	209-221	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , druga , phenytoin , drugb , or certain herbal supplements such as st .
DDI-DrugBank.d604.s4	phenytoin	drug	198-206	carbamazepine	drug	209-221	false	important non thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , druga , drugb , or certain herbal supplements such as st .
DDI-DrugBank.d604.s5	John's Wort	drug_n	0-10	hormonal contraceptive agents	group	17-45	effect	druga with drugb may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies .
DDI-DrugBank.d686.s0	Thiabendazole	drug	0-12	theophylline	drug	52-63	mechanism	druga may compete with other drugs , such as drugb , for sites of metabolism in the liver , thus elevating the serum levels of such compounds to potentially toxic levels .
DDI-DrugBank.d686.s1	thiabendazole	drug	35-47	xanthine derivatives	group	53-72	advise	therefore , when concomitant use of druga and drugb is anticipated , it may be necessary to monitor blood levels and / or reduce the dosage of such compounds .
DDI-DrugBank.d697.s0	Vitamin B1	drug	17-26	Thiamine	drug	29-36	false	interactions for druga ( drugb ) : loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0	Vitamin B1	drug	17-26	Loop Diuretics	group	41-54	int	interactions for druga ( thiamine ) : drugb , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0	Vitamin B1	drug	17-26	Contraceptives	group	62-75	int	interactions for druga ( thiamine ) : loop diuretics , oral drugb , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0	Vitamin B1	drug	17-26	Stavudine	drug	78-86	int	interactions for druga ( thiamine ) : loop diuretics , oral contraceptives , drugb , tricyclic antidepressants
DDI-DrugBank.d697.s0	Vitamin B1	drug	17-26	Tricyclic Antidepressants	group	89-113	int	interactions for druga ( thiamine ) : loop diuretics , oral contraceptives , stavudine , drugb
DDI-DrugBank.d697.s0	Thiamine	drug	29-36	Loop Diuretics	group	41-54	int	interactions for vitamin b1 ( druga ) : drugb , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0	Thiamine	drug	29-36	Contraceptives	group	62-75	int	interactions for vitamin b1 ( druga ) : loop diuretics , oral drugb , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0	Thiamine	drug	29-36	Stavudine	drug	78-86	int	interactions for vitamin b1 ( druga ) : loop diuretics , oral contraceptives , drugb , tricyclic antidepressants
DDI-DrugBank.d697.s0	Thiamine	drug	29-36	Tricyclic Antidepressants	group	89-113	int	interactions for vitamin b1 ( druga ) : loop diuretics , oral contraceptives , stavudine , drugb
DDI-DrugBank.d697.s0	Loop Diuretics	group	41-54	Contraceptives	group	62-75	false	interactions for vitamin b1 ( thiamine ) : druga , oral drugb , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0	Loop Diuretics	group	41-54	Stavudine	drug	78-86	false	interactions for vitamin b1 ( thiamine ) : druga , oral contraceptives , drugb , tricyclic antidepressants
DDI-DrugBank.d697.s0	Loop Diuretics	group	41-54	Tricyclic Antidepressants	group	89-113	false	interactions for vitamin b1 ( thiamine ) : druga , oral contraceptives , stavudine , drugb
DDI-DrugBank.d697.s0	Contraceptives	group	62-75	Stavudine	drug	78-86	false	interactions for vitamin b1 ( thiamine ) : loop diuretics , oral druga , drugb , tricyclic antidepressants
DDI-DrugBank.d697.s0	Contraceptives	group	62-75	Tricyclic Antidepressants	group	89-113	false	interactions for vitamin b1 ( thiamine ) : loop diuretics , oral druga , stavudine , drugb
DDI-DrugBank.d697.s0	Stavudine	drug	78-86	Tricyclic Antidepressants	group	89-113	false	interactions for vitamin b1 ( thiamine ) : loop diuretics , oral contraceptives , druga , drugb
DDI-DrugBank.d677.s0	Phenothiazines	group	0-13	CNS depressants	group	43-57	effect	druga are capable of potentiating drugb ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0	Phenothiazines	group	0-13	barbiturates	group	66-77	effect	druga are capable of potentiating cns depressants ( e.g. , drugb , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0	Phenothiazines	group	0-13	anesthetics	group	80-90	effect	druga are capable of potentiating cns depressants ( e.g. , barbiturates , drugb , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0	Phenothiazines	group	0-13	opiates	group	93-99	effect	druga are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , drugb , alcohol , etc . )
DDI-DrugBank.d677.s0	Phenothiazines	group	0-13	alcohol	drug	102-108	effect	druga are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , drugb , etc . )
DDI-DrugBank.d677.s0	CNS depressants	group	43-57	barbiturates	group	66-77	false	phenothiazines are capable of potentiating druga ( e.g. , drugb , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0	CNS depressants	group	43-57	anesthetics	group	80-90	false	phenothiazines are capable of potentiating druga ( e.g. , barbiturates , drugb , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0	CNS depressants	group	43-57	opiates	group	93-99	false	phenothiazines are capable of potentiating druga ( e.g. , barbiturates , anesthetics , drugb , alcohol , etc . )
DDI-DrugBank.d677.s0	CNS depressants	group	43-57	alcohol	drug	102-108	false	phenothiazines are capable of potentiating druga ( e.g. , barbiturates , anesthetics , opiates , drugb , etc . )
DDI-DrugBank.d677.s0	barbiturates	group	66-77	anesthetics	group	80-90	false	phenothiazines are capable of potentiating cns depressants ( e.g. , druga , drugb , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0	barbiturates	group	66-77	opiates	group	93-99	false	phenothiazines are capable of potentiating cns depressants ( e.g. , druga , anesthetics , drugb , alcohol , etc . )
DDI-DrugBank.d677.s0	barbiturates	group	66-77	alcohol	drug	102-108	false	phenothiazines are capable of potentiating cns depressants ( e.g. , druga , anesthetics , opiates , drugb , etc . )
DDI-DrugBank.d677.s0	anesthetics	group	80-90	opiates	group	93-99	false	phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , druga , drugb , alcohol , etc . )
DDI-DrugBank.d677.s0	anesthetics	group	80-90	alcohol	drug	102-108	false	phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , druga , opiates , drugb , etc . )
DDI-DrugBank.d677.s0	opiates	group	93-99	alcohol	drug	102-108	false	phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , druga , drugb , etc . )
DDI-DrugBank.d677.s1	atropine	drug	11-18	phosphorous insecticides	drug_n	24-47	false	as well as druga and drugb .
DDI-DrugBank.d722.s0	PURINETHOL	brand	51-60	mercaptopurine	drug	63-76	false	there is usually complete cross resistance between druga ( drugb ) and tabloid brand thioguanine .
DDI-DrugBank.d722.s0	PURINETHOL	brand	51-60	TABLOID	brand	83-89	effect	there is usually complete cross resistance between druga ( mercaptopurine ) and drugb brand thioguanine .
DDI-DrugBank.d722.s0	PURINETHOL	brand	51-60	Thioguanine	drug	97-107	effect	there is usually complete cross resistance between druga ( mercaptopurine ) and tabloid brand drugb .
DDI-DrugBank.d722.s0	mercaptopurine	drug	63-76	TABLOID	brand	83-89	effect	there is usually complete cross resistance between purinethol ( druga ) and drugb brand thioguanine .
DDI-DrugBank.d722.s0	mercaptopurine	drug	63-76	Thioguanine	drug	97-107	effect	there is usually complete cross resistance between purinethol ( druga ) and tabloid brand drugb .
DDI-DrugBank.d722.s0	TABLOID	brand	83-89	Thioguanine	drug	97-107	false	there is usually complete cross resistance between purinethol ( mercaptopurine ) and druga brand drugb .
DDI-DrugBank.d722.s1	aminosalicylate derivatives	group	35-61	olsalazine	drug	70-79	false	as there is in vitro evidence that druga ( e.g. , drugb , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1	aminosalicylate derivatives	group	35-61	mesalazine	drug	82-91	false	as there is in vitro evidence that druga ( e.g. , olsalazine , drugb , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1	aminosalicylate derivatives	group	35-61	sulphasalazine	drug	97-110	false	as there is in vitro evidence that druga ( e.g. , olsalazine , mesalazine , or drugb ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1	aminosalicylate derivatives	group	35-61	thioguanine	drug	212-222	mechanism	as there is in vitro evidence that druga ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
DDI-DrugBank.d722.s1	olsalazine	drug	70-79	mesalazine	drug	82-91	false	as there is in vitro evidence that aminosalicylate derivatives ( e.g. , druga , drugb , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1	olsalazine	drug	70-79	sulphasalazine	drug	97-110	false	as there is in vitro evidence that aminosalicylate derivatives ( e.g. , druga , mesalazine , or drugb ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1	olsalazine	drug	70-79	thioguanine	drug	212-222	mechanism	as there is in vitro evidence that aminosalicylate derivatives ( e.g. , druga , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
DDI-DrugBank.d722.s1	mesalazine	drug	82-91	sulphasalazine	drug	97-110	false	as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , druga , or drugb ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1	mesalazine	drug	82-91	thioguanine	drug	212-222	mechanism	as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , druga , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
DDI-DrugBank.d722.s1	sulphasalazine	drug	97-110	thioguanine	drug	212-222	mechanism	as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or druga ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
DDI-DrugBank.d616.s1	ZADAXIN	brand	47-53	immunomodulating drugs	group	89-110	advise	caution should be exercised when administering druga therapy in combination with other drugb .
DDI-DrugBank.d642.s0	tigecycline	drug	79-89	warfarin	drug	112-119	advise	prothrombin time or other suitable anticoagulation test should be monitored if druga is administered with drugb .
DDI-DrugBank.d642.s1	antibacterial drugs	group	18-36	contraceptives	group	48-61	effect	concurrent use of druga with oral drugb may render oral contraceptives less effective .
DDI-DrugBank.d642.s1	antibacterial drugs	group	18-36	contraceptives	group	79-92	false	concurrent use of druga with oral contraceptives may render oral drugb less effective .
DDI-DrugBank.d642.s1	contraceptives	group	48-61	contraceptives	group	79-92	false	concurrent use of antibacterial drugs with oral druga may render oral drugb less effective .
DDI-DrugBank.d721.s0	SKELID	brand	23-28	calcium	drug	50-56	mechanism	the bioavailability of druga is decreased dg % by drugb , when calcium and skelid are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	SKELID	brand	23-28	calcium	drug	64-70	false	the bioavailability of druga is decreased dg % by calcium , when drugb and skelid are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	SKELID	brand	23-28	SKELID	brand	76-81	false	the bioavailability of druga is decreased dg % by calcium , when calcium and drugb are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	SKELID	brand	23-28	aluminum	drug	134-141	false	the bioavailability of druga is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some drugb or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	SKELID	brand	23-28	magnesium	drug	147-155	false	the bioavailability of druga is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some aluminum or drugb containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	SKELID	brand	23-28	antacids	drug	168-175	false	the bioavailability of druga is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some aluminum or magnesium containing drugb , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	SKELID	brand	23-28	SKELID	brand	210-215	false	the bioavailability of druga is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before drugb .
DDI-DrugBank.d721.s0	calcium	drug	50-56	calcium	drug	64-70	false	the bioavailability of skelid is decreased dg % by druga , when drugb and skelid are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	calcium	drug	50-56	SKELID	brand	76-81	false	the bioavailability of skelid is decreased dg % by druga , when calcium and drugb are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	calcium	drug	50-56	aluminum	drug	134-141	false	the bioavailability of skelid is decreased dg % by druga , when calcium and skelid are administered at the same time , and dg % by some drugb or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	calcium	drug	50-56	magnesium	drug	147-155	false	the bioavailability of skelid is decreased dg % by druga , when calcium and skelid are administered at the same time , and dg % by some aluminum or drugb containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	calcium	drug	50-56	antacids	drug	168-175	false	the bioavailability of skelid is decreased dg % by druga , when calcium and skelid are administered at the same time , and dg % by some aluminum or magnesium containing drugb , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	calcium	drug	50-56	SKELID	brand	210-215	false	the bioavailability of skelid is decreased dg % by druga , when calcium and skelid are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before drugb .
DDI-DrugBank.d721.s0	calcium	drug	64-70	SKELID	brand	76-81	false	the bioavailability of skelid is decreased dg % by calcium , when druga and drugb are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	calcium	drug	64-70	aluminum	drug	134-141	false	the bioavailability of skelid is decreased dg % by calcium , when druga and skelid are administered at the same time , and dg % by some drugb or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	calcium	drug	64-70	magnesium	drug	147-155	false	the bioavailability of skelid is decreased dg % by calcium , when druga and skelid are administered at the same time , and dg % by some aluminum or drugb containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	calcium	drug	64-70	antacids	drug	168-175	false	the bioavailability of skelid is decreased dg % by calcium , when druga and skelid are administered at the same time , and dg % by some aluminum or magnesium containing drugb , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	calcium	drug	64-70	SKELID	brand	210-215	false	the bioavailability of skelid is decreased dg % by calcium , when druga and skelid are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before drugb .
DDI-DrugBank.d721.s0	SKELID	brand	76-81	aluminum	drug	134-141	false	the bioavailability of skelid is decreased dg % by calcium , when calcium and druga are administered at the same time , and dg % by some drugb or magnesium containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	SKELID	brand	76-81	magnesium	drug	147-155	false	the bioavailability of skelid is decreased dg % by calcium , when calcium and druga are administered at the same time , and dg % by some aluminum or drugb containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	SKELID	brand	76-81	antacids	drug	168-175	false	the bioavailability of skelid is decreased dg % by calcium , when calcium and druga are administered at the same time , and dg % by some aluminum or magnesium containing drugb , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	SKELID	brand	76-81	SKELID	brand	210-215	false	the bioavailability of skelid is decreased dg % by calcium , when calcium and druga are administered at the same time , and dg % by some aluminum or magnesium containing antacids , when administered dg hour before drugb .
DDI-DrugBank.d721.s0	aluminum	drug	134-141	magnesium	drug	147-155	false	the bioavailability of skelid is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some druga or drugb containing antacids , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	aluminum	drug	134-141	antacids	drug	168-175	false	the bioavailability of skelid is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some druga or magnesium containing drugb , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	aluminum	drug	134-141	SKELID	brand	210-215	mechanism	the bioavailability of skelid is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some druga or magnesium containing antacids , when administered dg hour before drugb .
DDI-DrugBank.d721.s0	magnesium	drug	147-155	antacids	drug	168-175	false	the bioavailability of skelid is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some aluminum or druga containing drugb , when administered dg hour before skelid .
DDI-DrugBank.d721.s0	magnesium	drug	147-155	SKELID	brand	210-215	mechanism	the bioavailability of skelid is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some aluminum or druga containing antacids , when administered dg hour before drugb .
DDI-DrugBank.d721.s0	antacids	drug	168-175	SKELID	brand	210-215	false	the bioavailability of skelid is decreased dg % by calcium , when calcium and skelid are administered at the same time , and dg % by some aluminum or magnesium containing druga , when administered dg hour before drugb .
DDI-DrugBank.d721.s1	Aspirin	brand	0-6	SKELID	brand	40-45	mechanism	druga may decrease bioavailability of drugb by up to dg % when taken dg hours after skelid .
DDI-DrugBank.d721.s1	Aspirin	brand	0-6	SKELID	brand	85-90	false	druga may decrease bioavailability of skelid by up to dg % when taken dg hours after drugb .
DDI-DrugBank.d721.s1	SKELID	brand	40-45	SKELID	brand	85-90	false	aspirin may decrease bioavailability of druga by up to dg % when taken dg hours after drugb .
DDI-DrugBank.d721.s2	SKELID	brand	23-28	indomethacin	drug	55-66	mechanism	the bioavailability of druga is increased dg dg fold by drugb but is not significantly altered by coadministration of diclofenac .
DDI-DrugBank.d721.s2	SKELID	brand	23-28	diclofenac	drug	124-133	false	the bioavailability of druga is increased dg dg fold by indomethacin but is not significantly altered by coadministration of drugb .
DDI-DrugBank.d721.s2	indomethacin	drug	55-66	diclofenac	drug	124-133	false	the bioavailability of skelid is increased dg dg fold by druga but is not significantly altered by coadministration of drugb .
DDI-DrugBank.d721.s3	digoxin	drug	34-40	SKELID	brand	76-81	false	the pharmacokinetic parameters of druga are not significantly modified by drugb coadministration .
DDI-DrugBank.d721.s4	tiludronate	drug	27-37	warfarin	drug	57-64	false	in vitro studies show that druga does not displace drugb from its binding site on protein .
DDI-DrugBank.d702.s1	sympathomimetic bronchodilators	group	14-44	methylxanthines	group	47-61	false	these include druga , drugb , and oral and inhaled steroids .
DDI-DrugBank.d702.s1	sympathomimetic bronchodilators	group	14-44	steroids	group	85-92	false	these include druga , methylxanthines , and oral and inhaled drugb .
DDI-DrugBank.d702.s1	methylxanthines	group	47-61	steroids	group	85-92	false	these include sympathomimetic bronchodilators , druga , and oral and inhaled drugb .
DDI-DrugBank.d702.s2	SPIRIVA	brand	36-42	anticholinergic	group	55-69	advise	however , the co administration of druga with other drugb containing drugs ( e.g. , ipratropium ) has not been studied and is therefore not recommended .
DDI-DrugBank.d702.s2	SPIRIVA	brand	36-42	ipratropium	drug	97-107	advise	however , the co administration of druga with other anticholinergic containing drugs ( e.g. , drugb ) has not been studied and is therefore not recommended .
DDI-DrugBank.d702.s2	anticholinergic	group	55-69	ipratropium	drug	97-107	false	however , the co administration of spiriva with other druga containing drugs ( e.g. , drugb ) has not been studied and is therefore not recommended .
DDI-DrugBank.d751.s0	AGGRASTAT	brand	0-8	aspirin	brand	46-52	false	druga has been studied on a background of drugb and heparin .
DDI-DrugBank.d751.s0	AGGRASTAT	brand	0-8	heparin	drug	58-64	false	druga has been studied on a background of aspirin and drugb .
DDI-DrugBank.d751.s0	aspirin	brand	46-52	heparin	drug	58-64	false	aggrastat has been studied on a background of druga and drugb .
DDI-DrugBank.d751.s1	AGGRASTAT	brand	11-19	heparin	drug	42-48	effect	the use of druga , in combination with drugb and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1	AGGRASTAT	brand	11-19	aspirin	brand	54-60	effect	the use of druga , in combination with heparin and drugb , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1	AGGRASTAT	brand	11-19	heparin	drug	124-130	false	the use of druga , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to drugb and aspirin alone ( see
DDI-DrugBank.d751.s1	AGGRASTAT	brand	11-19	aspirin	drug	136-142	false	the use of druga , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and drugb alone ( see
DDI-DrugBank.d751.s1	heparin	drug	42-48	aspirin	brand	54-60	false	the use of aggrastat , in combination with druga and drugb , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1	heparin	drug	42-48	heparin	drug	124-130	false	the use of aggrastat , in combination with druga and aspirin , has been associated with an increase in bleeding compared to drugb and aspirin alone ( see
DDI-DrugBank.d751.s1	heparin	drug	42-48	aspirin	drug	136-142	false	the use of aggrastat , in combination with druga and aspirin , has been associated with an increase in bleeding compared to heparin and drugb alone ( see
DDI-DrugBank.d751.s1	aspirin	brand	54-60	heparin	drug	124-130	false	the use of aggrastat , in combination with heparin and druga , has been associated with an increase in bleeding compared to drugb and aspirin alone ( see
DDI-DrugBank.d751.s1	aspirin	brand	54-60	aspirin	drug	136-142	false	the use of aggrastat , in combination with heparin and druga , has been associated with an increase in bleeding compared to heparin and drugb alone ( see
DDI-DrugBank.d751.s1	heparin	drug	124-130	aspirin	drug	136-142	false	the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to druga and drugb alone ( see
DDI-DrugBank.d624.s0	TOBI	brand	23-26	TOBI	brand	45-48	false	in clinical studies of druga , patients taking drugb concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	23-26	dornase alfa	drug	69-80	false	in clinical studies of druga , patients taking tobi concomitantly with drugb ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	23-26	PULMOZYME	brand	83-91	false	in clinical studies of druga , patients taking tobi concomitantly with dornase alfa ( drugb , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	23-26	(beta)-agonists	group	109-123	false	in clinical studies of druga , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , drugb , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	23-26	corticosteroids	group	134-148	false	in clinical studies of druga , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled drugb , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	23-26	anti-pseudomonal antibiotics	group	157-184	false	in clinical studies of druga , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other drugb , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	23-26	aminoglycosides	group	201-215	false	in clinical studies of druga , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	45-48	dornase alfa	drug	69-80	effect	in clinical studies of tobi , patients taking druga concomitantly with drugb ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	45-48	PULMOZYME	brand	83-91	effect	in clinical studies of tobi , patients taking druga concomitantly with dornase alfa ( drugb , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	45-48	(beta)-agonists	group	109-123	effect	in clinical studies of tobi , patients taking druga concomitantly with dornase alfa ( pulmozyme , genentech ) , drugb , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	45-48	corticosteroids	group	134-148	effect	in clinical studies of tobi , patients taking druga concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled drugb , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	45-48	anti-pseudomonal antibiotics	group	157-184	effect	in clinical studies of tobi , patients taking druga concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other drugb , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	TOBI	brand	45-48	aminoglycosides	group	201-215	effect	in clinical studies of tobi , patients taking druga concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	dornase alfa	drug	69-80	PULMOZYME	brand	83-91	false	in clinical studies of tobi , patients taking tobi concomitantly with druga ( drugb , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	dornase alfa	drug	69-80	(beta)-agonists	group	109-123	false	in clinical studies of tobi , patients taking tobi concomitantly with druga ( pulmozyme , genentech ) , drugb , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	dornase alfa	drug	69-80	corticosteroids	group	134-148	false	in clinical studies of tobi , patients taking tobi concomitantly with druga ( pulmozyme , genentech ) , ( beta ) agonists , inhaled drugb , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	dornase alfa	drug	69-80	anti-pseudomonal antibiotics	group	157-184	false	in clinical studies of tobi , patients taking tobi concomitantly with druga ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other drugb , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	dornase alfa	drug	69-80	aminoglycosides	group	201-215	false	in clinical studies of tobi , patients taking tobi concomitantly with druga ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	PULMOZYME	brand	83-91	(beta)-agonists	group	109-123	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( druga , genentech ) , drugb , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	PULMOZYME	brand	83-91	corticosteroids	group	134-148	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( druga , genentech ) , ( beta ) agonists , inhaled drugb , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	PULMOZYME	brand	83-91	anti-pseudomonal antibiotics	group	157-184	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( druga , genentech ) , ( beta ) agonists , inhaled corticosteroids , other drugb , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	PULMOZYME	brand	83-91	aminoglycosides	group	201-215	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( druga , genentech ) , ( beta ) agonists , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	(beta)-agonists	group	109-123	corticosteroids	group	134-148	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , druga , inhaled drugb , other anti pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	(beta)-agonists	group	109-123	anti-pseudomonal antibiotics	group	157-184	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , druga , inhaled corticosteroids , other drugb , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	(beta)-agonists	group	109-123	aminoglycosides	group	201-215	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , druga , inhaled corticosteroids , other anti pseudomonal antibiotics , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	corticosteroids	group	134-148	anti-pseudomonal antibiotics	group	157-184	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled druga , other drugb , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	corticosteroids	group	134-148	aminoglycosides	group	201-215	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled druga , other anti pseudomonal antibiotics , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0	anti-pseudomonal antibiotics	group	157-184	aminoglycosides	group	201-215	false	in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , ( beta ) agonists , inhaled corticosteroids , other druga , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s2	diuretics	group	5-13	aminoglycoside	group	27-40	effect	some druga can enhance drugb toxicity by altering antibiotic concentrations in serum and tissue .
DDI-DrugBank.d624.s2	diuretics	group	5-13	antibiotic	group	63-72	false	some druga can enhance aminoglycoside toxicity by altering drugb concentrations in serum and tissue .
DDI-DrugBank.d624.s2	aminoglycoside	group	27-40	antibiotic	group	63-72	false	some diuretics can enhance druga toxicity by altering drugb concentrations in serum and tissue .
DDI-DrugBank.d624.s3	TOBI	brand	0-3	ethacrynic acid	drug	51-65	advise	druga should not be administered concomitantly with drugb , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3	TOBI	brand	0-3	furosemide	drug	68-77	advise	druga should not be administered concomitantly with ethacrynic acid , drugb , urea , or mannitol .
DDI-DrugBank.d624.s3	TOBI	brand	0-3	urea	drug	80-83	advise	druga should not be administered concomitantly with ethacrynic acid , furosemide , drugb , or mannitol .
DDI-DrugBank.d624.s3	TOBI	brand	0-3	mannitol	drug	89-96	advise	druga should not be administered concomitantly with ethacrynic acid , furosemide , urea , or drugb .
DDI-DrugBank.d624.s3	ethacrynic acid	drug	51-65	furosemide	drug	68-77	false	tobi should not be administered concomitantly with druga , drugb , urea , or mannitol .
DDI-DrugBank.d624.s3	ethacrynic acid	drug	51-65	urea	drug	80-83	false	tobi should not be administered concomitantly with druga , furosemide , drugb , or mannitol .
DDI-DrugBank.d624.s3	ethacrynic acid	drug	51-65	mannitol	drug	89-96	false	tobi should not be administered concomitantly with druga , furosemide , urea , or drugb .
DDI-DrugBank.d624.s3	furosemide	drug	68-77	urea	drug	80-83	false	tobi should not be administered concomitantly with ethacrynic acid , druga , drugb , or mannitol .
DDI-DrugBank.d624.s3	furosemide	drug	68-77	mannitol	drug	89-96	false	tobi should not be administered concomitantly with ethacrynic acid , druga , urea , or drugb .
DDI-DrugBank.d624.s3	urea	drug	80-83	mannitol	drug	89-96	false	tobi should not be administered concomitantly with ethacrynic acid , furosemide , druga , or drugb .
DDI-DrugBank.d608.s0	warfarin	drug	24-31	tolmetin	drug	75-82	false	the in vitro binding of druga to human plasma proteins is unaffected by drugb , and tolmetin does not alter the prothrombin time of normal volunteers .
DDI-DrugBank.d608.s0	warfarin	drug	24-31	tolmetin	drug	89-96	false	the in vitro binding of druga to human plasma proteins is unaffected by tolmetin , and drugb does not alter the prothrombin time of normal volunteers .
DDI-DrugBank.d608.s0	tolmetin	drug	75-82	tolmetin	drug	89-96	false	the in vitro binding of warfarin to human plasma proteins is unaffected by druga , and drugb does not alter the prothrombin time of normal volunteers .
DDI-DrugBank.d608.s1	TOLECTIN	brand	95-102	warfarin	drug	108-115	effect	however , increased prothrombin time and bleeding have been reported in patients on concomitant druga and drugb therapy .
DDI-DrugBank.d608.s2	TOLECTIN	brand	58-65	anticoagulants	group	82-95	advise	therefore , caution should be exercised when administering druga to patients on drugb .
DDI-DrugBank.d608.s3	sulfonylureas	group	55-67	insulin	drug	72-78	false	in adult diabetic patients under treatment with either druga or drugb there is no change in the clinical effects of either tolectin or the hypoglycemic agents .
DDI-DrugBank.d608.s3	sulfonylureas	group	55-67	TOLECTIN	brand	133-140	false	in adult diabetic patients under treatment with either druga or insulin there is no change in the clinical effects of either drugb or the hypoglycemic agents .
DDI-DrugBank.d608.s3	sulfonylureas	group	55-67	hypoglycemic agents	group	149-167	false	in adult diabetic patients under treatment with either druga or insulin there is no change in the clinical effects of either tolectin or the drugb .
DDI-DrugBank.d608.s3	insulin	drug	72-78	TOLECTIN	brand	133-140	false	in adult diabetic patients under treatment with either sulfonylureas or druga there is no change in the clinical effects of either drugb or the hypoglycemic agents .
DDI-DrugBank.d608.s3	insulin	drug	72-78	hypoglycemic agents	group	149-167	false	in adult diabetic patients under treatment with either sulfonylureas or druga there is no change in the clinical effects of either tolectin or the drugb .
DDI-DrugBank.d608.s3	TOLECTIN	brand	133-140	hypoglycemic agents	group	149-167	false	in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either druga or the drugb .
DDI-DrugBank.d608.s4	TOLECTIN	brand	26-33	methotrexate	drug	70-81	advise	caution should be used if druga is administered concomitantly with drugb .
DDI-DrugBank.d608.s5	TOLECTIN	brand	0-7	nonsteroidal anti-inflammatory drugs	group	19-54	false	druga and other drugb have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate .
DDI-DrugBank.d608.s5	TOLECTIN	brand	0-7	methotrexate	drug	110-121	mechanism	druga and other nonsteroidal anti inflammatory drugs have been reported to reduce the tubular secretion of drugb in an animal model , possibly enhancing the toxicity of methotrexate .
DDI-DrugBank.d608.s5	TOLECTIN	brand	0-7	methotrexate	drug	178-189	false	druga and other nonsteroidal anti inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of drugb .
DDI-DrugBank.d608.s5	nonsteroidal anti-inflammatory drugs	group	19-54	methotrexate	drug	110-121	mechanism	tolectin and other druga have been reported to reduce the tubular secretion of drugb in an animal model , possibly enhancing the toxicity of methotrexate .
DDI-DrugBank.d608.s5	nonsteroidal anti-inflammatory drugs	group	19-54	methotrexate	drug	178-189	false	tolectin and other druga have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of drugb .
DDI-DrugBank.d608.s5	methotrexate	drug	110-121	methotrexate	drug	178-189	false	tolectin and other nonsteroidal anti inflammatory drugs have been reported to reduce the tubular secretion of druga in an animal model , possibly enhancing the toxicity of drugb .
DDI-DrugBank.d765.s0	Ketoconazole	drug	19-30	tolterodine	drug	135-145	mechanism	cyp3a4 inhibitors : druga , an inhibitor of the drug metabolizing enzyme cyp3a4 , significantly increased plasma concentrations of drugb when coadministered to subjects who were poor metabolizers ( see clinical pharmacology , variability in metabolism and drug drug interactions ) .
DDI-DrugBank.d765.s1	ketoconazole	drug	23-34	azole antifungals	group	84-100	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other drugb ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	ketoconazole	drug	23-34	itraconazole	drug	107-118	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , drugb , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	ketoconazole	drug	23-34	miconazole	drug	121-130	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , drugb ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	ketoconazole	drug	23-34	macrolide antibiotics	group	136-156	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or drugb ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	ketoconazole	drug	23-34	erythromycin	drug	163-174	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , drugb , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	ketoconazole	drug	23-34	clarithromycin	drug	177-190	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , drugb ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	ketoconazole	drug	23-34	cyclosporine	drug	196-207	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or drugb or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	ketoconazole	drug	23-34	vinblastine	drug	212-222	false	for patients receiving druga or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or drugb , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	ketoconazole	drug	23-34	DETROL LA	brand	249-257	advise	for patients receiving druga or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of drugb is dg mg daily .
DDI-DrugBank.d765.s1	azole antifungals	group	84-100	itraconazole	drug	107-118	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other druga ( eg , drugb , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	azole antifungals	group	84-100	miconazole	drug	121-130	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other druga ( eg , itraconazole , drugb ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	azole antifungals	group	84-100	macrolide antibiotics	group	136-156	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other druga ( eg , itraconazole , miconazole ) or drugb ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	azole antifungals	group	84-100	erythromycin	drug	163-174	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other druga ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , drugb , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	azole antifungals	group	84-100	clarithromycin	drug	177-190	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other druga ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , drugb ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	azole antifungals	group	84-100	cyclosporine	drug	196-207	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other druga ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or drugb or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	azole antifungals	group	84-100	vinblastine	drug	212-222	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other druga ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or drugb , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	azole antifungals	group	84-100	DETROL LA	brand	249-257	advise	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other druga ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of drugb is dg mg daily .
DDI-DrugBank.d765.s1	itraconazole	drug	107-118	miconazole	drug	121-130	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , druga , drugb ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	itraconazole	drug	107-118	macrolide antibiotics	group	136-156	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , druga , miconazole ) or drugb ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	itraconazole	drug	107-118	erythromycin	drug	163-174	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , druga , miconazole ) or macrolide antibiotics ( eg , drugb , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	itraconazole	drug	107-118	clarithromycin	drug	177-190	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , druga , miconazole ) or macrolide antibiotics ( eg , erythromycin , drugb ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	itraconazole	drug	107-118	cyclosporine	drug	196-207	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , druga , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or drugb or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	itraconazole	drug	107-118	vinblastine	drug	212-222	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , druga , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or drugb , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	itraconazole	drug	107-118	DETROL LA	brand	249-257	advise	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , druga , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of drugb is dg mg daily .
DDI-DrugBank.d765.s1	miconazole	drug	121-130	macrolide antibiotics	group	136-156	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , druga ) or drugb ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	miconazole	drug	121-130	erythromycin	drug	163-174	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , druga ) or macrolide antibiotics ( eg , drugb , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	miconazole	drug	121-130	clarithromycin	drug	177-190	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , druga ) or macrolide antibiotics ( eg , erythromycin , drugb ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	miconazole	drug	121-130	cyclosporine	drug	196-207	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , druga ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or drugb or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	miconazole	drug	121-130	vinblastine	drug	212-222	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , druga ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or drugb , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	miconazole	drug	121-130	DETROL LA	brand	249-257	advise	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , druga ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of drugb is dg mg daily .
DDI-DrugBank.d765.s1	macrolide antibiotics	group	136-156	erythromycin	drug	163-174	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or druga ( eg , drugb , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	macrolide antibiotics	group	136-156	clarithromycin	drug	177-190	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or druga ( eg , erythromycin , drugb ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	macrolide antibiotics	group	136-156	cyclosporine	drug	196-207	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or druga ( eg , erythromycin , clarithromycin ) or drugb or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	macrolide antibiotics	group	136-156	vinblastine	drug	212-222	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or druga ( eg , erythromycin , clarithromycin ) or cyclosporine or drugb , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	macrolide antibiotics	group	136-156	DETROL LA	brand	249-257	advise	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or druga ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of drugb is dg mg daily .
DDI-DrugBank.d765.s1	erythromycin	drug	163-174	clarithromycin	drug	177-190	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , druga , drugb ) or cyclosporine or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	erythromycin	drug	163-174	cyclosporine	drug	196-207	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , druga , clarithromycin ) or drugb or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	erythromycin	drug	163-174	vinblastine	drug	212-222	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , druga , clarithromycin ) or cyclosporine or drugb , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	erythromycin	drug	163-174	DETROL LA	brand	249-257	advise	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , druga , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of drugb is dg mg daily .
DDI-DrugBank.d765.s1	clarithromycin	drug	177-190	cyclosporine	drug	196-207	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , druga ) or drugb or vinblastine , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	clarithromycin	drug	177-190	vinblastine	drug	212-222	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , druga ) or cyclosporine or drugb , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	clarithromycin	drug	177-190	DETROL LA	brand	249-257	advise	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , druga ) or cyclosporine or vinblastine , the recommended dose of drugb is dg mg daily .
DDI-DrugBank.d765.s1	cyclosporine	drug	196-207	vinblastine	drug	212-222	false	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or druga or drugb , the recommended dose of detrol la is dg mg daily .
DDI-DrugBank.d765.s1	cyclosporine	drug	196-207	DETROL LA	brand	249-257	advise	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or druga or vinblastine , the recommended dose of drugb is dg mg daily .
DDI-DrugBank.d765.s1	vinblastine	drug	212-222	DETROL LA	brand	249-257	advise	for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or druga , the recommended dose of drugb is dg mg daily .
DDI-DrugBank.d712.s1	paclitaxel	drug	18-27	HERCEPTIN	brand	49-57	mechanism	administration of druga in combination with drugb resulted in a two fold decrease in herceptin clearance in a non human primate study and in a dg fold increase in herceptin serum levels in clinical studies .
DDI-DrugBank.d712.s1	paclitaxel	drug	18-27	HERCEPTIN	brand	94-102	false	administration of druga in combination with herceptin resulted in a two fold decrease in drugb clearance in a non human primate study and in a dg fold increase in herceptin serum levels in clinical studies .
DDI-DrugBank.d712.s1	paclitaxel	drug	18-27	HERCEPTIN	brand	173-181	false	administration of druga in combination with herceptin resulted in a two fold decrease in herceptin clearance in a non human primate study and in a dg fold increase in drugb serum levels in clinical studies .
DDI-DrugBank.d712.s1	HERCEPTIN	brand	49-57	HERCEPTIN	brand	94-102	false	administration of paclitaxel in combination with druga resulted in a two fold decrease in drugb clearance in a non human primate study and in a dg fold increase in herceptin serum levels in clinical studies .
DDI-DrugBank.d712.s1	HERCEPTIN	brand	49-57	HERCEPTIN	brand	173-181	false	administration of paclitaxel in combination with druga resulted in a two fold decrease in herceptin clearance in a non human primate study and in a dg fold increase in drugb serum levels in clinical studies .
DDI-DrugBank.d712.s1	HERCEPTIN	brand	94-102	HERCEPTIN	brand	173-181	false	administration of paclitaxel in combination with herceptin resulted in a two fold decrease in druga clearance in a non human primate study and in a dg fold increase in drugb serum levels in clinical studies .
DDI-DrugBank.d774.s0	Trilostane	drug	0-9	aminoglutethimide	drug	29-45	int	druga may interact with drugb or mitotane ( causing too great a decrease in adrenal function ) .
DDI-DrugBank.d774.s0	Trilostane	drug	0-9	mitotane	drug	50-57	int	druga may interact with aminoglutethimide or drugb ( causing too great a decrease in adrenal function ) .
DDI-DrugBank.d774.s0	aminoglutethimide	drug	29-45	mitotane	drug	50-57	false	trilostane may interact with druga or drugb ( causing too great a decrease in adrenal function ) .
DDI-DrugBank.d598.s0	Trimethoprim	drug	0-11	phenytoin	drug	51-59	mechanism	druga may inhibit the hepatic metabolism of drugb .
DDI-DrugBank.d598.s1	Trimethoprim	drug	0-11	phenytoin	drug	63-71	mechanism	druga , given at a common clinical dosage , increased the drugb half life by dg % and decreased the phenytoin metabolic clearance rate by dg % .
DDI-DrugBank.d598.s1	Trimethoprim	drug	0-11	phenytoin	drug	108-116	mechanism	druga , given at a common clinical dosage , increased the phenytoin half life by dg % and decreased the drugb metabolic clearance rate by dg % .
DDI-DrugBank.d598.s1	phenytoin	drug	63-71	phenytoin	drug	108-116	false	trimethoprim , given at a common clinical dosage , increased the druga half life by dg % and decreased the drugb metabolic clearance rate by dg % .
DDI-DrugBank.d766.s0	trimetrexate	drug	6-17	trimetrexate	drug	184-195	false	since druga is metabolized by a p450 enzyme system , drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug drug interactions that may alter drugb plasma concentrations .
DDI-DrugBank.d766.s1	trimetrexate	drug	41-52	erythromycin	drug	133-144	effect	agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include drugb , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1	trimetrexate	drug	41-52	rifampin	drug	147-154	effect	agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include erythromycin , drugb , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1	trimetrexate	drug	41-52	rifabutin	drug	157-165	effect	agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include erythromycin , rifampin , drugb , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1	trimetrexate	drug	41-52	ketoconazole	drug	168-179	effect	agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , drugb , and fluconazole .
DDI-DrugBank.d766.s1	trimetrexate	drug	41-52	fluconazole	drug	186-196	effect	agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and drugb .
DDI-DrugBank.d766.s1	erythromycin	drug	133-144	rifampin	drug	147-154	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include druga , drugb , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1	erythromycin	drug	133-144	rifabutin	drug	157-165	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include druga , rifampin , drugb , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1	erythromycin	drug	133-144	ketoconazole	drug	168-179	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include druga , rifampin , rifabutin , drugb , and fluconazole .
DDI-DrugBank.d766.s1	erythromycin	drug	133-144	fluconazole	drug	186-196	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include druga , rifampin , rifabutin , ketoconazole , and drugb .
DDI-DrugBank.d766.s1	rifampin	drug	147-154	rifabutin	drug	157-165	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , druga , drugb , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1	rifampin	drug	147-154	ketoconazole	drug	168-179	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , druga , rifabutin , drugb , and fluconazole .
DDI-DrugBank.d766.s1	rifampin	drug	147-154	fluconazole	drug	186-196	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , druga , rifabutin , ketoconazole , and drugb .
DDI-DrugBank.d766.s1	rifabutin	drug	157-165	ketoconazole	drug	168-179	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , druga , drugb , and fluconazole .
DDI-DrugBank.d766.s1	rifabutin	drug	157-165	fluconazole	drug	186-196	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , druga , ketoconazole , and drugb .
DDI-DrugBank.d766.s1	ketoconazole	drug	168-179	fluconazole	drug	186-196	false	agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , druga , and drugb .
DDI-DrugBank.d766.s2	cimetidine	drug	56-65	trimetrexate	drug	101-112	mechanism	in vitro perfusion of isolated rat liver has shown that druga caused a significant reduction in drugb metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites .
DDI-DrugBank.d766.s2	cimetidine	drug	56-65	acetaminophen	drug	134-146	false	in vitro perfusion of isolated rat liver has shown that druga caused a significant reduction in trimetrexate metabolism and that drugb altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites .
DDI-DrugBank.d766.s2	trimetrexate	drug	101-112	acetaminophen	drug	134-146	false	in vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in druga metabolism and that drugb altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites .
DDI-DrugBank.d766.s3	imidazole drugs	group	59-73	clotrimazole	drug	76-87	false	based on an in vitro rat liver model , nitrogen substituted druga ( drugb , ketoconazole , miconazole ) were potent , non competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3	imidazole drugs	group	59-73	ketoconazole	drug	90-101	false	based on an in vitro rat liver model , nitrogen substituted druga ( clotrimazole , drugb , miconazole ) were potent , non competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3	imidazole drugs	group	59-73	miconazole	drug	104-113	false	based on an in vitro rat liver model , nitrogen substituted druga ( clotrimazole , ketoconazole , drugb ) were potent , non competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3	imidazole drugs	group	59-73	trimetrexate	drug	159-170	mechanism	based on an in vitro rat liver model , nitrogen substituted druga ( clotrimazole , ketoconazole , miconazole ) were potent , non competitive inhibitors of drugb metabolism .
DDI-DrugBank.d766.s3	clotrimazole	drug	76-87	ketoconazole	drug	90-101	false	based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( druga , drugb , miconazole ) were potent , non competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3	clotrimazole	drug	76-87	miconazole	drug	104-113	false	based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( druga , ketoconazole , drugb ) were potent , non competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3	clotrimazole	drug	76-87	trimetrexate	drug	159-170	mechanism	based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( druga , ketoconazole , miconazole ) were potent , non competitive inhibitors of drugb metabolism .
DDI-DrugBank.d766.s3	ketoconazole	drug	90-101	miconazole	drug	104-113	false	based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , druga , drugb ) were potent , non competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3	ketoconazole	drug	90-101	trimetrexate	drug	159-170	mechanism	based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , druga , miconazole ) were potent , non competitive inhibitors of drugb metabolism .
DDI-DrugBank.d766.s3	miconazole	drug	104-113	trimetrexate	drug	159-170	mechanism	based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , druga ) were potent , non competitive inhibitors of drugb metabolism .
DDI-DrugBank.d615.s0	Triprolidine	drug	0-11	central nervous system depressants	group	49-82	effect	druga may enhance the sedative effects of drugb including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	Triprolidine	drug	0-11	alcohol	drug	94-100	effect	druga may enhance the sedative effects of central nervous system depressants including drugb , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	Triprolidine	drug	0-11	barbiturates	group	103-114	effect	druga may enhance the sedative effects of central nervous system depressants including alcohol , drugb , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	Triprolidine	drug	0-11	hypnotics	group	117-125	effect	druga may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , drugb , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	Triprolidine	drug	0-11	narcotic analgesics	group	128-146	effect	druga may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , drugb , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	Triprolidine	drug	0-11	sedatives	group	149-157	effect	druga may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , drugb , and tranquillisers .
DDI-DrugBank.d615.s0	Triprolidine	drug	0-11	tranquillisers	group	164-177	effect	druga may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and drugb .
DDI-DrugBank.d615.s0	central nervous system depressants	group	49-82	alcohol	drug	94-100	false	triprolidine may enhance the sedative effects of druga including drugb , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	central nervous system depressants	group	49-82	barbiturates	group	103-114	false	triprolidine may enhance the sedative effects of druga including alcohol , drugb , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	central nervous system depressants	group	49-82	hypnotics	group	117-125	false	triprolidine may enhance the sedative effects of druga including alcohol , barbiturates , drugb , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	central nervous system depressants	group	49-82	narcotic analgesics	group	128-146	false	triprolidine may enhance the sedative effects of druga including alcohol , barbiturates , hypnotics , drugb , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	central nervous system depressants	group	49-82	sedatives	group	149-157	false	triprolidine may enhance the sedative effects of druga including alcohol , barbiturates , hypnotics , narcotic analgesics , drugb , and tranquillisers .
DDI-DrugBank.d615.s0	central nervous system depressants	group	49-82	tranquillisers	group	164-177	false	triprolidine may enhance the sedative effects of druga including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and drugb .
DDI-DrugBank.d615.s0	alcohol	drug	94-100	barbiturates	group	103-114	false	triprolidine may enhance the sedative effects of central nervous system depressants including druga , drugb , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	alcohol	drug	94-100	hypnotics	group	117-125	false	triprolidine may enhance the sedative effects of central nervous system depressants including druga , barbiturates , drugb , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	alcohol	drug	94-100	narcotic analgesics	group	128-146	false	triprolidine may enhance the sedative effects of central nervous system depressants including druga , barbiturates , hypnotics , drugb , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	alcohol	drug	94-100	sedatives	group	149-157	false	triprolidine may enhance the sedative effects of central nervous system depressants including druga , barbiturates , hypnotics , narcotic analgesics , drugb , and tranquillisers .
DDI-DrugBank.d615.s0	alcohol	drug	94-100	tranquillisers	group	164-177	false	triprolidine may enhance the sedative effects of central nervous system depressants including druga , barbiturates , hypnotics , narcotic analgesics , sedatives , and drugb .
DDI-DrugBank.d615.s0	barbiturates	group	103-114	hypnotics	group	117-125	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , druga , drugb , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	barbiturates	group	103-114	narcotic analgesics	group	128-146	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , druga , hypnotics , drugb , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	barbiturates	group	103-114	sedatives	group	149-157	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , druga , hypnotics , narcotic analgesics , drugb , and tranquillisers .
DDI-DrugBank.d615.s0	barbiturates	group	103-114	tranquillisers	group	164-177	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , druga , hypnotics , narcotic analgesics , sedatives , and drugb .
DDI-DrugBank.d615.s0	hypnotics	group	117-125	narcotic analgesics	group	128-146	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , druga , drugb , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0	hypnotics	group	117-125	sedatives	group	149-157	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , druga , narcotic analgesics , drugb , and tranquillisers .
DDI-DrugBank.d615.s0	hypnotics	group	117-125	tranquillisers	group	164-177	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , druga , narcotic analgesics , sedatives , and drugb .
DDI-DrugBank.d615.s0	narcotic analgesics	group	128-146	sedatives	group	149-157	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , druga , drugb , and tranquillisers .
DDI-DrugBank.d615.s0	narcotic analgesics	group	128-146	tranquillisers	group	164-177	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , druga , sedatives , and drugb .
DDI-DrugBank.d615.s0	sedatives	group	149-157	tranquillisers	group	164-177	false	triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , druga , and drugb .
DDI-DrugBank.d615.s1	anticholinergic drugs	group	15-35	atropine	drug	46-53	false	the effects of druga , such as drugb and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine .
DDI-DrugBank.d615.s1	anticholinergic drugs	group	15-35	tricyclic antidepressants	group	59-83	false	the effects of druga , such as atropine and drugb may be enhanced by the concomitant administration of triprolidine .
DDI-DrugBank.d615.s1	anticholinergic drugs	group	15-35	triprolidine	drug	138-149	effect	the effects of druga , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of drugb .
DDI-DrugBank.d615.s1	atropine	drug	46-53	tricyclic antidepressants	group	59-83	false	the effects of anticholinergic drugs , such as druga and drugb may be enhanced by the concomitant administration of triprolidine .
DDI-DrugBank.d615.s1	atropine	drug	46-53	triprolidine	drug	138-149	effect	the effects of anticholinergic drugs , such as druga and tricyclic antidepressants may be enhanced by the concomitant administration of drugb .
DDI-DrugBank.d615.s1	tricyclic antidepressants	group	59-83	triprolidine	drug	138-149	effect	the effects of anticholinergic drugs , such as atropine and druga may be enhanced by the concomitant administration of drugb .
DDI-DrugBank.d713.s0	Sanctura	brand	23-30	anticholinergic agents	group	43-64	effect	the concomitant use of druga with other drugb that produce dry mouth , constipation , and other anticholinergic pharmacological effects may increase the frequency and / or severity of such effects .
DDI-DrugBank.d713.s2	Sanctura	brand	101-108	Sanctura	brand	135-142	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with druga have not been conducted , drugb has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	101-108	digoxin	drug	266-272	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with druga have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. drugb , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	101-108	procainamide	drug	275-286	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with druga have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , drugb , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	101-108	pancuronium	drug	289-299	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with druga have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , drugb , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	101-108	morphine	drug	302-309	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with druga have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , drugb , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	101-108	vancomycin	drug	312-321	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with druga have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , drugb , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	101-108	metformin	drug	324-332	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with druga have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , drugb and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	101-108	tenofovir	drug	338-346	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with druga have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and drugb ) .
DDI-DrugBank.d713.s2	Sanctura	brand	135-142	digoxin	drug	266-272	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. drugb , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	135-142	procainamide	drug	275-286	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , drugb , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	135-142	pancuronium	drug	289-299	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , drugb , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	135-142	morphine	drug	302-309	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , drugb , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	135-142	vancomycin	drug	312-321	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , drugb , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	135-142	metformin	drug	324-332	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , drugb and tenofovir ) .
DDI-DrugBank.d713.s2	Sanctura	brand	135-142	tenofovir	drug	338-346	mechanism	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and drugb ) .
DDI-DrugBank.d713.s2	digoxin	drug	266-272	procainamide	drug	275-286	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. druga , drugb , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	digoxin	drug	266-272	pancuronium	drug	289-299	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. druga , procainamide , drugb , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	digoxin	drug	266-272	morphine	drug	302-309	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. druga , procainamide , pancuronium , drugb , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	digoxin	drug	266-272	vancomycin	drug	312-321	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. druga , procainamide , pancuronium , morphine , drugb , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	digoxin	drug	266-272	metformin	drug	324-332	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. druga , procainamide , pancuronium , morphine , vancomycin , drugb and tenofovir ) .
DDI-DrugBank.d713.s2	digoxin	drug	266-272	tenofovir	drug	338-346	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. druga , procainamide , pancuronium , morphine , vancomycin , metformin and drugb ) .
DDI-DrugBank.d713.s2	procainamide	drug	275-286	pancuronium	drug	289-299	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , druga , drugb , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	procainamide	drug	275-286	morphine	drug	302-309	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , druga , pancuronium , drugb , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	procainamide	drug	275-286	vancomycin	drug	312-321	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , druga , pancuronium , morphine , drugb , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	procainamide	drug	275-286	metformin	drug	324-332	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , druga , pancuronium , morphine , vancomycin , drugb and tenofovir ) .
DDI-DrugBank.d713.s2	procainamide	drug	275-286	tenofovir	drug	338-346	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , druga , pancuronium , morphine , vancomycin , metformin and drugb ) .
DDI-DrugBank.d713.s2	pancuronium	drug	289-299	morphine	drug	302-309	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , druga , drugb , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	pancuronium	drug	289-299	vancomycin	drug	312-321	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , druga , morphine , drugb , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	pancuronium	drug	289-299	metformin	drug	324-332	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , druga , morphine , vancomycin , drugb and tenofovir ) .
DDI-DrugBank.d713.s2	pancuronium	drug	289-299	tenofovir	drug	338-346	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , druga , morphine , vancomycin , metformin and drugb ) .
DDI-DrugBank.d713.s2	morphine	drug	302-309	vancomycin	drug	312-321	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , druga , drugb , metformin and tenofovir ) .
DDI-DrugBank.d713.s2	morphine	drug	302-309	metformin	drug	324-332	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , druga , vancomycin , drugb and tenofovir ) .
DDI-DrugBank.d713.s2	morphine	drug	302-309	tenofovir	drug	338-346	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , druga , vancomycin , metformin and drugb ) .
DDI-DrugBank.d713.s2	vancomycin	drug	312-321	metformin	drug	324-332	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , druga , drugb and tenofovir ) .
DDI-DrugBank.d713.s2	vancomycin	drug	312-321	tenofovir	drug	338-346	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , druga , metformin and drugb ) .
DDI-DrugBank.d713.s2	metformin	drug	324-332	tenofovir	drug	338-346	false	drugs eliminated by active tubular secretion : although studies to assess drug drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , druga and drugb ) .
DDI-DrugBank.d713.s3	Sanctura	brand	20-27	Sanctura	brand	134-141	false	coadministration of druga with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of drugb and / or the coadministered drug due to competition for this elimination pathway .
DDI-DrugBank.d669.s0	vancomycin	drug	30-39	anesthetic agents	group	45-61	effect	concomitant administration of druga and drugb has been associated with erythema and histamine like flushing and anaphylactoid reactions .
DDI-DrugBank.d669.s1	amphotericin B	drug	119-132	aminoglycosides	group	135-149	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as druga , drugb , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	amphotericin B	drug	119-132	bacitracin	drug	152-161	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as druga , aminoglycosides , drugb , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	amphotericin B	drug	119-132	polymyxin B	drug	164-174	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as druga , aminoglycosides , bacitracin , drugb , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	amphotericin B	drug	119-132	colistin	drug	177-184	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as druga , aminoglycosides , bacitracin , polymyxin b , drugb , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	amphotericin B	drug	119-132	viomycin	drug	187-194	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as druga , aminoglycosides , bacitracin , polymyxin b , colistin , drugb , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	amphotericin B	drug	119-132	cisplatin	drug	200-208	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as druga , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or drugb , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	aminoglycosides	group	135-149	bacitracin	drug	152-161	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , druga , drugb , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	aminoglycosides	group	135-149	polymyxin B	drug	164-174	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , druga , bacitracin , drugb , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	aminoglycosides	group	135-149	colistin	drug	177-184	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , druga , bacitracin , polymyxin b , drugb , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	aminoglycosides	group	135-149	viomycin	drug	187-194	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , druga , bacitracin , polymyxin b , colistin , drugb , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	aminoglycosides	group	135-149	cisplatin	drug	200-208	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , druga , bacitracin , polymyxin b , colistin , viomycin , or drugb , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	bacitracin	drug	152-161	polymyxin B	drug	164-174	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , druga , drugb , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	bacitracin	drug	152-161	colistin	drug	177-184	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , druga , polymyxin b , drugb , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	bacitracin	drug	152-161	viomycin	drug	187-194	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , druga , polymyxin b , colistin , drugb , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	bacitracin	drug	152-161	cisplatin	drug	200-208	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , druga , polymyxin b , colistin , viomycin , or drugb , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	polymyxin B	drug	164-174	colistin	drug	177-184	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , druga , drugb , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	polymyxin B	drug	164-174	viomycin	drug	187-194	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , druga , colistin , drugb , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	polymyxin B	drug	164-174	cisplatin	drug	200-208	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , druga , colistin , viomycin , or drugb , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	colistin	drug	177-184	viomycin	drug	187-194	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , druga , drugb , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	colistin	drug	177-184	cisplatin	drug	200-208	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , druga , viomycin , or drugb , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1	viomycin	drug	187-194	cisplatin	drug	200-208	false	concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , druga , or drugb , when indicated , requires careful monitoring .
DDI-DrugBank.d613.s0	vigabatrin	drug	37-46	carbamazepine	drug	115-127	mechanism	a study published in dg found that druga causes a statistically significant increase in plasma clearance of drugb .
DDI-DrugBank.d613.s1	vigabatrin	drug	87-96	phenytoin	drug	103-111	mechanism	in dg , drs rimmer and richens at the university of wales reported that administering druga with drugb lowered the serum phenytoin concentration in patients with treatment resistant epilepsy .
DDI-DrugBank.d613.s1	vigabatrin	drug	87-96	phenytoin	drug	131-139	false	in dg , drs rimmer and richens at the university of wales reported that administering druga with phenytoin lowered the serum drugb concentration in patients with treatment resistant epilepsy .
DDI-DrugBank.d613.s1	phenytoin	drug	103-111	phenytoin	drug	131-139	false	in dg , drs rimmer and richens at the university of wales reported that administering vigabatrin with druga lowered the serum drugb concentration in patients with treatment resistant epilepsy .
DDI-DrugBank.d782.s0	Vindesine	drug	0-8	Phenytoin	drug	310-318	int	druga can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity drugb : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Vindesine	drug	0-8	Live virus vaccines	group	353-371	int	druga can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity drugb : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Vindesine	drug	0-8	vaccine	drug	412-418	false	druga can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the drugb virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Vindesine	drug	0-8	Mitomycin-C	drug	526-536	int	druga can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine drugb : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Vindesine	drug	0-8	Killed virus vaccines	group	588-608	int	druga can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm drugb : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Vindesine	drug	0-8	vaccine	group	650-656	false	druga can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the drugb
DDI-DrugBank.d782.s0	Phenytoin	drug	310-318	Live virus vaccines	group	353-371	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity druga : can increase seizure activity drugb : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Phenytoin	drug	310-318	vaccine	drug	412-418	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity druga : can increase seizure activity live virus vaccines : may potentiate the replication of the drugb virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Phenytoin	drug	310-318	Mitomycin-C	drug	526-536	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity druga : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine drugb : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Phenytoin	drug	310-318	Killed virus vaccines	group	588-608	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity druga : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm drugb : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Phenytoin	drug	310-318	vaccine	group	650-656	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity druga : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the drugb
DDI-DrugBank.d782.s0	Live virus vaccines	group	353-371	vaccine	drug	412-418	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity druga : may potentiate the replication of the drugb virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Live virus vaccines	group	353-371	Mitomycin-C	drug	526-536	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity druga : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine drugb : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Live virus vaccines	group	353-371	Killed virus vaccines	group	588-608	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity druga : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm drugb : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Live virus vaccines	group	353-371	vaccine	group	650-656	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity druga : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the drugb
DDI-DrugBank.d782.s0	vaccine	drug	412-418	Mitomycin-C	drug	526-536	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the druga virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine drugb : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	vaccine	drug	412-418	Killed virus vaccines	group	588-608	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the druga virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm drugb : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	vaccine	drug	412-418	vaccine	group	650-656	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the druga virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the drugb
DDI-DrugBank.d782.s0	Mitomycin-C	drug	526-536	Killed virus vaccines	group	588-608	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine druga : may cause shortness of breath and bronchospasm drugb : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0	Mitomycin-C	drug	526-536	vaccine	group	650-656	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine druga : may cause shortness of breath and bronchospasm killed virus vaccines : may decrease patient 's response to the drugb
DDI-DrugBank.d782.s0	Killed virus vaccines	group	588-608	vaccine	group	650-656	false	vindesine can interact with the drugs of the following categories : blood dyscrasia : can cause unpredictable myelotoxicity bone marrow depressants : can cause a predictable dose related myelotoxicity radiation therapy : may cause marrow depression neurotoxic medications : can cause neurologic toxicity phenytoin : can increase seizure activity live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine mitomycin c : may cause shortness of breath and bronchospasm druga : may decrease patient 's response to the drugb
DDI-DrugBank.d651.s0	contraceptives	group	33-46	vitamin A	group	92-100	mechanism	drug interactions : women on oral druga have shown a significant increase in plasma drugb levels .
DDI-DrugBank.d759.s0	ascorbic acid	drug	31-43	bishydroxycoumarin	drug	99-116	mechanism	limited evidence suggests that druga may influence the intensity and duration of action of drugb .
DDI-DrugBank.d769.s0	Coumarin-Derivative Anticoagulants	group	0-33	ZOLINZA	brand	151-157	false	druga : prolongation of prothrombin time ( pt ) and international normalized ratio ( inr ) were observed in patients receiving drugb concomitantly with coumarin derivative anticoagulants .
DDI-DrugBank.d769.s0	Coumarin-Derivative Anticoagulants	group	0-33	coumarin-derivative anticoagulants	group	178-211	false	druga : prolongation of prothrombin time ( pt ) and international normalized ratio ( inr ) were observed in patients receiving zolinza concomitantly with drugb .
DDI-DrugBank.d769.s0	ZOLINZA	brand	151-157	coumarin-derivative anticoagulants	group	178-211	effect	coumarin derivative anticoagulants : prolongation of prothrombin time ( pt ) and international normalized ratio ( inr ) were observed in patients receiving druga concomitantly with drugb .
DDI-DrugBank.d769.s1	ZOLINZA	brand	85-91	coumarin derivatives	group	97-116	advise	physicians should carefully monitor pt and inr in patients concurrently administered druga and drugb .
DDI-DrugBank.d769.s2	HDAC Inhibitors	group	6-20	ZOLINZA	brand	119-125	false	other druga severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of drugb and other hdac inhibitors ( e.g. , valproic acid ) .
DDI-DrugBank.d769.s2	HDAC Inhibitors	group	6-20	HDAC inhibitors	group	137-151	false	other druga severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other drugb ( e.g. , valproic acid ) .
DDI-DrugBank.d769.s2	HDAC Inhibitors	group	6-20	valproic acid	drug	160-172	false	other druga severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors ( e.g. , drugb ) .
DDI-DrugBank.d769.s2	ZOLINZA	brand	119-125	HDAC inhibitors	group	137-151	effect	other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of druga and other drugb ( e.g. , valproic acid ) .
DDI-DrugBank.d769.s2	ZOLINZA	brand	119-125	valproic acid	drug	160-172	effect	other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of druga and other hdac inhibitors ( e.g. , drugb ) .
DDI-DrugBank.d769.s2	HDAC inhibitors	group	137-151	valproic acid	drug	160-172	false	other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other druga ( e.g. , drugb ) .
